- entity: node
  type: pdq_cancer_information_summary
  title: 'Breast Cancer Screening (PDQ®)–Health Professional Version'
  status: 1
  langcode: en
  field_hhs_syndication:
    - syndicate: 1
      keywords: breast cancer, disease screening
  moderation_state:
    value: published
  field_pdq_url:
    value: /types/breast/hp/breast-screening-pdq
  field_pdq_cdr_id:
    value: 62751
  field_pdq_audience:
    value: Health Professionals
  field_pdq_summary_type:
    value: Screening
  field_date_posted:
    value: '2019-03-11'
  field_date_updated:
    value: '2018-10-08'
  field_browser_title:
    value: 'Breast Cancer Screening'
  field_page_description:
    value: 'Breast cancer screening most often includes mammography but can also include ultrasound, MRI, and other tests. Get detailed information about the potential benefits and harms of the tests used to screen for breast cancer in this summary for clinicians.'
  field_public_use:
    value: 1
  field_summary_sections:
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _1
      field_pdq_section_title:
        - format: plain_text
          value: 'Overview'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_1" class="pdq-sections"><div class="pdq-hp-patient-toggle"><a href="/types/breast/patient/breast-screening-pdq">Go to Patient Version</a></div><p id="_3" tabindex="-1">Note: Separate PDQ summaries on <a href="/types/breast/hp/breast-prevention-pdq">Breast Cancer Prevention</a>, <a href="/types/breast/hp/breast-treatment-pdq">Breast Cancer Treatment</a>, <a href="/types/breast/hp/male-breast-treatment-pdq">Male Breast Cancer Treatment</a>, and <a href="/types/breast/hp/pregnancy-breast-treatment-pdq">Breast Cancer Treatment During Pregnancy</a> are also available.</p><p id="_207" tabindex="-1">Mammography is the most widely used screening modality for the detection of breast cancer. There is evidence that it decreases breast cancer mortality in women aged 50 to 69 years and that it is associated with harms, including the detection of clinically insignificant cancers that pose no threat to life (overdiagnosis).  The benefit of mammography for women aged 40 to 49 years is uncertain.[<a href="#cit/section_1.1">1</a>,<a href="#cit/section_1.2">2</a>] Clinical breast examination (CBE) has not been studied as an independent screening test. Breast self-exam has been shown to have no mortality benefit. Technologies such as ultrasound, magnetic resonance imaging, and molecular breast imaging are being evaluated, usually as adjuncts to mammography, and are not primary screening tools in the average population.</p><p id="_712" tabindex="-1">Informed medical decision making is increasingly recommended for individuals who are considering cancer screening.   Many different types and formats of decision aids have been studied. (Refer to the PDQ summary on <a href="/about-cancer/screening/hp-screening-overview-pdq">Cancer Screening Overview</a> for more information.)</p><section id="_7"><h3 id="_7_toc">Screening With Mammography</h3><section id="_10"><h4 id="_10_toc">Benefits</h4><p id="_701" tabindex="-1">Randomized controlled trials (RCTs) initiated 50 years ago provide evidence that screening mammography improves breast cancer survival for women aged 60 to 69 years (solid evidence) and women aged 50 to 59 years (fair evidence).   Population-based studies done more recently raise questions as to the benefits to screened populations who participate in screening for longer time periods.</p><p id="_702" tabindex="-1"><strong>Magnitude of Effect:</strong> Based on a meta-analysis of RCTs, the number of women needed to invite for screening to prevent one breast cancer death depends on the woman&#x2019;s age: for women aged 39 to 49 years,  1,904 women needed (95% confidence interval [CI], 929&#x2013;6,378); for women aged 50 to 59 years, 1,339 women needed (95% CI, 322&#x2013;7,455);
            and for women aged 60 to 69 years, 377 women needed (95% CI, 230&#x2013;1,050).[<a href="#cit/section_1.3">3</a>]</p><div class="pdq-content-list"><ul id="_24" class="pdq-address-block"><li><strong>Study Design</strong>: RCTs, population-based evidence.</li><li><strong>Internal Validity</strong>: Variable, but meta-analysis of RCTs is good.</li><li><strong>Consistency</strong>: Poor.</li><li><strong>External Validity</strong>: Uncertain.</li></ul></div><p id="_704" tabindex="-1">The validity of meta-analyses of RCT demonstrating a mortality benefit is limited by improvements in medical imaging and treatment in the decades since their completion. The 25-year follow-up from the Canadian National Breast Screening Study (CNBSS),[<a href="#cit/section_1.4">4</a>] completed in 2014, showed no survival benefit associated with screening mammograms.</p></section><section id="_13"><h4 id="_13_toc">Harms</h4><p id="_14" tabindex="-1">Based on solid evidence, screening mammography may lead to the following harms: </p><div class="pdq-content-list"><ul id="_25"><li><strong>Overdiagnosis and Resulting Treatment of Insignificant Cancers</strong>: Some screen-detected cancers are life threatening and others are not, with no definitive way of discriminating between them. Therefore, standard cancer therapies, including surgery, radiation, endocrine therapy, chemotherapy, and therapies targeting the <em>HER2</em> receptor, are recommended for all cases, even for patients who will gain no benefit.<div class="pdq-content-list"><ul id="_26" class="pdq-address-block"><li><strong>Magnitude of Effect</strong>:  Between 20% and 50% of screen-detected cancers represent overdiagnosis  based on patient age, life expectancy, and tumor type (ductal carcinoma <em>in situ</em> and/or invasive).[<a href="#cit/section_1.5">5</a>,<a href="#cit/section_1.6">6</a>] These estimates are based on two imperfect analytic methods:[<a href="#cit/section_1.5">5</a>,<a href="#cit/section_1.7">7</a>]<div class="pdq-content-list"><ol id="_705"><li>Long-term follow-up of RCTs of screening.</li><li>The calculation of excess incidence in large screening programs.[<a href="#cit/section_1.5">5</a>,<a href="#cit/section_1.6">6</a>]</li></ol></div></li><li><strong>Study Design</strong>: RCTs, descriptive, population-based comparisons, autopsy series, and series of mammary reduction specimens.</li></ul></div></li><li><strong>False Positives with Additional Testing and Anxiety.</strong><div class="pdq-content-list"><ul id="_27" class="pdq-address-block"><li><strong>Magnitude of Effect</strong>: In the United States, approximately 10% of women are recalled for further testing after a screening examination, however, only 0.5% of tested women have cancer; thus, approximately 9.5% of tested women will have a false-positive exam.[<a href="#cit/section_1.8">8</a>,<a href="#cit/section_1.9">9</a>] Approximately 50% of women screened annually for 10 years in the United States will experience a false positive; of these, 7% to 17%  will undergo biopsies.[<a href="#cit/section_1.10">10</a>,<a href="#cit/section_1.11">11</a>] Additional testing is less likely when prior mammograms are available for comparison.</li><li><strong>Study Design</strong>: Descriptive, population based.</li></ul></div></li><li><strong>False Negatives with False Sense of Security and Potential Delay in Cancer Diagnosis.</strong><div class="pdq-content-list"><ul id="_28" class="pdq-address-block"><li><strong>Magnitude of Effect</strong>: Invasive breast cancer will be present but undetected  by mammography (false negative) in 6% to 46% of exams.   False-negative exams are more likely for mucinous and lobular types of cancer, for rapidly growing <em>interval</em> tumors which become detectable between regular mammograms and in dense breasts, which are common in younger women.[<a href="#cit/section_1.12">12</a>-<a href="#cit/section_1.14">14</a>]</li><li><strong>Study design</strong>: Descriptive, population-based.</li></ul></div></li><li><strong>Radiation-Induced Breast Cancer</strong>: Radiation-induced mutations occur with radiation doses higher than those used in a single mammography examination, so the exposure associated with a typical two-view mammogram is extremely unlikely to cause cancer.[<a href="#cit/section_1.15">15</a>,<a href="#cit/section_1.16">16</a>]<div class="pdq-content-list"><ul id="_29" class="pdq-address-block"><li><strong>Magnitude of Effect</strong>: Theoretically, annual mammograms in women aged 40  to 80 years may cause up to one breast cancer per 1,000 women.[<a href="#cit/section_1.15">15</a>,<a href="#cit/section_1.16">16</a>]</li><li><strong>Study design</strong>: Descriptive, population-based.</li></ul></div></li></ul></div><p id="_30" tabindex="-1">For all of these conclusions regarding potential harms from screening mammography, internal validity, consistency, and external validity are good.</p></section></section><section id="_15"><h3 id="_15_toc">Clinical Breast Examination (CBE)</h3><section id="_16"><h4 id="_16_toc">Benefits</h4><p id="_17" tabindex="-1">The Canadian NBSS trial did not study the efficacy of CBE versus no screening.   Ongoing randomized trials, two in India and one in Egypt, are designed to assess the efficacy of screening CBE but have not reported mortality data.[<a href="#cit/section_1.17">17</a>-<a href="#cit/section_1.22">22</a>] Thus, the efficacy of screening CBE cannot be assessed yet.</p><div class="pdq-content-list"><ul id="_31" class="pdq-address-block"><li><strong>Magnitude of Effect</strong>: The current evidence is insufficient to assess the additional benefits and harms of CBE.  The single RCT comparing high-quality CBE with screening mammography showed equivalent benefit.  CBE accuracy in the community setting might be lower than in the RCT.[<a href="#cit/section_1.17">17</a>-<a href="#cit/section_1.20">20</a>]</li><li><strong>Study Design</strong>: Single RCT, population cohort studies.</li><li><strong>Internal Validity</strong>: Good.</li><li><strong>Consistency and External Validity</strong>: Poor.</li></ul></div></section><section id="_20"><h4 id="_20_toc">Harms</h4><p id="_21" tabindex="-1">Screening by CBE may lead to the following harms: </p><div class="pdq-content-list"><ul id="_22"><li><strong>False Positives with Additional Testing and Anxiety.</strong><div class="pdq-content-list"><ul id="_23" class="pdq-address-block"><li><strong>Magnitude of effect</strong>: Specificity in women aged 50 to 59 years was 88% to 99%, yielding a false-positive rate of 1% to 12% for all women screened.[<a href="#cit/section_1.23">23</a>]</li><li><strong>Study Design</strong>: Descriptive, population based.</li><li><strong>Internal Validity, Consistency, and External Validity</strong>: Good.</li></ul></div></li><li><strong>False Negatives with Potential False Reassurance and Delay in Cancer Diagnosis.</strong><div class="pdq-content-list"><ul id="_32" class="pdq-address-block"><li><strong>Magnitude of Effect</strong>: Of women with cancer, 17% to 43% have a negative CBE.  Sensitivity is higher with longer duration and higher quality of the examination by trained personnel.</li><li><strong>Study Design</strong>: Descriptive, population based.</li><li><strong>Internal and External Validity</strong>: Good.</li><li><strong>Consistency</strong>: Fair.</li></ul></div></li></ul></div></section></section><section id="_33"><h3 id="_33_toc">Breast Self-Examination (BSE)</h3><section id="_34"><h4 id="_34_toc">Benefits</h4><p id="_35" tabindex="-1">BSE has been compared with no screening and has been shown to have no benefit in reducing breast cancer mortality.</p><div class="pdq-content-list"><ul id="_36" class="pdq-address-block"><li><strong>Magnitude of Effect</strong>: No effect.[<a href="#cit/section_1.24">24</a>,<a href="#cit/section_1.25">25</a>]</li><li><strong>Study Design</strong>: Two RCTs.</li><li><strong>Internal Validity and Consistency</strong>: Fair.</li><li><strong>External Validity</strong>: Poor.</li></ul></div></section><section id="_37"><h4 id="_37_toc">Harms</h4><p id="_38" tabindex="-1">There is solid evidence that formal instruction and encouragement to perform BSE leads to more breast biopsies and more diagnoses of benign breast lesions.</p><div class="pdq-content-list"><ul id="_39" class="pdq-address-block"><li><strong>Magnitude of Effects on Health Outcomes</strong>: Biopsy rate was 1.8% among the study population compared with 1.0% among the control group.[<a href="#cit/section_1.24">24</a>]</li><li><strong>Study Design</strong>: Two RCTs, cohort studies.</li><li><strong>Internal Validity</strong>: Good.</li><li><strong>Consistency</strong>: Fair.</li><li><strong>External Validity</strong>: Poor.</li></ul></div></section></section><h6 do-not-show="toc">References</h6><ol><li id="section_1.1">Moss SM, Cuckle H, Evans A, et al.: Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet 368 (9552): 2053-60, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17161727&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17161727&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.2">Moss SM, Wale C, Smith R, et al.: Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial. Lancet Oncol 16 (9): 1123-32, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26206144&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26206144&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.3">Nelson HD, Tyne K, Naik A, et al.: Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med 151 (10): 727-37, W237-42, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19920273&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19920273&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.4">Miller AB, Wall C, Baines CJ, et al.: Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ 348: g366, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24519768&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24519768&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.5">Welch HG, Black WC: Overdiagnosis in cancer. J Natl Cancer Inst 102 (9): 605-13, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20413742&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20413742&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.6">Bleyer A, Welch HG: Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 367 (21): 1998-2005, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23171096&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23171096&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.7">Yen MF, Tab&#xE1;r L, Vitak B, et al.: Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. Eur J Cancer 39 (12): 1746-54, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12888370&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12888370&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.8">J&#xF8;rgensen KJ, G&#xF8;tzsche PC: Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ 339: b2587, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19589821&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19589821&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.9">Rosenberg RD, Yankaskas BC, Abraham LA, et al.: Performance benchmarks for screening mammography. Radiology 241 (1): 55-66, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16990671&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16990671&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.10">Elmore JG, Barton MB, Moceri VM, et al.: Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 338 (16): 1089-96, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9545356&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9545356&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.11">Hubbard RA, Kerlikowske K, Flowers CI, et al.: Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann Intern Med 155 (8): 481-92, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22007042&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22007042&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.12">Rosenberg RD, Hunt WC, Williamson MR, et al.: Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico. Radiology 209 (2): 511-8, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9807581&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9807581&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.13">Kerlikowske K, Grady D, Barclay J, et al.: Likelihood ratios for modern screening mammography. Risk of breast cancer based on age and mammographic interpretation. JAMA 276 (1): 39-43, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8667537&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8667537&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.14">Porter PL, El-Bastawissi AY, Mandelson MT, et al.: Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 91 (23): 2020-8, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10580027&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10580027&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.15">Ronckers CM, Erdmann CA, Land CE: Radiation and breast cancer: a review of current evidence. Breast Cancer Res 7 (1): 21-32, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15642178&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15642178&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.16">Goss PE, Sierra S: Current perspectives on radiation-induced breast cancer. J Clin Oncol 16 (1): 338-47, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9440762&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9440762&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.17">Hassan LM, Mahmoud N, Miller AB, et al.: Evaluation of effect of self-examination and physical examination on breast cancer. Breast 24 (4): 487-90, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25977176&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25977176&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.18">Anderson BO, Bevers TB, Carlson RW: Clinical Breast Examination and Breast Cancer Screening Guideline. JAMA 315 (13): 1403-4, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27046372&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27046372&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.19">Yen AM, Tsau HS, Fann JC, et al.: Population-Based Breast Cancer Screening With Risk-Based and Universal Mammography Screening Compared With Clinical Breast Examination: A Propensity Score Analysis of 1&#x202F;429&#x202F;890 Taiwanese Women. JAMA Oncol 2 (7): 915-21, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27030951&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27030951&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.20">Myers ER, Moorman P, Gierisch JM, et al.: Benefits and Harms of Breast Cancer Screening: A Systematic Review. JAMA 314 (15): 1615-34, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26501537&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26501537&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.21">Mittra I, Mishra GA, Singh S, et al.: A cluster randomized, controlled trial of breast and cervix cancer screening in Mumbai, India: methodology and interim results after three rounds of screening. Int J Cancer 126 (4): 976-84, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19697326&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19697326&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.22">Sankaranarayanan R, Ramadas K, Thara S, et al.: Clinical breast examination: preliminary results from a cluster randomized controlled trial in India. J Natl Cancer Inst 103 (19): 1476-80, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21862730&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21862730&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.23">Fenton JJ, Rolnick SJ, Harris EL, et al.: Specificity of clinical breast examination in community practice. J Gen Intern Med 22 (3): 332-7, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17356964&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17356964&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.24">Thomas DB, Gao DL, Ray RM, et al.: Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst 94 (19): 1445-57, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12359854&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12359854&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.25">Semiglazov VF, Manikhas AG, Moiseenko VM, et al.: [Results of a prospective randomized investigation [Russia (St.Petersburg)/WHO] to evaluate the significance of self-examination for the early detection of breast cancer]. Vopr Onkol 49 (4): 434-41, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14569932&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14569932&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _40
      field_pdq_section_title:
        - format: plain_text
          value: 'Description of the Evidence'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_40" class="pdq-sections"><section id="_41"><h3 id="_41_toc">Breast Cancer Incidence and Mortality</h3><p id="_43" tabindex="-1">Breast cancer is the most common noncutaneous cancer in U.S. women, with an estimated 266,120 cases of invasive disease, 63,960 cases of <em>in situ</em> disease, and 40,920 deaths expected in 2018.[<a href="#cit/section_2.1">1</a>]  Women with inherited risk, especially <em>BRCA1</em> and <em>BRCA2</em> gene carriers, comprise no more than 10% of breast cancer cases. Males account for 1% of breast cancer cases and breast cancer deaths.</p><p id="_649" tabindex="-1">The biggest risk factor for breast cancer is being female followed by advancing age.  Other risk factors include hormonal aspects (such as early menarche, late menopause, nulliparity, late first pregnancy, and postmenopausal hormone therapy), alcohol consumption, and exposure to ionizing radiation.</p><p id="_650" tabindex="-1">Breast cancer incidence in white women is higher than in black women, who also have a lower survival rate for every stage when diagnosed. This may  reflect differences in screening behavior and access to healthcare.  Hispanic and Asian-Pacific islanders have lower incidence and mortality than whites or blacks.[<a href="#cit/section_2.2">2</a>]</p><p id="_651" tabindex="-1">Breast cancer incidence depends on reproductive issues (such as early vs. late pregnancy, multiparity, and breastfeeding), participation in screening, and postmenopausal hormone usage.  The incidence of breast cancer (especially ductal carcinoma <em>in situ</em> [DCIS]) increased dramatically after mammography was widely adopted in the United States and the United Kingdom.[<a href="#cit/section_2.3">3</a>]  Widespread use of postmenopausal hormone therapy was associated with a dramatic increase in breast cancer incidence, a trend that reversed when its use decreased.[<a href="#cit/section_2.4">4</a>]</p><p id="_706" tabindex="-1">In any population, the adoption of screening is not followed by a decline in the incidence of advanced-stage cancer.</p></section><section id="_560"><h3 id="_560_toc">Evaluation of Breast Symptoms</h3><p id="_561" tabindex="-1">Women with breast symptoms undergo diagnostic mammography as opposed to screening mammography, which is done in asymptomatic women. In a 10-year study of breast symptoms prompting medical attention,  a breast mass led to a cancer diagnosis in 10.7% of cases, whereas pain was associated with cancer in only 1.8% of cases.[<a href="#cit/section_2.5">5</a>]</p></section><section id="_4"><h3 id="_4_toc">Pathologic Evaluation of Breast Tissue</h3><section id="_64"><h4 id="_64_toc">Invasive breast cancer</h4><p id="_65" tabindex="-1">Breast cancer can be diagnosed when breast tissue cells removed during a biopsy are studied microscopically. The breast tissue to be sampled can be identified by an abnormality on an imaging study or because it is palpable. Breast biopsies can be performed with a thin needle attached to a syringe  (fine-needle aspirate), a larger needle (core biopsy), or by excision (excisional biopsy). Image guidance can improve accuracy. Needle biopsies  sample an abnormal area large enough to make a diagnosis. Excisional biopsies aim to remove the entire region of abnormality.</p></section><section id="_66"><h4 id="_66_toc">Ductal carcinoma <em>in situ</em> (DCIS)</h4><p id="_67" tabindex="-1">DCIS is a noninvasive condition that can be associated with, or evolve into, invasive cancer, with variable frequency and time course.[<a href="#cit/section_2.6">6</a>] Some authors include DCIS with invasive breast cancer statistics, but others argue that it would be better if the term were replaced with ductal intraepithelial neoplasia, similar to the terminology used for cervical and prostate precursor lesions, and that excluding DCIS from breast cancer statistics should be considered.</p><p id="_68" tabindex="-1">DCIS is most often diagnosed by mammography. In the United States, only 4,900 women were diagnosed with DCIS in 1983 before the adoption of mammography screening, compared with approximately 63,960 women who are expected to be diagnosed in  2018.[<a href="#cit/section_2.1">1</a>,<a href="#cit/section_2.6">6</a>,<a href="#cit/section_2.7">7</a>]  The Canadian National Breast Screening Study-2, which evaluated women aged 50 to 59 years, found a fourfold increase in DCIS cases in women screened by clinical breast examination (CBE) plus mammography compared with those screened by CBE alone, with no difference in breast cancer mortality.[<a href="#cit/section_2.8">8</a>] (Refer to the PDQ summary on <a href="/types/breast/hp/breast-treatment-pdq">Breast Cancer Treatment</a> for more information.)</p><p id="_69" tabindex="-1">The natural history of DCIS is poorly understood because nearly all DCIS cases are detected by screening and nearly all are treated. Development of breast cancer after treatment of DCIS depends on the pathologic characteristics of the lesion and on the treatment. In a randomized trial, 13.4% of women whose DCIS was excised by lumpectomy developed ipsilateral invasive breast cancer within 90 months, compared with 3.9% of those treated by both lumpectomy and radiation.[<a href="#cit/section_2.9">9</a>] Among women diagnosed and treated for DCIS, the percentage of women who died of breast cancer is lower than that for the age-matched population at large.[<a href="#cit/section_2.10">10</a>,<a href="#cit/section_2.11">11</a>] This favorable outcome may reflect the benign nature of the condition, the benefits of treatment, or the volunteer effect (i.e., women who undergo breast cancer screening are generally healthier than those who do not do so).</p></section><section id="_562"><h4 id="_562_toc">Atypia</h4><p id="_563" tabindex="-1">Atypia, which is a risk factor for breast cancer, is found in 4% to 10% of breast biopsies.[<a href="#cit/section_2.12">12</a>,<a href="#cit/section_2.13">13</a>]  Atypia is a diagnostic classification with considerable variation among practicing pathologists.[<a href="#cit/section_2.14">14</a>]</p></section><section id="_564"><h4 id="_564_toc">Variability of pathologists&#x2019; diagnoses on the interpretation of breast biopsy specimens</h4><p id="_565" tabindex="-1">The range of pathologists' diagnoses of breast tissue includes benign without atypia, atypia, DCIS, and invasive breast cancer. The incidence of atypia and DCIS breast lesions has increased over the past three decades as a result of widespread mammography screening, although atypia is generally mammographically occult.[<a href="#cit/section_2.15">15</a>,<a href="#cit/section_2.16">16</a>] Misclassification of breast lesions may contribute to either overtreatment or undertreatment of lesions&#x2014;with variability especially in the diagnoses of atypia and DCIS.[<a href="#cit/section_2.14">14</a>,<a href="#cit/section_2.17">17</a>-<a href="#cit/section_2.21">21</a>]</p><p id="_609" tabindex="-1"> The largest study on this topic, the B-Path study, involved 115 practicing U.S. pathologists who interpreted a single-breast biopsy slide per case, and it compared their interpretations with an expert consensus-derived reference diagnosis.[<a href="#cit/section_2.14">14</a>] While the overall agreement between the individual pathologists&#x2019; interpretations and the expert reference diagnoses was highest for invasive carcinoma, there were markedly lower levels of agreement for DCIS and atypia.[<a href="#cit/section_2.14">14</a>] As the B-Path study included higher proportions of cases of atypia and DCIS than typically seen in clinical practice, the authors expanded their work by applying Bayes&#x2019; theorem to estimate how diagnostic variability affects accuracy from the perspective of a U.S. woman aged 50 to 59 years having a breast biopsy.[<a href="#cit/section_2.17">17</a>] At the U.S. population level, it is estimated that 92.3% (confidence interval [CI], 91.4%&#x2013;93.1%) of breast biopsy diagnoses would be verified by an expert reference consensus diagnosis, with 4.6% (CI, 3.9%&#x2013;5.3%) of initial breast biopsies estimated to be overinterpreted and 3.2% (CI, 2.7%&#x2013;3.6%) under interpreted. <a href="/types/breast/hp/breast-screening-pdq#link/_610">Figure 1</a> shows the predicted outcomes per 100 breast biopsies, overall and by diagnostic category.</p><figure id="figure_610" class="image-center"><a href="https://www.cancer.gov/images/cdr/live/CDR784729.jpg" target="_blank" class="article-image-enlarge">Enlarge</a><img id="_610" alt="Charts showing the predicted outcomes for 100 breast biopsies, overall and by diagnostic category." title="Charts showing the predicted outcomes for 100 breast biopsies, overall and by diagnostic category." src="https://www.cancer.gov/images/cdr/live/CDR784729-750.jpg"><figcaption class="caption-container">Figure 1.  Predicted outcomes per 100 breast biopsies, overall and by diagnostic category. From Annals of Internal Medicine, Elmore JG, Nelson HD, Pepe MS, Longton GM, Tosteson AN, Geller B, Onega T, Carney PA, Jackson SL, Allison KH, Weaver DL, Variability in Pathologists' Interpretations of Individual Breast Biopsy Slides: A Population Perspective, Volume 164, Issue 10, Pages 649&#x2013;55, Copyright &#xA9; 2016 American College of Physicians. All Rights Reserved. Reprinted with the permission of American College of Physicians, Inc.</figcaption></figure><p id="_575" tabindex="-1">To address the high rates of discordance in breast tissue diagnosis, laboratory policies that require second opinions are becoming more common. A national survey of 252 breast pathologists participating in the B-Path study found that 65% of respondents reported having a laboratory policy that requires second opinions for all cases initially diagnosed as invasive disease.  Additionally, 56% of respondents reported policies that require second opinions for initial diagnoses of DCIS, while 36% of respondents reported mandatory second opinion policies for cases initially diagnosed as atypical ductal hyperplasia.[<a href="#cit/section_2.22">22</a>] In this same survey, pathologists overwhelmingly agreed that second opinions improved diagnostic accuracy (96%).</p><p id="_608" tabindex="-1">A simulation study that used B-Path study data evaluated 12 strategies for obtaining second opinions to improve interpretation of breast histopathology.[<a href="#cit/section_2.23">23</a>] Accuracy improved significantly with all second-opinion strategies, except for the strategy limiting second opinions only to cases of invasive cancer.  Accuracy improved regardless of the pathologists&#x2019; confidence in their diagnosis or their level of experience.   While the second opinions improved accuracy, they did not completely eliminate diagnostic variability, especially in the challenging case of breast atypia.</p></section></section><section id="_123"><h3 id="_123_toc">Special Populations</h3><section id="_143"><h4 id="_143_toc">Women  at increased risk who may receive more benefit from screening </h4><section id="_661"><h5 id="_661_toc">Women with <em>BRCA1</em> and <em>BRCA2</em> genetic mutations</h5><p id="_662" tabindex="-1">Women with an increased risk of breast cancer caused by a <em>BRCA1</em> or <em>BRCA2</em> genetic mutation might benefit from increased  screening. (Refer to the PDQ summary on <a href="/types/breast/hp/breast-ovarian-genetics-pdq">Genetics of Breast and Gynecologic Cancers</a> for more information.) </p></section><section id="_663"><h5 id="_663_toc">Recipients of  thoracic radiation</h5></section><p id="_675" tabindex="-1">Women with Hodgkin and non-Hodgkin lymphoma who were treated with mantle irradiation have an increased risk of breast cancer, starting 10 years after completing therapy and continuing life-long. Therefore, screening mammography has been advocated, even though it may begin at a relatively young age.[<a href="#cit/section_2.24">24</a>,<a href="#cit/section_2.25">25</a>]</p></section><section id="_664"><h4 id="_664_toc">Individuals who receive little benefit from screening</h4><section id="_676"><h5 id="_676_toc">Women with limited life expectancy</h5><p id="_677" tabindex="-1">The potential benefits of screening mammography occur well after the examination, often many years later, whereas the harms occur immediately.  Therefore, women with limited life expectancy and comorbidities who suffer harms may  do so without benefit. Nonetheless, many of these women undergo screening mammography.[<a href="#cit/section_2.26">26</a>] In one study, approximately 9% of women with advanced cancer underwent  cancer screening tests.[<a href="#cit/section_2.27">27</a>]</p></section><section id="_678"><h5 id="_678_toc">Elderly women</h5><p id="_679" tabindex="-1">Screening mammography may yield cancer diagnoses in approximately 1% of elderly women , but most of these cancers are low risk.[<a href="#cit/section_2.28">28</a>] The question remains whether the diagnosis and treatment of localized breast cancer in elderly women is beneficial.</p></section><section id="_680"><h5 id="_680_toc">Young women</h5><p id="_681" tabindex="-1">There is no evidence of benefit in performing screening mammography in average-risk women younger than 40 years.</p></section><section id="_682"><h5 id="_682_toc">Men</h5><p id="_683" tabindex="-1">Approximately 1% of all breast cancers occur in men.[<a href="#cit/section_2.29">29</a>] Most cases are diagnosed during the evaluation of palpable lesions, which are generally easy to detect.  Treatment consists of surgery, radiation, and systemic adjuvant hormone therapy or chemotherapy. (Refer to the PDQ summary on <a href="/types/breast/hp/male-breast-treatment-pdq">Male Breast Cancer Treatment</a> for more information.)  Screening is unlikely to be beneficial.</p></section></section></section><h6 do-not-show="toc">References</h6><ol><li id="section_2.1">American Cancer Society: Cancer Facts and Figures 2018. Atlanta, Ga: American Cancer Society, 2018. <a href="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf" title="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf">Available online</a>. Last accessed August 3, 2018.</li><li id="section_2.2">Howlader N, Noone AM, Krapcho M, et al., eds.: SEER Cancer Statistics Review, 1975-2011. Bethesda, Md: National Cancer Institute, 2014. <a href="http://seer.cancer.gov/csr/1975_2011/" title="http://seer.cancer.gov/csr/1975_2011/">Also available online</a>. Last accessed October 8, 2018.</li><li id="section_2.3">Johnson A, Shekhdar J: Breast cancer incidence: what do the figures mean? J Eval Clin Pract 11 (1): 27-31, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15660534&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15660534&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.4">Haas JS, Kaplan CP, Gerstenberger EP, et al.: Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 140 (3): 184-8, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14757616&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14757616&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.5">Barton MB, Elmore JG, Fletcher SW: Breast symptoms among women enrolled in a health maintenance organization: frequency, evaluation, and outcome. Ann Intern Med 130 (8): 651-7, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10215561&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10215561&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.6">Allegra CJ, Aberle DR, Ganschow P, et al.: National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009. J Natl Cancer Inst 102 (3): 161-9, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20071686&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20071686&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.7">Virnig BA, Tuttle TM, Shamliyan T, et al.: Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 102 (3): 170-8, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20071685&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20071685&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.8">Miller AB, To T, Baines CJ, et al.: Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years. J Natl Cancer Inst 92 (18): 1490-9, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10995804&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10995804&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.9">Fisher B, Dignam J, Wolmark N, et al.: Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16 (2): 441-52, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9469327&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9469327&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.10">Ernster VL, Barclay J, Kerlikowske K, et al.: Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 160 (7): 953-8, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10761960&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10761960&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.11">Welch HG, Prorok PC, O'Malley AJ, et al.: Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. N Engl J Med 375 (15): 1438-1447, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27732805&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27732805&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.12">Weaver DL, Rosenberg RD, Barlow WE, et al.: Pathologic findings from the Breast Cancer Surveillance Consortium: population-based outcomes in women undergoing biopsy after screening mammography. Cancer 106 (4): 732-42, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16411214&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16411214&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.13">Rubin E, Visscher DW, Alexander RW, et al.: Proliferative disease and atypia in biopsies performed for nonpalpable lesions detected mammographically. Cancer 61 (10): 2077-82, 1988.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3359405&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3359405&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.14">Elmore JG, Longton GM, Carney PA, et al.: Diagnostic concordance among pathologists interpreting breast biopsy specimens. JAMA 313 (11): 1122-32, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25781441&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25781441&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.15">Bleyer A, Welch HG: Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 367 (21): 1998-2005, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23171096&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23171096&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.16">Hall FM: Identification, biopsy, and treatment of poorly understood premalignant, in situ, and indolent low-grade cancers: are we becoming victims of our own success? Radiology 254 (3): 655-9, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20177083&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20177083&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.17">Elmore JG, Nelson HD, Pepe MS, et al.: Variability in Pathologists' Interpretations of Individual Breast Biopsy Slides: A Population Perspective. Ann Intern Med 164 (10): 649-55, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26999810&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26999810&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.18">Rosai J: Borderline epithelial lesions of the breast. Am J Surg Pathol 15 (3): 209-21, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1847606&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1847606&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.19">Schnitt SJ, Connolly JL, Tavassoli FA, et al.: Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am J Surg Pathol 16 (12): 1133-43, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1463092&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1463092&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.20">Wells WA, Carney PA, Eliassen MS, et al.: Statewide study of diagnostic agreement in breast pathology. J Natl Cancer Inst 90 (2): 142-5, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9450574&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9450574&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.21">Della Mea V, Puglisi F, Bonzanini M, et al.: Fine-needle aspiration cytology of the breast: a preliminary report on telepathology through Internet multimedia electronic mail. Mod Pathol 10 (6): 636-41, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9195583&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9195583&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.22">Geller BM, Nelson HD, Carney PA, et al.: Second opinion in breast pathology: policy, practice and perception. J Clin Pathol 67 (11): 955-60, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25053542&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25053542&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.23">Elmore JG, Tosteson AN, Pepe MS, et al.: Evaluation of 12 strategies for obtaining second opinions to improve interpretation of breast histopathology: simulation study. BMJ 353: i3069, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27334105&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27334105&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.24">Mariscotti G, Belli P, Bernardi D, et al.: Mammography and MRI for screening women who underwent chest radiation therapy (lymphoma survivors): recommendations for surveillance from the Italian College of Breast Radiologists by SIRM. Radiol Med 121 (11): 834-837, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27406629&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27406629&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.25">Allen SD, Wallis MG, Cooke R, et al.: Radiologic features of breast cancer after mantle radiation therapy for Hodgkin disease: a study of 230 cases. Radiology 272 (1): 73-8, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24666474&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24666474&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.26">Walter LC, Lindquist K, Covinsky KE: Relationship between health status and use of screening mammography and Papanicolaou smears among women older than 70 years of age. Ann Intern Med 140 (9): 681-8, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15126251&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15126251&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.27">Sima CS, Panageas KS, Schrag D: Cancer screening among patients with advanced cancer. JAMA 304 (14): 1584-91, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20940384&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20940384&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.28">Smith-Bindman R, Kerlikowske K, Gebretsadik T, et al.: Is screening mammography effective in elderly women? Am J Med 108 (2): 112-9, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11126304&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11126304&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.29">Fentiman IS, Fourquet A, Hortobagyi GN: Male breast cancer. Lancet 367 (9510): 595-604, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16488803&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16488803&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _51
      field_pdq_section_title:
        - format: plain_text
          value: 'Mammography'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_51" class="pdq-sections"><section id="_89"><h3 id="_89_toc">Description and Background</h3><p id="_90" tabindex="-1">Mammography utilizes ionizing radiation to image breast tissue. The examination is performed by compressing the breast firmly between two plates, which spreads out overlapping tissues and reduces the amount of radiation needed for the image. For routine screening in the United States, examinations are taken in both mediolateral oblique and craniocaudal projections.[<a href="#cit/section_3.1">1</a>] Both views will include breast tissue from the nipple to the pectoral muscle. Radiation exposure is 4 to 24 mSv per standard two-view screening examination. Two-view examinations have a lower recall rate than single-view examinations because they reduce concern about abnormalities caused by superimposition of normal breast structures.[<a href="#cit/section_3.2">2</a>] Two-view exams have lower interval cancer rates than single-view exams.[<a href="#cit/section_3.3">3</a>]</p><p id="_91" tabindex="-1">Under the Mammography Quality Standards Act (MQSA) enacted by Congress in 1992, all U.S. facilities that perform mammography must be certified by the U.S. Food and Drug Administration (FDA) to ensure the use of standardized  training for personnel and a standardized mammography technique utilizing a low radiation dose.[<a href="#cit/section_3.4">4</a>] (Refer to the FDA's web page on <a href="https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm094405.htm" title="https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm094405.htm">Mammography Facility Surveys, Mammography Equipment Evaluations, and Medical Physicist Qualification Requirement under MQSA</a>.) The 1998 MQSA Reauthorization Act requires that patients receive a written lay-language summary of mammography results.</p><p id="_92" tabindex="-1">The following Breast Imaging Reporting and Data System (BI-RADS) categories are used for reporting mammographic results:[<a href="#cit/section_3.5">5</a>]</p><div class="pdq-content-list"><ul id="_471" class="pdq-address-block"><li>0: Incomplete&#x2014;needs additional image evaluation and/or prior mammograms for comparison.</li><li>1: Negative; the risk of cancer diagnosis within 1 year is 1%.</li><li>2: Benign; the risk of cancer diagnosis within 1 year is 1%.</li><li>3: Probably benign; the risk of cancer diagnosis within 1 year is 2%.</li><li>4: Suspicious; the risk of cancer diagnosis within 1 year is 2%&#x2013;95%.<div class="pdq-content-list"><ul id="_658" class="pdq-address-block"><li>4a: 2%&#x2013;10%.</li><li>4b: 10%&#x2013;50%.</li><li>4c: 50%&#x2013;95%.</li></ul></div></li><li>5: Highly suggestive of malignancy; the risk of cancer diagnosis within 1 year is 95%.</li><li>6: Known biopsy&#x2014;proven malignancy.</li></ul></div><p id="_209" tabindex="-1">Most screening mammograms are interpreted as negative or benign (BI-RADS 1 or 2, respectively); about 10% of women in the United States are asked to return for additional evaluation.[<a href="#cit/section_3.6">6</a>]  The percentage of women asked to return for additional evaluation varies not only by the inherent characteristics of each woman but also by the mammography facility and radiologist.[<a href="#cit/section_3.7">7</a>]</p></section><section id="_524"><h3 id="_524_toc">Digital Mammography and Computer-Aided Detection</h3><p id="_525" tabindex="-1">Digital mammography is more expensive than screen-film mammography (SFM) but is more amenable to data storage and sharing. Performance of both SFM and digital mammography for cancer detection rate, sensitivity, specificity, and positive predictive value (PPV)  has been compared directly in several trials, with  similar results in most patient groups.</p><p id="_526" tabindex="-1">The Digital Mammographic Imaging Screening Trial (DMIST) compared the findings of digital and film mammograms in 42,760 women at 33 U.S. centers.  Although digital mammography detected more cancers in women younger than 50 years (area under the curve [AUC] of 0.84 +/- 0.03 for digital; AUC of 0.69 +/- 0.05 for film; <em>P</em> = .002), there was no difference in breast cancer detection overall.[<a href="#cit/section_3.8">8</a>]  A second DMIST report found a trend toward higher AUC for film mammography than for digital mammography in women aged 65 years and older.[<a href="#cit/section_3.9">9</a>]</p><p id="_528" tabindex="-1">Another large U.S. cohort study [<a href="#cit/section_3.10">10</a>]  also found slightly better sensitivity for film mammography for women younger than 50 years with similar specificity. </p><p id="_654" tabindex="-1">A Dutch study compared the findings of 1.5 million digital versus 4.5 million screen-film screening mammograms performed between 2004 and 2010. A higher recall and cancer detection rate was observed for the digital screens.[<a href="#cit/section_3.11">11</a>] A meta-analysis [<a href="#cit/section_3.12">12</a>] of 10 studies, including the DMIST  [<a href="#cit/section_3.8">8</a>,<a href="#cit/section_3.9">9</a>] and the U.S. cohort study,[<a href="#cit/section_3.10">10</a>] compared digital mammography and film mammography in 82,573 women who underwent both types of the exam.  In a random-effects model, there was no statistically significant difference in cancer detection between the two types of mammography (AUC of 0.92 for film and AUC of 0.91 for digital).  For women younger than 50 years, all studies found that sensitivity was higher for digital mammography, but specificity was either the same or higher for film mammography.</p><p id="_655" tabindex="-1">Computer-aided detection (CAD) systems highlight suspicious regions, such as clustered microcalcifications and masses,[<a href="#cit/section_3.13">13</a>] generally increasing sensitivity, decreasing specificity,[<a href="#cit/section_3.14">14</a>] and increasing detection of ductal carcinoma <em>in situ</em> (DCIS).[<a href="#cit/section_3.15">15</a>] Several CAD systems are in use. One large population-based study that compared recall rates and breast cancer detection rates before and after the introduction of CAD systems, found no change in either rate.[<a href="#cit/section_3.13">13</a>,<a href="#cit/section_3.16">16</a>] Another large study noted an increase in recall rate and increased DCIS detection but no improvement in invasive cancer detection rate.[<a href="#cit/section_3.15">15</a>,<a href="#cit/section_3.17">17</a>] Another study, using a large database and digital mammography in women aged 40 to 89 years, found  that CAD did not improve sensitivity, specificity, or detection of interval cancers, but it did detect more DCIS.[<a href="#cit/section_3.18">18</a>]</p><p id="_656" tabindex="-1">The use of new screening mammography modalities by more than 270,000 women aged 65 years and older in two time periods, 2001 to 2002 and 2008 to 2009, was examined, relying on a Surveillance, Epidemiology, and End Results (SEER)&#x2013;Medicare-linked database.  Digital mammography increased from 2% to 30%, CAD increased from 3% to 33%, and spending increased from $660 million to $962 million. CAD was used in 74% of screening mammograms paid for by Medicare in 2008, almost twice as many screening mammograms as in 2004. There was no difference in detection rates of early-stage (DCIS or stage I) or late-stage (stage IV) tumors.[<a href="#cit/section_3.19">19</a>]</p></section><section id="_535"><h3 id="_535_toc">Tomosynthesis</h3><p id="_537" tabindex="-1">Tomosynthesis, or 3-dimensional (3-D) mammography, like standard 2-D mammography, compresses the breast and uses x-rays to create the image. Multiple short-exposure x-rays are obtained at different angles.  Some cancers are better seen with this method than on mammography or ultrasound. The radiation dose is double that of 2-D mammography.</p><p id="_657" tabindex="-1">Tomosynthesis has been evaluated only in limited studies, and some professional groups  consider it investigational. It is not universally reimbursed.</p></section><section id="_72"><h3 id="_72_toc">Characteristics of Cancers Detected by Breast Imaging </h3><p id="_112" tabindex="-1">Regardless of stage, nodal status, and tumor size, screen-detected cancers have a better prognosis than those diagnosed outside of screening.[<a href="#cit/section_3.2">2</a>] This suggests that they are biologically less lethal (perhaps slower growing and less likely to invade locally and metastasize), and are useful for predicting prognosis and for treatment planning.</p><p id="_114" tabindex="-1">A 10-year follow-up study of 1,983 Finnish women with invasive breast cancer demonstrated that the method of cancer detection is an independent prognostic variable. When controlled for age, nodal status, and tumor size, screen-detected cancers had a lower risk of relapse and better overall survival. For women whose cancers were detected outside of screening, the hazard ratio (HR) for death was 1.90 (95% confidence interval [CI], 1.15&#x2013;3.11), even though they were more likely to receive adjuvant systemic therapy.[<a href="#cit/section_3.20">20</a>]</p><p id="_115" tabindex="-1">Similarly, an examination of the breast cancers found in three randomized screening trials (Health Insurance Plan, National Breast Screening Study [NBSS]-1, and NBSS-2) accounted for stage, nodal status, and tumor size and determined that patients whose cancer was found via screening had a more favorable prognosis. The relative risks (RR) for death were 1.53 (95% CI, 1.17&#x2013;2.00) for interval and incident cancers, compared with screen-detected cancers; and 1.36 (95% CI, 1.10&#x2013;1.68) for cancers in the control group, compared with screen-detected cancers.[<a href="#cit/section_3.21">21</a>]</p><p id="_116" tabindex="-1">A third study compared the outcomes of 5,604 English women with screen-detected cancers to those with symptomatic breast cancers diagnosed between 1998 and 2003. After controlling for tumor size, nodal status, grade, and patient age, researchers found that the women with screen-detected cancers fared better. The HR for survival of the symptomatic women was 0.79 (95% CI, 0.63&#x2013;0.99).[<a href="#cit/section_3.20">20</a>,<a href="#cit/section_3.22">22</a>]</p><p id="_707" tabindex="-1">The findings of these studies are also consistent with the evidence that some screen-detected cancers are low risk and represent overdiagnosis.</p><section id="_49"><h4 id="_49_toc">Screening biases&#x2013;concepts</h4><p id="_77" tabindex="-1">Numerous uncontrolled trials and retrospective series have documented the ability of mammography to diagnose small, early-stage breast cancers, which have a favorable clinical course.[<a href="#cit/section_3.23">23</a>]  Individuals whose cancer is detected by screening show a higher survival rate than those whose cancers are not detected by screening even when screening has not prolonged any lives. This concept is explained by the following four types of statistical bias:</p><div class="pdq-content-list"><ol id="_78"><li>Lead-time bias: Cancer detected by screening earlier than the cancer would have been detected based on symptoms does nothing but advance the date of diagnosis. Earlier detection and treatment does not alter the natural disease progression. The 5-year survival rate from the time of diagnosis is longer for a cancer caught early even when the screening has made no difference in how long the person lives.</li><li>Length bias: Screening mammography detects slowly growing cancers that have a better prognosis than cancers presenting clinically (detected by the doctor or the person when he or she gets ill). Adding these nonprogressive cancers to the life-threatening cancers (whose outcome is not affected by earlier treatment) increases the 5-year survival rate, even though screening has made no difference in how many lives are saved. </li><li>Overdiagnosis bias: Screening detects cancers that would never cause symptoms or death and will increase survival rates without changing length of life.</li><li>Healthy volunteer bias: Those who volunteer to participate in screening may be the healthiest, and the most health-conscious women in the general population. Therefore, their outcomes will be better than those of women who are neither healthy nor health-conscious, regardless of possible benefits of early diagnosis.</li></ol></div><p id="_79" tabindex="-1">The impact of these biases is not known. A new randomized controlled trial (RCT) with cause-specific mortality as the endpoint is needed to determine both survival benefit and impact of overdiagnosis, lead time, length time, and healthy volunteer biases. This is not achievable; randomizing patients to screen and nonscreen groups would be unethical, and at least three decades of follow-up would be needed, during which time changes in treatment and imaging technology would invalidate the results.  Decisions must therefore be based on available RCTs, despite their limitations, and on ecologic or cohort studies with adequate control groups and adjustment for confounding. (Refer to the PDQ summary on <a href="/about-cancer/screening/hp-screening-overview-pdq">Cancer Screening Overview</a> for more information.)</p></section><section id="_80"><h4 id="_80_toc">Assessment of performance and accuracy</h4><p id="_216" tabindex="-1">Performance benchmarks for screening mammography in the United States are described on the <a href="http://www.bcsc-research.org/statistics/benchmarks/screening/2009/table7.html" title="http://www.bcsc-research.org/statistics/benchmarks/screening/2009/table7.html">Breast Cancer Surveillance Consortium (BCSC) website</a>. (Refer to the PDQ summary on <a href="/about-cancer/screening/hp-screening-overview-pdq">Cancer Screening Overview</a> for more information.) </p></section><section id="_81"><h4 id="_81_toc">Sensitivity</h4><p id="_82" tabindex="-1">The sensitivity of mammography is the percentage of  women with breast cancers detected by mammographic screening. Sensitivity depends on tumor size, conspicuity, hormone sensitivity, breast tissue density, patient age, timing within the menstrual cycle, overall image quality, and interpretive skill of the radiologist. Overall sensitivity is approximately 79% but is lower in younger women and in those with dense breast tissue (see the <a href="https://breastscreening.cancer.gov/" title="https://breastscreening.cancer.gov/">BCSC website</a>).[<a href="#cit/section_3.24">24</a>-<a href="#cit/section_3.26">26</a>] Sensitivity is not the same as benefit because some woman with possible breast cancer are harmed by overdiagnosis. According to the Physician's Insurance Association of America (PIAA), delay in diagnosis of breast cancer and errors in diagnosis are common causes of medical malpractice litigation. PIAA data from 2002 through 2011 note that the largest total indemnity payments for breast cancer claims are for errors in diagnosis, with an average indemnity payment of $444,557.[<a href="#cit/section_3.27">27</a>]</p></section><section id="_83"><h4 id="_83_toc">Specificity and false-positive rate</h4><p id="_84" tabindex="-1">The specificity of mammography is the percentage of all women without breast cancer whose mammograms are negative.  The false-positive rate is the likelihood of a positive test in women without breast cancer. Low specificity and high rate of false positives result in unnecessary follow-up examinations and procedures. Because specificity includes all women without cancer in the denominator, even a small percentage of false positives turns out to be a large number in absolute terms. Thus&#x2014;in screening&#x2014;a <em>good</em> specificity must be very high. Even 95% specificity is quite low for a screening test.</p></section><section id="_85"><h4 id="_85_toc">Interval cancers</h4><p id="_86" tabindex="-1">Interval cancers are cancers that are diagnosed in the interval between a normal screening examination and the anticipated date of the next screening mammogram. One study found interval cancers occurred more often in women younger than 50 years, and had mucinous or lobular histology, high histologic grade, high proliferative activity with relatively benign mammographic features, and no calcifications.  Conversely, screen-detected cancers often had tubular histology, small size, low stage, hormone sensitivity, and a major component of DCIS.[<a href="#cit/section_3.28">28</a>]  Overall, interval cancers have characteristics of rapid growth,[<a href="#cit/section_3.28">28</a>,<a href="#cit/section_3.29">29</a>] are  diagnosed at an advanced stage, and carry a poor prognosis.[<a href="#cit/section_3.30">30</a>]</p><p id="_603" tabindex="-1">A Nova Scotia Breast Screening Program defined missed cancers as those that were false negatives on the previous screening exam, occurring less often than 1 per 1,000 women. It concluded that interval cancers occurred in approximately 1 per 1,000 women aged 40 to 49 years, and 3 per 1,000 women aged 50 to 59 years.[<a href="#cit/section_3.31">31</a>]</p><p id="_87" tabindex="-1">Conversely, a larger trial found that interval cancers were more prevalent in  women aged 40 to 49 years.  Those appearing within 12 months of a negative screening mammogram were usually attributable to greater breast density.  Those appearing within a 24-month interval were related to decreased mammographic sensitivity caused by greater breast density or to rapid tumor growth.[<a href="#cit/section_3.32">32</a>]</p></section></section><section id="_119"><h3 id="_119_toc">Variables Associated with Accuracy</h3><section id="_163"><h4 id="_163_toc">Patient characteristics</h4><p id="_164" tabindex="-1">The accuracy of mammography  depends on a woman's age, breast density, whether it is her first or subsequent exam, and the time since her last mammogram.  Younger women have lower sensitivity and higher false-positive rates than do older women.</p><p id="_165" tabindex="-1">For women of all ages, high breast density is associated with 10% to 29% lower sensitivity.[<a href="#cit/section_3.25">25</a>] High breast density is an inherent trait, which can be familial [<a href="#cit/section_3.33">33</a>,<a href="#cit/section_3.34">34</a>] and can also be affected by age, endogenous [<a href="#cit/section_3.35">35</a>] and exogenous [<a href="#cit/section_3.36">36</a>,<a href="#cit/section_3.37">37</a>] hormones,[<a href="#cit/section_3.38">38</a>] selective estrogen receptor modulators, such as tamoxifen,[<a href="#cit/section_3.39">39</a>] and diet.[<a href="#cit/section_3.40">40</a>] Hormone therapy is associated with increased breast density with lower sensitivity but also with an increased rate of interval cancers.[<a href="#cit/section_3.41">41</a>]</p><p id="_166" tabindex="-1">The Million Women Study in the United Kingdom revealed three patient characteristics that were associated with decreased sensitivity and specificity in women aged 50 to 64 years: use of postmenopausal hormone therapy, prior breast surgery, and body mass index below 25.[<a href="#cit/section_3.42">42</a>] In addition, a longer interval since the last mammogram increases sensitivity, recall rate, and cancer-detection rate and decreases specificity.[<a href="#cit/section_3.43">43</a>]</p><p id="_167" tabindex="-1">Strategies have been proposed to improve sensitivity by altering diet, timing mammograms with menstrual cycles, interrupting hormone therapy before the examination, or using digital mammography machines.[<a href="#cit/section_3.8">8</a>] Obese women have more than a 20% increased risk of having false-positive mammography, although sensitivity is unchanged.[<a href="#cit/section_3.44">44</a>]</p></section><section id="_210"><h4 id="_210_toc">Tumor characteristics</h4><p id="_211" tabindex="-1">Mucinous and lobular cancers are more easily detected by mammography. Rapidly growing cancers can be mistaken for normal breast tissue, medullary carcinomas;[<a href="#cit/section_3.28">28</a>,<a href="#cit/section_3.45">45</a>]  some cancers associated with <em>BRCA1/2</em> mutations, which may appear indolent, can be missed.[<a href="#cit/section_3.46">46</a>,<a href="#cit/section_3.47">47</a>]</p></section><section id="_168"><h4 id="_168_toc">Physician characteristics</h4><p id="_169" tabindex="-1"> Radiologists&#x2019; performance is variable, affected by levels of experience and the volume of mammograms they interpret.[<a href="#cit/section_3.48">48</a>]  Biopsy recommendations of radiologists in academic settings have a higher positive PPV than do community radiologists.[<a href="#cit/section_3.49">49</a>] Fellowship training in breast imaging may improve detection.[<a href="#cit/section_3.8">8</a>]</p><p id="_659" tabindex="-1">Performance also varies by facility. Mammographic screening accuracy was higher at facilities offering only screening examinations than at those also performing diagnostic tests. Accuracy was also better at facilities with a breast imaging specialist on staff,  performing single rather than double readings, and reviewing performance audits two or more times each year.[<a href="#cit/section_3.50">50</a>]</p><p id="_660" tabindex="-1">False-positive rates are higher at facilities where concern about malpractice is high  and at facilities serving vulnerable women (racial or ethnic minorities and women with less education, limited household income, or rural residence).[<a href="#cit/section_3.51">51</a>] These populations may have a higher cancer prevalence and a lack of follow-up.[<a href="#cit/section_3.52">52</a>] </p></section><section id="_173"><h4 id="_173_toc">International comparisons</h4><p id="_174" tabindex="-1">International comparisons of screening mammography have found higher specificity in countries with more highly centralized screening systems and national quality assurance programs.[<a href="#cit/section_3.53">53</a>,<a href="#cit/section_3.54">54</a>]</p><p id="_697" tabindex="-1"> The recall rate in the United States is twice that of the United Kingdom, with no difference in the rate of cancer detection.[<a href="#cit/section_3.53">53</a>]</p></section><section id="_175"><h4 id="_175_toc">Prevalent versus subsequent  examination and the interval between exams</h4><p id="_176" tabindex="-1">The likelihood of diagnosing cancer is highest with the prevalent (first) screening examination, ranging from 9 to 26 cancers per 1,000 screens, depending on the woman&#x2019;s age. The likelihood decreases for follow-up examinations, ranging from 1 to 3 cancers per 1,000 screens.[<a href="#cit/section_3.55">55</a>]</p><p id="_694" tabindex="-1"> The optimal interval between screening mammograms is unknown; there is little variability across the trials despite differences in protocols and screening intervals. A prospective U.K. trial randomly assigned women aged 50 to 62 years to receive mammograms annually or triennially. Although tumor grade and nodal status were similar in the two groups, more cancers of slightly smaller size were detected in the annual screening group than in the triennial screening group.[<a href="#cit/section_3.56">56</a>]</p><p id="_177" tabindex="-1">A large observational study found a slightly increased risk of late-stage disease at diagnosis for women in their 40s who were adhering to a 2-year versus a 1-year schedule (28% vs. 21%; odds ratio [OR], 1.35; 95% CI, 1.01&#x2013;1.81), but no difference was seen for women in their 50s or 60s based on schedule difference.[<a href="#cit/section_3.57">57</a>,<a href="#cit/section_3.58">58</a>]</p><p id="_215" tabindex="-1">A Finnish study of 14,765 women aged 40 to 49 years  randomly assigned women to receive either annual screens  or triennial screens. There were 18 deaths from breast cancer in 100,738 life-years in the triennial screening group and 18 deaths from breast cancer in 88,780 life-years in the annual screening group (HR, 0.88; 95% CI, 0.59&#x2013;1.27).[<a href="#cit/section_3.59">59</a>]</p></section></section><section id="_93"><h3 id="_93_toc">Benefit of Mammographic Screening on Breast Cancer Mortality</h3><section id="_94"><h4 id="_94_toc">Randomized controlled trials (RCTs)</h4><p id="_95" tabindex="-1">RCTs that studied the effect of screening mammography on breast cancer mortality were performed between 1963 and 2015, with participation by over half-a-million women in four countries. One trial, the Canadian NBSS-2, compared mammography plus clinical breast examination (CBE) to CBE alone; the other trials compared screening mammography with or without CBE to  usual care. Refer to the <a href="/types/breast/hp/breast-screening-pdq#link/_377">Appendix of Randomized Controlled Trials</a> section of this summary for a detailed description of the trials.</p><p id="_219" tabindex="-1">The trials differed in design, recruitment of participants, interventions (both screening and treatment), management of the control group, compliance with assignment to screening and control groups, and analysis of outcomes. Some trials used individual randomization, while others used cluster randomization in which cohorts were identified and then offered screening; one trial used nonrandomized allocation by day of birth in any given month. Cluster randomization sometimes led to imbalances between the intervention and control groups. Age differences have been identified in several trials, although the differences had no major effect on the trial outcome.[<a href="#cit/section_3.60">60</a>] In the Edinburgh Trial, socioeconomic status, which correlates with the risk of breast cancer mortality, differed markedly between the intervention and control groups, rendering the results uninterpretable.</p><p id="_96" tabindex="-1">Breast cancer mortality was the major outcome parameter for each of these trials, so the attribution of cause of death required scrupulous attention. The use of a blinded monitoring committee (New York) and a linkage to independent data sources, such as national mortality registries (Swedish trials), were incorporated but could not ensure impartial attributions of cancer death for women in the screening or control arms. Possible misclassification of breast cancer deaths in the Two-County Trial biasing the results in favor of screening has been suggested.[<a href="#cit/section_3.61">61</a>]</p><p id="_97" tabindex="-1">There were also differences in the methodology used to analyze the results of these trials. Four of the five Swedish trials were designed to include a single screening mammogram in the control group and were timed to correspond with the end of the series of screening mammograms in the study group. The initial analysis of these trials used an <em>evaluation</em> analysis, tallying only the breast cancer deaths that occurred in women whose cancer was discovered at or before the last study mammogram. In some of the trials, a delay occurred in the performance of the end-of-study mammogram, resulting in more time for members of the control group to develop or be diagnosed with breast cancer. Other trials used a <em>follow-up</em> analysis, which counts all deaths attributed to breast cancer, regardless of the time of diagnosis. This type of analysis was used in a meta-analysis of four of the five Swedish trials as a response to concerns about the <em>evaluation</em> analyses.[<a href="#cit/section_3.61">61</a>]</p><p id="_98" tabindex="-1">The accessibility of the data for international audits and verification also varied, with a formal audit having been undertaken only in the Canadian trials. Other trials have been audited to varying degrees, but with less rigor.[<a href="#cit/section_3.62">62</a>]</p><p id="_99" tabindex="-1">All of these studies were  designed to study breast cancer mortality rather than all-cause mortality because breast cancer deaths contribute only a small proportion of total mortality in any given population. When all-cause mortality in these trials was examined retrospectively, only the Edinburgh Trial showed a difference attributable to the previously noted socioeconomic differences in the study groups. The meta-analysis (follow-up methods) of the four Swedish trials also showed a small improvement in all-cause mortality.</p><p id="_103" tabindex="-1">The relative improvement in breast cancer mortality attributable to screening is approximately 15% to 20%, and the absolute improvement at the individual level is much less.  The potential benefit of breast cancer screening can be expressed as the number of lives extended because of early breast cancer detection.[<a href="#cit/section_3.63">63</a>,<a href="#cit/section_3.64">64</a>]</p><p id="_104" tabindex="-1">The RCT results represent experiences in a defined period of regular examinations, but in practice, women undergo 20 to 30 years of screening throughout their lifetimes.[<a href="#cit/section_3.58">58</a>,<a href="#cit/section_3.65">65</a>]</p><p id="_557" tabindex="-1">There are several problems with using these RCTs that were performed up to 50 years ago to estimate the current benefits of screening on breast cancer mortality. These problems include the following:</p><div class="pdq-content-list"><ol id="_558"><li>Improvements in mammography technology, with the ability to identify increasingly subtle abnormalities.</li><li>Enhanced breast cancer awareness in the general population, with women seeking evaluation and treatment earlier.</li><li>Changes in the risk factors for breast cancer in the population (including age at menarche, age at first pregnancy, obesity, and use of postmenopausal hormone treatment). </li><li>Improvements in breast cancer treatment, such that larger, more advanced cancers have higher cure rates than in the past.</li><li>Applying results of short-term RCTs (e.g., 5 to 10 years) to make estimates of lifetime effects of breast cancer screening.</li></ol></div><p id="_559" tabindex="-1">For these reasons, estimates of the breast cancer mortality reduction resulting from current screening are based on well-conducted cohort and ecologic studies in addition to the RCTs. </p></section><section id="_105"><h4 id="_105_toc">Effectiveness of population-based screening programs </h4><p id="_106" tabindex="-1">An estimate of screening effectiveness can be obtained from nonrandomized controlled studies of screened versus nonscreened populations, case-control studies of screening in real communities, and modeling studies that examine the impact of screening on large populations.   These studies must be designed to minimize or exclude the effects of unrelated trends influencing breast cancer mortality such as improved treatment and heightened awareness of breast cancer in the community.</p><p id="_107" tabindex="-1">Three population-based, observational studies from Sweden compared breast cancer mortality in the presence and absence of screening mammography programs. One study compared two adjacent time periods in 7 of the 25 counties in Sweden and found a statistically significant breast cancer mortality reduction of 18% to 32% attributable to screening.[<a href="#cit/section_3.66">66</a>] The most important bias in this study is that the advent of screening in these counties occurred over a period during which dramatic improvements in the effectiveness of adjuvant breast cancer therapy were being made, changes that were not addressed by the study authors. The second study considered an 11-year period comparing seven counties with screening programs with five counties without them.[<a href="#cit/section_3.67">67</a>] There was a trend in favor of screening, but again, the authors did not consider the effect of adjuvant therapy or differences in geography (urban vs. rural) that might affect treatment practices.</p><p id="_394" tabindex="-1">The third study attempted to account for the effects of treatment by using a detailed analysis by county. It found screening had little impact, a conclusion weakened by several flaws in design and analysis.[<a href="#cit/section_3.68">68</a>]</p><p id="_108" tabindex="-1">In Nijmegen, the Netherlands, where a population-based screening program was undertaken in 1975, a case-cohort study found that screened women had decreased mortality compared with unscreened women (OR, 0.48).[<a href="#cit/section_3.69">69</a>]  However, a subsequent study comparing Nijmegen breast cancer mortality rates with neighboring Arnhem in the Netherlands, which had no screening program, showed no difference in breast cancer mortality.[<a href="#cit/section_3.70">70</a>]</p><p id="_109" tabindex="-1">A community-based case-control study of screening in high-quality U.S. health care systems between 1983 and 1998 found no association between previous screening and reduced breast cancer mortality, but the mammography screening rates were generally low.[<a href="#cit/section_3.71">71</a>]</p><p id="_212" tabindex="-1">A well-conducted ecologic study compared three pairs of neighboring European countries that were matched on similarity in health care systems and population structure, one of which had started a national screening program some years earlier than the others.  The investigators found that each country had experienced a reduction in breast cancer mortality, with no difference between matched pairs that could be attributed to screening.  The authors suggested that improvements in breast cancer treatment and/or health care organizations were more likely responsible for the reduction in mortality than was screening.[<a href="#cit/section_3.72">72</a>]</p><p id="_213" tabindex="-1">A systematic review of ecologic and large cohort studies published  through March 2011 compared breast cancer mortality in large populations of women, aged 50 to 69 years, who started breast cancer screening at different times.  Seventeen studies met inclusion criteria, but all studies had methodological problems, including control group dissimilarities, insufficient adjustment for differences between areas in breast cancer risk and breast cancer treatment, and problems with similarity of measurement of breast cancer mortality between compared areas.  There was great variation in results among the studies, with four studies finding a relative reduction in breast cancer mortality of 33% or more (with wide CIs) and five studies finding no reduction in breast cancer mortality.   Because only a part of the overall reduction in breast cancer mortality could possibly be attributed to screening, the review concluded that any relative reduction in breast cancer mortality resulting from screening would likely be no more than 10%.[<a href="#cit/section_3.73">73</a>]</p><p id="_396" tabindex="-1">A U.S. ecologic analysis conducted between 1976 and 2008 examined the incidence of early-stage versus late-stage breast cancer for women aged 40 years and older.  To assess a screening effect, the authors compared the magnitude of increase in early-stage cancer with the magnitude of an expected decrease in late-stage cancer.  Over the study, the absolute increase in the incidence of early-stage cancer was 122 cancers per 100,000 women, while the absolute decrease in late-stage cancers was 8 cases per 100,000 women.  After adjusting for changes in incidence resulting from hormone therapy and other undefined causes, the authors concluded (1) the benefit of screening  on breast cancer mortality  was small, (2) between 22% and 31% of diagnosed breast cancers represented overdiagnosis, and (3) the observed improvement in breast cancer mortality was probably attributable to improved treatment rather than screening.[<a href="#cit/section_3.74">74</a>] </p><p id="_622" tabindex="-1">An analytic approach was used to approximate the contributions of screening versus treatment to breast cancer mortality reduction and the magnitude of overdiagnosis.[<a href="#cit/section_3.75">75</a>]  The shift in the size distribution of breast cancers in the United States  (before the introduction of mammography) to 2012  (after its widespread dissemination), was investigated using SEER data in women aged 40 years and older. The rate of clinically meaningful breast cancer was assumed to be stable during this time.  The authors documented a lower incidence of larger (&#x2265;2 cm) tumors as well as a reduction in breast cancer case fatality.  The lower mortality for women with larger tumors was attributed to improvements in therapy.  Two-thirds of the decline in size-specific case fatality was ascribed to improved treatment.</p><figure id="figure_642" class="image-center"><a href="https://www.cancer.gov/images/cdr/live/CDR788362.jpg" target="_blank" class="article-image-enlarge">Enlarge</a><img id="_642" alt="Chart showing the temporal relationship between the introduction of screening mammography and increased incidence of invasive breast cancer." title="Chart showing the temporal relationship between the introduction of screening mammography and increased incidence of invasive breast cancer." src="https://www.cancer.gov/images/cdr/live/CDR788362-750.jpg"><figcaption class="caption-container">Figure 2.  Screening mammography and increased incidence of invasive breast cancer. Shown are the incidences of overall invasive breast cancer and metastatic breast cancer among women 40 years of age or older at nine sites of the Surveillance, Epidemiology, and End Results (SEER) program, during the period from 1975 through 2012. From New England Journal of Medicine, Welch HG, Prorok PC, O'Malley AJ, Kramer BS, Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness, Volume 375, Issue 15, Pages 1438-47, Copyright &#xA9; 2016 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.</figcaption></figure><p id="_452" tabindex="-1">A prospective cohort study of community-based screening programs in the United States found that annual compared with biennial screening mammography did not reduce the proportion of unfavorable breast cancers detected in women aged 50 to 74 years or in women aged 40 to 49 years  without extremely dense breasts.  Women aged 40 to 49 years with extremely dense breasts did have a reduction in cancers larger than 2.0 cm with annual screening (OR, 2.39; 95% CI, 1.37&#x2013;4.18).[<a href="#cit/section_3.76">76</a>]</p><p id="_724" tabindex="-1">An observational study of women aged  40 to 74 years conducted in 7 of 12 Canadian screening programs compared breast cancer mortality in those participants screened at least once between 1990 and 2009 (85% of the population) with those not screened (15% of the population). The abstract reported a 40%  average breast cancer mortality among participants; however, it was likely intended to report a 40% reduction in breast cancer mortality on the basis of language utilized in the Discussion section.[<a href="#cit/section_3.77">77</a>]</p><p id="_725" tabindex="-1">Limitations of this study included the lack of all-cause mortality data, the extent of screening, screening outside of the study, screening prior to the study, the method used for calculating expected mortality and the <em>referent rates</em> of nonparticipants, nonparticipant survival, province-specific population differences,  the extent to which limitations of the database prevented correcting for age and other differences between participants, the generalizability of the substudy data of a single province (British Columbia), and the potentially large impact of selection bias. Overall, the study lacked  important data and had limitations in methodology and data analysis.</p></section><section id="_110"><h4 id="_110_toc">Statistical modeling of breast cancer incidence and mortality in the United States</h4><p id="_214" tabindex="-1">The optimal screening interval has been addressed by modelers. Modeling makes assumptions that may not be correct; however, the credibility of modeling is greater when the model produces overall results that are consistent with randomized trials and when the model is used to interpolate or extrapolate. For example, if a model&#x2019;s output agrees with RCT outcomes for annual screening, it has greater credibility to compare the relative effectiveness of biennial versus annual screening.</p><p id="_220" tabindex="-1">In 2000, the National Cancer Institute formed a consortium of modeling groups (Cancer Intervention and Surveillance Modeling Network [CISNET]) to address the relative contribution of screening and adjuvant therapy to the observed decline in breast cancer mortality in the United States.[<a href="#cit/section_3.78">78</a>] These models predicted reductions in breast cancer mortality similar to those expected in the circumstances of the RCTs but updated to the use of modern adjuvant therapy. In 2009, CISNET modelers addressed several questions related to the harms and benefits of mammography, including comparing annual versus biennial screening.[<a href="#cit/section_3.58">58</a>] Women aged 50 to 74 years received most of the mortality benefit of annual screening by having a mammogram every 2 years. The reduction in breast cancer deaths that was maintained because of the move from annual to biennial screening ranged across the six models from 72% to 95%, with a median of 80%.</p><p id="_719" tabindex="-1">Data are limited as to how much of the reduction in mortality, seen over time from 1990 onward, is attributable to advances in imaging techniques for screening and as to how much is the result of the improved effectiveness of therapy. In one CISNET study of six simulation models, about one-third of the decrease in breast cancer mortality in 2012 was attributable to screening, with the balance attributed to treatment.[<a href="#cit/section_3.79">79</a>]  In this CISNET study, the mean estimated reduction in overall breast cancer mortality rate was 49% (model range, 39%&#x2013;58%), relative to the estimated baseline rate in 2012 if there was no screening or treatment; 37% (model range, 26%&#x2013;51%) of this reduction was associated with screening, and 63% (model range, 49%&#x2013;74%) of this reduction was associated with treatment. </p></section></section><section id="_402"><h3 id="_402_toc">Harms of Mammographic Screening</h3><p id="_403" tabindex="-1">The negative effects of screening mammography are overdiagnosis (true positives that will not become clinically significant), false positives (related to the specificity of the test), false negatives (related to the sensitivity of the test), discomfort associated with the test,  radiation risk, psychological harm, financial stress, and opportunity costs.</p><p id="_480" tabindex="-1"><a href="/types/breast/hp/breast-screening-pdq#link/_483">Table 1</a>  provides an overview of the estimated benefits and harms of screening mammography for 10,000 women who underwent annual screening mammography over a 10-year period.[<a href="#cit/section_3.80">80</a>]</p><table id="_483" class="table-default expandable-container"><caption>Table 1.  Estimated Benefits and Harms of Mammography Screening for 10,000 Women Who Underwent Annual Screening Mammography During a 10-Year Period<span class="sup">a</span></caption><colgroup><col width="14.10%"><col width="18.05%"><col width="16.36%"><col width="15.93%"><col width="16.64%"><col width="18.89%"></colgroup><THead><tr><th>Age, y</th><th>No. of Breast Cancer Deaths Averted With Mammography Screening During the Next 15 y<span class="sup">b</span></th><th>No. (95% CI) With &#x2265;1 False-Positive Result During the 10 y<span class="sup">c</span></th><th>No. (95% CI) With &#x2265;1 False Positive Resulting in a Biopsy During the 10 y<span class="sup">c</span></th><th colspan="2">No. of Breast Cancers or DCIS Diagnosed During the 10 y That Would Never Become Clinically Important (Overdiagnosis)<span class="sup">d</span></th></tr></THead><TFoot class="pdq-footer"><tr><td colspan="6">No. = number; CI = confidence interval; DCIS = ductal carcinoma <em>in situ</em>.</td></tr><tr><td colspan="6"><span class="sup">a</span>Adapted from Pace and Keating.[<a href="#cit/section_3.80">80</a>]</td></tr><tr><td colspan="6"><span class="sup">b</span>Number of deaths averted are from Welch and Passow.[<a href="#cit/section_3.81">81</a>] The lower bound represents breast cancer mortality reduction if the breast cancer mortality relative risk were 0.95 (based on minimal benefit from the Canadian trials [<a href="#cit/section_3.82">82</a>,<a href="#cit/section_3.83">83</a>]), and the upper bound represents the breast cancer mortality reduction if the relative risk were 0.64 (based on the Swedish 2-County Trial [<a href="#cit/section_3.84">84</a>]).</td></tr><tr><td colspan="6"><span class="sup">c</span>False positive and biopsy estimates and 95% confidence intervals are 10-year cumulative risks reported in Hubbard et al. [<a href="#cit/section_3.85">85</a>] and Braithwaite et al.[<a href="#cit/section_3.86">86</a>] </td></tr><tr><td colspan="6"><span class="sup">d</span>The number of overdiagnosed cases are calculated by Welch and Passow.[<a href="#cit/section_3.81">81</a>] The lower bound represents overdiagnosis based on results from the Malm&#xF6; trial,[<a href="#cit/section_3.87">87</a>] whereas the upper bound represents the estimate from Bleyer and Welch.[<a href="#cit/section_3.74">74</a>]</td></tr><tr><td colspan="6"><span class="sup">e</span>The lower-bound estimate for overdiagnosis reported by Welch and Passow [<a href="#cit/section_3.81">81</a>] came from the Malm&#xF6; study.[<a href="#cit/section_3.87">87</a>] The study did not enroll women younger than 50 years.</td></tr></TFoot><tbody><tr><td align="Center" scope="col">40</td><td align="Center" scope="col">1&#x2013;16</td><td align="Center" scope="col">6,130 (5,940&#x2013;6,310)</td><td align="Center" scope="col">700 (610&#x2013;780)</td><td colspan="2" align="Center" scope="col">?&#x2013;104<span class="sup">e</span></td></tr><tr><td align="Center" scope="col">50</td><td align="Center" scope="col">3&#x2013;32</td><td align="Center" scope="col">6,130 (5,800&#x2013;6,470)</td><td align="Center" scope="col">940 (740&#x2013;1,150)</td><td colspan="2" align="Center" scope="col">30&#x2013;137</td></tr><tr><td align="Center" scope="col">60</td><td align="Center" scope="col">5&#x2013;49</td><td align="Center" scope="col">4,970 (4,780&#x2013;5,150)</td><td align="Center" scope="col">980 (840&#x2013;1,130)</td><td colspan="2" align="Center" scope="col">64&#x2013;194</td></tr></tbody></table><section id="_666"><h4 id="_666_toc">Overdiagnosis</h4><p id="_684" tabindex="-1">Overdiagnosis occurs when screening procedures detect cancers that would never become clinically significant. The magnitude of overdiagnosis is debated, particularly regarding DCIS, a cancer precursor whose natural history is unknown. By reason of this inability to predict confidently the tumor behavior at time of diagnosis, standard treatment for invasive cancers and DCIS can cause overtreatment. The related harms include treatment-related side effects and the number of harms associated with a cancer diagnosis, which are immediate. Conversely, a mortality benefit would occur at an uncertain point in the future.</p><p id="_685" tabindex="-1">One approach to understanding overdiagnosis is to examine the prevalence of occult cancer in women who died of noncancer causes. In an overview of seven autopsy studies, the median prevalence of occult invasive breast cancer was 1.3% (range, 0%&#x2013;1.8%) and of DCIS was 8.9% (range, 0%&#x2013;14.7%).[<a href="#cit/section_3.88">88</a>,<a href="#cit/section_3.89">89</a>]</p><p id="_686" tabindex="-1">Overdiagnosis can be indirectly measured by comparing breast cancer incidence in screened versus unscreened populations. These comparisons can be confounded by differences in the populations, such as time, geography, health behaviors, and hormone usage. The calculations of overdiagnosis can vary in their adjustment for lead-time bias.[<a href="#cit/section_3.90">90</a>,<a href="#cit/section_3.91">91</a>] An overview of 29 studies found calculated rates of overdiagnosis to be 0%&#x2013;54%, with rates from randomized studies between 11% and 22%.[<a href="#cit/section_3.92">92</a>] In Denmark, where screened and unscreened populations existed concurrently, the rate of overdiagnosis of invasive cancer was calculated to be 14% and 39%, using two different methodologies. If DCIS cases were included, the overdiagnosis rates were 24% and 48%.  The second methodology accounts for regional differences in women younger than the screening age and is likely more accurate.[<a href="#cit/section_3.93">93</a>]</p><p id="_687" tabindex="-1">Theoretically, in a given population, the detection of more breast cancers at an early stage would result in a subsequent reduction in the incidence of advanced-stage cancers.  This has not occurred in any of the populations studied to date.  Thus, the detection of more early stage cancers likely represents overdiagnosis. A population-based study in the Netherlands showed that about one-half of all screen-detected breast cancers, including DCIS, would represent overdiagnosis and is consistent with other studies, which showed substantial rates of overdiagnosis associated with screening.[<a href="#cit/section_3.94">94</a>]</p><p id="_688" tabindex="-1">A cohort study in Norway compared the increase in cancer incidence in women who were eligible for screening with the cancer incidence in younger women who were not eligible for screening, eligibility was based on age and residence. Eligible women experienced a 60% increase in incidence of localized cancers (RR, 1.60; 95% CI, 1.42&#x2013;1.79), while the incidence of advanced cancers remained similar in the two groups (RR, 1.08; 95% CI, 0.86&#x2013;1.35).[<a href="#cit/section_3.95">95</a>]</p><p id="_689" tabindex="-1">A population study that compared different counties in the United States showed that higher rates of screening mammography use were associated with higher rates of breast cancer diagnoses, yet there was no corresponding decrease in 10-year breast cancer mortality.[<a href="#cit/section_3.96">96</a>] The strengths of this study include its very large size (16 million women) and the strength and consistency of correlation observed across counties. The limitations of this study include the self-reporting of mammograms, the use of a 2-year window to estimate screening prevalence, and the period of analysis (when menopausal hormone use was present).[<a href="#cit/section_3.96">96</a>]</p><p id="_690" tabindex="-1">The extent of overdiagnosis has been estimated in the Canadian NBSS, a randomized clinical trial. At the end of the five screening rounds, 142 more invasive breast cancer cases were diagnosed in the mammography arm, compared with the control arm.[<a href="#cit/section_3.97">97</a>] At 15 years, the excess number of cancer cases in the mammography arm versus the control arm was 106, representing an overdiagnosis rate of 22% for the 484 screen-detected invasive cancers.[<a href="#cit/section_3.97">97</a>]</p><p id="_713" tabindex="-1">As a consequence of screening mammography, greater numbers of breast cancers with indolent behavior are now identified, resulting in potential overtreatment. In a secondary analysis of a randomized trial of tamoxifen versus no systemic therapy in patients with early breast cancer, the authors utilized the 70-gene MammaPrint assay and identified 15% of patients at ultra-low risk, with 20-year disease-specific survival rates of 97% in the tamoxifen group and 94% in the control group. Thus, these patients would likely have extremely good outcomes with surgery alone. The frequency of such ultra-low risk cancers in the screened population is likely around 25%. Tools such as the 70-gene MammaPrint assay might be utilized in the future to identify these cancers, and thereby, reduce the risk of overtreatment. However, additional studies are needed to confirm these findings.[<a href="#cit/section_3.98">98</a>]</p><p id="_691" tabindex="-1"><a href="/types/breast/hp/breast-screening-pdq#link/_483">Table 1</a>, above, shows results from a 10-year period of screening 10,000 women, estimating the number of women with breast cancer or DCIS that would never become clinically important (overdiagnosis). There was likely no overdiagnosis in the Health Insurance Plan study, which used old-technology mammography and CBE. Overdiagnosis has become more prominent in the era of improved-technology mammography. The improved technology has not, however, been shown to make further reductions in mortality than the original technology.[<a href="#cit/section_3.80">80</a>]</p></section><section id="_406"><h4 id="_406_toc">False positives leading to additional interventions</h4><p id="_407" tabindex="-1">Because fewer than 5 per 1,000 women  screened have breast cancer, most abnormal mammograms are false positives, even given the 90% specificity of mammography (i.e., 90% of all women without breast cancer will have a negative mammogram).[<a href="#cit/section_3.55">55</a>]</p><p id="_698" tabindex="-1">This high false positive rate of mammography is underestimated and can seem counterintuitive because of a statistically based cognitive bias known as the base rate fallacy. Because the base rate of breast cancer is low, (5/1000), the false-positive rate vastly exceeds the true-positive rate, even when utilizing a very accurate test.</p><p id="_699" tabindex="-1">Mammography&#x2019;s true-positive rate of approximately 90% means that, of women with breast cancer, approximately 90% will test positive. The true-negative rate of 90% means that, of women without breast cancer, 90% will test negative.  A 10% false-positive rate over 1,000 people means that there will be 100 false positives in 1,000 people. If 5 in 1,000 women have breast cancer, then 4.5 women with breast cancer will have a positive test. In other words, there will approximately 100 false positive for every 4.5 true positives.</p><p id="_700" tabindex="-1">Further, abnormal results from screening mammograms prompt additional tests and procedures, such as mammographic views of the region of concern, ultrasound, magnetic resonance imaging, and  tissue sampling (by fine-needle aspiration, core biopsy, or excisional biopsy). Overall, the harm from unnecessary tests and treatments must be weighed against the benefit of early detection.</p><p id="_408" tabindex="-1">A study of breast cancer screening in 2,400 women enrolled in a health maintenance organization found that over a decade, 88 cancers were diagnosed, 58 of which were identified by mammography. One-third of the women had an abnormal mammogram result that required additional testing: 539 additional mammograms, 186 ultrasound examinations, and 188 biopsies. The cumulative biopsy rate (the rate of true positives) resulting from mammographic findings was approximately 1 in 4 (23.6%). The PPV of an abnormal screening mammogram in this population was 6.3% for women aged 40 to 49 years, 6.6% for women aged 50 to 59 years, and 7.8% for women aged 60 to 69 years.[<a href="#cit/section_3.99">99</a>] A subsequent analysis and modeling of data from the same cohort of women, estimated that the risk of having at least one false-positive mammogram was 7.4% (95% CI, 6.4%&#x2013;8.5%) at the first mammogram, 26.0% (95% CI, 24.0%&#x2013;28.2%) by the fifth mammogram, and 43.1% (95% CI, 36.6%&#x2013;53.6%) by the ninth mammogram.[<a href="#cit/section_3.100">100</a>] Cumulative risk of at least one false-positive result  depended on four patient variables (younger age, higher number of previous breast biopsies, family history of breast cancer, and current estrogen use) and three radiologic variables (longer time between screenings, failure to compare the current and previous mammograms, and the individual radiologist&#x2019;s tendency to interpret mammograms as abnormal). Overall, the factor most responsible for a false-positive mammogram was the individual radiologist&#x2019;s tendency to read mammograms as abnormal.
            </p><p id="_453" tabindex="-1">A prospective cohort study of community-based screening found that a greater proportion of women undergoing annual screening had at least one false-positive screen after 10 years than did women undergoing biennial screening, regardless of breast density.  For women with scattered fibroglandular densities, the difference was 68.9% (annual) versus 46.3% (biennial) for women in their 40s.  For women aged 50 to 74 years, the difference for this density group was 49.8% (annual) versus 30.7% (biennial).[<a href="#cit/section_3.76">76</a>]</p><p id="_631" tabindex="-1">As shown in <a href="/types/breast/hp/breast-screening-pdq#link/_483">Table 1</a>, the estimated number of women out of 10,000 who underwent annual screening mammography during a 10-year period with at least one false-positive test result is 6,130 for women aged 40 to 50 years and 4,970 for women aged 60 years. The number of women with a false-positive test that results in a biopsy is estimated to range from 700 to 980, depending on age.[<a href="#cit/section_3.80">80</a>]</p></section><section id="_412"><h4 id="_412_toc">False negatives leading to a false sense of security</h4><p id="_413" tabindex="-1">The sensitivity of mammography ranges from 70% to 90%, depending on characteristics of the interpreting radiologist (level of experience) and characteristics of the  woman (age, breast density, hormone status, and diet). Assuming an average sensitivity of 80%, mammograms will miss approximately 20% of the breast cancers that are present at the time of screening (false negatives).  Many of these missed cancers are high risk, with adverse biologic characteristics. If a <em>normal</em> mammogram dissuades or postpones a woman or her doctor from evaluating breast symptoms, she may suffer adverse consequences. Thus, a negative mammogram should never dissuade a woman or her physician from additional evaluation of breast symptoms.</p></section><section id="_429"><h4 id="_429_toc">Discomfort</h4><p id="_430" tabindex="-1">Positioning of the woman and breast compression  reduce motion artifact and improve mammogram image quality.  Pain and/or discomfort was reported by 90% of women undergoing mammography, with 12% of women rating the sensation as intense or intolerable.[<a href="#cit/section_3.101">101</a>] A systematic review of 22 studies investigating mammography-associated pain and discomfort  found wide variations, some of which were associated with  menstrual cycle stage, anxiety, and premammography anticipation of pain.[<a href="#cit/section_3.102">102</a>]</p></section><section id="_414"><h4 id="_414_toc">Radiation exposure</h4><p id="_415" tabindex="-1">The major risk factors for radiation-associated breast cancer are young age at exposure and dose; however, rarely there are women with an inherited susceptibility to radiation-induced damage who must avoid radiation exposure at any age.[<a href="#cit/section_3.103">103</a>,<a href="#cit/section_3.104">104</a>] For many women older than 40 years, the likely benefits of screening mammography  outweigh the risks.[<a href="#cit/section_3.105">105</a>,<a href="#cit/section_3.103">103</a>,<a href="#cit/section_3.106">106</a>]  Standard 2-view screening mammography exposes the breasts to a mean dose of 4 mSv, and the whole body to 0.29 mSv.[<a href="#cit/section_3.104">104</a>,<a href="#cit/section_3.107">107</a>] Thus,  up to one breast cancer may be induced per 1,000 women undergoing annual mammograms from ages 40 to 80 years. Such risk is doubled in women with large breasts who require increased radiation doses and in women with breast augmentation who require additional views.  Radiation-induced breast cancers may be reduced fivefold for women who begin biennial screening at age 50 years rather than annually at age 40 years.[<a href="#cit/section_3.108">108</a>]</p></section><section id="_431"><h4 id="_431_toc">Psychological harms of false positives</h4><p id="_432" tabindex="-1">A telephone survey of 308 women performed 3 months after screening mammography revealed that about one-fourth of the 68 women  recalled for additional testing were still experiencing worry that affected their mood or functioning, even though that testing had ruled out  cancer.[<a href="#cit/section_3.109">109</a>] Research into whether the psychological impact of a false-positive test is long-standing yields  mixed results.  A cohort study in Spain in 2002 found immediate psychological impact to a woman after receiving a false-positive mammogram, but these results dissipated within a few months.[<a href="#cit/section_3.110">110</a>]  A cohort study in Denmark in 2013 that measured the psychological effects of a false-positive test result several years after the event found long-term negative psychological consequences.[<a href="#cit/section_3.111">111</a>] Several studies have shown that the anxiety after evaluation of a false-positive test leads to increased participation in future screening examinations.[<a href="#cit/section_3.112">112</a>-<a href="#cit/section_3.115">115</a>]</p></section><section id="_695"><h4 id="_695_toc">Financial strain and opportunity costs</h4><p id="_696" tabindex="-1">These potential harms of screening have not been well researched, but it is clear that they exist.</p></section></section><h6 do-not-show="toc">References</h6><ol><li id="section_3.1">Siu AL; U.S. Preventive Services Task Force: Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 164 (4): 279-96, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26757170&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26757170&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.2">Sickles EA: Findings at mammographic screening on only one standard projection: outcomes analysis. Radiology 208 (2): 471-5, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9680578&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9680578&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.3">Dibden A, Offman J, Parmar D, et al.: Reduction in interval cancer rates following the introduction of two-view mammography in the UK breast screening programme. Br J Cancer 110 (3): 560-4, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24366303&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24366303&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.4">Lillie-Blanton M: Mammography Quality Standards Act : X-ray Quality Improved, Access Unaffected, but Impact on Health Outcomes Unknown: Testimony Before the Subcommittee on Health and the Environment, Committee on Commerce, House of Representatives. Washington, D.C.: Committee on Commerce, 1998. <a href="https://www.ncbi.nlm.nih.gov/nlmcatalog/?term=Mammography+Quality+Standards+Act+%3A+X-ray+Quality+Improved%2C+Access+Unaffected%2C+but+Impact+on+Health+Outcomes+Unknown%3A+Testimony+Before+the+Subcommittee+on+Health+and+the+Environment%2C+Committee+on+Commerce%2C+House+of+Representatives" title="https://www.ncbi.nlm.nih.gov/nlmcatalog/?term=Mammography+Quality+Standards+Act+%3A+X-ray+Quality+Improved%2C+Access+Unaffected%2C+but+Impact+on+Health+Outcomes+Unknown%3A+Testimony+Before+the+Subcommittee+on+Health+and+the+Environment%2C+Committee+on+Commerce%2C+House+of+Representatives">Available online</a>. Last accessed October 8, 2018.</li><li id="section_3.5">D'Orsi CJ, Sickles EA, Mendelson EB, et al.: ACR BI-RADS Atlas, Breast Imaging Reporting and Data System. 5th ed. Reston, Va: American College of Radiology, 2013. <a href="https://www.acr.org/Quality-Safety/Resources/BIRADS" title="https://www.acr.org/Quality-Safety/Resources/BIRADS">Also available online</a>. Last accessed October 8, 2018.</li><li id="section_3.6">Rosenberg RD, Yankaskas BC, Abraham LA, et al.: Performance benchmarks for screening mammography. Radiology 241 (1): 55-66, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16990671&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16990671&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.7">Sickles EA, D'Orsi CJ, Bassett LW, et al.: ACR BI-RADS Mammography. In: D'Orsi CJ, Sickles EA, Mendelson EB, et al.: ACR BI-RADS Atlas, Breast Imaging Reporting and Data System. 5th ed. Reston, Va: American College of Radiology, 2013, pp 3-171. <a href="https://www.acr.org/Quality-Safety/Resources/BIRADS/Mammography" title="https://www.acr.org/Quality-Safety/Resources/BIRADS/Mammography">Also available online</a>. Last accessed October 8, 2018.</li><li id="section_3.8">Pisano ED, Gatsonis C, Hendrick E, et al.: Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 353 (17): 1773-83, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16169887&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16169887&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.9">Pisano ED, Hendrick RE, Yaffe MJ, et al.: Diagnostic accuracy of digital versus film mammography: exploratory analysis of selected population subgroups in DMIST. Radiology 246 (2): 376-83, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18227537&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18227537&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.10">Kerlikowske K, Hubbard RA, Miglioretti DL, et al.: Comparative effectiveness of digital versus film-screen mammography in community practice in the United States: a cohort study. Ann Intern Med 155 (8): 493-502, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22007043&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22007043&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.11">van Luijt PA, Fracheboud J, Heijnsdijk EA, et al.: Nation-wide data on screening performance during the transition to digital mammography: observations in 6 million screens. Eur J Cancer 49 (16): 3517-25, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23871248&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23871248&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.12">Souza FH, Wendland EM, Rosa MI, et al.: Is full-field digital mammography more accurate than screen-film mammography in overall population screening? A systematic review and meta-analysis. Breast 22 (3): 217-24, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23489759&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23489759&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.13">Gur D, Sumkin JH, Rockette HE, et al.: Changes in breast cancer detection and mammography recall rates after the introduction of a computer-aided detection system. J Natl Cancer Inst 96 (3): 185-90, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14759985&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14759985&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.14">Ciatto S, Del Turco MR, Risso G, et al.: Comparison of standard reading and computer aided detection (CAD) on a national proficiency test of screening mammography. Eur J Radiol 45 (2): 135-8, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12536093&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12536093&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.15">Fenton JJ, Taplin SH, Carney PA, et al.: Influence of computer-aided detection on performance of screening mammography. N Engl J Med 356 (14): 1399-409, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17409321&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17409321&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.16">Elmore JG, Carney PA: Computer-aided detection of breast cancer: has promise outstripped performance? J Natl Cancer Inst 96 (3): 162-3, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14759974&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14759974&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.17">Fenton JJ, Xing G, Elmore JG, et al.: Short-term outcomes of screening mammography using computer-aided detection: a population-based study of medicare enrollees. Ann Intern Med 158 (8): 580-7, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23588746&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23588746&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.18">Lehman CD, Wellman RD, Buist DS, et al.: Diagnostic Accuracy of Digital Screening Mammography With and Without Computer-Aided Detection. JAMA Intern Med 175 (11): 1828-37, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26414882&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26414882&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.19">Killelea BK, Long JB, Chagpar AB, et al.: Evolution of breast cancer screening in the Medicare population: clinical and economic implications. J Natl Cancer Inst 106 (8): , 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25031307&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25031307&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.20">Joensuu H, Lehtim&#xE4;ki T, Holli K, et al.: Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 292 (9): 1064-73, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15339900&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15339900&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.21">Shen Y, Yang Y, Inoue LY, et al.: Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 97 (16): 1195-203, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16106024&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16106024&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.22">Wishart GC, Greenberg DC, Britton PD, et al.: Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone? Br J Cancer 98 (11): 1741-4, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18506175&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18506175&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.23">Moody-Ayers SY, Wells CK, Feinstein AR: "Benign" tumors and "early detection" in mammography-screened patients of a natural cohort with breast cancer. Arch Intern Med 160 (8): 1109-15, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10789603&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10789603&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.24">Carney PA, Miglioretti DL, Yankaskas BC, et al.: Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 138 (3): 168-75, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12558355&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12558355&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.25">Rosenberg RD, Hunt WC, Williamson MR, et al.: Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico. Radiology 209 (2): 511-8, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9807581&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9807581&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.26">Kerlikowske K, Grady D, Barclay J, et al.: Likelihood ratios for modern screening mammography. Risk of breast cancer based on age and mammographic interpretation. JAMA 276 (1): 39-43, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8667537&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8667537&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.27">New PIAA Study Analyzes Diagnosis and Treatment of Breast Cancer [News Release]. Rockville, MD: Physician's Insurance Association of America, 2013. <a href="https://www.piaa.us/docs/News_Releases/2013_PressRelease_BreastCancerStudy.pdf" title="https://www.piaa.us/docs/News_Releases/2013_PressRelease_BreastCancerStudy.pdf">Available online</a>. Last accessed October 8, 2018.</li><li id="section_3.28">Porter PL, El-Bastawissi AY, Mandelson MT, et al.: Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 91 (23): 2020-8, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10580027&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10580027&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.29">Hakama M, Holli K, Isola J, et al.: Aggressiveness of screen-detected breast cancers. Lancet 345 (8944): 221-4, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7741862&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7741862&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.30">Tab&#xE1;r L, Faberberg G, Day NE, et al.: What is the optimum interval between mammographic screening examinations? An analysis based on the latest results of the Swedish two-county breast cancer screening trial. Br J Cancer 55 (5): 547-51, 1987.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3606947&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3606947&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.31">Payne JI, Caines JS, Gallant J, et al.: A review of interval breast cancers diagnosed among participants of the Nova Scotia Breast Screening Program. Radiology 266 (1): 96-103, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23169791&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23169791&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.32">Buist DS, Porter PL, Lehman C, et al.: Factors contributing to mammography failure in women aged 40-49 years. J Natl Cancer Inst 96 (19): 1432-40, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15467032&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15467032&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.33">Pankow JS, Vachon CM, Kuni CC, et al.: Genetic analysis of mammographic breast density in adult women: evidence of a gene effect. J Natl Cancer Inst 89 (8): 549-56, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9106643&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9106643&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.34">Boyd NF, Dite GS, Stone J, et al.: Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med 347 (12): 886-94, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12239257&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12239257&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.35">White E, Velentgas P, Mandelson MT, et al.: Variation in mammographic breast density by time in menstrual cycle among women aged 40-49 years. J Natl Cancer Inst 90 (12): 906-10, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9637139&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9637139&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.36">Harvey JA, Pinkerton JV, Herman CR: Short-term cessation of hormone replacement therapy and improvement of mammographic specificity. J Natl Cancer Inst 89 (21): 1623-5, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9362162&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9362162&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.37">Laya MB, Larson EB, Taplin SH, et al.: Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J Natl Cancer Inst 88 (10): 643-9, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8627640&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8627640&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.38">Baines CJ, Dayan R: A tangled web: factors likely to affect the efficacy of screening mammography. J Natl Cancer Inst 91 (10): 833-8, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10340902&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10340902&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.39">Brisson J, Brisson B, Cot&#xE9; G, et al.: Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 9 (9): 911-5, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11008908&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11008908&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.40">Boyd NF, Greenberg C, Lockwood G, et al.: Effects at two years of a low-fat, high-carbohydrate diet on radiologic features of the breast: results from a randomized trial. Canadian Diet and Breast Cancer Prevention Study Group. J Natl Cancer Inst 89 (7): 488-96, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9086005&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9086005&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.41">Crouchley K, Wylie E, Khong E: Hormone replacement therapy and mammographic screening outcomes in Western Australia. J Med Screen 13 (2): 93-7, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16792833&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16792833&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.42">Banks E, Reeves G, Beral V, et al.: Influence of personal characteristics of individual women on sensitivity and specificity of mammography in the Million Women Study: cohort study. BMJ 329 (7464): 477, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15331472&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15331472&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.43">Yankaskas BC, Taplin SH, Ichikawa L, et al.: Association between mammography timing and measures of screening performance in the United States. Radiology 234 (2): 363-73, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15670994&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15670994&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.44">Elmore JG, Carney PA, Abraham LA, et al.: The association between obesity and screening mammography accuracy. Arch Intern Med 164 (10): 1140-7, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15159273&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15159273&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.45">Wallis MG, Walsh MT, Lee JR: A review of false negative mammography in a symptomatic population. Clin Radiol 44 (1): 13-5, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1873944&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1873944&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.46">Tilanus-Linthorst M, Verhoog L, Obdeijn IM, et al.: A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer 102 (1): 91-5, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12353239&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12353239&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.47">Ganott MA, Harris KM, Klaman HM, et al.: Analysis of False-Negative Cancer Cases Identified with a Mammography Audit. Breast J 5 (3): 166-175, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11348280&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11348280&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.48">Elmore JG, Jackson SL, Abraham L, et al.: Variability in interpretive performance at screening mammography and radiologists' characteristics associated with accuracy. Radiology 253 (3): 641-51, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19864507&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19864507&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.49">Meyer JE, Eberlein TJ, Stomper PC, et al.: Biopsy of occult breast lesions. Analysis of 1261 abnormalities. JAMA 263 (17): 2341-3, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2157903&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2157903&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.50">Taplin S, Abraham L, Barlow WE, et al.: Mammography facility characteristics associated with interpretive accuracy of screening mammography. J Natl Cancer Inst 100 (12): 876-87, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18544742&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18544742&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.51">Jackson SL, Taplin SH, Sickles EA, et al.: Variability of interpretive accuracy among diagnostic mammography facilities. J Natl Cancer Inst 101 (11): 814-27, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19470953&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19470953&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.52">Goldman LE, Walker R, Miglioretti DL, et al.: Accuracy of diagnostic mammography at facilities serving vulnerable women. Med Care 49 (1): 67-75, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20966780&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20966780&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.53">Smith-Bindman R, Chu PW, Miglioretti DL, et al.: Comparison of screening mammography in the United States and the United kingdom. JAMA 290 (16): 2129-37, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14570948&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14570948&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.54">Elmore JG, Nakano CY, Koepsell TD, et al.: International variation in screening mammography interpretations in community-based programs. J Natl Cancer Inst 95 (18): 1384-93, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=13130114&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=13130114&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.55">Kerlikowske K, Grady D, Barclay J, et al.: Positive predictive value of screening mammography by age and family history of breast cancer. JAMA 270 (20): 2444-50, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8230621&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8230621&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.56">The Breast Screening Frequency Trial Group: The frequency of breast cancer screening: results from the UKCCCR Randomised Trial. United Kingdom Co-ordinating Committee on Cancer Research. Eur J Cancer 38 (11): 1458-64, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12110490&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12110490&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.57">White E, Miglioretti DL, Yankaskas BC, et al.: Biennial versus annual mammography and the risk of late-stage breast cancer. J Natl Cancer Inst 96 (24): 1832-9, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15601639&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15601639&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.58">Mandelblatt JS, Cronin KA, Bailey S, et al.: Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med 151 (10): 738-47, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19920274&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19920274&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.59">Parvinen I, Chiu S, Pylkk&#xE4;nen L, et al.: Effects of annual vs triennial mammography interval on breast cancer incidence and mortality in ages 40-49 in Finland. Br J Cancer 105 (9): 1388-91, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21934688&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21934688&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.60">G&#xF8;tzsche PC, Olsen O: Is screening for breast cancer with mammography justifiable? Lancet 355 (9198): 129-34, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10675181&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10675181&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.61">G&#xF8;tzsche PC, Nielsen M: Screening for breast cancer with mammography. Cochrane Database Syst Rev  (4): CD001877, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17054145&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17054145&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.62">Nystr&#xF6;m L, Andersson I, Bjurstam N, et al.: Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 359 (9310): 909-19, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11918907&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11918907&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.63">Kerlikowske K: Efficacy of screening mammography among women aged 40 to 49 years and 50 to 69 years: comparison of relative and absolute benefit. J Natl Cancer Inst Monogr  (22): 79-86, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9709281&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9709281&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.64">Glasziou PP, Woodward AJ, Mahon CM: Mammographic screening trials for women aged under 50. A quality assessment and meta-analysis. Med J Aust 162 (12): 625-9, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7603372&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7603372&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.65">Nelson HD, Tyne K, Naik A, et al.: Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med 151 (10): 727-37, W237-42, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19920273&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19920273&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.66">Duffy SW, Tab&#xE1;r L, Chen HH, et al.: The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties. Cancer 95 (3): 458-69, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12209737&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12209737&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.67">Jonsson H, Nystr&#xF6;m L, T&#xF6;rnberg S, et al.: Service screening with mammography of women aged 50-69 years in Sweden: effects on mortality from breast cancer. J Med Screen 8 (3): 152-60, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11678556&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11678556&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.68">Autier P, Koechlin A, Smans M, et al.: Mammography screening and breast cancer mortality in Sweden. J Natl Cancer Inst 104 (14): 1080-93, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22811439&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22811439&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.69">Broeders MJ, Peer PG, Straatman H, et al.: Diverging breast cancer mortality rates in relation to screening? A comparison of Nijmegen to Arnhem and the Netherlands, 1969-1997. Int J Cancer 92 (2): 303-8, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11291061&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11291061&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.70">Verbeek AL, Hendriks JH, Holland R, et al.: Reduction of breast cancer mortality through mass screening with modern mammography. First results of the Nijmegen project, 1975-1981. Lancet 1 (8388): 1222-4, 1984.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6144933&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6144933&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.71">Elmore JG, Reisch LM, Barton MB, et al.: Efficacy of breast cancer screening in the community according to risk level. J Natl Cancer Inst 97 (14): 1035-43, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16030301&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16030301&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.72">Autier P, Boniol M, Gavin A, et al.: Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ 343: d4411, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21798968&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21798968&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.73">Harris R, Yeatts J, Kinsinger L: Breast cancer screening for women ages 50 to 69 years a systematic review of observational evidence. Prev Med 53 (3): 108-14, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21820465&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21820465&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.74">Bleyer A, Welch HG: Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 367 (21): 1998-2005, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23171096&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23171096&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.75">Welch HG, Prorok PC, O'Malley AJ, et al.: Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. N Engl J Med 375 (15): 1438-1447, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27732805&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27732805&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.76">Kerlikowske K, Zhu W, Hubbard RA, et al.: Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy. JAMA Intern Med 173 (9): 807-16, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23552817&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23552817&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.77">Coldman A, Phillips N, Wilson C, et al.: Pan-Canadian study of mammography screening and mortality from breast cancer. J Natl Cancer Inst 106 (11): , 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25274578&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25274578&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.78">Berry DA, Cronin KA, Plevritis SK, et al.: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353 (17): 1784-92, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16251534&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16251534&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.79">Plevritis SK, Munoz D, Kurian AW, et al.: Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012. JAMA 319 (2): 154-164, 2018.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=29318276&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=29318276&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.80">Pace LE, Keating NL: A systematic assessment of benefits and risks to guide breast cancer screening decisions. JAMA 311 (13): 1327-35, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24691608&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24691608&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.81">Welch HG, Passow HJ: Quantifying the benefits and harms of screening mammography. JAMA Intern Med 174 (3): 448-54, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24380095&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24380095&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.82">Miller AB, To T, Baines CJ, et al.: The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years. Ann Intern Med 137 (5 Part 1): 305-12, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12204013&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12204013&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.83">Miller AB, To T, Baines CJ, et al.: Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years. J Natl Cancer Inst 92 (18): 1490-9, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10995804&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10995804&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.84">Tab&#xE1;r L, Vitak B, Chen TH, et al.: Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology 260 (3): 658-63, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21712474&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21712474&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.85">Hubbard RA, Kerlikowske K, Flowers CI, et al.: Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann Intern Med 155 (8): 481-92, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22007042&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22007042&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.86">Braithwaite D, Zhu W, Hubbard RA, et al.: Screening outcomes in older US women undergoing multiple mammograms in community practice: does interval, age, or comorbidity score affect tumor characteristics or false positive rates? J Natl Cancer Inst 105 (5): 334-41, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23385442&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23385442&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.87">Zackrisson S, Andersson I, Janzon L, et al.: Rate of over-diagnosis of breast cancer 15 years after end of Malm&#xF6; mammographic screening trial: follow-up study. BMJ 332 (7543): 689-92, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16517548&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16517548&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.88">Welch HG, Black WC: Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med 127 (11): 1023-8, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9412284&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9412284&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.89">Black WC, Welch HG: Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med 328 (17): 1237-43, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8464435&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8464435&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.90">Duffy SW, Lynge E, Jonsson H, et al.: Complexities in the estimation of overdiagnosis in breast cancer screening. Br J Cancer 99 (7): 1176-8, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18766185&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18766185&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.91">G&#xF8;tzsche PC, J&#xF8;rgensen KJ, Maehlen J, et al.: Estimation of lead time and overdiagnosis in breast cancer screening. Br J Cancer 100 (1): 219; author reply 220, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19127274&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19127274&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.92">Nelson HD, Pappas M, Cantor A, et al.: Harms of Breast Cancer Screening: Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation. Ann Intern Med 164 (4): 256-67, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26756737&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26756737&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.93">J&#xF8;rgensen KJ, G&#xF8;tzsche PC, Kalager M, et al.: Breast Cancer Screening in Denmark: A Cohort Study of Tumor Size and Overdiagnosis. Ann Intern Med 166 (5): 313-323, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28114661&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28114661&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.94">Autier P, Boniol M, Koechlin A, et al.: Effectiveness of and overdiagnosis from mammography screening in the Netherlands: population based study. BMJ 359: j5224, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=29208760&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=29208760&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.95">Lousdal ML, Kristiansen IS, M&#xF8;ller B, et al.: Effect of organised mammography screening on stage-specific incidence in Norway: population study. Br J Cancer 114 (5): 590-6, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26835975&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26835975&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.96">Harding C, Pompei F, Burmistrov D, et al.: Breast Cancer Screening, Incidence, and Mortality Across US Counties. JAMA Intern Med 175 (9): 1483-9, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26147578&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26147578&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.97">Miller AB, Wall C, Baines CJ, et al.: Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ 348: g366, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24519768&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24519768&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.98">Esserman LJ, Yau C, Thompson CK, et al.: Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades. JAMA Oncol 3 (11): 1503-1510, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28662222&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28662222&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.99">Elmore JG, Barton MB, Moceri VM, et al.: Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 338 (16): 1089-96, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9545356&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9545356&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.100">Christiansen CL, Wang F, Barton MB, et al.: Predicting the cumulative risk of false-positive mammograms. J Natl Cancer Inst 92 (20): 1657-66, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11036111&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11036111&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.101">Freitas R 2nd, Fiori WF, Ramos FJ, et al.: [Discomfort and pain during mammography]. Rev Assoc Med Bras 52 (5): 333-6, 2006 Sep-Oct.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17160308&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17160308&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.102">Armstrong K, Moye E, Williams S, et al.: Screening mammography in women 40 to 49 years of age: a systematic review for the American College of Physicians. Ann Intern Med 146 (7): 516-26, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17404354&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17404354&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.103">Swift M, Morrell D, Massey RB, et al.: Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 325 (26): 1831-6, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1961222&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1961222&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.104">Kopans DB: Mammography and radiation risk. In: Janower ML, Linton OW, eds.: Radiation Risk: a Primer. Reston, Va: American College of Radiology, 1996, pp 21-22.</li><li id="section_3.105">Feig SA, Ehrlich SM: Estimation of radiation risk from screening mammography: recent trends and comparison with expected benefits. Radiology 174 (3 Pt 1): 638-47, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2305043&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2305043&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.106">Helzlsouer KJ, Harris EL, Parshad R, et al.: Familial clustering of breast cancer: possible interaction between DNA repair proficiency and radiation exposure in the development of breast cancer. Int J Cancer 64 (1): 14-7, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7665242&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7665242&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.107">Suleiman OH, Spelic DC, McCrohan JL, et al.: Mammography in the 1990s: the United States and Canada. Radiology 210 (2): 345-51, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10207413&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10207413&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.108">Miglioretti DL, Lange J, van den Broek JJ, et al.: Radiation-Induced Breast Cancer Incidence and Mortality From Digital Mammography Screening: A Modeling Study. Ann Intern Med 164 (4): 205-14, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26756460&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26756460&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.109">Lerman C, Trock B, Rimer BK, et al.: Psychological side effects of breast cancer screening. Health Psychol 10 (4): 259-67, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1915212&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1915212&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.110">Sandin B, Chorot P, Valiente RM, et al.: Adverse psychological effects in women attending a second-stage breast cancer screening. J Psychosom Res 52 (5): 303-9, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12023127&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12023127&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.111">Brodersen J, Siersma VD: Long-term psychosocial consequences of false-positive screening mammography. Ann Fam Med 11 (2): 106-15, 2013 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23508596&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23508596&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.112">Gram IT, Lund E, Slenker SE: Quality of life following a false positive mammogram. Br J Cancer 62 (6): 1018-22, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2257206&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2257206&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.113">Burman ML, Taplin SH, Herta DF, et al.: Effect of false-positive mammograms on interval breast cancer screening in a health maintenance organization. Ann Intern Med 131 (1): 1-6, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10391809&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10391809&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.114">Pisano ED, Earp J, Schell M, et al.: Screening behavior of women after a false-positive mammogram. Radiology 208 (1): 245-9, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9646820&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9646820&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.115">Brewer NT, Salz T, Lillie SE: Systematic review: the long-term effects of false-positive mammograms. Ann Intern Med 146 (7): 502-10, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17404352&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17404352&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _543
      field_pdq_section_title:
        - format: plain_text
          value: 'Other Imaging Modalities: Ultrasound, Magnetic Resonance Imaging (MRI), Thermography'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_543" class="pdq-sections"><p id="_709" tabindex="-1"><strong>Ultrasound</strong></p><p id="_544" tabindex="-1">Ultrasound is used for the diagnostic evaluation of palpable or mammographically identified masses, rather than serving as a primary screening modality. A review of the literature and expert opinion by the European Group for Breast Cancer Screening concluded that &#x201C;there is little evidence to support the use of ultrasound in population breast cancer screening at any age.&#x201D;[<a href="#cit/section_4.1">1</a>]</p><p id="_710" tabindex="-1"><strong>Breast MRI</strong></p><p id="_692" tabindex="-1">Breast MRI is used in women for diagnostic evaluation, including evaluating the integrity of silicone breast implants, assessing palpable masses after surgery or radiation therapy, detecting mammographically and sonographically occult breast cancer in patients with axillary nodal metastasis, and preoperative planning for some patients with known breast cancer.  There is no ionizing radiation exposure with this procedure. MRI has been promoted as a screening test for breast cancer among women at elevated risk of breast cancer based on <em>BRCA1/2</em> mutation carriers, a strong family history of breast cancer, or several genetic syndromes, such as Li-Fraumeni syndrome or Cowden disease.[<a href="#cit/section_4.2">2</a>-<a href="#cit/section_4.4">4</a>]  Breast MRI is  more sensitive but less specific than screening mammography [<a href="#cit/section_4.5">5</a>,<a href="#cit/section_4.6">6</a>]  and is up to 35 times as expensive.[<a href="#cit/section_4.7">7</a>-<a href="#cit/section_4.11">11</a>]</p><p id="_711" tabindex="-1"><strong>Thermography</strong></p><p id="_548" tabindex="-1">Using infrared imaging techniques, thermography of the breast identifies temperature changes in the skin as a possible indicator of an underlying tumor, displaying these changes in color patterns. Thermographic devices have been approved by the U.S. Food and Drug Administration under the 510(k) process, but no randomized trials have compared thermography to other screening modalities. Small cohort studies do not suggest any additional benefit for the use of thermography as an adjunct modality.[<a href="#cit/section_4.12">12</a>,<a href="#cit/section_4.13">13</a>]</p><h6 do-not-show="toc">References</h6><ol><li id="section_4.1">Teh W, Wilson AR: The role of ultrasound in breast cancer screening. A consensus statement by the European Group for Breast Cancer Screening. Eur J Cancer 34 (4): 449-50, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9713292&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9713292&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.2">Warner E, Plewes DB, Hill KA, et al.: Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292 (11): 1317-25, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15367553&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15367553&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.3">Kriege M, Brekelmans CT, Boetes C, et al.: Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351 (5): 427-37, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15282350&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15282350&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.4">Warner E, Hill K, Causer P, et al.: Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 29 (13): 1664-9, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21444874&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21444874&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.5">Lord SJ, Lei W, Craft P, et al.: A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer 43 (13): 1905-17, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17681781&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17681781&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.6">Lehman CD, Gatsonis C, Kuhl CK, et al.: MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 356 (13): 1295-303, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17392300&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17392300&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.7">Pataky R, Armstrong L, Chia S, et al.: Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers. BMC Cancer 13: 339, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23837641&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23837641&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.8">Saadatmand S, Tilanus-Linthorst MM, Rutgers EJ, et al.: Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging. J Natl Cancer Inst 105 (17): 1314-21, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23940285&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23940285&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.9">Ahern CH, Shih YC, Dong W, et al.: Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk. Br J Cancer 111 (8): 1542-51, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25137022&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25137022&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.10">Pistolese CA, Ciarrapico AM, della Gatta F, et al.: Inappropriateness of breast imaging: cost analysis. Radiol Med 118 (6): 984-94, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23801396&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23801396&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.11">Cott Chubiz JE, Lee JM, Gilmore ME, et al.: Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers. Cancer 119 (6): 1266-76, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23184400&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23184400&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.12">Wishart GC, Campisi M, Boswell M, et al.: The accuracy of digital infrared imaging for breast cancer detection in women undergoing breast biopsy. Eur J Surg Oncol 36 (6): 535-40, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20452740&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20452740&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.13">Arora N, Martins D, Ruggerio D, et al.: Effectiveness of a noninvasive digital infrared thermal imaging system in the detection of breast cancer. Am J Surg 196 (4): 523-6, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18809055&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18809055&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _121
      field_pdq_section_title:
        - format: plain_text
          value: 'Nonimaging Screening Modalities'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_121" class="pdq-sections"><section id="_187"><h3 id="_187_toc">Clinical Breast Examination</h3><p id="_188" tabindex="-1">The effect of screening clinical breast examination (CBE) on breast cancer mortality has not been fully established. The Canadian National Breast Screening Study (NBSS) compared high-quality CBE plus mammography with CBE alone in women aged 50 to 59 years.  CBE, lasting 5 to 10 minutes per breast, was conducted by trained health professionals, with periodic evaluations of performance quality. The frequency of cancer diagnosis, stage, interval cancers, and breast cancer mortality were similar in the two groups and similar to outcomes with mammography alone.[<a href="#cit/section_5.1">1</a>] With a mean follow-up of 13 years, breast cancer mortality was similar in the two groups (mortality rate ratio, 1.02 [95% confidence interval [CI], 0.78&#x2013;1.33]).[<a href="#cit/section_5.2">2</a>] The investigators estimated the operating characteristics for CBE alone;  for 19,965 women aged 50 to 59 years, sensitivity was 83%, 71%, 57%, 83%, and 77% for years 1, 2, 3, 4, and 5 of the trial, respectively; specificity ranged between 88% and 96%. Positive predictive value (PPV), which is the proportion of cancers detected per abnormal examination, was estimated to be 3% to 4%. For 25,620 women aged 40 to 49 years who were examined only at entry, the estimated sensitivity was 71%, specificity was 84%, and PPV was 1.5%.[<a href="#cit/section_5.3">3</a>]</p><p id="_189" tabindex="-1">In clinical trials involving community clinicians, CBE-type screening had higher specificity (97%&#x2013;99%) [<a href="#cit/section_5.4">4</a>] and lower sensitivity (22%&#x2013;36%) than that experienced by examiners.[<a href="#cit/section_5.5">5</a>-<a href="#cit/section_5.8">8</a>] A study of screening in women with a positive family history of breast cancer showed that, after a normal initial evaluation, the patient herself, or her clinician performing a CBE, identified more cancers than did mammography.[<a href="#cit/section_5.9">9</a>]</p><p id="_708" tabindex="-1"> Another study examined the usefulness of adding CBE to screening mammography;  among 61,688 women older than 40 years and screened by mammography and CBE, sensitivity for mammography was 78%, and combined mammography-CBE sensitivity was  82%. Specificity was lower for women undergoing both screening modalities than it was for women undergoing mammography alone (97% vs. 99%).[<a href="#cit/section_5.10">10</a>]   Other international trials of CBE are under way, two  in India and  one in Egypt.</p></section><section id="_190"><h3 id="_190_toc">Breast Self-Examination (BSE)</h3><p id="_191" tabindex="-1">Monthly BSE has been promoted, but there is no evidence that it reduces breast cancer mortality.[<a href="#cit/section_5.11">11</a>,<a href="#cit/section_5.12">12</a>] The only large,  randomized clinical trial of BSE assigned 266,064 female Shanghai factory workers to either  BSE instruction with reinforcement and encouragement, or instruction on the prevention of lower back pain. Neither group underwent any other breast cancer screening. After 10 to 11 years of follow-up, 135 breast cancer deaths occurred in the instruction group, and 131 cancer deaths occurred in the control group (relative risk [RR], 1.04; 95% CI, 0.82&#x2013;1.33). Although the number of invasive breast cancers diagnosed in the two groups was about the same, women in the instruction group had more breast biopsies and more benign lesions diagnosed than did women in the control group.[<a href="#cit/section_5.13">13</a>]</p><p id="_192" tabindex="-1">Other research results on BSE come from three trials.  First, more than 100,000 Leningrad women were assigned to BSE training or control by cluster randomization; the BSE group training had more breast biopsies  without improved breast cancer mortality.[<a href="#cit/section_5.14">14</a>] Second, in the United Kingdom Trial of Early Detection of Breast Cancer, more than 63,500 women aged 45 to 64 years  were invited to educational sessions about BSE. After 10 years of follow-up, breast cancer mortality rates were similar to the rates in centers without organized BSE education (RR, 1.07; 95% CI, 0.93&#x2013;1.22).[<a href="#cit/section_5.15">15</a>]  Thirdly, in contrast, a case-control study nested within the Canadian NBSS compared self-reported BSE frequency before enrollment with breast cancer mortality. Women who examined their breasts visually, used their finger pads for palpation, and used their three middle fingers had a lower breast cancer mortality rate.[<a href="#cit/section_5.16">16</a>]</p></section><section id="_201"><h3 id="_201_toc">Tissue sampling (fine-needle aspiration, nipple aspirate, ductal lavage)</h3><p id="_202" tabindex="-1">Various methods to analyze breast tissue for malignancy have been proposed to screen for breast cancer, but none have been shown to be associated with mortality reduction.</p></section><h6 do-not-show="toc">References</h6><ol><li id="section_5.1">Baines CJ: The Canadian National Breast Screening Study: a perspective on criticisms. Ann Intern Med 120 (4): 326-34, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8291826&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8291826&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.2">Miller AB, To T, Baines CJ, et al.: Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years. J Natl Cancer Inst 92 (18): 1490-9, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10995804&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10995804&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.3">Baines CJ, Miller AB, Bassett AA: Physical examination. Its role as a single screening modality in the Canadian National Breast Screening Study. Cancer 63 (9): 1816-22, 1989.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2702588&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2702588&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.4">Fenton JJ, Rolnick SJ, Harris EL, et al.: Specificity of clinical breast examination in community practice. J Gen Intern Med 22 (3): 332-7, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17356964&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17356964&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.5">Fenton JJ, Barton MB, Geiger AM, et al.: Screening clinical breast examination: how often does it miss lethal breast cancer? J Natl Cancer Inst Monogr  (35): 67-71, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16287888&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16287888&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.6">Bobo JK, Lee NC, Thames SF: Findings from 752,081 clinical breast examinations reported to a national screening program from 1995 through 1998. J Natl Cancer Inst 92 (12): 971-6, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10861308&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10861308&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.7">Oestreicher N, White E, Lehman CD, et al.: Predictors of sensitivity of clinical breast examination (CBE). Breast Cancer Res Treat 76 (1): 73-81, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12408378&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12408378&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.8">Kolb TM, Lichy J, Newhouse JH: Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology 225 (1): 165-75, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12355001&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12355001&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.9">Gui GP, Hogben RK, Walsh G, et al.: The incidence of breast cancer from screening women according to predicted family history risk: Does annual clinical examination add to mammography? Eur J Cancer 37 (13): 1668-73, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11527694&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11527694&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.10">Oestreicher N, Lehman CD, Seger DJ, et al.: The incremental contribution of clinical breast examination to invasive cancer detection in a mammography screening program. AJR Am J Roentgenol 184 (2): 428-32, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15671358&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15671358&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.11">Baxter N; Canadian Task Force on Preventive Health Care: Preventive health care, 2001 update: should women be routinely taught breast self-examination to screen for breast cancer? CMAJ 164 (13): 1837-46, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11450279&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11450279&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.12">Humphrey LL, Helfand M, Chan BK, et al.: Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137 (5 Part 1): 347-60, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12204020&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12204020&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.13">Thomas DB, Gao DL, Ray RM, et al.: Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst 94 (19): 1445-57, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12359854&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12359854&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.14">Semiglazov VF, Moiseyenko VM, Bavli JL, et al.: The role of breast self-examination in early breast cancer detection (results of the 5-years USSR/WHO randomized study in Leningrad). Eur J Epidemiol 8 (4): 498-502, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1397215&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1397215&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.15">Ellman R, Moss SM, Coleman D, et al.: Breast cancer mortality after 10 years in the UK trial of early detection of breast cancer. UK Trial of Early Detection of Breast Cancer Group. The Breast  2 (1): 13-20, 1993.</li><li id="section_5.16">Harvey BJ, Miller AB, Baines CJ, et al.: Effect of breast self-examination techniques on the risk of death from breast cancer. CMAJ 157 (9): 1205-12, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9361639&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9361639&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _377
      field_pdq_section_title:
        - format: plain_text
          value: 'Appendix of Randomized Controlled Trials'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_377" class="pdq-sections"><p id="_73" tabindex="-1"><strong> Health Insurance Plan, United States 1963 </strong>[<a href="#cit/section_6.1">1</a>,<a href="#cit/section_6.2">2</a>]
            </p><div class="pdq-content-list"><ul id="_378" class="pdq-address-block"><li><strong>Age at entry:</strong> 40 to 64 years.</li><li><strong>Randomization:</strong> Individual, but with significant imbalances in the
            distribution of women between assigned arms, as evidenced by menopausal status (<em>P</em> &lt; .0001)
            and education (<em>P</em> =  .05).
            </li><li><strong>Sample size:</strong> 30,000 to 31,092 in study group and 30,565 to 30,765 in control
            group.</li><li><strong>Consistency of reports:</strong> Variation in sample size reports.
            </li><li><strong>Intervention:</strong> Annual two-view mammography (MMG) and clinical breast examination (CBE) for 3 years.
            </li><li><strong>Control:</strong> Usual care.
            </li><li>
            <strong>Compliance: </strong> Nonattenders to first screening (35% of the screened population)
            were not reinvited.</li><li><strong>Contamination:</strong> Screening MMG was not available outside the trial; frequency of CBE performance among control women is unknown.</li><li>
            <strong>Cause of death attribution:</strong>   Women who died of breast cancer that had been diagnosed before entry into the study were excluded from the comparison between the screening and control groups. However, these exclusions were determined differently within the two groups. Women in the screening
            group were excluded based on determinations made during the study
            period at their initial screening visits. These women were dropped
            from all further consideration in the study. By design, controls did
            not have regular clinic visits, so the prestudy cancer status of
            control patients was not determined. When a control patient died and
            her cause of death was determined to be breast cancer, a
            retrospective examination was made to determine the date of diagnosis
            of her disease. If the date preceded the study period, the control patient was
            excluded from the analysis. This difference in methodology has the
            potential for a substantial bias when comparing breast cancer mortality
            between the two groups, and this bias is likely to favor screening.</li><li><strong>Analysis:</strong> Follow-up.</li><li><strong>External audit:</strong> No.
            </li><li><strong>Follow-up duration:</strong> 18 years.</li><li><strong>Relative risk of breast cancer death, screening versus control (95% confidence interval [CI]):</strong> 0.71
            (0.55&#x2013;0.93) at 10 years and 0.77 (0.61&#x2013;0.97) at 15 years.
            </li><li><strong>Comments:</strong> The MMGs were of poor quality compared with  those of later
            trials, because of outdated equipment and techniques.  The intervention consisted of both MMG and CBE.  Major concerns about trial
            performance are the validity of the initial randomization and the differential
            exclusion of women with a prior history of breast cancer.
            </li></ul></div><p id="_379" tabindex="-1"><strong>Malmo, Sweden 1976</strong> [<a href="#cit/section_6.3">3</a>,<a href="#cit/section_6.4">4</a>]
            </p><div class="pdq-content-list"><ul id="_113" class="pdq-address-block"><li>	<strong>Age at entry:</strong> 45 to 69 years.</li><li>
            <strong>Randomization:</strong> Individual, within each birth-year cohort for the first phase,
            MMG screening trial (MMST I).  Individual for the entire birth cohort 1933 to 1945 for MMST II but with
            variations imposed by limited resources.  Validation by analysis of age in both
            groups shows no significant difference.</li><li><strong>Exclusions:</strong> In a Swedish meta-analysis, there were 393 women with pre-existing
            breast cancer excluded from the intervention group and 412 from the control
            group.  Overall, however, 86 more women were excluded from the
            intervention group than from the control group.</li><li><strong>Sample size:</strong>
            21,088 study and 21,195 control.</li><li>
            <strong>Consistency of reports:</strong>    No variation in patient numbers.</li><li><strong>Intervention:</strong>   Two-view MMG every 18 to 24 months &#xD7; 5.</li><li>
            <strong>Control:</strong> Usual care, with MMG at study end.</li><li><strong>Compliance:</strong> Participants migrating from Malmo (2% per year) were not followed.
            The participation rate of study women was 74% for the first round and 70% for
            subsequent rounds.</li><li>
            <strong>Contamination:</strong> 24% of all control women had at least one MMG, as did 35% of the
            control women aged 45 to 49 years.</li><li><strong>Cause of death attribution:</strong> 76% autopsy rate in early report, lower rate later.
            Cause of death assessment blinded for women with a breast cancer diagnosis.
            Linked to Swedish Cause of Death Registry.</li><li><strong>Analysis:</strong> Evaluation, initially.  Follow-up analysis, as part of the Swedish
            meta-analysis.[<a href="#cit/section_6.5">5</a>]</li><li><strong>External audit:</strong> No.</li><li><strong>Follow-up duration: </strong>12 years.</li><li><strong>Relative risk of breast cancer death, screening versus control (95% CI):</strong> 0.81
            (0.62&#x2013;1.07).</li><li><strong>Comments:</strong> Evaluation analysis required a correction factor for the delay in the
            performance of MMG in the control group.  The two Malmo trials, MMST I and MMST II,
            have been combined for most analyses.</li></ul></div><p id="_380" tabindex="-1"><strong>&#xD6;sterg&#xF6;tland (County E of Two-County Trial), Sweden 1977</strong> [<a href="#cit/section_6.6">6</a>-<a href="#cit/section_6.8">8</a>]
            </p><div class="pdq-content-list"><ul id="_381" class="pdq-address-block"><li><strong>Age at entry:</strong> 40 to 74 years.</li><li>
            <strong>Randomization:</strong> Geographic cluster, with stratification for residence (urban or
            rural), socioeconomic factors, and size.  Baseline breast cancer incidence and
            mortality were comparable between the randomly assigned geographic clusters.
            The study women were older than the control women, <em>P</em> &lt; .0001, which would not have had a major effect on the outcome of the trial.  </li><li><strong>Exclusions:</strong> Women with pre-existing breast cancer were excluded from both
            groups, but the numbers were reported differently in different publications.
            The Swedish meta-analysis excluded all women with a prior breast cancer
            diagnosis, regardless of group assignment.</li><li><strong>Sample size:</strong> Variably reported, ranging from 38,405 to 39,034 in the study and from
            37,145 to 37,936 in the control.</li><li><strong>Consistency of reports:</strong> Variable.</li><li><strong>Intervention:</strong> Three single-view MMGs every 2 years for women younger than 50 years and every 33 months
            for women  50 years and older.</li><li><strong>Control:</strong> Usual care, with MMG at study end.</li><li><strong>Compliance:</strong> 89% screened.</li><li><strong>Contamination:</strong> 13% of women in the Two-County trial had MMG as part of routine care,
            mostly in 1983 and 1984.</li><li>
            <strong>Cause of death attribution:</strong> Determined by a team of local physicians.  When
            results were recalculated in the Swedish meta-analysis, using data from the
            Swedish Cause of Death Registry, there was less benefit for screening than had
            been previously reported.</li><li><strong>Analysis:</strong> Evaluation initially, with correction for delay in control group MMG.
            Follow-up analysis, as part of the Swedish meta-analysis.[<a href="#cit/section_6.5">5</a>]</li><li><strong>External audit:</strong> No. However, breast cancer cases and deaths were adjudicated by a Swedish panel that included the trial's investigators.[<a href="#cit/section_6.9">9</a>]</li><li><strong>Follow-up duration:</strong> 12 years.</li><li><strong>Relative risk of breast cancer death, screening versus control (95% CI):</strong> 0.82
            (0.64&#x2013;1.05),  &#xD6;sterg&#xF6;tland.</li><li>
            <strong>Comments:</strong> Concerns were raised about the randomization methodology and the
            evaluation analysis, which required a correction for late performance of the
            control group MMG.  The Swedish meta-analysis resolved these questions
            appropriately.</li></ul></div><p id="_382" tabindex="-1"><strong>Kopparberg (County W of Two-County Trial), Sweden 1977 </strong> [<a href="#cit/section_6.6">6</a>-<a href="#cit/section_6.8">8</a>]
            </p><div class="pdq-content-list"><ul id="_383" class="pdq-address-block"><li><strong>Age at entry:</strong> 40 to 74 years.</li><li>
            <strong>Randomization:</strong> Geographic cluster, with stratification for residence (urban or
            rural), socioeconomic factors, and size.  The process for randomization has not
            been described.  The study women were older than the control women, <em>P</em> &lt; .0001, but this would not have had a major effect on the outcome of the trial.
            </li><li><strong>Exclusions:</strong> Women with pre-existing breast cancer were excluded from both
            groups, but the numbers were reported differently in different publications.</li><li><strong>Sample size:</strong> Variably reported, ranging from 38,562 to 39,051 in intervention
            and from 18,478 to 18,846 in control.</li><li><strong>Consistency of reports:</strong> Variable.</li><li><strong>Intervention:</strong> Three single-view MMGs every 2 years for women younger than 50 years and every 33 months
            for women aged 50 years and older.</li><li><strong>Control:</strong> Usual care, with MMG at study end.</li><li><strong>Compliance:</strong> 89% participation.</li><li><strong>Contamination:</strong>
            13% of women in the Two-County trial had MMG as part of routine care,
            mostly between 1983 and 1984.</li><li><strong>Cause of death attribution:</strong>
            Determined by a team of local physicians (see
            &#xD6;sterg&#xF6;tland).</li><li><strong>Analysis:</strong> Evaluation.</li><li>
            <strong>External audit:</strong> No.  However, breast cancer cases and deaths were adjudicated by a Swedish panel that included the trial's investigators.[<a href="#cit/section_6.9">9</a>]</li><li><strong>Follow-up duration:</strong> 12 years.</li><li><strong>Relative risk of breast cancer death, screening versus control (95% CI):</strong> 0.68
            (0.52&#x2013;0.89).</li></ul></div><p id="_384" tabindex="-1"><strong>Edinburgh, United Kingdom 1976 </strong> [<a href="#cit/section_6.10">10</a>]
            </p><div class="pdq-content-list"><ul id="_385" class="pdq-address-block"><li><strong>Age at entry:</strong> 45 to 64 years.</li><li>
            <strong>Randomization:</strong> Cluster by physician practices, though many randomization
            assignments were changed after study start.  Within each practice, there was
            inconsistent recruitment of women, according to the physician&#x2019;s judgment about
            each woman&#x2019;s suitability for the trial.  Large differences in socioeconomic
            status between practices were not recognized until after the study end.</li><li><strong>Exclusions:</strong> More women (338) with pre-existing breast cancer were excluded
            from the intervention group than from the control group (177).</li><li>
            <strong>Sample size:</strong> 23,226 study  and 21,904 control.</li><li>
            <strong>Consistency of reports:</strong> Good.</li><li><strong>Intervention:</strong> Initially, two-view MMG and CBE; then annual CBE, with single-view MMG
            in years 3, 5, and 7.</li><li>
            <strong>Control:</strong> Usual care.</li><li>
            <strong>Compliance:</strong> 61% screened.</li><li>
            <strong>Contamination:</strong> None.</li><li><strong>Cause of death attribution:</strong>
            Cancer Registry Data.</li><li>
            <strong>Analysis:</strong> Follow-up.</li><li><strong>External audit:</strong>
            No.</li><li><strong>Follow-up duration:</strong> 10 years.</li><li>
            <strong>Relative risk of breast cancer death, screening versus control (95% CI):</strong> 0.84
            (0.63&#x2013;1.12).</li><li><strong>Comments:</strong> Randomization process was flawed.  Socioeconomic differences between
            study and control groups probably account for the higher all-cause mortality in control
            women compared with  screened women.  This difference in all-cause mortality was four
            times greater than the breast cancer mortality in the control group, and
            therefore, may account for the higher breast cancer mortality in the control group
            compared with  screened women.  Although a correction factor was used in the
            final analysis, this may not adjust the analysis sufficiently.</li></ul></div><p id="_386" tabindex="-1">The study design and conduct make these results difficult to assess or combine
            with the results of other trials.
            </p><p id="_387" tabindex="-1"><strong>National Breast Screening Study (NBSS)-1, Canada 1980 </strong>
            [<a href="#cit/section_6.11">11</a>]</p><div class="pdq-content-list"><ul id="_388" class="pdq-address-block"><li><strong>Age at entry:</strong> 40 to 49 years.</li><li>
            <strong>Randomization:</strong> Individual volunteers, with names entered successively on
            allocation lists.  Although criticisms of the randomization procedure have
            been made, a thorough independent review found no evidence of subversion and
            that subversion on a scale large enough to affect the results was unlikely.[<a href="#cit/section_6.12">12</a>]</li><li><strong>Exclusions:</strong>
            Few, balanced between groups.</li><li>
            <strong>Sample size:</strong> 25,214 study (100% screened after entry CBE) and 25,216 control.</li><li><strong>Consistency of reports:</strong>
            Good.</li><li>
            <strong>Intervention:</strong> Annual two-view MMG and CBE for 4 to 5 years.</li><li>
            <strong>Control:</strong> Usual care.</li><li>
            <strong>Compliance:</strong> Initially 100%, decreased to 85.5% by screen five.</li><li>
            <strong>Contamination:</strong> 26.4% in usual care group.</li><li><strong>Cause of death attribution:</strong>
            Death certificates, with review of questionable
            cases by a blinded review panel.  Also linked with the Canadian Mortality Data
            Base, Statistics Canada.</li><li>
            <strong>Analysis:</strong> Follow-up.</li><li><strong>External audit:</strong>
            Yes. Independent, with analysis of data by several reviewers.</li><li><strong>Follow-up duration:</strong> 25 years.</li><li><strong>Relative risk of breast cancer death, screening versus control (95% CI):</strong>
            1.09 (0.80&#x2013;1.49).</li><li><strong>Comments:</strong>
            This is the only trial specifically designed to study women aged 40
            to 49 years.  Cancers diagnosed at entry in both study and control groups were
            included.  Concerns were expressed before the completion of the trial about
            the technical adequacy of the MMGs, the training of the radiologists, and the
            standardization of the equipment, which prompted an independent external
            review.  The primary deficiency identified by this review was the use of the
            mediolateral view from 1980 to 1985 instead of the mediolateral oblique view,
            which was used after 1985.[<a href="#cit/section_6.13">13</a>]  Subsequent analyses found the size and stage
            of the cancers detected mammographically in this trial to be equivalent to
            those of other trials.[<a href="#cit/section_6.14">14</a>]  This trial and NBSS-2 differ from the other RCTs in
            the consistent use of adjuvant hormone therapy and chemotherapy following local breast
            cancer therapy in women with axillary node-positive disease.</li></ul></div><p id="_389" tabindex="-1"><strong>NBSS-2, Canada 1980 </strong>[<a href="#cit/section_6.15">15</a>]
            </p><div class="pdq-content-list"><ul id="_390" class="pdq-address-block"><li><strong>Age at entry:</strong> 50 to 59 years.</li><li><strong>Randomization:</strong>
            Individual volunteer (see <a href="/types/breast/hp/breast-screening-pdq#link/_387">NBSS-1</a>).</li><li><strong>Exclusions:</strong> Few, balanced between groups.</li><li><strong>Sample size:</strong> 19,711 study (100% screened after entry CBE) and 19,694 control.</li><li><strong>Intervention:</strong> Annual two-view MMG and CBE.</li><li><strong>Control:</strong>
            Annual CBE.</li><li><strong>Compliance:</strong> Initially 100%, decreased to 86.7% by screen five in the MMG and CBE
            group.  Initially 100%, decreased to 85.4% by screen five in the CBE only group.</li><li><strong>Contamination:</strong> 16.9% of the CBE only group.</li><li><strong>Cause of death attribution:</strong> Death certificates, with review of questionable
            cases by a blinded review panel.  Also linked with the Canadian Mortality Data
            Base, Statistics Canada.</li><li>
            <strong>Analysis:</strong> Follow-up.</li><li>
            <strong>External audit:</strong> Yes.  Independent with analysis of data by several reviewers.</li><li><strong>Follow-up duration:</strong> 25 years.</li><li>
            <strong>Relative risk of breast cancer death, screening versus control:</strong> 1.02 (95% CI, 0.77&#x2013;1.36)</li><li><strong>Comments:</strong> This trial is unique in that it compares one screening modality to
            another and does not include an unscreened control.  Regarding criticisms and
            comments about this trial, see <a href="/types/breast/hp/breast-screening-pdq#link/_387">NBSS-1</a>.
            </li></ul></div><p id="_391" tabindex="-1"><strong>Stockholm, Sweden 1981 </strong> [<a href="#cit/section_6.16">16</a>]
            </p><div class="pdq-content-list"><ul id="_120" class="pdq-address-block"><li><strong>Age at entry:</strong> 40 to 64 years.</li><li><strong>Randomization:</strong>
            Cluster by birth date.  There were two subtrials with balanced
            randomization in the first and a significant imbalance in the second, with 508
            more women in the screened group than the control.</li><li><strong>Exclusions:</strong> Inconsistently reported.</li><li><strong>Sample size:</strong> Between published reports, the size declined from 40,318 to 38,525 in the intervention group and rose from
            19,943 to 20,978 in the control group.</li><li>
            <strong>Consistency of reports:</strong> Variable.</li><li><strong>Intervention:</strong>
            Single-view MMG every 28 months &#xD7;    2.</li><li>
            <strong>Control:</strong> MMG at year 5.</li><li><strong>Compliance:</strong> 82% screened.</li><li>
            <strong>Contamination:</strong> 25% of women entering the study had MMG in the 3 years before
            entry.</li><li><strong>Cause of death attribution:</strong>
            Linked to Swedish Cause of Death Registry.</li><li><strong>Analysis:</strong> Evaluation, with 1-year delay in the post-trial MMG in the control
            group.  Follow-up analysis as part of the Swedish meta-analysis.[<a href="#cit/section_6.5">5</a>]</li><li><strong>External audit:</strong> No.</li><li><strong>Follow-up duration:</strong>
            8 years.</li><li>
            <strong>Relative risk of breast cancer death, screening versus control (95% CI):</strong> 0.80
            (0.53&#x2013;1.22).</li><li><strong>Comments:</strong> Concerns exist about randomization, especially in the second
            subtrial, exclusions, and the delay in control group MMG.
            Inclusion of these data in the Swedish meta-analysis resolves many of these
            questions.</li></ul></div><p id="_392" tabindex="-1"><strong>Gothenburg, Sweden 1982</strong></p><div class="pdq-content-list"><ul id="_393" class="pdq-address-block"><li><strong>Age at entry:</strong>  39 to 59 years.</li><li><strong>Randomization:</strong> Complex; cluster randomly assigned within birth year by day of birth for older group (aged 50&#x2013;59 years) and by individual for younger group (aged 39&#x2013;49 years); ratio of study to control varied by year depending on MMG availability (randomization took place,  1982&#x2013;1984).</li><li><strong>Exclusions:</strong>
            A similar proportion of women were excluded from both groups for
            prior breast cancer diagnosis (1.2% each).</li><li><strong>Sample size:</strong> Most recent publication: 21,650 invited; 29,961 control.</li><li>
            <strong>Consistency of reports:</strong> Variable.</li><li>
            <strong>Intervention:</strong> Initial two-view MMG, then single-view MMG every 18 months &#xD7;         4. Single-read first  three rounds, then double-read.</li><li><strong>Control:</strong> Control group received one screening exam approximately 3 to 8 months after the final screen in study group.</li><li><strong>Cause of death attribution:</strong> Linked to Swedish Cause of Death Registry; also used an independent endpoint committee.</li><li><strong>Analysis:</strong>  Both evaluation and follow-up methods.[<a href="#cit/section_6.5">5</a>]</li><li><strong>External audit:</strong> No.</li><li><strong>Follow-up duration:</strong> 12 to14 years.</li><li><strong>Relative risk of breast cancer death, screening versus control (95% CI):</strong> 	Aged 39 to 59 years: 0.79 (0.58&#x2013;1.08) [evaluation]; 0.77 (0.60&#x2013;1.00) [follow-up].</li><li><strong>Comments:</strong>  No reduction for women aged 50 to 54 years, but similar reductions for other 5-year age groups.
            </li><li><strong>Conclusions:</strong> Delay in the performance of MMG in the control group and unequal numbers of women in invited and control groups (complex randomization process) complicates interpretation. </li></ul></div><p id="_375" tabindex="-1"><strong>AGE Trial</strong> [<a href="#cit/section_6.17">17</a>,<a href="#cit/section_6.18">18</a>]</p><div class="pdq-content-list"><ul id="_376" class="pdq-address-block"><li><strong>Age at entry:</strong>  39 to 41 years.</li><li><strong>Randomization:</strong> Individuals from lists of general practitioners in geographically defined areas of England, Wales, and Scotland; allocation was concealed.</li><li><strong>Exclusions:</strong>
            Small (n = 30 in invited group and n = 51 in not invited group) number excluded in each group because individuals could not be located   or were deceased.</li><li><strong>Sample size:</strong> 160,921 (53,884 invited; 106,956 not invited).</li><li>
            <strong>Consistency of reports:</strong> Not applicable.</li><li>
            <strong>Intervention:</strong> Invited group aged 48 years and younger were offered annual screening by MMG (double-view first screen, then single mediolateral oblique view thereafter); 68% accepted first screening and 69% to 70% were reinvited (81% attended at least one screen).</li><li><strong>Control:</strong> Those who were not invited received usual medical care, unaware of their participation, and few were screened before randomization.</li><li><strong>Cause of death attribution:</strong> From the National Health Service  (NHS) central register, death certificate code accepted.</li><li><strong>Analysis:</strong>  Follow-up method  was intention-to-treat (although all women aged 50 years would be offered screening by NHS).</li><li><strong>External audit:</strong> None.</li><li><strong>Follow-up duration:</strong> 10.7 years.</li><li><strong>Relative risk of breast cancer death, screening versus control (95% CI):</strong> 	0.83 (0.66&#x2013;1.04).</li><li><strong>Conclusions:</strong> Not a statistically significant result, but fits with other studies.</li><li><strong>Follow-up duration:</strong> Restricted to 10 years from randomization.</li><li><strong>Relative risk of breast cancer death, screening versus control (95% CI):</strong> 0.75 (0.58&#x2013;0.97).</li><li><strong>Conclusions:</strong> A statistically significant result.</li><li><strong>Follow-up duration:</strong> Median 17.7 years.</li><li><strong>Relative risk of breast cancer death, screening versus control (95% CI):</strong> 0.88 (0.74&#x2013;1.04).</li><li><strong>Conclusions:</strong> Not a statistically significant result.</li><li><strong>Follow-up duration:</strong> Median 17.7 years.</li><li><strong>Relative risk of all-cause mortality, screening versus control (95% CI):</strong> 0.98 (0.93&#x2013;1.03).</li><li><strong>Conclusions:</strong> Not a statistically significant result.</li></ul></div><p id="_588" tabindex="-1">The reduction in breast cancer mortality at a median follow-up of 17.7 years corresponds to an absolute risk reduction of 0.1 of 1,000 (or 1 of 10,000) fewer deaths.</p><p id="_589" tabindex="-1">The evidence is inadequate to support the conclusion of a clinically significant breast cancer mortality reduction attributable to initiation of screening mammography among women aged 39 to 49 years. The reported mortality reduction is a very small, transient reduction in breast cancer mortality based on a nonstandard imaging schedule, nonstandard imaging protocol, and nonstandard threshold for biopsy; therefore, it is of uncertain relevance to the general population. In absolute terms, it corresponds to an absolute risk reduction of 0.1 of 1,000 (or 1 of 10,000) fewer deaths.  Additionally, the mortality reduction is based on a re-analysis of the original data set, which was not statistically significant, and the recalculation of breast cancer mortality in a subgroup restricted to 10 years of follow-up.   At 20 years of follow-up, there was no statistically significant decrease in risk of breast cancer or all-cause mortality.[<a href="#cit/section_6.18">18</a>]</p><p id="_590" tabindex="-1">The evidence is inadequate to make a clear determination of the magnitude of overdiagnosis. Because the evidence is based on subgroup analysis and nonstandard imaging schedule, nonstandard imaging protocol, and a nonstandard threshold for biopsy with uncertain relevance to the general population, it does not support the investigators' conclusion of &#x201C;at worst a small amount of overdiagnosis."[<a href="#cit/section_6.18">18</a>]</p><h6 do-not-show="toc">References</h6><ol><li id="section_6.1">Shapiro S, Venet W, Strax P, et al.: Ten- to fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst 69 (2): 349-55, 1982.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6955542&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6955542&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.2">Shapiro S: Periodic screening for breast cancer: the Health Insurance Plan project and its sequelae, 1963-1986. Baltimore, Md: Johns Hopkins University Press, 1988.</li><li id="section_6.3">Andersson I, Aspegren K, Janzon L, et al.: Mammographic screening and mortality from breast cancer: the Malm&#xF6; mammographic screening trial. BMJ 297 (6654): 943-8, 1988.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3142562&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3142562&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.4">Nystr&#xF6;m L, Rutqvist LE, Wall S, et al.: Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet 341 (8851): 973-8, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8096941&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8096941&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.5">Nystr&#xF6;m L, Andersson I, Bjurstam N, et al.: Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 359 (9310): 909-19, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11918907&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11918907&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.6">Tab&#xE1;r L, Fagerberg CJ, Gad A, et al.: Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet 1 (8433): 829-32, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2858707&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2858707&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.7">Tab&#xE0;r L, Fagerberg G, Duffy SW, et al.: Update of the Swedish two-county program of mammographic screening for breast cancer. Radiol Clin North Am 30 (1): 187-210, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1732926&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1732926&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.8">Tabar L, Fagerberg G, Duffy SW, et al.: The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit. J Epidemiol Community Health 43 (2): 107-14, 1989.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2512366&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2512366&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.9">Holmberg L, Duffy SW, Yen AM, et al.: Differences in endpoints between the Swedish W-E (two county) trial of mammographic screening and the Swedish overview: methodological consequences. J Med Screen 16 (2): 73-80, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19564519&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19564519&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.10">Roberts MM, Alexander FE, Anderson TJ, et al.: Edinburgh trial of screening for breast cancer: mortality at seven years. Lancet 335 (8684): 241-6, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1967717&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1967717&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.11">Miller AB, To T, Baines CJ, et al.: The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years. Ann Intern Med 137 (5 Part 1): 305-12, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12204013&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12204013&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.12">Bailar JC 3rd, MacMahon B: Randomization in the Canadian National Breast Screening Study: a review for evidence of subversion. CMAJ 156 (2): 193-9, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9012720&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9012720&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.13">Baines CJ, Miller AB, Kopans DB, et al.: Canadian National Breast Screening Study: assessment of technical quality by external review. AJR Am J Roentgenol 155 (4): 743-7; discussion 748-9, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2119103&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2119103&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.14">Fletcher SW, Black W, Harris R, et al.: Report of the International Workshop on Screening for Breast Cancer. J Natl Cancer Inst 85 (20): 1644-56, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8105098&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8105098&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.15">Miller AB, Baines CJ, To T, et al.: Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years. CMAJ 147 (10): 1477-88, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1423088&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1423088&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.16">Frisell J, Eklund G, Hellstr&#xF6;m L, et al.: Randomized study of mammography screening--preliminary report on mortality in the Stockholm trial. Breast Cancer Res Treat 18 (1): 49-56, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1854979&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1854979&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.17">Moss SM, Cuckle H, Evans A, et al.: Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet 368 (9552): 2053-60, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17161727&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17161727&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.18">Moss SM, Wale C, Smith R, et al.: Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial. Lancet Oncol 16 (9): 1123-32, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26206144&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26206144&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _74
      field_pdq_section_title:
        - format: plain_text
          value: 'Changes to This Summary (10/08/2018)'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_74" class="pdq-sections"><p id="_397" tabindex="-1">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.</p><p id="_726" tabindex="-1"><strong><a href="/types/breast/hp/breast-screening-pdq#link/_51">Mammography</a></strong></p><p id="_727" tabindex="-1">Added <a href="/types/breast/hp/breast-screening-pdq#link/_724">text</a> about an observational study of women aged 40 to 74 years conducted in 7 of 12 Canadian screening programs that compared breast cancer mortality in those participants screened at least once between 1990 and 2009 with those not screened which reported a 40% average breast cancer mortality among participants but likely intended to report a 40% reduction in breast cancer mortality on the basis of language utilized in the Discussion section (cited Coldman et al. as reference 77). Also added text to state the limitations of this study including a lack of important data and limitations in methodology and data analysis.</p><p id="_728" tabindex="-1">Revised <a href="/types/breast/hp/breast-screening-pdq#link/_691">text</a> to state that improved screening technology has not been shown to make further reductions in mortality than the original technology.</p><p id="_disclaimerHP_3" tabindex="-1">This summary is written and maintained by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/screening-prevention" title="https://www.cancer.gov/publications/pdq/editorial-boards/screening-prevention">PDQ Screening and Prevention Editorial Board</a>, which is
            editorially independent of NCI.  The summary reflects an independent review of
            the literature and does not represent a policy statement of NCI or NIH.  More
            information about summary policies and the role of the PDQ Editorial Boards  in
            maintaining the PDQ summaries can be found on the <a href="/types/breast/hp/breast-screening-pdq#link/_AboutThis_1">About This PDQ Summary</a> and <a href="https://www.cancer.gov/publications/pdq" title="https://www.cancer.gov/publications/pdq">PDQ&#xAE; - NCI's Comprehensive Cancer Database</a> pages.
            </p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _AboutThis_1
      field_pdq_section_title:
        - format: plain_text
          value: 'About This PDQ Summary'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_AboutThis_1" class="pdq-sections"><section id="_AboutThis_2"><h3 id="_AboutThis_2_toc">Purpose of This Summary</h3><p id="_AboutThis_3" tabindex="-1">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about breast cancer screening. It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</p></section><section id="_AboutThis_4"><h3 id="_AboutThis_4_toc">Reviewers and Updates</h3><p id="_AboutThis_5" tabindex="-1">This summary is reviewed regularly and updated as necessary by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/screening-prevention" title="https://www.cancer.gov/publications/pdq/editorial-boards/screening-prevention">PDQ Screening and Prevention Editorial Board</a>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</p><p id="_AboutThis_22" tabindex="-1"> Board members review recently published articles each month to determine whether an article should:</p><div class="pdq-content-list"><ul id="_AboutThis_6"><li>be discussed at a meeting,</li><li>be cited with text, or</li><li>replace or update an existing article that is already cited.</li></ul></div><p id="_AboutThis_7" tabindex="-1">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</p><p id="_AboutThis_9" tabindex="-1">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us">Email Us</a>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</p></section><section id="_AboutThis_10"><h3 id="_AboutThis_10_toc">Levels of Evidence</h3><p id="_AboutThis_11" tabindex="-1">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Screening and Prevention Editorial Board uses a <a href="/publications/pdq/levels-evidence/screening-prevention">formal evidence ranking system</a> in developing its level-of-evidence designations.</p></section><section id="_AboutThis_12"><h3 id="_AboutThis_12_toc">Permission to Use This Summary</h3><p id="_AboutThis_13" tabindex="-1">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as &#x201C;NCI&#x2019;s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].&#x201D;</p><p id="_AboutThis_14" tabindex="-1">The preferred citation for this PDQ summary is:</p><p id="_AboutThis_15" tabindex="-1">PDQ&#xAE; Screening and Prevention Editorial Board. PDQ Breast Cancer Screening. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <a href="https://www.cancer.gov/types/breast/hp/breast-screening-pdq" title="https://www.cancer.gov/types/breast/hp/breast-screening-pdq">https://www.cancer.gov/types/breast/hp/breast-screening-pdq</a>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389344]</p><p id="_AboutThis_16" tabindex="-1">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <a href="https://visualsonline.cancer.gov/" title="https://visualsonline.cancer.gov/">Visuals Online</a>, a collection of over 2,000 scientific images.
            </p></section><section id="_AboutThis_17"><h3 id="_AboutThis_17_toc">Disclaimer</h3><p id="_AboutThis_19" tabindex="-1">The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <a href="https://www.cancer.gov/about-cancer/managing-care" title="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</a> page.</p></section><section id="_AboutThis_20"><h3 id="_AboutThis_20_toc">Contact Us</h3><p id="_AboutThis_21" tabindex="-1">More information about contacting us or receiving help with the Cancer.gov website can be found on our <a href="https://www.cancer.gov/contact" title="https://www.cancer.gov/contact">Contact Us for Help</a> page. Questions can also be submitted to Cancer.gov through the website&#x2019;s <a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us">Email Us</a>.</p></section></div>
  title__ES:
    value: 'Exámenes de detección del cáncer de seno (mama) (PDQ®)–Versión para profesionales de salud'
  status__ES:
    value: 1
  langcode__ES:
    value: es
  moderation_state__ES:
    value: published
  field_pdq_url__ES:
    value: /tipos/seno/pro/deteccion-seno-pdq
  field_pdq_cdr_id__ES:
    value: 744470
  field_pdq_audience__ES:
    value: Health Professionals
  field_pdq_summary_type__ES:
    value: Screening
  field_date_posted__ES:
    value: '2013-01-04'
  field_date_updated__ES:
    value: '2018-06-19'
  field_browser_title__ES:
    value: 'Exámenes de detección del cáncer de seno (mama)'
  field_page_description__ES:
    value: 'Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de mama.'
  field_public_use__ES:
    value: 1
  field_summary_sections__ES:
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _1
      field_pdq_section_title:
        - format: plain_text
          value: 'Aspectos generales'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_1" class="pdq-sections"><div class="pdq-hp-patient-toggle"><a href="/espanol/tipos/seno/paciente/deteccion-seno-pdq">Vaya a la versi&#xF3;n para pacientes</a></div><p id="_3" tabindex="-1">Nota: Tambi&#xE9;n se dispone de sumarios por separado sobre <a href="/espanol/tipos/seno/pro/prevencion-seno-pdq">Prevenci&#xF3;n del c&#xE1;ncer de seno (mama)</a>; <a href="/espanol/tipos/seno/pro/tratamiento-seno-pdq">Tratamiento del c&#xE1;ncer de seno (mama)</a>; <a href="/espanol/tipos/seno/pro/tratamiento-seno-masculino-pdq">Tratamiento del c&#xE1;ncer de seno (mama) masculino</a> y <a href="/espanol/tipos/seno/pro/tratamiento-seno-embarazo-pdq">Tratamiento del c&#xE1;ncer de seno (mama) durante el embarazo</a>.</p><p id="_207" tabindex="-1">La mamograf&#xED;a constituye la modalidad de ex&#xE1;menes de detecci&#xF3;n que m&#xE1;s se usa para la detecci&#xF3;n del c&#xE1;ncer de mama. Hay pruebas de que disminuye la mortalidad por c&#xE1;ncer de mama en las mujeres de 50 a 69 a&#xF1;os y que se relaciona con perjuicios; entre estos, la detecci&#xF3;n de c&#xE1;nceres que carecen de importancia cl&#xED;nica y que no ponen en peligro la vida del paciente (sobrediagn&#xF3;stico). Es incierto el beneficio de la mamograf&#xED;a para las mujeres de 40 a 49 a&#xF1;os.[<a href="#cit/section_1.1">1</a>,<a href="#cit/section_1.2">2</a>] El uso del examen cl&#xED;nico de la mama (ECM) no se ha estudiado como examen de detecci&#xF3;n por separado. Se ha demostrado que el autoexamen de la mama no ofrece ning&#xFA;n beneficio con respecto a la mortalidad. Se encuentran en evaluaci&#xF3;n t&#xE9;cnicas como la ecograf&#xED;a, las im&#xE1;genes por resonancia magn&#xE9;tica y otras t&#xE9;cnicas de im&#xE1;genes moleculares de la mama que, a menudo, se usan para complementar la mamograf&#xED;a, pero que no son los instrumentos de detecci&#xF3;n principales para la poblaci&#xF3;n general.</p><p id="_712" tabindex="-1">Tomar una decisi&#xF3;n m&#xE9;dica con pleno conocimiento de causa, es algo que cada vez se recomienda m&#xE1;s a las personas que contemplan someterse a un examen de detecci&#xF3;n del c&#xE1;ncer. Se han estudiado distintas formas de ofrecer ayuda para la toma de decisiones. (Para obtener m&#xE1;s informaci&#xF3;n, consultar el sumario del PDQ sobre <a href="/about-cancer/screening/hp-screening-overview-pdq">Aspectos generales de los ex&#xE1;menes de detecci&#xF3;n del c&#xE1;ncer</a>).</p><section id="_7"><h3 id="_7_toc">Ex&#xE1;menes de detecci&#xF3;n con mamograf&#xED;a</h3><section id="_10"><h4 id="_10_toc">Beneficios</h4><p id="_701" tabindex="-1">Los ensayos cl&#xED;nicos controlados aleatorizados (ECA) que se iniciaron hace 50 a&#xF1;os ofrecen pruebas de que la detecci&#xF3;n con mamograf&#xED;a mejora la supervivencia de las mujeres de 60 a 69 a&#xF1;os (datos probatorios s&#xF3;lidos) y las mujeres de 50 a 59 a&#xF1;os (datos probatorios aceptables). En los estudios de poblaci&#xF3;n m&#xE1;s recientes, se plantean dudas acerca del beneficio para las poblaciones que se someten a ex&#xE1;menes de detecci&#xF3;n durante per&#xED;odos prolongados.</p><p id="_702" tabindex="-1"><strong>Magnitud del efecto:</strong> a partir de un metan&#xE1;lisis de ECA, el n&#xFA;mero de mujeres que se necesita invitar a participar en los ex&#xE1;menes de detecci&#xF3;n para evitar una muerte por c&#xE1;ncer de mama depende de la edad de la mujer: entre 39 y 49 a&#xF1;os, se necesitan 1904 mujeres (intervalo de confianza [IC], 95&#xA0;%; 929&#x2013;6378); entre 50 y 59 a&#xF1;os, se necesitan 1339 mujeres (IC, 95&#xA0;%; 322&#x2013;7455); y entre 60 y 69 a&#xF1;os, se necesitan 377 mujeres (IC, 95&#xA0;%, 230&#x2013;1050).[<a href="#cit/section_1.3">3</a>]</p><div class="pdq-content-list"><ul id="_24" class="pdq-address-block"><li><strong>Dise&#xF1;o del estudio:</strong> ECA, datos probatorios de poblaci&#xF3;n.</li><li><strong>Validez interna:</strong> variable, pero el metan&#xE1;lisis de los ECA es bueno.</li><li><strong>Congruencia:</strong> deficiente.</li><li><strong>Validez externa:</strong> incierta.</li></ul></div><p id="_704" tabindex="-1">La validez de los metan&#xE1;lisis de ECA que demuestran un beneficio para la mortalidad est&#xE1; limitada por los avances en las t&#xE9;cnicas de diagn&#xF3;stico por im&#xE1;genes y tratamiento que se produjeron en las d&#xE9;cadas posteriores a los ensayos. En el Canadian National Breast Screening Study (CNBSS) de 25 a&#xF1;os de seguimiento,[<a href="#cit/section_1.4">4</a>] que se complet&#xF3; en 2014, no se observ&#xF3; un beneficio de supervivencia relacionado con el uso de las mamograf&#xED;as de detecci&#xF3;n.</p></section><section id="_13"><h4 id="_13_toc">Perjuicios</h4><p id="_14" tabindex="-1">Sobre la base de datos probatorios s&#xF3;lidos, es posible que las mamograf&#xED;as de detecci&#xF3;n produzcan los siguientes perjuicios:</p><div class="pdq-content-list"><ul id="_25"><li><strong>Sobrediagn&#xF3;stico y tratamiento resultante de c&#xE1;nceres insignificantes:</strong> algunos de los c&#xE1;nceres que se encuentran mediante los ex&#xE1;menes de detecci&#xF3;n amenazan la vida de la persona y otros no; no hay una forma definitiva de distinguir entre estos. Por lo tanto, los tratamientos est&#xE1;ndar del c&#xE1;ncer, que incluyen cirug&#xED;a, radiaci&#xF3;n, terapia endocrina, quimioterapia y terapias dirigidas al receptor <em>HER2</em>, se recomiendan en todos los casos, incluso para las pacientes que no obtendr&#xE1;n ning&#xFA;n beneficio.<div class="pdq-content-list"><ul id="_26" class="pdq-address-block"><li><strong>Magnitud del efecto:</strong> entre 20 y 50&#xA0;% de los c&#xE1;nceres que se encuentran mediante los ex&#xE1;menes de detecci&#xF3;n representan sobrediagn&#xF3;sticos seg&#xFA;n la edad, la expectativa de vida y el tipo de tumor (carcinoma ductal <em>in situ</em> o invasivo).[<a href="#cit/section_1.5">5</a>,<a href="#cit/section_1.6">6</a>] Estos c&#xE1;lculos se basan en dos m&#xE9;todos anal&#xED;ticos imperfectos:[<a href="#cit/section_1.5">5</a>,<a href="#cit/section_1.7">7</a>]<div class="pdq-content-list"><ol id="_705"><li>Seguimiento a largo plazo en ECA de ex&#xE1;menes de detecci&#xF3;n.</li><li>C&#xE1;lculos del exceso de incidencia en programas de detecci&#xF3;n grandes.[<a href="#cit/section_1.5">5</a>,<a href="#cit/section_1.6">6</a>]</li></ol></div></li><li><strong>Dise&#xF1;o del estudio:</strong> ECA, comparaciones descriptivas de poblaci&#xF3;n, series de autopsias y series de muestras de reducci&#xF3;n mamaria.</li></ul></div></li><li>
            <strong>Resultados positivos falsos con pruebas adicionales y ansiedad.</strong>
            <div class="pdq-content-list"><ul id="_27" class="pdq-address-block"><li><strong>Magnitud del efecto:</strong> en los Estados Unidos, se vuelve a llamar a cerca de 10&#xA0;% de las mujeres para que se sometan a pruebas adicionales despu&#xE9;s de un examen de detecci&#xF3;n; sin embargo, solo 0,5&#xA0;% de las mujeres que lo hacen presentan c&#xE1;ncer; es decir, alrededor de 9,5&#xA0;% de las mujeres tendr&#xE1;n una prueba con resultado positivo falso.[<a href="#cit/section_1.8">8</a>,<a href="#cit/section_1.9">9</a>] Cerca de 50&#xA0;% de las mujeres que se someten a ex&#xE1;menes de detecci&#xF3;n anuales durante 10 a&#xF1;os en los Estados Unidos obtendr&#xE1;n un resultado positivo falso, y de 7 a 17&#xA0;% de estas mujeres se someter&#xE1;n a biopsias.[<a href="#cit/section_1.10">10</a>,<a href="#cit/section_1.11">11</a>] Es menos probable que se necesiten pruebas adicionales cuando se dispone de mamograf&#xED;as anteriores para hacer una comparaci&#xF3;n.</li><li><strong>Dise&#xF1;o del estudio:</strong> descriptivos y de poblaci&#xF3;n.</li></ul></div>
            </li><li>
            <strong>Resultados negativos falsos, con un falso sentido de seguridad y posible retraso en el diagn&#xF3;stico de c&#xE1;ncer.</strong>
            <div class="pdq-content-list"><ul id="_28" class="pdq-address-block"><li><strong>Magnitud del efecto:</strong> la mamograf&#xED;a no detectar&#xE1; el c&#xE1;ncer de mama invasivo en 6 a 46&#xA0;% de los ex&#xE1;menes de detecci&#xF3;n (negativo falso). Es m&#xE1;s probable que se obtenga un resultado negativo falso en los c&#xE1;nceres de tipo mucinoso y lobulillar, los tumores de <em>intervalo</em> de crecimiento r&#xE1;pido y en las mamas densas, que son comunes en las mujeres j&#xF3;venes.[<a href="#cit/section_1.12">12</a>-<a href="#cit/section_1.14">14</a>]</li><li><strong>Dise&#xF1;o del estudio:</strong> descriptivos y de poblaci&#xF3;n.</li></ul></div>
            </li><li><strong>C&#xE1;ncer de mama inducido por radiaci&#xF3;n:</strong> las mutaciones provocadas por la radiaci&#xF3;n se producen con dosis de radiaci&#xF3;n m&#xE1;s altas que las que se utilizan en una sola mamograf&#xED;a; por lo tanto, es muy improbable que la exposici&#xF3;n durante una mamograf&#xED;a t&#xED;pica de dos proyecciones cause c&#xE1;ncer.[<a href="#cit/section_1.15">15</a>,<a href="#cit/section_1.16">16</a>]<div class="pdq-content-list"><ul id="_29" class="pdq-address-block"><li><strong>Magnitud del efecto:</strong> en teor&#xED;a, las mamograf&#xED;as anuales en mujeres de 40 a 80 a&#xF1;os pueden causar hasta 1 c&#xE1;ncer de mama en cada 1000 mujeres.[<a href="#cit/section_1.15">15</a>,<a href="#cit/section_1.16">16</a>]</li><li><strong>Dise&#xF1;o del estudio:</strong> descriptivos y de poblaci&#xF3;n.</li></ul></div></li></ul></div><p id="_30" tabindex="-1">La validez interna, la congruencia y la validez externa son buenas para todas las conclusiones sobre los posibles perjuicios de los ex&#xE1;menes de detecci&#xF3;n con mamograf&#xED;a.</p></section></section><section id="_15"><h3 id="_15_toc">Examen cl&#xED;nico de la mama</h3><section id="_16"><h4 id="_16_toc">Beneficios</h4><p id="_17" tabindex="-1">En el ensayo Canadian National Breast Screening Study (CNBSS), no se estudi&#xF3; la eficacia del examen cl&#xED;nico de la mama (ECM) en comparaci&#xF3;n con la ausencia de ex&#xE1;menes de detecci&#xF3;n. Los ensayos aleatorizados en curso, dos en India y uno en Egipto, se dise&#xF1;aron para evaluar la eficacia del ECM pero no se notificaron datos de mortalidad.[<a href="#cit/section_1.17">17</a>-<a href="#cit/section_1.22">22</a>] Por este motivo, a&#xFA;n no es posible evaluar la eficacia del ECM como m&#xE9;todo de detecci&#xF3;n.</p><div class="pdq-content-list"><ul id="_31" class="pdq-address-block"><li><strong>Magnitud del efecto:</strong> los datos probatorios actuales no son suficientes para evaluar los beneficios y perjuicios adicionales del ECM. En el &#xFA;nico ECA en el que se compar&#xF3; el ECM de calidad alta con los ex&#xE1;menes de detecci&#xF3;n con mamograf&#xED;a se observ&#xF3; el mismo beneficio. La precisi&#xF3;n en el entorno comunitario quiz&#xE1;s sea menor que en el de los ECA.[<a href="#cit/section_1.17">17</a>-<a href="#cit/section_1.20">20</a>]</li><li><strong>Dise&#xF1;o del estudio:</strong> un solo ECA, estudios de cohortes de poblaci&#xF3;n.</li><li><strong>Validez interna:</strong> buena.</li><li><strong>Congruencia y validez externa:</strong> deficiente.</li></ul></div></section><section id="_20"><h4 id="_20_toc">Perjuicios</h4><p id="_21" tabindex="-1">Los ex&#xE1;menes de detecci&#xF3;n con ECM pueden tener los siguientes perjuicios:</p><div class="pdq-content-list"><ul id="_22"><li>
            <strong>Resultados positivos falsos con pruebas adicionales y ansiedad.</strong>
            <div class="pdq-content-list"><ul id="_23" class="pdq-address-block"><li><strong>Magnitud del efecto:</strong> la especificidad en las mujeres de 50 a 59 a&#xF1;os fue de 88 a 99&#xA0;%, lo que dio lugar a una tasa de resultados positivos falsos de 1 a 12&#xA0;% para todas las mujeres que se sometieron a ex&#xE1;menes de detecci&#xF3;n.[<a href="#cit/section_1.23">23</a>]</li><li><strong>Dise&#xF1;o del estudio:</strong> descriptivos y de poblaci&#xF3;n.</li><li><strong>Validez interna, congruencia y validez externa:</strong> buena.</li></ul></div>
            </li><li>
            <strong>Resultados negativos falsos con posible confirmaci&#xF3;n falsa y retraso en el diagn&#xF3;stico de c&#xE1;ncer.</strong>
            <div class="pdq-content-list"><ul id="_32" class="pdq-address-block"><li><strong>Magnitud del efecto:</strong> de las mujeres con c&#xE1;ncer, entre 17 y 43&#xA0;% tiene un ECM que da resultado negativo. La sensibilidad es m&#xE1;s alta con una duraci&#xF3;n m&#xE1;s larga y una calidad m&#xE1;s alta del examen cuando lo lleva a cabo personal capacitado.</li><li><strong>Dise&#xF1;o del estudio:</strong> descriptivos y de poblaci&#xF3;n.</li><li><strong>Validez interna y externa:</strong> buena.</li><li><strong>Congruencia:</strong> razonable.</li></ul></div>
            </li></ul></div></section></section><section id="_33"><h3 id="_33_toc">Autoexamen de la mama</h3><section id="_34"><h4 id="_34_toc">Beneficios</h4><p id="_35" tabindex="-1">El autoexamen de la mama (AEM) se compar&#xF3; con la ausencia de ex&#xE1;menes de detecci&#xF3;n y no se observ&#xF3; ning&#xFA;n beneficio para disminuir la mortalidad por c&#xE1;ncer de mama.</p><div class="pdq-content-list"><ul id="_36" class="pdq-address-block"><li><strong>Magnitud del efecto:</strong> sin efecto.[<a href="#cit/section_1.24">24</a>,<a href="#cit/section_1.25">25</a>]</li><li><strong>Dise&#xF1;o del estudio:</strong> dos ECA.</li><li><strong>Validez interna y congruencia:</strong> razonable.</li><li><strong>Validez externa:</strong> deficiente.</li></ul></div></section><section id="_37"><h4 id="_37_toc">Perjuicios</h4><p id="_38" tabindex="-1">A partir de datos probatorios s&#xF3;lidos, la educaci&#xF3;n formal y la motivaci&#xF3;n para realizarse el AEM conduce a m&#xE1;s biopsias de mama y m&#xE1;s diagn&#xF3;sticos de lesiones de mama benignas.</p><div class="pdq-content-list"><ul id="_39" class="pdq-address-block"><li><strong>Magnitud de los efectos en los resultados de salud:</strong> la tasa de biopsia fue de 1,8&#xA0;% en la poblaci&#xF3;n de estudio, en comparaci&#xF3;n con 1,0&#xA0;% en el grupo de control.[<a href="#cit/section_1.24">24</a>]</li><li><strong>Dise&#xF1;o del estudio:</strong> dos ECA, estudios de cohortes.</li><li><strong>Validez interna:</strong> buena.</li><li><strong>Congruencia:</strong> razonable.</li><li><strong>Validez externa:</strong> deficiente.</li></ul></div></section></section><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_1.1">Moss SM, Cuckle H, Evans A, et al.: Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet 368 (9552): 2053-60, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17161727&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17161727&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.2">Moss SM, Wale C, Smith R, et al.: Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial. Lancet Oncol 16 (9): 1123-32, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26206144&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26206144&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.3">Nelson HD, Tyne K, Naik A, et al.: Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med 151 (10): 727-37, W237-42, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19920273&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19920273&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.4">Miller AB, Wall C, Baines CJ, et al.: Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ 348: g366, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24519768&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24519768&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.5">Welch HG, Black WC: Overdiagnosis in cancer. J Natl Cancer Inst 102 (9): 605-13, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20413742&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20413742&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.6">Bleyer A, Welch HG: Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 367 (21): 1998-2005, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23171096&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23171096&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.7">Yen MF, Tab&#xE1;r L, Vitak B, et al.: Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. Eur J Cancer 39 (12): 1746-54, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12888370&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12888370&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.8">J&#xF8;rgensen KJ, G&#xF8;tzsche PC: Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ 339: b2587, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19589821&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19589821&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.9">Rosenberg RD, Yankaskas BC, Abraham LA, et al.: Performance benchmarks for screening mammography. Radiology 241 (1): 55-66, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16990671&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16990671&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.10">Elmore JG, Barton MB, Moceri VM, et al.: Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 338 (16): 1089-96, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9545356&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9545356&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.11">Hubbard RA, Kerlikowske K, Flowers CI, et al.: Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann Intern Med 155 (8): 481-92, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22007042&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22007042&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.12">Rosenberg RD, Hunt WC, Williamson MR, et al.: Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico. Radiology 209 (2): 511-8, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9807581&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9807581&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.13">Kerlikowske K, Grady D, Barclay J, et al.: Likelihood ratios for modern screening mammography. Risk of breast cancer based on age and mammographic interpretation. JAMA 276 (1): 39-43, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8667537&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8667537&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.14">Porter PL, El-Bastawissi AY, Mandelson MT, et al.: Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 91 (23): 2020-8, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10580027&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10580027&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.15">Ronckers CM, Erdmann CA, Land CE: Radiation and breast cancer: a review of current evidence. Breast Cancer Res 7 (1): 21-32, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15642178&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15642178&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.16">Goss PE, Sierra S: Current perspectives on radiation-induced breast cancer. J Clin Oncol 16 (1): 338-47, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9440762&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9440762&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.17">Hassan LM, Mahmoud N, Miller AB, et al.: Evaluation of effect of self-examination and physical examination on breast cancer. Breast 24 (4): 487-90, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25977176&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25977176&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.18">Anderson BO, Bevers TB, Carlson RW: Clinical Breast Examination and Breast Cancer Screening Guideline. JAMA 315 (13): 1403-4, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27046372&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27046372&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.19">Yen AM, Tsau HS, Fann JC, et al.: Population-Based Breast Cancer Screening With Risk-Based and Universal Mammography Screening Compared With Clinical Breast Examination: A Propensity Score Analysis of 1&#x202F;429&#x202F;890 Taiwanese Women. JAMA Oncol 2 (7): 915-21, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27030951&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27030951&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.20">Myers ER, Moorman P, Gierisch JM, et al.: Benefits and Harms of Breast Cancer Screening: A Systematic Review. JAMA 314 (15): 1615-34, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26501537&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26501537&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.21">Mittra I, Mishra GA, Singh S, et al.: A cluster randomized, controlled trial of breast and cervix cancer screening in Mumbai, India: methodology and interim results after three rounds of screening. Int J Cancer 126 (4): 976-84, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19697326&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19697326&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.22">Sankaranarayanan R, Ramadas K, Thara S, et al.: Clinical breast examination: preliminary results from a cluster randomized controlled trial in India. J Natl Cancer Inst 103 (19): 1476-80, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21862730&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21862730&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.23">Fenton JJ, Rolnick SJ, Harris EL, et al.: Specificity of clinical breast examination in community practice. J Gen Intern Med 22 (3): 332-7, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17356964&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17356964&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.24">Thomas DB, Gao DL, Ray RM, et al.: Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst 94 (19): 1445-57, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12359854&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12359854&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.25">Semiglazov VF, Manikhas AG, Moiseenko VM, et al.: [Results of a prospective randomized investigation [Russia (St.Petersburg)/WHO] to evaluate the significance of self-examination for the early detection of breast cancer]. Vopr Onkol 49 (4): 434-41, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14569932&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14569932&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _40
      field_pdq_section_title:
        - format: plain_text
          value: 'Descripción de los datos probatorios'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_40" class="pdq-sections"><section id="_41"><h3 id="_41_toc">Incidencia del c&#xE1;ncer de mama y mortalidad</h3><p id="_43" tabindex="-1">El c&#xE1;ncer de mama es el c&#xE1;ncer no cut&#xE1;neo m&#xE1;s com&#xFA;n en las mujeres en los Estados Unidos, con alrededor de 266&#xA0;120 casos nuevos de enfermedad invasiva, 63&#xA0;960 casos de enfermedad <em>in situ</em> y 40&#xA0;920 defunciones previstas para 2018.[<a href="#cit/section_2.1">1</a>] Las mujeres con riesgo hereditario, en especial las portadoras de los genes <em>BRCA1</em> y <em>BRCA2</em>, representan no m&#xE1;s de 10&#xA0;% de los casos de c&#xE1;ncer de mama. Los hombres representan 1&#xA0;% de los casos de c&#xE1;ncer de mama y de las muertes por este tipo de c&#xE1;ncer.</p><p id="_649" tabindex="-1">El factor de riesgo principal del c&#xE1;ncer de mama es ser mujer seguido por la edad avanzada. Otros factores de riesgo se relacionan con aspectos hormonales (como menarquia, menopausia tard&#xED;a, nuliparidad, primer embarazo tard&#xED;o y hormonoterapia posmenop&#xE1;usica), el consumo de bebidas alcoh&#xF3;licas y la exposici&#xF3;n a la radiaci&#xF3;n ionizante.</p><p id="_650" tabindex="-1">La incidencia del c&#xE1;ncer de mama es m&#xE1;s alta en las mujeres blancas que en las mujeres negras que, adem&#xE1;s, tienen una tasa de supervivencia m&#xE1;s baja en el momento del diagn&#xF3;stico en cualquier estadio. Estas diferencias tal vez se deban a la conducta relacionada con los ex&#xE1;menes de detecci&#xF3;n y el acceso a la atenci&#xF3;n de la salud. Las personas hispanas y de las islas del Pac&#xED;fico asi&#xE1;tico presentan menos incidencia y mortalidad que las personas blancas o negras.[<a href="#cit/section_2.2">2</a>]</p><p id="_651" tabindex="-1">La incidencia del c&#xE1;ncer de mama depende de aspectos vinculados a la reproducci&#xF3;n (como el embarazo precoz o tard&#xED;o, la multiparidad y la lactancia materna), la participaci&#xF3;n en los ex&#xE1;menes de detecci&#xF3;n y el uso de hormonas en la posmenopausia. Se observ&#xF3; un aumento considerable en la incidencia del c&#xE1;ncer de mama (en especial del carcinoma ductal <em>in situ</em> [CDIS]) despu&#xE9;s de la adopci&#xF3;n generalizada de los ex&#xE1;menes de detecci&#xF3;n con mamograf&#xED;a en los Estados Unidos y en el Reino Unido.[<a href="#cit/section_2.3">3</a>] El uso generalizado de la hormonoterapia posmenop&#xE1;usica se relacion&#xF3; con un aumento notable en la incidencia de c&#xE1;ncer de mama, una tendencia que se revirti&#xF3; cuando disminuy&#xF3; su uso.[<a href="#cit/section_2.4">4</a>]</p><p id="_706" tabindex="-1">La adopci&#xF3;n de los ex&#xE1;menes de detecci&#xF3;n no es seguida por una disminuci&#xF3;n en la incidencia de c&#xE1;ncer en estadio avanzado en ninguna poblaci&#xF3;n.</p></section><section id="_560"><h3 id="_560_toc">Evaluaci&#xF3;n de los s&#xED;ntomas mamarios</h3><p id="_561" tabindex="-1">Las mujeres con s&#xED;ntomas de c&#xE1;ncer de mama se someten al diagn&#xF3;stico por mamograf&#xED;a, en vez de la mamograf&#xED;a de detecci&#xF3;n, que se lleva a cabo con mujeres asintom&#xE1;ticas. En un estudio de 10 a&#xF1;os de s&#xED;ntomas de c&#xE1;ncer de mama para los que se necesit&#xF3; atenci&#xF3;n m&#xE9;dica, una masa en la mama condujo a un diagn&#xF3;stico de c&#xE1;ncer en 10,7&#xA0;% de los casos, mientras que el dolor se relacion&#xF3; con el c&#xE1;ncer en solo 1,8&#xA0;% de los casos.[<a href="#cit/section_2.5">5</a>]</p></section><section id="_4"><h3 id="_4_toc">Evaluaci&#xF3;n anatomopatol&#xF3;gica del tejido mamario</h3><section id="_64"><h4 id="_64_toc">C&#xE1;ncer de mama invasivo</h4><p id="_65" tabindex="-1">Es posible diagnosticar el c&#xE1;ncer de mama mediante la extracci&#xF3;n de c&#xE9;lulas de tejido mamario durante una biopsia para su estudio al microscopio. La anomal&#xED;a en el tejido mamario se identifica en una muestra mediante un estudio de im&#xE1;genes o al palparlo. Para las biopsias de mama se usa una jeringa con aguja fina (aspiraci&#xF3;n con aguja fina), una aguja gruesa (biopsia con aguja gruesa) o se extrae la muestra por escisi&#xF3;n (biopsia por escisi&#xF3;n). A veces se utilizan im&#xE1;genes que mejoran la precisi&#xF3;n. Mediante las biopsias con aguja se extraen muestras de un &#xE1;rea anormal bastante grande que permiten realizar un diagn&#xF3;stico. Las biopsias por escisi&#xF3;n tienen como fin extirpar el &#xE1;rea anormal por completo.</p></section><section id="_66"><h4 id="_66_toc">Carcinoma ductal <em>in situ</em></h4><p id="_67" tabindex="-1">El carcinoma ductal in situ (CDIS) es una afecci&#xF3;n no invasiva que se relaciona con el c&#xE1;ncer invasivo o evoluciona hasta convertirse en c&#xE1;ncer invasivo, con frecuencia y tiempo variables.[<a href="#cit/section_2.6">6</a>] Algunos autores incluyen el CDIS en las estad&#xED;sticas de c&#xE1;ncer de mama invasivo, pero otros argumentan que ser&#xED;a mejor que el t&#xE9;rmino se reemplace por neoplasia intraepitelial ductal, de acuerdo con la terminolog&#xED;a que se usa para designar las lesiones precursoras del cuello uterino y la pr&#xF3;stata, y que se debe considerar la exclusi&#xF3;n de estos casos de CDIS de las estad&#xED;sticas de c&#xE1;ncer de mama.</p><p id="_68" tabindex="-1">El CDIS se diagnostica con m&#xE1;s frecuencia mediante mamograf&#xED;a. En los Estados Unidos, solo 4900 mujeres recibieron un diagn&#xF3;stico de CDIS en 1983 antes de la adopci&#xF3;n de ex&#xE1;menes de detecci&#xF3;n con mamograf&#xED;a, en comparaci&#xF3;n con alrededor de 63&#xA0;960 mujeres que se prev&#xE9; recibir&#xE1;n un diagn&#xF3;stico en 2018.[<a href="#cit/section_2.1">1</a>,<a href="#cit/section_2.6">6</a>,<a href="#cit/section_2.7">7</a>] En el Canadian National Breast Screening Study-2 de mujeres de 50 a 59 a&#xF1;os, se observ&#xF3; un aumento cu&#xE1;druple de casos de CDIS en las mujeres que se sometieron al examen cl&#xED;nico de la mama (ECM) y la mamograf&#xED;a, en comparaci&#xF3;n con quienes se sometieron solo al ECM, sin diferencia en la mortalidad por c&#xE1;ncer de mama.[<a href="#cit/section_2.8">8</a>] (Para obtener m&#xE1;s informaci&#xF3;n, consultar el sumario del PDQ <a href="/espanol/tipos/seno/pro/tratamiento-seno-pdq">Tratamiento del c&#xE1;ncer de seno [mama]</a>).</p><p id="_69" tabindex="-1">La evoluci&#xF3;n natural del CDIS no se entiende por completo porque casi todos los casos de CDIS se encuentran durante los ex&#xE1;menes de detecci&#xF3;n y casi todos se tratan. La presentaci&#xF3;n del c&#xE1;ncer de mama despu&#xE9;s del tratamiento del CDIS depende de las caracter&#xED;sticas patol&#xF3;gicas de la lesi&#xF3;n, as&#xED; como del tratamiento que se administre. En un ensayo aleatorizado, se encontr&#xF3; que 13,4&#xA0;% de las mujeres con CDIS que se sometieron a una sola lumpectom&#xED;a presentaron c&#xE1;ncer de mama invasivo ipsilateral en el t&#xE9;rmino de 90 meses, en comparaci&#xF3;n con 3,9&#xA0;% de las mujeres tratadas con lumpectom&#xED;a y radiaci&#xF3;n.[<a href="#cit/section_2.9">9</a>] De las mujeres diagnosticadas con CDIS y que recibieron tratamiento, el porcentaje de mujeres que murieron por c&#xE1;ncer de mama es m&#xE1;s bajo que el de la poblaci&#xF3;n general de la misma edad.[<a href="#cit/section_2.10">10</a>,<a href="#cit/section_2.11">11</a>] Es posible que este desenlace favorable refleje la naturaleza benigna de la afecci&#xF3;n, los beneficios del tratamiento o el efecto voluntario (es decir, las mujeres que se someten a ex&#xE1;menes de detecci&#xF3;n del c&#xE1;ncer de mama son, por lo general, m&#xE1;s saludables que quienes no lo hacen).</p></section><section id="_562"><h4 id="_562_toc">Atipia</h4><p id="_563" tabindex="-1">La atipia, que es un factor de riesgo de riesgo de c&#xE1;ncer de mama, se encuentra en 4 a 10&#xA0;% de las biopsias de mama.[<a href="#cit/section_2.12">12</a>,<a href="#cit/section_2.13">13</a>] La atipia es una clasificaci&#xF3;n diagn&#xF3;stica con una variaci&#xF3;n importante entre los anatomopat&#xF3;logos.[<a href="#cit/section_2.14">14</a>]</p></section><section id="_564"><h4 id="_564_toc">Variabilidad entre los diagn&#xF3;sticos de los anatomopat&#xF3;logos en cuanto a la interpretaci&#xF3;n de las muestras de biopsia de mama.</h4><p id="_565" tabindex="-1">El diagn&#xF3;stico de los anatomopat&#xF3;logos del tejido mamario abarca desde benigno sin atipia, atipia, CDIS y c&#xE1;ncer de mama invasivo. La incidencia de la atipia y el CDIS ha aumentado en las &#xFA;ltimas tres d&#xE9;cadas debido al uso generalizado de las mamograf&#xED;as, aunque la atipia suele estar oculta en las mamograf&#xED;as.[<a href="#cit/section_2.15">15</a>,<a href="#cit/section_2.16">16</a>] La clasificaci&#xF3;n incorrecta de las lesiones mamarias podr&#xED;a contribuir al exceso de tratamiento o a un tratamiento insuficiente de estas lesiones; en especial, con variabilidad en los diagn&#xF3;sticos de atipia y CDIS.[<a href="#cit/section_2.14">14</a>,<a href="#cit/section_2.17">17</a>-<a href="#cit/section_2.21">21</a>]</p><p id="_609" tabindex="-1">En el estudio m&#xE1;s grande sobre este tema, el estudio B-Path, participaron 115 anatomopat&#xF3;logos en ejercicio de la profesi&#xF3;n en los Estados Unidos que interpretaron una biopsia de mama de un solo corte histol&#xF3;gico por caso; luego, se compararon sus interpretaciones con un diagn&#xF3;stico de referencia derivado de un consenso de expertos.[<a href="#cit/section_2.14">14</a>] Aunque el acuerdo general entre las interpretaciones individuales de los anatomopat&#xF3;logos y los diagn&#xF3;sticos de referencia de los expertos fue m&#xE1;s alta en los casos de carcinoma invasivo, hubo mucho menos acuerdo para las interpretaciones del CDIS y la atipia.[<a href="#cit/section_2.14">14</a>] Dado que en el estudio B-Path se incluy&#xF3; una mayor proporci&#xF3;n de casos de atipia y CDIS que los que se suelen observar en la pr&#xE1;ctica cl&#xED;nica, los autores ampliaron su labor y aplicaron el teorema de Bayes para calcular la forma en que la variabilidad diagn&#xF3;stica influye en la precisi&#xF3;n desde el punto de vista de una mujer en los Estados Unidos de 50 a 59 a&#xF1;os que se somete a una biopsia.[<a href="#cit/section_2.17">17</a>] Para la poblaci&#xF3;n de los Estados Unidos, se calcula que 92,3&#xA0;% (intervalo de confianza [IC], 91,4&#x2013;93,1&#xA0;%) de los diagn&#xF3;sticos de biopsia de mama ser&#xED;an verificados por un diagn&#xF3;stico de referencia derivado del consenso de expertos; se calcula una sobreinterpretaci&#xF3;n de 4,6&#xA0;% (IC, 3,9&#x2013;5,3&#xA0;%) y una subinterpretaci&#xF3;n de 3,2&#xA0;% (IC, 2,7&#x2013;3,6&#xA0;%) de las biopsias de mama iniciales. En la <a href="/espanol/tipos/seno/pro/deteccion-seno-pdq#link/_714">Figura 1</a> se observan los desenlaces previstos, globales y por categor&#xED;a diagn&#xF3;stica, de 100 biopsias de mama.</p><figure id="figure_714" class="image-center"><a href="https://www.cancer.gov/images/cdr/live/CDR785685.jpg" target="_blank" class="article-image-enlarge">Ampliar</a><img id="_714" alt="El gr&#xE1;fico muestra los resultados previstos de 100 biopsias de mama: global y por categor&#xED;a diagn&#xF3;stica." title="El gr&#xE1;fico muestra los resultados previstos de 100 biopsias de mama: global y por categor&#xED;a diagn&#xF3;stica." src="https://www.cancer.gov/images/cdr/live/CDR785685-750.jpg"><figcaption class="caption-container">Figure 1.  Resultados previstos para 100 biopsias de mama: global y por categor&#xED;a diagn&#xF3;stica. De Annals of Internal Medicine, Elmore JG, Nelson HD, Pepe MS, Longton GM, Tosteson AN, Geller B, Onega T, Carney PA, Jackson SL, Allison KH, Weaver DL, Variability in Pathologists' Interpretations of Individual Breast Biopsy Slides: A Population Perspective, Volume 164, Issue 10, Pages 649&#x2013;55, Derechos de autor &#xA9;&#xA0;2016 American College of Physicians. Todos los derechos reservados. Reimpresi&#xF3;n autorizada por el American College of Physicians, Inc.</figcaption></figure><p id="_575" tabindex="-1">Para abordar las tasas altas de discordancia en el diagn&#xF3;stico del tejido de mama, cada vez es m&#xE1;s com&#xFA;n que en las directrices de los laboratorios se exija una segunda opini&#xF3;n. En una encuesta nacional de 252 anatomopat&#xF3;logos expertos en la mama que participaron en el estudio B-Path, se encontr&#xF3; que 65&#xA0;% de los encuestados informaron que contaban con una directriz del laboratorio que exige una segunda opini&#xF3;n para todos los diagn&#xF3;sticos iniciales de casos de enfermedad invasiva. Adem&#xE1;s, 56&#xA0;% de los encuestados informaron que contaban con directrices en las que se exige una segunda opini&#xF3;n para el diagn&#xF3;stico inicial de CDIS, mientras que 36&#xA0;% informaron que la segunda opini&#xF3;n era obligatoria para los casos con diagn&#xF3;stico inicial de hiperplasia ductal at&#xED;pica.[<a href="#cit/section_2.22">22</a>] En esta misma encuesta, el acuerdo entre los anatomopat&#xF3;logos fue contundente en cuanto a la mayor exactitud del diagn&#xF3;stico al obtener un segundo diagn&#xF3;stico (96&#xA0;%).</p><p id="_608" tabindex="-1">En un estudio de simulaci&#xF3;n para el que se emplearon datos del estudio B-Path, se evaluaron 12 estrategias para obtener segundas opiniones que mejoraran la interpretaci&#xF3;n de la histopatolog&#xED;a mamaria.[<a href="#cit/section_2.23">23</a>] La precisi&#xF3;n mejor&#xF3; de forma significativa en todas las estrategias que incorporaron una segunda opini&#xF3;n, salvo en el caso de estrategias que limitaron la segunda opini&#xF3;n solo a casos de c&#xE1;ncer invasivo. La precisi&#xF3;n fue mayor con independencia de la confianza que tuvieran los anatomopat&#xF3;logos en su propio diagn&#xF3;stico o grado de experiencia. Aunque las segundas opiniones mejoraron la precisi&#xF3;n, no se elimin&#xF3; por completo la variabilidad diagn&#xF3;stica; en particular, en el caso problem&#xE1;tico de las muestras de tejido mamario con atipia.</p></section></section><section id="_123"><h3 id="_123_toc">Poblaciones especiales</h3><section id="_143"><h4 id="_143_toc">Mujeres con mayor riesgo que tal vez se beneficien m&#xE1;s de los ex&#xE1;menes de detecci&#xF3;n</h4><section id="_661"><h5 id="_661_toc">Mujeres que exhiben las mutaciones gen&#xE9;ticas <em>BRCA1</em> y <em>BRCA2</em></h5><p id="_662" tabindex="-1">Las mujeres con aumento de riesgo de presentar c&#xE1;ncer de mama debido a una mutaci&#xF3;n gen&#xE9;tica <em>BRCA1</em> o <em>BRCA2</em> tal vez obtengan beneficio de someterse a m&#xE1;s ex&#xE1;menes de detecci&#xF3;n. (Para obtener m&#xE1;s informaci&#xF3;n, consultar el sumario en ingl&#xE9;s del PDQ <a href="/types/breast/hp/breast-ovarian-genetics-pdq">Genetics of Breast and Gynecologic Cancers</a>).</p></section><section id="_663"><h5 id="_663_toc">Mujeres sometidas a radiaci&#xF3;n tor&#xE1;cica</h5></section><p id="_675" tabindex="-1">Las mujeres con linfoma de Hodgkin y linfoma no Hodgkin que se trataron con irradiaci&#xF3;n dirigida al manto tienen un aumento de riesgo de c&#xE1;ncer de mama a partir de los 10 a&#xF1;os posteriores al tratamiento y durante el resto de su vida. Por lo tanto, se promueve el uso de mamograf&#xED;as de detecci&#xF3;n, a pesar de que comience a una edad relativamente temprana.[<a href="#cit/section_2.24">24</a>,<a href="#cit/section_2.25">25</a>]</p></section><section id="_664"><h4 id="_664_toc">Personas que se benefician poco de los ex&#xE1;menes de detecci&#xF3;n</h4><section id="_676"><h5 id="_676_toc">Mujeres con expectativa de vida limitada</h5><p id="_677" tabindex="-1">Los beneficios potenciales de la mamograf&#xED;a de detecci&#xF3;n se presentan mucho despu&#xE9;s del examen, con frecuencia muchos a&#xF1;os despu&#xE9;s, mientras que los perjuicios son inmediatos. En consecuencia, es posible que las mujeres con expectativa de vida limitada y comorbilidades sufran de perjuicios sin ning&#xFA;n beneficio. De todas formas, muchas de estas mujeres se someten a mamograf&#xED;as de detecci&#xF3;n.[<a href="#cit/section_2.26">26</a>] En un estudio, alrededor de 9&#xA0;% de las mujeres con c&#xE1;ncer avanzado se sometieron a ex&#xE1;menes de detecci&#xF3;n del c&#xE1;ncer.[<a href="#cit/section_2.27">27</a>]</p></section><section id="_678"><h5 id="_678_toc">Mujeres de edad avanzada</h5><p id="_679" tabindex="-1">La mamograf&#xED;a de detecci&#xF3;n pueden resultar en diagn&#xF3;sticos de c&#xE1;ncer en alrededor de 1&#xA0;% de las mujeres de 66&#x2013;79 a&#xF1;os, pero la mayor&#xED;a de estos c&#xE1;nceres son de riesgo bajo.[<a href="#cit/section_2.28">28</a>] El interrogante es si el diagn&#xF3;stico y el tratamiento del c&#xE1;ncer de mama localizado en mujeres de edad avanzada es beneficioso.</p></section><section id="_680"><h5 id="_680_toc">Mujeres j&#xF3;venes</h5><p id="_681" tabindex="-1">No hay datos probatorios del beneficio de la mamograf&#xED;a de detecci&#xF3;n en mujeres menores de 40 a&#xF1;os con riesgo promedio.</p></section><section id="_682"><h5 id="_682_toc">Hombres</h5><p id="_683" tabindex="-1">Alrededor de 1&#xA0;% de todos los c&#xE1;nceres de mama se presenta en hombres.[<a href="#cit/section_2.29">29</a>] La mayor&#xED;a de los casos se diagnostica durante una evaluaci&#xF3;n de lesiones palpables que son, por lo general, f&#xE1;ciles de detectar. El tratamiento consiste en cirug&#xED;a, radiaci&#xF3;n y hormonoterapia sist&#xE9;mica adyuvante o quimioterapia. (Para obtener m&#xE1;s informaci&#xF3;n, consultar el sumario del PDQ <a href="/espanol/tipos/seno/pro/tratamiento-seno-masculino-pdq">Tratamiento del c&#xE1;ncer de seno [mama] masculino</a>). No es probable que los ex&#xE1;menes de detecci&#xF3;n ofrezcan beneficios.</p></section></section></section><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_2.1">American Cancer Society: Cancer Facts and Figures 2018. Atlanta, Ga: American Cancer Society, 2018. <a href="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf" title="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf">Available online</a>. Last accessed August 3, 2018.</li><li id="section_2.2">Howlader N, Noone AM, Krapcho M, et al., eds.: SEER Cancer Statistics Review, 1975-2011. Bethesda, Md: National Cancer Institute, 2014. <a href="http://seer.cancer.gov/csr/1975_2011/" title="http://seer.cancer.gov/csr/1975_2011/">Also available online</a>. Last accessed October 8, 2018.</li><li id="section_2.3">Johnson A, Shekhdar J: Breast cancer incidence: what do the figures mean? J Eval Clin Pract 11 (1): 27-31, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15660534&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15660534&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.4">Haas JS, Kaplan CP, Gerstenberger EP, et al.: Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 140 (3): 184-8, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14757616&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14757616&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.5">Barton MB, Elmore JG, Fletcher SW: Breast symptoms among women enrolled in a health maintenance organization: frequency, evaluation, and outcome. Ann Intern Med 130 (8): 651-7, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10215561&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10215561&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.6">Allegra CJ, Aberle DR, Ganschow P, et al.: National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009. J Natl Cancer Inst 102 (3): 161-9, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20071686&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20071686&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.7">Virnig BA, Tuttle TM, Shamliyan T, et al.: Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 102 (3): 170-8, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20071685&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20071685&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.8">Miller AB, To T, Baines CJ, et al.: Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years. J Natl Cancer Inst 92 (18): 1490-9, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10995804&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10995804&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.9">Fisher B, Dignam J, Wolmark N, et al.: Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16 (2): 441-52, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9469327&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9469327&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.10">Ernster VL, Barclay J, Kerlikowske K, et al.: Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med 160 (7): 953-8, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10761960&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10761960&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.11">Welch HG, Prorok PC, O'Malley AJ, et al.: Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. N Engl J Med 375 (15): 1438-1447, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27732805&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27732805&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.12">Weaver DL, Rosenberg RD, Barlow WE, et al.: Pathologic findings from the Breast Cancer Surveillance Consortium: population-based outcomes in women undergoing biopsy after screening mammography. Cancer 106 (4): 732-42, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16411214&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16411214&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.13">Rubin E, Visscher DW, Alexander RW, et al.: Proliferative disease and atypia in biopsies performed for nonpalpable lesions detected mammographically. Cancer 61 (10): 2077-82, 1988.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3359405&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3359405&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.14">Elmore JG, Longton GM, Carney PA, et al.: Diagnostic concordance among pathologists interpreting breast biopsy specimens. JAMA 313 (11): 1122-32, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25781441&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25781441&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.15">Bleyer A, Welch HG: Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 367 (21): 1998-2005, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23171096&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23171096&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.16">Hall FM: Identification, biopsy, and treatment of poorly understood premalignant, in situ, and indolent low-grade cancers: are we becoming victims of our own success? Radiology 254 (3): 655-9, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20177083&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20177083&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.17">Elmore JG, Nelson HD, Pepe MS, et al.: Variability in Pathologists' Interpretations of Individual Breast Biopsy Slides: A Population Perspective. Ann Intern Med 164 (10): 649-55, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26999810&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26999810&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.18">Rosai J: Borderline epithelial lesions of the breast. Am J Surg Pathol 15 (3): 209-21, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1847606&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1847606&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.19">Schnitt SJ, Connolly JL, Tavassoli FA, et al.: Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am J Surg Pathol 16 (12): 1133-43, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1463092&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1463092&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.20">Wells WA, Carney PA, Eliassen MS, et al.: Statewide study of diagnostic agreement in breast pathology. J Natl Cancer Inst 90 (2): 142-5, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9450574&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9450574&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.21">Della Mea V, Puglisi F, Bonzanini M, et al.: Fine-needle aspiration cytology of the breast: a preliminary report on telepathology through Internet multimedia electronic mail. Mod Pathol 10 (6): 636-41, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9195583&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9195583&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.22">Geller BM, Nelson HD, Carney PA, et al.: Second opinion in breast pathology: policy, practice and perception. J Clin Pathol 67 (11): 955-60, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25053542&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25053542&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.23">Elmore JG, Tosteson AN, Pepe MS, et al.: Evaluation of 12 strategies for obtaining second opinions to improve interpretation of breast histopathology: simulation study. BMJ 353: i3069, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27334105&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27334105&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.24">Mariscotti G, Belli P, Bernardi D, et al.: Mammography and MRI for screening women who underwent chest radiation therapy (lymphoma survivors): recommendations for surveillance from the Italian College of Breast Radiologists by SIRM. Radiol Med 121 (11): 834-837, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27406629&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27406629&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.25">Allen SD, Wallis MG, Cooke R, et al.: Radiologic features of breast cancer after mantle radiation therapy for Hodgkin disease: a study of 230 cases. Radiology 272 (1): 73-8, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24666474&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24666474&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.26">Walter LC, Lindquist K, Covinsky KE: Relationship between health status and use of screening mammography and Papanicolaou smears among women older than 70 years of age. Ann Intern Med 140 (9): 681-8, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15126251&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15126251&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.27">Sima CS, Panageas KS, Schrag D: Cancer screening among patients with advanced cancer. JAMA 304 (14): 1584-91, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20940384&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20940384&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.28">Smith-Bindman R, Kerlikowske K, Gebretsadik T, et al.: Is screening mammography effective in elderly women? Am J Med 108 (2): 112-9, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11126304&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11126304&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.29">Fentiman IS, Fourquet A, Hortobagyi GN: Male breast cancer. Lancet 367 (9510): 595-604, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16488803&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16488803&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _51
      field_pdq_section_title:
        - format: plain_text
          value: 'Mamografía'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_51" class="pdq-sections"><section id="_89"><h3 id="_89_toc">Descripci&#xF3;n y antecedentes</h3><p id="_90" tabindex="-1">Para la mamograf&#xED;a se utiliza radiaci&#xF3;n ionizante a fin de obtener im&#xE1;genes del tejido mamario. El examen se lleva a cabo mediante la compresi&#xF3;n firme de la mama entre dos placas; esta compresi&#xF3;n despliega los tejidos superpuestos y reduce la cantidad de radiaci&#xF3;n necesaria para tomar la imagen. En los Estados Unidos, las pruebas se toman en proyecciones oblicuas mediolaterales y craneocaudales en los ex&#xE1;menes de detecci&#xF3;n de rutina.[<a href="#cit/section_3.1">1</a>] Ambas proyecciones incluyen tejido mamario desde el pez&#xF3;n hasta el m&#xFA;sculo pectoral. La exposici&#xF3;n a la radiaci&#xF3;n es de 4 a 24 mSv por examen de detecci&#xF3;n est&#xE1;ndar con dos proyecciones. Los ex&#xE1;menes con dos proyecciones tienen una tasa m&#xE1;s baja de repetici&#xF3;n que aquellos con una sola proyecci&#xF3;n, debido a que se presentan menos problemas de anomal&#xED;as causadas por la superposici&#xF3;n de las estructuras mamarias normales.[<a href="#cit/section_3.2">2</a>] Los ex&#xE1;menes con dos proyecciones se relacionan con una tasa de c&#xE1;nceres de intervalos m&#xE1;s baja que los ex&#xE1;menes con una sola proyecci&#xF3;n.[<a href="#cit/section_3.3">3</a>]</p><p id="_91" tabindex="-1">Seg&#xFA;n la Mammography Quality Standards Act (MQSA), sancionada por el Congreso en 1992, todos los establecimientos que realicen mamograf&#xED;as en los Estados Unidos deben tener certificaci&#xF3;n de la Administraci&#xF3;n de Alimentos y Medicamentos de los Estados Unidos (FDA) a fin de asegurar el empleo de personal entrenado y el uso de una t&#xE9;cnica mamogr&#xE1;fica estandarizada con dosis bajas de radiaci&#xF3;n.[<a href="#cit/section_3.4">4</a>] (Consultar la informaci&#xF3;n en ingl&#xE9;s de la p&#xE1;gina de Internet de la FDA <a href="https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm094405.htm" title="https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm094405.htm">Mammography Facility Surveys, Mammography Equipment Evaluations, and Medical Physicist Qualification Requirement under MQSA</a>). La MQSA Reauthorization Act de 1998 establece que los pacientes reciban un resumen escrito en lenguaje sencillo de los resultados de la mamograf&#xED;a.</p><p id="_92" tabindex="-1">Para notificar los resultados de las mamograf&#xED;as, se emplean las siguientes categor&#xED;as del Breast Imaging Reporting and Data System (BI-RADS):[<a href="#cit/section_3.5">5</a>]</p><div class="pdq-content-list"><ul id="_471" class="pdq-address-block"><li>0: 0: hallazgo incompleto; se necesitan realizar evaluaciones adicionales de la imagen o mamograf&#xED;as anteriores para comparar.</li><li>1: hallazgo negativo; el riesgo de un diagn&#xF3;stico de c&#xE1;ncer dentro de 1 a&#xF1;o es de 1&#xA0;%.</li><li>2: hallazgo benigno; el riesgo de un diagn&#xF3;stico de c&#xE1;ncer dentro de 1 a&#xF1;o es de 1&#xA0;%.</li><li>3: hallazgo probablemente benigno; el riesgo de un diagn&#xF3;stico de c&#xE1;ncer dentro de 1 a&#xF1;o es de 2&#xA0;%.</li><li>4: hallazgo sospechoso; el riesgo de un diagn&#xF3;stico de c&#xE1;ncer dentro de 1 a&#xF1;o es de 2&#x2013;95&#xA0;%.<div class="pdq-content-list"><ul id="_658" class="pdq-address-block"><li>4a: 2&#x2013;10&#xA0;%.</li><li>4b: 10&#x2013;50&#xA0;%.</li><li>4c: 50&#x2013;95&#xA0;%.</li></ul></div></li><li>5: hallazgo altamente indicativo de neoplasia maligna; el riesgo de un diagn&#xF3;stico de c&#xE1;ncer dentro de 1 a&#xF1;o es de 95&#xA0;%.</li><li>6: biopsia conocida; neoplasia maligna comprobada.</li></ul></div><p id="_209" tabindex="-1">La mayor&#xED;a de las mamograf&#xED;as de detecci&#xF3;n se interpretan como negativas o benignas (BI-RADS 1 o 2, respectivamente); a alrededor de 10&#xA0;% de las mujeres en los Estados Unidos se les pide que regresen para una evaluaci&#xF3;n adicional.[<a href="#cit/section_3.6">6</a>] El porcentaje de mujeres a las que se les pide que regresen para una evaluaci&#xF3;n adicional var&#xED;a no solo por las caracter&#xED;sticas particulares de cada mujer sino, tambi&#xE9;n, por el establecimiento radiol&#xF3;gico y el radi&#xF3;logo.[<a href="#cit/section_3.7">7</a>]</p></section><section id="_524"><h3 id="_524_toc">Mamograf&#xED;a digital y detecci&#xF3;n asistida por computadora</h3><p id="_525" tabindex="-1">La mamograf&#xED;a digital es m&#xE1;s costosa que la mamograf&#xED;a con pel&#xED;cula radiogr&#xE1;fica (MPR), pero es m&#xE1;s f&#xE1;cil gestionar su almacenamiento e intercambio de datos. En varios ensayos se compararon directamente la MPR con la mamograf&#xED;a digital para determinar la tasa de detecci&#xF3;n del c&#xE1;ncer, la sensibilidad, la especificidad y el valor predictivo positivo (VPP); los ensayos produjeron resultados similares en la mayor&#xED;a de los grupos de pacientes.</p><p id="_526" tabindex="-1">En el Digital Mammographic Imaging Screening Trial (DMIST) se compararon los hallazgos de mamograf&#xED;as digitales y de MPR de 42&#xA0;760 mujeres en 33 centros de los Estados Unidos. Aunque con la mamograf&#xED;a digital se detectaron m&#xE1;s c&#xE1;nceres en mujeres menores de 50 a&#xF1;os (&#xE1;rea bajo la curva [ABC] de 0,84 +/- 0,03 con mamograf&#xED;a digital; ABC de 0,69 +/- 0,05 con pel&#xED;cula radiogr&#xE1;fica; <em>P</em> = 0,002), no hubo diferencias en la detecci&#xF3;n del c&#xE1;ncer de mama en general.[<a href="#cit/section_3.8">8</a>] En un segundo informe del DMIST se encontr&#xF3; que, en las mujeres de 65 a&#xF1;os y m&#xE1;s, la tendencia de ABC fue m&#xE1;s alta con el uso de la MPR que con la mamograf&#xED;a digital.[<a href="#cit/section_3.9">9</a>]</p><p id="_528" tabindex="-1">En otro estudio de cohortes grande en los Estados Unidos [<a href="#cit/section_3.10">10</a>] tambi&#xE9;n se encontr&#xF3; que, en las mujeres menores de 50 a&#xF1;os, la sensibilidad fue un poco m&#xE1;s alta con la mamograf&#xED;a digital, pero la especificidad fue la misma.</p><p id="_654" tabindex="-1">En un estudio holand&#xE9;s se compararon los hallazgos de 1,5 millones de mamograf&#xED;as digitales con 4,5 millones de MPR que se realizaron entre 2004 y 2010. Se observaron tasas m&#xE1;s altas de repetici&#xF3;n y de detecci&#xF3;n de c&#xE1;ncer con el uso de las mamograf&#xED;as digitales.[<a href="#cit/section_3.11">11</a>] En un metan&#xE1;lisis [<a href="#cit/section_3.12">12</a>] de 10 estudios, incluso el DMIST [<a href="#cit/section_3.8">8</a>,<a href="#cit/section_3.9">9</a>] y el estudio de cohortes en los Estados Unidos,[<a href="#cit/section_3.10">10</a>] se compar&#xF3; el uso de mamograf&#xED;a digital y MPR en 82&#xA0;573 mujeres que se sometieron a ambos tipos de ex&#xE1;menes. En un modelo de efectos aleatorios, no hubo diferencia con significaci&#xF3;n estad&#xED;stica entre los dos tipos de mamograf&#xED;a (ABC de 0,92 con MPR; ABC de 0,91 con mamograf&#xED;a digital) para la detecci&#xF3;n del c&#xE1;ncer. En todos los estudios se encontr&#xF3; que, en las mujeres menores de 50 a&#xF1;os, la sensibilidad fue m&#xE1;s alta con la mamograf&#xED;a digital, pero la especificidad fue la misma o m&#xE1;s alta con la mamograf&#xED;a con pel&#xED;cula radiogr&#xE1;fica.</p><p id="_655" tabindex="-1">Los sistemas de detecci&#xF3;n asistida por computadora (CAD) destacan regiones sospechosas como las microcalcificaciones en racimo y masas,[<a href="#cit/section_3.13">13</a>] que en general aumentan la sensibilidad, disminuyen la especificidad,[<a href="#cit/section_3.14">14</a>] y aumentan la detecci&#xF3;n de carcinoma ductal <em>in situ</em> (CDIS).[<a href="#cit/section_3.15">15</a>] Hay varios sistemas de CAD en uso. En un estudio grande de poblaci&#xF3;n, en el que se compararon las tasas de repetici&#xF3;n y las tasas de detecci&#xF3;n del c&#xE1;ncer de mama antes y despu&#xE9;s de la adopci&#xF3;n de los sistemas de CAD, se encontr&#xF3; que no hubo cambio en ninguna de las tasas.[<a href="#cit/section_3.13">13</a>,<a href="#cit/section_3.16">16</a>] En otro estudio grande, se not&#xF3; un aumento en la tasa de repetici&#xF3;n y detecci&#xF3;n del CDIS, pero ninguna mejor&#xED;a en la tasa de detecci&#xF3;n del c&#xE1;ncer invasivo.[<a href="#cit/section_3.15">15</a>,<a href="#cit/section_3.17">17</a>] En otro estudio para el que se us&#xF3; una base de datos grande y mamograf&#xED;as digitales de mujeres de 40 a 89 a&#xF1;os, se hall&#xF3; que la CAD no mejor&#xF3; la sensibilidad, la especificidad ni la detecci&#xF3;n de los c&#xE1;nceres de intervalo, pero detect&#xF3; m&#xE1;s CDIS.[<a href="#cit/section_3.18">18</a>]</p><p id="_656" tabindex="-1">A partir de la base de datos del Surveillance, Epidemiology, and End Results (SEER) vinculada a Medicare, se analiz&#xF3; el uso de nuevas modalidades de ex&#xE1;menes de detecci&#xF3;n por mamograf&#xED;a en m&#xE1;s de 270&#xA0;000 mujeres de 65 a&#xF1;os o m&#xE1;s en dos per&#xED;odos: de 2001 a 2002 y de 2008 a 2009. La mamograf&#xED;a digital aument&#xF3; de 2 a 30&#xA0;%, la CAD aument&#xF3; de 3 a 33&#xA0;% y los gastos se incrementaron de $660 a $962 millones de d&#xF3;lares. La CAD se utiliz&#xF3; en 74&#xA0;% de los ex&#xE1;menes de detecci&#xF3;n por mamograf&#xED;a que pag&#xF3; Medicare en 2008, casi el doble de las mamograf&#xED;as de detecci&#xF3;n de 2004. No hubo diferencia en las tasas de detecci&#xF3;n de tumores en estadio temprano (CDIS o estadio I) ni en estadio avanzado (estadio IV).[<a href="#cit/section_3.19">19</a>]</p></section><section id="_535"><h3 id="_535_toc">Tomos&#xED;ntesis</h3><p id="_537" tabindex="-1">La tomos&#xED;ntesis o mamograf&#xED;a tridimensional (3-D), al igual que la mamograf&#xED;a est&#xE1;ndar 2-D, comprime la mama y usa rayos X para crear la imagen. En la tomos&#xED;ntesis, se obtienen m&#xFA;ltiples radiograf&#xED;as de exposici&#xF3;n corta desde diferentes &#xE1;ngulos. Algunos c&#xE1;nceres se observan mejor con este m&#xE9;todo que con mamograf&#xED;a o ecograf&#xED;a. La dosis radiactiva es el doble de la dosis de la mamograf&#xED;a 2-D.</p><p id="_657" tabindex="-1">La tomos&#xED;ntesis se ha evaluado en un n&#xFA;mero limitado de estudios y algunos grupos profesionales la consideran una t&#xE9;cnica en fase de investigaci&#xF3;n. En general, no se reembolsa.</p></section><section id="_72"><h3 id="_72_toc">Caracter&#xED;sticas de los c&#xE1;nceres identificados mediante im&#xE1;genes de mama</h3><p id="_112" tabindex="-1">Con independencia del estadio, el estado ganglionar y el tama&#xF1;o tumoral, los c&#xE1;nceres identificados con ex&#xE1;menes de detecci&#xF3;n tuvieron un mejor pron&#xF3;stico que los que se no diagnosticaron mediante ex&#xE1;menes de detecci&#xF3;n.[<a href="#cit/section_3.2">2</a>] Esto parece indicar que, desde el punto de vista biol&#xF3;gico, son menos mortales (quiz&#xE1;s de crecimiento m&#xE1;s lento y con menos probabilidad de invasi&#xF3;n local o met&#xE1;stasis) y m&#xE1;s &#xFA;tiles para predecir el pron&#xF3;stico y planificar el tratamiento.</p><p id="_114" tabindex="-1">En un estudio de seguimiento a 10 a&#xF1;os de 1983 mujeres finlandesas con c&#xE1;ncer de mama invasivo, se demostr&#xF3; que el m&#xE9;todo de detecci&#xF3;n del c&#xE1;ncer es una variable pron&#xF3;stica independiente. Cuando se controlaron por edad, compromiso ganglionar y tama&#xF1;o tumoral, los c&#xE1;nceres identificados con ex&#xE1;menes de detecci&#xF3;n tuvieron un riesgo m&#xE1;s bajo de reca&#xED;da y una mejor supervivencia general. Para las mujeres cuyos c&#xE1;nceres se identificaron sin ex&#xE1;menes de detecci&#xF3;n, el cociente de riesgos instant&#xE1;neos (CRI) de muerte fue de 1,90 (intervalo de confianza [IC] 95&#xA0;%, 1,15&#x2013;3,11), a pesar de que era m&#xE1;s probable que hubieran recibido tratamiento sist&#xE9;mico adyuvante.[<a href="#cit/section_3.20">20</a>]</p><p id="_115" tabindex="-1">De igual modo, en un an&#xE1;lisis de c&#xE1;nceres de mama en tres ensayos aleatorizados de ex&#xE1;menes de detecci&#xF3;n (Health Insurance Plan, National Breast Screening Study [NBSS]-1, y NBSS-2), se tuvo en cuenta el estadio, el estado ganglionar y el tama&#xF1;o del tumor; se determin&#xF3; que las pacientes cuyo c&#xE1;ncer se identific&#xF3; con ex&#xE1;menes de detecci&#xF3;n tuvieron un pron&#xF3;stico m&#xE1;s favorable. Los riesgos relativos (RR) de muerte fueron de 1,53 (IC 95&#xA0;%, 1,17&#x2013;2,00) para c&#xE1;nceres de intervalo y nuevos, en comparaci&#xF3;n con c&#xE1;nceres que se identificaron con ex&#xE1;menes de detecci&#xF3;n, y de 1,36 (IC 95&#xA0;%, 1,10&#x2013;1,68) para los c&#xE1;nceres en el grupo de control, en comparaci&#xF3;n con los c&#xE1;nceres que se identificaron con ex&#xE1;menes de detecci&#xF3;n.[<a href="#cit/section_3.21">21</a>]</p><p id="_116" tabindex="-1">En un tercer estudio, se compararon los desenlaces de 5604 mujeres inglesas con c&#xE1;nceres de mama que se identificaron entre 1998 y 2003 mediante el diagn&#xF3;stico por ex&#xE1;menes de detecci&#xF3;n o el diagn&#xF3;stico sintom&#xE1;tico. Tras realizar ajustes de control por el tama&#xF1;o del tumor, el estado ganglionar y la edad de la paciente, los investigadores hallaron que les fue mejor a las mujeres con c&#xE1;nceres identificados mediante ex&#xE1;menes de detecci&#xF3;n. El CRI de supervivencia de las mujeres sintom&#xE1;ticas fue de 0,79 (IC 95&#xA0;%, 0,63&#x2013;0,99).[<a href="#cit/section_3.20">20</a>,<a href="#cit/section_3.22">22</a>]</p><p id="_707" tabindex="-1">Los hallazgos de estos estudios tambi&#xE9;n son congruentes con los datos probatorios que indican que algunos c&#xE1;nceres que se identifican con ex&#xE1;menes de detecci&#xF3;n son de riesgo bajo y reflejan un sobrediagn&#xF3;stico.</p><section id="_49"><h4 id="_49_toc">Concepto de sesgos en los ex&#xE1;menes de detecci&#xF3;n</h4><p id="_77" tabindex="-1">En varios ensayos no controlados y series retrospectivas, se document&#xF3; la capacidad de la mamograf&#xED;a de diagnosticar c&#xE1;nceres de mama peque&#xF1;os en estadio temprano que tienen una evoluci&#xF3;n cl&#xED;nica favorable.[<a href="#cit/section_3.23">23</a>] Las personas cuyo c&#xE1;ncer se encuentra durante los ex&#xE1;menes de detecci&#xF3;n presentan tasas de supervivencia m&#xE1;s altas que las personas con c&#xE1;ncer que no se encontr&#xF3; durante los ex&#xE1;menes de detecci&#xF3;n, aunque la detecci&#xF3;n no haya prolongado la vida de nadie. Este concepto se explica mediante cuatro tipos de sesgo estad&#xED;stico.</p><div class="pdq-content-list"><ol id="_78"><li>Sesgo de anticipaci&#xF3;n diagn&#xF3;stica: identificaci&#xF3;n temprana del c&#xE1;ncer mediante ex&#xE1;menes de detecci&#xF3;n antes que la detecci&#xF3;n por la presentaci&#xF3;n de s&#xED;ntomas; no hace m&#xE1;s que adelantar la fecha del diagn&#xF3;stico. La detecci&#xF3;n y el tratamiento tempranos no alteran la progresi&#xF3;n natural de la enfermedad. La tasa de supervivencia a 5 a&#xF1;os desde el momento del diagn&#xF3;stico es m&#xE1;s alta cuando el c&#xE1;ncer se encuentra temprano, aunque la detecci&#xF3;n precoz no haga ninguna diferencia en la cantidad de tiempo que vive la persona.</li><li>Sesgo de duraci&#xF3;n: identificaci&#xF3;n por mamograf&#xED;a de detecci&#xF3;n de c&#xE1;nceres de crecimiento lento que tiene un pron&#xF3;stico m&#xE1;s favorable que el c&#xE1;ncer que se presenta en la cl&#xED;nica (detectado por el m&#xE9;dico o la persona cuando se enferma). Agrupar estos c&#xE1;nceres sin progresi&#xF3;n con los c&#xE1;nceres potencialmente mortales (cuyo tratamiento temprano no influye en el desenlace) aumenta la tasa de supervivencia a 5 a&#xF1;os, aunque los ex&#xE1;menes de detecci&#xF3;n no producen ninguna diferencia en la cantidad de vidas que se salvan.</li><li>Sesgo de sobrediagn&#xF3;stico: identificaci&#xF3;n por mamograf&#xED;a de detecci&#xF3;n de c&#xE1;nceres que nunca causar&#xED;an s&#xED;ntomas o la muerte, pero aumentan las tasas de supervivencia sin cambiar el tiempo de vida.</li><li>Sesgo de voluntarias sanas: participaci&#xF3;n de voluntarias en los ex&#xE1;menes de detecci&#xF3;n que quiz&#xE1;s sean las m&#xE1;s sanas y m&#xE1;s preocupadas por su salud en la poblaci&#xF3;n general. En consecuencia, los desenlaces ser&#xE1;n mejores que los de las mujeres que no son sanas ni se preocupan por su salud, con independencia de los beneficios del diagn&#xF3;stico temprano.</li></ol></div><p id="_79" tabindex="-1">No se conoce la repercusi&#xF3;n de estos sesgos. Se necesita un nuevo ensayo controlado aleatorizado (ECA) con un criterio de valoraci&#xF3;n de mortalidad por causa espec&#xED;fica para determinar el beneficio de supervivencia y la repercusi&#xF3;n de los sesgos relacionados con el sobrediagn&#xF3;stico, la anticipaci&#xF3;n diagn&#xF3;stica, la duraci&#xF3;n y las voluntarias sanas. No es posible lograr esto. La aleatorizaci&#xF3;n de pacientes a grupos que se someten a ex&#xE1;menes de detecci&#xF3;n y que no se someten a estos ser&#xED;a contraria a la &#xE9;tica; adem&#xE1;s se necesitar&#xED;a un seguimiento m&#xED;nimo de tres d&#xE9;cadas, tiempo durante el cual los cambios en los tratamientos y las t&#xE9;cnicas de obtenci&#xF3;n de im&#xE1;genes quitar&#xED;an validez a los resultados. Por ende, las decisiones se deben fundamentar en los ECA disponibles, a pesar de sus limitaciones, y en estudios ecol&#xF3;gicos o de cohortes con grupos de control adecuados y ajuste por variables de confusi&#xF3;n. (Para obtener m&#xE1;s informaci&#xF3;n, consultar el sumario del PDQ <a href="/espanol/cancer/deteccion/aspectos-generales-deteccion-pro-pdq">Aspectos generales de los ex&#xE1;menes de detecci&#xF3;n del c&#xE1;ncer</a>).</p></section><section id="_80"><h4 id="_80_toc">Evaluaci&#xF3;n de la eficacia y la precisi&#xF3;n</h4><p id="_216" tabindex="-1">Los par&#xE1;metros de eficacia de los ex&#xE1;menes de detecci&#xF3;n con mamograf&#xED;a en los Estados Unidos se describen en ingl&#xE9;s en la p&#xE1;gina de Internet del <a href="http://breastscreening.cancer.gov/statistics/benchmarks/screening/2009/table7.html" title="http://breastscreening.cancer.gov/statistics/benchmarks/screening/2009/table7.html">Breast Cancer Surveillance Consortium</a> (BCSC). (Para obtener m&#xE1;s informaci&#xF3;n, consultar el sumario del PDQ <a href="/espanol/cancer/deteccion/aspectos-generales-deteccion-pro-pdq">Aspectos generales de los ex&#xE1;menes de detecci&#xF3;n del c&#xE1;ncer</a>).</p></section><section id="_81"><h4 id="_81_toc">Sensibilidad</h4><p id="_82" tabindex="-1">La sensibilidad de la mamograf&#xED;a se mide seg&#xFA;n el porcentaje de mujeres con c&#xE1;ncer de mama que se identifican mediante los ex&#xE1;menes de detecci&#xF3;n con mamograf&#xED;a. La sensibilidad depende del tama&#xF1;o del tumor, el grado de visibilidad del tumor, la sensibilidad hormonal, la densidad del tejido mamario, la edad de la paciente, la etapa del ciclo menstrual, la calidad general de la imagen y la habilidad de interpretaci&#xF3;n del radi&#xF3;logo. La sensibilidad general es de alrededor de 79&#xA0;%, pero es m&#xE1;s baja en las mujeres m&#xE1;s j&#xF3;venes y en aquellas con tejido mamario denso (consultar el <a href="http://breastscreening.cancer.gov/" title="http://breastscreening.cancer.gov/">portal de Internet del BCSC</a>).[<a href="#cit/section_3.24">24</a>-<a href="#cit/section_3.26">26</a>] La sensibilidad no equivale al beneficio ya que algunas mujeres que podr&#xED;an tener c&#xE1;ncer de mama se ven perjudicadas por el sobrediagn&#xF3;stico. De acuerdo con la Physician's Insurance Association of America (PIAA), la demora en el diagn&#xF3;stico del c&#xE1;ncer de mama y los errores de diagn&#xF3;stico son causas comunes de litigio por negligencia m&#xE9;dica. En los datos de la PIAA de 2002 a 2011, se destaca que las indemnizaciones m&#xE1;s altas por demandas relacionadas con el c&#xE1;ncer de mama se deben a errores de diagn&#xF3;stico, con un promedio de pagos por indemnizaciones de $444&#xA0;557.[<a href="#cit/section_3.27">27</a>]</p></section><section id="_83"><h4 id="_83_toc">Tasa de especificidad y de positivos falsos</h4><p id="_84" tabindex="-1">La especificidad de la mamograf&#xED;a se mide seg&#xFA;n el porcentaje total de mujeres sin c&#xE1;ncer de mama que obtienen resultados negativos en los ex&#xE1;menes de detecci&#xF3;n con mamograf&#xED;a. La tasa de positivos falsos es la probabilidad de que la prueba tenga un resultado positivo en mujeres sin c&#xE1;ncer de mama. La especificidad baja junto con una tasa de positivos falsos alta dan lugar a ex&#xE1;menes y procedimientos de seguimiento innecesarios. Debido a que la especificidad tiene como denominador a todas las mujeres sin c&#xE1;ncer, el n&#xFA;mero de positivos falsos es muy alto en t&#xE9;rminos absolutos, aunque el porcentaje sea bajo. Por lo tanto, para los ex&#xE1;menes de detecci&#xF3;n, una especificidad <em>satisfactoria</em> debe ser muy alta. Incluso 95&#xA0;% de especificidad es bastante bajo para un examen de detecci&#xF3;n.</p></section><section id="_85"><h4 id="_85_toc">C&#xE1;nceres de intervalos</h4><p id="_86" tabindex="-1">Los c&#xE1;nceres de intervalos son c&#xE1;nceres que se diagnostican en el intervalo entre un examen de detecci&#xF3;n normal y la fecha anticipada de la siguiente mamograf&#xED;a de detecci&#xF3;n. En un estudio, se encontr&#xF3; que los c&#xE1;nceres de intervalo se presentaron con mayor frecuencia en mujeres menores de 50 a&#xF1;os con caracter&#xED;sticas histol&#xF3;gicas mucinosas o lobulillares, grado histol&#xF3;gico alto, actividad proliferativa alta con mamograf&#xED;as de caracter&#xED;sticas relativamente benignas y sin calcificaciones. Por el contrario, los c&#xE1;nceres que se identificaron por medio de ex&#xE1;menes de detecci&#xF3;n con frecuencia presentaron caracter&#xED;sticas histol&#xF3;gicas de tipo tubular, tama&#xF1;o m&#xE1;s peque&#xF1;o, estadio bajo, sensibilidad a las hormonas y un componente importante de CDIS.[<a href="#cit/section_3.28">28</a>] En general, los c&#xE1;nceres de intervalo tienen caracter&#xED;sticas de crecimiento r&#xE1;pido,[<a href="#cit/section_3.28">28</a>,<a href="#cit/section_3.29">29</a>] se diagnostican en estadio avanzado y tienen un pron&#xF3;stico precario.[<a href="#cit/section_3.30">30</a>]</p><p id="_603" tabindex="-1">En el Nova Scotia Breast Screening Program se definieron los c&#xE1;nceres no detectados como aquellos que exhibieron resultados negativos falsos durante el examen de detecci&#xF3;n anterior; esto se produjo con una frecuencia menor de 1 por cada 1000 mujeres. Se lleg&#xF3; a la conclusi&#xF3;n de que los c&#xE1;nceres de intervalo se producen el alrededor de 1 de cada 1000 mujeres de 40 a 49 a&#xF1;os y en 3 de cada 1000 mujeres de 50 a 59 a&#xF1;os.[<a href="#cit/section_3.31">31</a>]</p><p id="_87" tabindex="-1">Por el contrario, en un estudio m&#xE1;s numeroso se encontr&#xF3; que los c&#xE1;nceres de intervalo fueron m&#xE1;s prevalentes en las mujeres de 40 a 49 a&#xF1;os. Esos c&#xE1;nceres, que se presentaron dentro de los 12 meses de un examen de detecci&#xF3;n con resultado negativo, se atribuyeron por lo general a una mayor densidad mamaria. Aquellos que se presentaron en el intervalo de 24 meses, se relacionaron con una disminuci&#xF3;n de la sensibilidad mamogr&#xE1;fica debido a una densidad mamaria m&#xE1;s alta o a un crecimiento tumoral r&#xE1;pido.[<a href="#cit/section_3.32">32</a>]</p></section></section><section id="_119"><h3 id="_119_toc">Variables relacionadas con la precisi&#xF3;n</h3><section id="_163"><h4 id="_163_toc">Caracter&#xED;sticas de la paciente</h4><p id="_164" tabindex="-1">La precisi&#xF3;n de las mamograf&#xED;as depende de la edad de la mujer, la densidad mamaria, si se trata de su primer examen o de uno posterior, y del tiempo transcurrido desde la &#xFA;ltima mamograf&#xED;a. Las mujeres j&#xF3;venes tienen una sensibilidad m&#xE1;s baja y tasas de resultados positivos falsos m&#xE1;s altas que las mujeres de m&#xE1;s edad.</p><p id="_165" tabindex="-1">En las mujeres de todas las edades, la densidad mamaria alta se relaciona con una sensibilidad de 10 a 29&#xA0;% m&#xE1;s baja.[<a href="#cit/section_3.25">25</a>] La densidad mamaria alta es un rasgo intr&#xED;nseco que puede ser familiar [<a href="#cit/section_3.33">33</a>,<a href="#cit/section_3.34">34</a>] y que tambi&#xE9;n puede obedecer a la edad, las hormonas end&#xF3;genas [<a href="#cit/section_3.35">35</a>] y ex&#xF3;genas [<a href="#cit/section_3.36">36</a>,<a href="#cit/section_3.37">37</a>],[<a href="#cit/section_3.38">38</a>] los moduladores selectivos de los receptores de estr&#xF3;geno, como el tamoxifeno,[<a href="#cit/section_3.39">39</a>] y la alimentaci&#xF3;n.[<a href="#cit/section_3.40">40</a>] La hormonoterapia no solo se relaciona con un aumento de la densidad mamaria y sensibilidad m&#xE1;s baja sino tambi&#xE9;n con un aumento en la tasa de c&#xE1;nceres de intervalo.[<a href="#cit/section_3.41">41</a>]</p><p id="_166" tabindex="-1">En el Million Women Study del Reino Unido, se revelaron tres caracter&#xED;sticas de las pacientes relacionadas con una disminuci&#xF3;n de la sensibilidad y la especificidad de los ex&#xE1;menes de detecci&#xF3;n en mujeres de 50 a 64 a&#xF1;os: uso de hormonoterapia posmenop&#xE1;usica, cirug&#xED;a de mama anterior e &#xED;ndice de masa corporal inferior a 25.[<a href="#cit/section_3.42">42</a>] Por otra parte, un intervalo m&#xE1;s largo desde la &#xFA;ltima mamograf&#xED;a aumenta la sensibilidad, la tasa de repeticiones y la tasa de detecci&#xF3;n del c&#xE1;ncer, adem&#xE1;s de disminuir la especificidad.[<a href="#cit/section_3.43">43</a>]</p><p id="_167" tabindex="-1">Se propusieron estrategias para mejorar la sensibilidad mediante la modificaci&#xF3;n del r&#xE9;gimen alimentario, la sincronizaci&#xF3;n de las mamograf&#xED;as con los ciclos menstruales, la interrupci&#xF3;n de la hormonoterapia antes del examen de detecci&#xF3;n o el uso de mam&#xF3;grafos digitales.[<a href="#cit/section_3.8">8</a>] Las mujeres obesas tienen un aumento de m&#xE1;s de 20&#xA0;% de riesgo de obtener una mamograf&#xED;a con resultado positivo falso, aunque la sensibilidad no cambie.[<a href="#cit/section_3.44">44</a>]</p></section><section id="_210"><h4 id="_210_toc">Caracter&#xED;sticas tumorales</h4><p id="_211" tabindex="-1">Las mamograf&#xED;as detectan los c&#xE1;nceres de tipo mucinoso y lobulillar con mayor facilidad. Los c&#xE1;nceres de crecimiento r&#xE1;pido se pueden confundir con el tejido mamario normal o con carcinomas medulares;[<a href="#cit/section_3.28">28</a>,<a href="#cit/section_3.45">45</a>] es posible que no se detecten algunos c&#xE1;nceres relacionados con mutaciones en <em>BRCA1/2</em> de crecimiento lento.[<a href="#cit/section_3.46">46</a>,<a href="#cit/section_3.47">47</a>]</p></section><section id="_168"><h4 id="_168_toc">Caracter&#xED;sticas de los m&#xE9;dicos</h4><p id="_169" tabindex="-1">El desempe&#xF1;o de los radi&#xF3;logos var&#xED;a y depende del grado de experiencia y la cantidad de mamograf&#xED;as que interpretan.[<a href="#cit/section_3.48">48</a>] Al igual que para cualquier otro examen, la sensibilidad y la especificidad se contraponen; mientras mayor sea la frecuencia con que un radi&#xF3;logo pase por alto un c&#xE1;ncer, mayor ser&#xE1; la frecuencia con que una mujer obtenga un resultado positivo falso en la mamograf&#xED;a. Los radi&#xF3;logos del &#xE1;mbito acad&#xE9;mico exhiben un valor pron&#xF3;stico positivo (VPP) m&#xE1;s alto en sus recomendaciones para la pr&#xE1;ctica de una biopsia que aquellos en la comunidad.[<a href="#cit/section_3.49">49</a>] La capacitaci&#xF3;n de especialistas durante su formaci&#xF3;n tal vez ayude a mejorar la detecci&#xF3;n por im&#xE1;genes mamogr&#xE1;ficas.[<a href="#cit/section_3.8">8</a>]</p><p id="_659" tabindex="-1">La eficacia tambi&#xE9;n depende del establecimiento. La precisi&#xF3;n de la detecci&#xF3;n mamogr&#xE1;fica fue m&#xE1;s alta en centros donde solo se ofrec&#xED;an ex&#xE1;menes de detecci&#xF3;n que en los que se realizaban otros ex&#xE1;menes de diagn&#xF3;stico. Se observ&#xF3; una mayor precisi&#xF3;n en centros dotados con un especialista permanente en imaginolog&#xED;a de la mama que realizaba lecturas simples en lugar de dobles y se somet&#xED;an a auditor&#xED;as de sus prestaciones dos o m&#xE1;s veces por a&#xF1;o.[<a href="#cit/section_3.50">50</a>]</p><p id="_660" tabindex="-1">Las tasas de resultados positivos falsos son m&#xE1;s altas en establecimientos donde hay una mayor preocupaci&#xF3;n por negligencia m&#xE9;dica y atienden a mujeres vulnerables (mujeres de minor&#xED;as raciales o &#xE9;tnicas y mujeres con menor nivel educativo, ingreso familiar limitado o que viven en zonas rurales).[<a href="#cit/section_3.51">51</a>] Es posible que estas poblaciones presenten una prevalencia de c&#xE1;ncer m&#xE1;s alta y carezcan de seguimiento.[<a href="#cit/section_3.52">52</a>]</p></section><section id="_173"><h4 id="_173_toc">Comparaciones internacionales</h4><p id="_174" tabindex="-1">En comparaciones internacionales de los ex&#xE1;menes de detecci&#xF3;n por mamograf&#xED;a, se determin&#xF3; que la especificidad es m&#xE1;s alta en pa&#xED;ses con sistemas de detecci&#xF3;n mucho m&#xE1;s centralizados y programas nacionales de garant&#xED;a de la calidad.[<a href="#cit/section_3.53">53</a>,<a href="#cit/section_3.54">54</a>]</p><p id="_697" tabindex="-1">La tasa de repetici&#xF3;n es dos veces m&#xE1;s alta en los Estados Unidos que en el Reino Unido; sin embargo, no hay diferencia en la tasa de c&#xE1;nceres que se detectan.[<a href="#cit/section_3.53">53</a>]</p></section><section id="_175"><h4 id="_175_toc">Comparaci&#xF3;n entre el examen prevalente y el examen posterior, e intervalo entre ex&#xE1;menes</h4><p id="_176" tabindex="-1">La probabilidad de diagnosticar c&#xE1;ncer es m&#xE1;s alta con el examen de detecci&#xF3;n prevalente (el primero) y oscila entre 9 y 26 c&#xE1;nceres por 1000 ex&#xE1;menes de detecci&#xF3;n, seg&#xFA;n la edad de la mujer. La probabilidad disminuye para los ex&#xE1;menes de seguimiento y oscila entre 1 y 3 c&#xE1;nceres por 1000 ex&#xE1;menes de detecci&#xF3;n.[<a href="#cit/section_3.55">55</a>]</p><p id="_694" tabindex="-1">Se desconoce el intervalo &#xF3;ptimo entre las mamograf&#xED;as de detecci&#xF3;n; hay poca variabilidad entre los ensayos a pesar de las diferencias de protocolos y los intervalos de los ex&#xE1;menes de detecci&#xF3;n. En un ensayo prospectivo realizado en el Reino Unido, se asign&#xF3; al azar a mujeres de 50 a 62 a&#xF1;os a someterse a mamograf&#xED;as cada a&#xF1;o o cada 3 a&#xF1;os. Aunque el grado del tumor y el estado ganglionar fueron similares en ambos grupos, se detectaron m&#xE1;s c&#xE1;nceres de tama&#xF1;o un poco m&#xE1;s peque&#xF1;o en el grupo de ex&#xE1;menes de detecci&#xF3;n anuales que en el grupo de ex&#xE1;menes de detecci&#xF3;n trienales.[<a href="#cit/section_3.56">56</a>]</p><p id="_177" tabindex="-1">En un estudio de observaci&#xF3;n grande, se encontr&#xF3; un aumento leve del riesgo de enfermedad en estadio avanzado en el momento del diagn&#xF3;stico en mujeres de 40 a 49 a&#xF1;os que se adhirieron a un plan de 2 a&#xF1;os en lugar de 1 a&#xF1;o (28 vs. 21&#xA0;%; oportunidad relativa [OR], 1,35; intervalo de confianza [IC] 95&#xA0;%, 1,01&#x2013;1,81), pero no se observ&#xF3; diferencia debido a los cronogramas en mujeres de 50 a 59 a&#xF1;os y de 60 a 69 a&#xF1;os.[<a href="#cit/section_3.57">57</a>,<a href="#cit/section_3.58">58</a>]</p><p id="_215" tabindex="-1">En un estudio finland&#xE9;s de 14&#xA0;765 mujeres de 40 a 49 a&#xF1;os, se asign&#xF3; al azar a las mujeres a ex&#xE1;menes de detecci&#xF3;n anuales y trienales. Hubo 18 defunciones por c&#xE1;ncer de mama en 100&#xA0;738 a&#xF1;os-vida en el grupo sometido a ex&#xE1;menes de detecci&#xF3;n trienales, y 18 defunciones por c&#xE1;ncer de mama en 88&#xA0;780 a&#xF1;os-vida en el grupo de ex&#xE1;menes de detecci&#xF3;n anuales (cociente de riesgos instant&#xE1;neos [CRI], 0,88; IC 95&#xA0;%, 0,59&#x2013;1,27).[<a href="#cit/section_3.59">59</a>]</p></section></section><section id="_93"><h3 id="_93_toc">Efecto de los ex&#xE1;menes de detecci&#xF3;n con mamograf&#xED;a en la mortalidad por c&#xE1;ncer de mama</h3><section id="_94"><h4 id="_94_toc">Ensayos controlados aleatorizados</h4><p id="_95" tabindex="-1">Se realizaron ensayos controlados aleatorizados (ECA) sobre la mortalidad por c&#xE1;ncer de mama entre 1963 y 2015, con la participaci&#xF3;n de m&#xE1;s de medio mill&#xF3;n de mujeres en cuatro pa&#xED;ses. En un ensayo, el Canadian National Breast Screening Study-2 (CNBSS-2), se llev&#xF3; a cabo una comparaci&#xF3;n entre el uso de la mamograf&#xED;a con el examen cl&#xED;nico de la mama (ECM) y el uso del ECM solo; en los otros ensayos se compararon la mamograf&#xED;a de detecci&#xF3;n con el ECM o sin este, y la atenci&#xF3;n de rutina. Para obtener una descripci&#xF3;n detallada de los ensayos, consultar la secci&#xF3;n <a href="/espanol/tipos/seno/pro/deteccion-seno-pdq#link/_377">Ap&#xE9;ndice de ensayos controlados aleatorizados</a> de este sumario.</p><p id="_219" tabindex="-1">Los ensayos se diferenciaron con respecto al dise&#xF1;o, la inscripci&#xF3;n de las participantes, las intervenciones (tanto de examen de detecci&#xF3;n como de tratamiento), el manejo del grupo de control, el cumplimiento de la asignaci&#xF3;n a grupos de ex&#xE1;menes de detecci&#xF3;n y de control, y el an&#xE1;lisis de los resultados. En algunos ensayos, se utiliz&#xF3; la aleatorizaci&#xF3;n individual, mientras que en otros se utiliz&#xF3; la aleatorizaci&#xF3;n por grupos en la que se identificaron cohortes y luego se les ofrecieron ex&#xE1;menes de detecci&#xF3;n; en un ensayo, se hizo una asignaci&#xF3;n no aleatorizada por d&#xED;a de nacimiento en cualquier mes dado. Algunas veces, la aleatorizaci&#xF3;n por grupos produjo desequilibrios entre los grupos de intervenci&#xF3;n y de control. En varios ensayos, se identificaron diferencias de edad, aunque no tuvieron un efecto importante en el resultado del ensayo.[<a href="#cit/section_3.60">60</a>] En el Edinburgh Trial, el &#xED;ndice socioecon&#xF3;mico, que se correlaciona con el riesgo de mortalidad por c&#xE1;ncer de mama, difiri&#xF3; de forma notable entre los grupos de intervenci&#xF3;n y de control; esto impidi&#xF3; interpretar los resultados.</p><p id="_96" tabindex="-1">La mortalidad por c&#xE1;ncer de mama fue el par&#xE1;metro principal del desenlace en cada uno de estos ensayos, por lo que las causas de muerte atribuidas exigieron una atenci&#xF3;n meticulosa. Se incorpor&#xF3; el uso de un comit&#xE9; de vigilancia an&#xF3;nimo (Nueva York) y una vinculaci&#xF3;n a fuentes de datos independientes, como los registros nacionales de mortalidad (ensayos suecos), pero no se pudo asegurar la atribuci&#xF3;n imparcial de la causa de muerte en el caso de las mujeres en los grupos de ex&#xE1;menes de detecci&#xF3;n o los grupos de control. Se indic&#xF3; una posible clasificaci&#xF3;n err&#xF3;nea de las muertes por c&#xE1;ncer de mama en el Two-County Trial, que pudieron tener sesgos en los resultados a favor de los ex&#xE1;menes de detecci&#xF3;n.[<a href="#cit/section_3.61">61</a>]</p><p id="_97" tabindex="-1">Tambi&#xE9;n hubo diferencias en la metodolog&#xED;a que se us&#xF3; para analizar los resultados de estos ensayos. Cuatro de los cinco ensayos suecos se dise&#xF1;aron para incluir una sola mamograf&#xED;a de detecci&#xF3;n en el grupo de control, con sincronizaci&#xF3;n para que se correspondiera con el final de la serie de mamograf&#xED;as de detecci&#xF3;n en el grupo de estudio. El an&#xE1;lisis inicial de estos ensayos se utiliz&#xF3; con fines de <em>evaluaci&#xF3;n</em>, ya que solo se tuvieron en cuenta las muertes por c&#xE1;ncer de mama de mujeres cuyo c&#xE1;ncer se descubri&#xF3; en la &#xFA;ltima mamograf&#xED;a del estudio o antes de este. En algunos de los ensayos, se present&#xF3; un retraso en la realizaci&#xF3;n de la mamograf&#xED;a prevista para el final del estudio, con lo cual las mujeres en el grupo de control tuvieron m&#xE1;s tiempo para presentar o recibir un diagn&#xF3;stico de c&#xE1;ncer de mama. En otros ensayos, se utiliz&#xF3; un an&#xE1;lisis de <em>seguimiento</em>, que tiene en cuenta todas las muertes atribuidas al c&#xE1;ncer de mama, sin importar el momento del diagn&#xF3;stico. Este tipo de an&#xE1;lisis se us&#xF3; en un metan&#xE1;lisis de 4 de los 5 ensayos suecos como soluci&#xF3;n al problema de los an&#xE1;lisis de <em>evaluaci&#xF3;n</em>.[<a href="#cit/section_3.61">61</a>]</p><p id="_98" tabindex="-1">Asimismo, hubo variaciones en la facilidad de acceso a los datos de auditor&#xED;a y verificaci&#xF3;n internacionales; solo los ensayos canadienses llevaron a cabo una auditor&#xED;a formal. Hay otros ensayos sometidos a auditor&#xED;as de diferentes grados, pero fueron menos rigurosas.[<a href="#cit/section_3.62">62</a>]</p><p id="_99" tabindex="-1">Todos estos estudios se dise&#xF1;aron para analizar la mortalidad por c&#xE1;ncer de mama en lugar de la mortalidad por todas las causas, ya que las defunciones por c&#xE1;ncer de mama son solo una proporci&#xF3;n peque&#xF1;a del n&#xFA;mero total de defunciones en cualquier poblaci&#xF3;n. Cuando se hicieron an&#xE1;lisis retrospectivos de la mortalidad por todas las causas en estos ensayos, solo se observ&#xF3; una diferencia marcada en el Edinburgh Trial, que se atribuye a diferencias socioecon&#xF3;micas observadas con anterioridad en los grupos del estudio. El metan&#xE1;lisis (m&#xE9;todos de seguimiento) de los cuatro ensayos suecos tambi&#xE9;n revel&#xF3; una mejora peque&#xF1;a de la mortalidad por todas las causas.</p><p id="_103" tabindex="-1">La mejora relativa en la mortalidad por c&#xE1;ncer de mama que se atribuye a los ex&#xE1;menes de detecci&#xF3;n es de alrededor de 15 a 20&#xA0;%, y la mejora absoluta a nivel individual es mucho menor. El posible beneficio de los ex&#xE1;menes de detecci&#xF3;n del c&#xE1;ncer de mama se traduce en el n&#xFA;mero de vidas prolongadas debido a la detecci&#xF3;n temprana de este c&#xE1;ncer.[<a href="#cit/section_3.63">63</a>,<a href="#cit/section_3.64">64</a>]</p><p id="_104" tabindex="-1">Los resultados de los ECA representan experiencias en un plazo determinado de ex&#xE1;menes peri&#xF3;dicos pero, en la pr&#xE1;ctica, las mujeres se someten a 20 o 30 a&#xF1;os de ex&#xE1;menes de detecci&#xF3;n durante toda su vida.[<a href="#cit/section_3.58">58</a>,<a href="#cit/section_3.65">65</a>]</p><p id="_557" tabindex="-1">El uso de esos ECA que se realizaron hace 50 a&#xF1;os o m&#xE1;s presenta varios problemas para calcular el beneficio actual de los ex&#xE1;menes de detecci&#xF3;n para la mortalidad del c&#xE1;ncer de mama. Estos problemas son los siguientes:</p><div class="pdq-content-list"><ol id="_558"><li>Mejoras en la tecnolog&#xED;a mamogr&#xE1;fica, con la capacidad de identificar anomal&#xED;as cada vez m&#xE1;s sutiles.</li><li>Mayor conciencia de la poblaci&#xF3;n general sobre el c&#xE1;ncer de mama, que hace que las mujeres soliciten evaluaciones y tratamiento m&#xE1;s temprano.</li><li>Cambios en la distribuci&#xF3;n de los factores de riesgo en la poblaci&#xF3;n (incluso la edad de la menarquia, la edad del primer embarazo, la obesidad y el tratamiento hormonal posmenop&#xE1;usico).</li><li>Mejoras en el tratamiento del c&#xE1;ncer de mama, con tasas de curaci&#xF3;n m&#xE1;s altas que las anteriores para c&#xE1;nceres m&#xE1;s grandes y en estadio m&#xE1;s avanzado.</li><li>Aplicaci&#xF3;n de resultados de ECA de corto plazo (por ejemplo, de 5 a 10 a&#xF1;os) para calcular los efectos durante toda la vida de los ex&#xE1;menes de detecci&#xF3;n del c&#xE1;ncer de mama.</li></ol></div><p id="_559" tabindex="-1">Por estos motivos, la reducci&#xF3;n de la mortalidad del c&#xE1;ncer de mama por los ex&#xE1;menes de detecci&#xF3;n vigentes se calcula a partir de estudios de cohortes y ecol&#xF3;gicos bien realizados, adem&#xE1;s de los ECA.</p></section><section id="_105"><h4 id="_105_toc">Eficacia de los programas poblacionales de ex&#xE1;menes de detecci&#xF3;n</h4><p id="_106" tabindex="-1">Es posible calcular la eficacia de los ex&#xE1;menes de detecci&#xF3;n mediante estudios controlados no aleatorizados de poblaciones que se sometieron a ex&#xE1;menes de detecci&#xF3;n comparadas con poblaciones que no lo hicieron, estudios de casos y controles de ex&#xE1;menes de detecci&#xF3;n en comunidades reales y estudios de modelos que eval&#xFA;an el efecto de los ex&#xE1;menes de detecci&#xF3;n en poblaciones numerosas. Estos estudios se deben dise&#xF1;ar para reducir al m&#xED;nimo o eliminar los efectos de tendencias no relacionadas que influyen en la mortalidad del c&#xE1;ncer de mama; por ejemplo, mejoras en el tratamiento y mayor sensibilizaci&#xF3;n sobre el c&#xE1;ncer de mama en la comunidad.</p><p id="_107" tabindex="-1">En tres estudios de observaci&#xF3;n de una poblaci&#xF3;n de Suecia, se compar&#xF3; la mortalidad por c&#xE1;ncer de mama frente a la presencia y la ausencia de programas de ex&#xE1;menes de detecci&#xF3;n con mamograf&#xED;a. En un estudio se compararon dos per&#xED;odos contiguos en 7 de los 25 condados suecos y se hall&#xF3; una reducci&#xF3;n con significaci&#xF3;n estad&#xED;stica de la mortalidad por c&#xE1;ncer de mama de 18 a 32&#xA0;% atribuible a los ex&#xE1;menes de detecci&#xF3;n.[<a href="#cit/section_3.66">66</a>] El sesgo m&#xE1;s importante en este estudio es que la adopci&#xF3;n de los ex&#xE1;menes de detecci&#xF3;n se present&#xF3; en estos pa&#xED;ses en un per&#xED;odo en el que se realizaban mejoras considerables en la eficacia del tratamiento adyuvante de c&#xE1;ncer de mama que los autores del estudio no tuvieron en cuenta. En el segundo estudio se consider&#xF3; un per&#xED;odo de 11 a&#xF1;os en el que se compararon 7 condados con programas de ex&#xE1;menes de detecci&#xF3;n con 5 que no los ten&#xED;an.[<a href="#cit/section_3.67">67</a>] Hubo una tendencia en favor de los ex&#xE1;menes de detecci&#xF3;n pero, una vez m&#xE1;s, los autores no tuvieron en cuenta el efecto del tratamiento adyuvante ni las diferencias geogr&#xE1;ficas (&#xE1;reas urbanas vs. rurales) que podr&#xED;an afectar la administraci&#xF3;n del tratamiento.</p><p id="_394" tabindex="-1">En el tercer estudio se intentaron explicar los efectos del tratamiento mediante un an&#xE1;lisis detallado por condado. Se encontr&#xF3; que los ex&#xE1;menes de detecci&#xF3;n tuvieron poco efecto, una conclusi&#xF3;n debilitada por varios errores de dise&#xF1;o y an&#xE1;lisis.[<a href="#cit/section_3.68">68</a>]</p><p id="_108" tabindex="-1">En un programa poblacional de ex&#xE1;menes de detecci&#xF3;n realizado en 1975 en Nijmegen (Pa&#xED;ses Bajos), se hall&#xF3; en un estudio de casos y cohortes que las mujeres que se sometieron a ex&#xE1;menes de detecci&#xF3;n tuvieron una disminuci&#xF3;n de la mortalidad (oportunidad relativa [OR] = 0,48).[<a href="#cit/section_3.69">69</a>] Sin embargo, en un estudio posterior se compararon las tasas de mortalidad por c&#xE1;ncer de mama de Nijmegen con las de la ciudad vecina de Arnhem (Pa&#xED;ses Bajos), en donde no hab&#xED;a un programa de ex&#xE1;menes de detecci&#xF3;n, y no se observ&#xF3; ninguna diferencia en la mortalidad por c&#xE1;ncer de mama.[<a href="#cit/section_3.70">70</a>]</p><p id="_109" tabindex="-1">En un estudio comunitario de casos y controles de ex&#xE1;menes de detecci&#xF3;n realizados entre 1983 y 1998 en sistemas de atenci&#xF3;n sanitaria de alta calidad de los Estados Unidos, no se encontr&#xF3; ninguna relaci&#xF3;n entre los ex&#xE1;menes de detecci&#xF3;n anteriores y la disminuci&#xF3;n de la mortalidad por c&#xE1;ncer de mama; sin embargo, las tasas de ex&#xE1;menes de detecci&#xF3;n por mamograf&#xED;a fueron bajas en general.[<a href="#cit/section_3.71">71</a>]</p><p id="_212" tabindex="-1">En un estudio ecol&#xF3;gico bien realizado, se compararon tres pares de pa&#xED;ses europeos vecinos, compatibles en cuanto a la similitud de sus sistemas de salud y su estructura demogr&#xE1;fica; uno de estos pa&#xED;ses hab&#xED;a iniciado un programa nacional de ex&#xE1;menes de detecci&#xF3;n algunos a&#xF1;os antes que los otros pa&#xED;ses. Los investigadores determinaron que cada pa&#xED;s tuvo una reducci&#xF3;n de la mortalidad por c&#xE1;ncer de mama, sin diferencia entre los pares compatibles, que se podr&#xED;a atribuir a los ex&#xE1;menes de detecci&#xF3;n. Los autores indicaron que era m&#xE1;s probable que las mejoras en el tratamiento del c&#xE1;ncer de mama o en las organizaciones de atenci&#xF3;n de la salud produjeran la disminuci&#xF3;n en la mortalidad que el uso de los ex&#xE1;menes de detecci&#xF3;n.[<a href="#cit/section_3.72">72</a>]</p><p id="_213" tabindex="-1">En una revisi&#xF3;n sistem&#xE1;tica de estudios ecol&#xF3;gicos y de cohortes grandes publicada en marzo de 2011, se compar&#xF3; la mortalidad por c&#xE1;ncer de mama en poblaciones numerosas de mujeres de 50 a 69 a&#xF1;os que se comenzaron a someter a ex&#xE1;menes de detecci&#xF3;n del c&#xE1;ncer de mama en distintos momentos. Hubo 17 estudios que cumplieron con los criterios de participaci&#xF3;n, pero todos presentaron problemas metodol&#xF3;gicos, como diferencias en los grupos de control, ajuste insuficiente por las diferencias entre las &#xE1;reas de riesgo de c&#xE1;ncer de mama y su tratamiento, adem&#xE1;s de problemas de similitud de mediciones para la mortalidad por c&#xE1;ncer de mama entre las zonas comparadas. Hubo una variaci&#xF3;n considerable en los resultados de los estudios: en 4 estudios se encontr&#xF3; una reducci&#xF3;n relativa en la mortalidad por c&#xE1;ncer de mama de 33&#xA0;% o m&#xE1;s (con IC amplios); en otros 5 estudios no se encontr&#xF3; una reducci&#xF3;n de la mortalidad por c&#xE1;ncer de mama. Dado que solo una parte de la disminuci&#xF3;n general de la mortalidad por c&#xE1;ncer de mama se pod&#xED;a atribuir a los ex&#xE1;menes de detecci&#xF3;n, en la conclusi&#xF3;n de la revisi&#xF3;n se indic&#xF3; que era probable que la disminuci&#xF3;n relativa en la mortalidad por c&#xE1;ncer de mama como resultado de los ex&#xE1;menes de detecci&#xF3;n no superar&#xED;a 10&#xA0;%.[<a href="#cit/section_3.73">73</a>]</p><p id="_396" tabindex="-1">En un an&#xE1;lisis ecol&#xF3;gico en los Estados Unidos, realizado entre 1976 y 2008, se examin&#xF3; la incidencia del c&#xE1;ncer de mama en estadio temprano versus estadio avanzado en mujeres de 40 a&#xF1;os o m&#xE1;s. A fin de evaluar el efecto de los ex&#xE1;menes de detecci&#xF3;n, los autores compararon la magnitud del aumento de c&#xE1;ncer en estadio temprano con la magnitud de la disminuci&#xF3;n prevista del c&#xE1;ncer en estadio avanzado. A lo largo del estudio, el aumento absoluto de la incidencia del c&#xE1;ncer en estadio temprano fue de 122 c&#xE1;nceres por 100&#xA0;000 mujeres, mientras que la disminuci&#xF3;n absoluta de los c&#xE1;nceres en estadio avanzado fue de 8 casos por 100&#xA0;000 mujeres. Despu&#xE9;s de un ajuste por los cambios en la incidencia que produjo la hormonoterapia y otras causas indefinidas, los autores llegaron a las siguientes conclusiones: 1) el beneficio de los ex&#xE1;menes de detecci&#xF3;n para la mortalidad fue peque&#xF1;o; 2) entre 22 y 31&#xA0;% de los c&#xE1;nceres diagnosticados representaron sobrediagn&#xF3;sticos; y 3) es probable que la mejora observada en la tasa de mortalidad por c&#xE1;ncer de mama sea atribuible a las mejoras de tratamiento y no a los ex&#xE1;menes de detecci&#xF3;n.[<a href="#cit/section_3.74">74</a>]</p><p id="_622" tabindex="-1">Se utiliz&#xF3; un enfoque anal&#xED;tico para aproximar los aportes de los ex&#xE1;menes de detecci&#xF3;n versus el tratamiento en cuanto a la disminuci&#xF3;n de la tasa de mortalidad por c&#xE1;ncer de mama y la magnitud del sobrediagn&#xF3;stico.[<a href="#cit/section_3.75">75</a>] El cambio en el tama&#xF1;o de la distribuci&#xF3;n de los c&#xE1;nceres de mama en los Estados Unidos desde antes de la introducci&#xF3;n de la mamograf&#xED;a hasta despu&#xE9;s de su difusi&#xF3;n generalizada en 2012, se investig&#xF3; mediante el uso de datos del SEER para mujeres de 40 a&#xF1;os o m&#xE1;s. Se parti&#xF3; de la base que la tasa del c&#xE1;ncer de mama con importancia cl&#xED;nica permaneci&#xF3; estable durante este per&#xED;odo. Los autores documentaron una incidencia m&#xE1;s baja de tumores m&#xE1;s grandes (&#x2265; 2 cm), al igual que una disminuci&#xF3;n de la tasa de letalidad por c&#xE1;ncer de mama. La mortalidad m&#xE1;s baja para las mujeres con tumores de mayor tama&#xF1;o se atribuy&#xF3; a las mejoras del tratamiento. Dos tercios de la disminuci&#xF3;n en la tasa de letalidad por tama&#xF1;o se atribuyeron a las mejoras del tratamiento.</p><figure id="figure_718" class="image-center"><a href="https://www.cancer.gov/images/cdr/live/CDR788703.jpg" target="_blank" class="article-image-enlarge">Ampliar</a><img id="_718" alt="El gr&#xE1;fico muestra la relaci&#xF3;n temporal entre la introducci&#xF3;n de la mamograf&#xED;a de detecci&#xF3;n y el aumento de la incidencia del c&#xE1;ncer de mama invasivo." title="El gr&#xE1;fico muestra la relaci&#xF3;n temporal entre la introducci&#xF3;n de la mamograf&#xED;a de detecci&#xF3;n y el aumento de la incidencia del c&#xE1;ncer de mama invasivo." src="https://www.cancer.gov/images/cdr/live/CDR788703-750.jpg"><figcaption class="caption-container">Figura 2.  Se muestran las incidencias generales del c&#xE1;ncer de mama  invasivo y c&#xE1;ncer de mama metast&#xE1;sico en mujeres de 40 o m&#xE1;s a&#xF1;os en 9 sitios del programa Surveillance, Epidemiology, and End Results (SEER)  durante el per&#xED;odo de 1975 a 2012.  New England Journal of Medicine, Welch HG, Prorok PC, O'Malley AJ, Kramer BS, Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness, Volume 375, Issue 15, Pages 1438-47, Derechos de autor &#xA9; 2016 Massachusetts Medical Society. Reproducci&#xF3;n autorizada por la  Massachusetts Medical Society.</figcaption></figure><p id="_452" tabindex="-1">En un estudio prospectivo de cohortes de los programas comunitarios de detecci&#xF3;n de los Estados Unidos, se encontr&#xF3; que la mamograf&#xED;a de detecci&#xF3;n anual comparada con la bienal no redujo la proporci&#xF3;n de c&#xE1;nceres de mama desfavorables detectados en mujeres de 50 a 74 a&#xF1;os o en mujeres de 40 a 49 a&#xF1;os sin mamas sumamente densas. Las mujeres de 40 a 49 a&#xF1;os con mamas sumamente densas s&#xED; exhibieron una reducci&#xF3;n en los c&#xE1;nceres de m&#xE1;s de 2,0 cm con los ex&#xE1;menes de detecci&#xF3;n anuales (OR, 2,39; IC 95&#xA0;%, 1,37&#x2013;4,18).[<a href="#cit/section_3.76">76</a>]</p></section><section id="_110"><h4 id="_110_toc">Modelo estad&#xED;stico de la incidencia del c&#xE1;ncer de mama y la mortalidad en los Estados Unidos</h4><p id="_214" tabindex="-1">Los dise&#xF1;adores del modelo abordaron el intervalo de detecci&#xF3;n &#xF3;ptimo. La creaci&#xF3;n de modelos plantea hip&#xF3;tesis que tal vez no sean correctas; sin embargo, la credibilidad de los modelos es superior cuando producen resultados generales que son congruentes con los ensayos aleatorizados y cuando el modelo se usa para interpolar o extrapolar. Por ejemplo, si el resultado de un modelo concuerda con los resultados de un ECA para la detecci&#xF3;n anual, la credibilidad es mayor en la comparaci&#xF3;n de la eficacia relativa del examen de detecci&#xF3;n bienal con el anual.</p><p id="_220" tabindex="-1">En el a&#xF1;o 2000, el Instituto Nacional del C&#xE1;ncer form&#xF3; un consorcio de grupos para la formulaci&#xF3;n de modelos (Cancer Intervention and Surveillance Modeling Network [CISNET]) a fin de abordar la contribuci&#xF3;n relativa de los ex&#xE1;menes de detecci&#xF3;n y el tratamiento adyuvante a la disminuci&#xF3;n de la mortalidad por c&#xE1;ncer de mama observada en los Estados Unidos.[<a href="#cit/section_3.77">77</a>] Estos modelos predijeron reducciones de la mortalidad por c&#xE1;ncer de mama similares a las previstas en las circunstancias de los ECA, pero actualizadas seg&#xFA;n el uso de terapias adyuvantes modernas. En 2009, los autores de modelos de CISNET abordaron varias preguntas sobre los perjuicios y beneficios de la mamograf&#xED;a, incluso la comparaci&#xF3;n entre los ex&#xE1;menes de detecci&#xF3;n anuales y bienales.[<a href="#cit/section_3.58">58</a>] Las mujeres de 50 a 74 a&#xF1;os obtuvieron el mayor beneficio de mortalidad por ex&#xE1;menes de detecci&#xF3;n anuales con mamograf&#xED;a cada 2 a&#xF1;os. La disminuci&#xF3;n de la mortalidad por c&#xE1;ncer de mama que se mantiene al pasar de un examen de detecci&#xF3;n anual a uno bienal oscil&#xF3; en los seis modelos de 72 a 95&#xA0;%, con una mediana de 80&#xA0;%.</p><p id="_719" tabindex="-1">Hay poco datos sobre la reducci&#xF3;n de la mortalidad, vista a lo largo del tiempo a partir de 1990, que se puede atribuir a los avances en las t&#xE9;cnicas de im&#xE1;genes que se usan como ex&#xE1;menes de detecci&#xF3;n y qu&#xE9; tanta reducci&#xF3;n es el resultado de la mejora en la eficacia del tratamiento. En un estudio de la CISNET de seis modelos de simulaci&#xF3;n, cerca de un tercio de la disminuci&#xF3;n en la mortalidad por c&#xE1;ncer de mama en 2012 se atribuy&#xF3; a la detecci&#xF3;n y el resto se atribuy&#xF3; al tratamiento.[<a href="#cit/section_3.78">78</a>] En este estudio de la CISNET, el c&#xE1;lculo de la media de reducci&#xF3;n en la tasa de mortalidad por c&#xE1;ncer de mama fue de 49&#xA0;% (intervalo del modelo, 39&#x2013;58&#xA0;%), en relaci&#xF3;n con la tasa de referencia calculada en 2012 sin ex&#xE1;menes de detecci&#xF3;n ni tratamiento; 37&#xA0;% (intervalo del modelo, 26&#x2013;51&#xA0;%) de esta reducci&#xF3;n se relacion&#xF3; con la detecci&#xF3;n y 63&#xA0;% (intervalo  del modelo, 49&#x2013;74&#xA0;%) de esta reducci&#xF3;n se relacion&#xF3; con el tratamiento.</p></section></section><section id="_402"><h3 id="_402_toc">Perjuicios de los ex&#xE1;menes de detecci&#xF3;n con mamograf&#xED;a</h3><p id="_403" tabindex="-1">Los efectos perjudiciales de las mamograf&#xED;as de detecci&#xF3;n son: sobrediagn&#xF3;stico (positivos verdaderos que no tendr&#xE1;n importancia cl&#xED;nica), positivos falsos (relacionados con la especificidad de la prueba), negativos falsos (relacionados con la sensibilidad de la prueba), molestias vinculadas al examen, riesgo de la radiaci&#xF3;n, perjuicios psicol&#xF3;gicos, tensi&#xF3;n financiera y costos de oportunidad.</p><p id="_480" tabindex="-1">En el <a href="/espanol/tipos/seno/pro/deteccion-seno-pdq#link/_483">Cuadro 1</a>, se proporciona un resumen del c&#xE1;lculo de beneficios y perjuicios de la detecci&#xF3;n por mamograf&#xED;a para 10&#xA0;000 mujeres sometidas a este examen anual durante un per&#xED;odo de 10 a&#xF1;os.[<a href="#cit/section_3.79">79</a>]</p><table id="_483" class="table-default expandable-container"><caption>Cuadro 1.  C&#xE1;lculo de beneficios y perjuicios de la detecci&#xF3;n por mamograf&#xED;a para 10&#xA0;000 mujeres sometidas a mamograf&#xED;as de detecci&#xF3;n anuales durante un per&#xED;odo de 10 a&#xF1;os<span class="sup">a</span></caption><colgroup><col width="14.10%"><col width="18.05%"><col width="16.36%"><col width="15.93%"><col width="16.64%"><col width="18.89%"></colgroup>
            <THead>
            <tr>
            <th>Edad (a&#xF1;os)</th>
            <th>N&#xFA;mero de muertes por c&#xE1;ncer de mama evitadas mediante ex&#xE1;menes de detecci&#xF3;n con mamograf&#xED;a durante los pr&#xF3;ximos 15 a&#xF1;os<span class="sup">b</span></th>
            <th>N&#xFA;mero (IC 95&#xA0;%) con &#x2265;1 resultados positivos falsos durante los 10 a&#xF1;os<span class="sup">c</span></th>
            <th>N&#xFA;mero (IC 95&#xA0;%) con &#x2265;1 resultados positivos falsos que condujeron a una biopsia durante los 10 a&#xF1;os<span class="sup">c</span></th>
            <th colspan="2">N&#xFA;mero de c&#xE1;nceres de mama o CDIS diagnosticados durante los 10 a&#xF1;os que nunca habr&#xED;an pasado a tener importancia cl&#xED;nica (sobrediagn&#xF3;stico)<span class="sup">d</span></th>
            </tr>
            </THead>
            <TFoot class="pdq-footer">
            <tr>
            <td colspan="6">IC = intervalo de confianza; CDIS = carcinoma ductal <em>in situ</em>.</td>
            </tr>
            <tr>
            <td colspan="6"><span class="sup">a</span>Adaptado de Pace y Keating.[<a href="#cit/section_3.79">79</a>]</td>
            </tr>
            <tr>
            <td colspan="6"><span class="sup">b</span>El n&#xFA;mero de muertes evitadas proviene de Welch y Passow.[<a href="#cit/section_3.80">80</a>] El l&#xED;mite m&#xE1;s bajo representa la disminuci&#xF3;n de la mortalidad por c&#xE1;ncer de mama si el riesgo relativo fuera de 0,95 (seg&#xFA;n el beneficio m&#xED;nimo de los ensayos canadienses [<a href="#cit/section_3.81">81</a>,<a href="#cit/section_3.82">82</a>]) y el l&#xED;mite m&#xE1;s alto representa la disminuci&#xF3;n de la mortalidad por c&#xE1;ncer de mama si el riesgo relativo fuera de 0,64 (seg&#xFA;n el Swedish 2-County Trial [<a href="#cit/section_3.83">83</a>]).</td>
            </tr>
            <tr>
            <td colspan="6"><span class="sup">c</span>Los c&#xE1;lculos de los resultados positivos falsos y de las biopsias, y los intervalos de confianza de 95&#xA0;% son riesgos acumulados a 10 a&#xF1;os notificados por Hubbard et al. [<a href="#cit/section_3.84">84</a>] y Braithwaite et al.[<a href="#cit/section_3.85">85</a>]</td>
            </tr>
            <tr>
            <td colspan="6"><span class="sup">d</span>El n&#xFA;mero de casos sobrediagnosticados se tom&#xF3; de Welch y Passow.[<a href="#cit/section_3.80">80</a>] El l&#xED;mite m&#xE1;s bajo representa el sobrediagn&#xF3;stico seg&#xFA;n los resultados del ensayo de Malm&#xF6;,[<a href="#cit/section_3.86">86</a>] mientras que el l&#xED;mite m&#xE1;s alto representa el c&#xE1;lculo de Bleyer y Welch.[<a href="#cit/section_3.74">74</a>]</td>
            </tr>
            <tr>
            <td colspan="6"><span class="sup">e</span>El c&#xE1;lculo m&#xE1;s bajo de sobrediagn&#xF3;stico notificado por Welch y Passow [<a href="#cit/section_3.80">80</a>] proviene del estudio Malm&#xF6;.[<a href="#cit/section_3.86">86</a>] En este estudio no se inscribieron mujeres menores de 50 a&#xF1;os.</td>
            </tr>
            </TFoot>
            <tbody>
            <tr>
            <td align="Center" scope="col">40</td>
            <td align="Center" scope="col">1&#x2013;16</td>
            <td align="Center" scope="col">6130 (5940&#x2013;6310)</td>
            <td align="Center" scope="col">700 (610&#x2013;780)</td>
            <td colspan="2" align="Center" scope="col">?&#x2013;104<span class="sup">e</span></td>
            </tr>
            <tr>
            <td align="Center" scope="col">50</td>
            <td align="Center" scope="col">3&#x2013;32</td>
            <td align="Center" scope="col">6130 (5800&#x2013;6470)</td>
            <td align="Center" scope="col">940 (740&#x2013;1150)</td>
            <td colspan="2" align="Center" scope="col">30&#x2013;137</td>
            </tr>
            <tr>
            <td align="Center" scope="col">60</td>
            <td align="Center" scope="col">5&#x2013;49</td>
            <td align="Center" scope="col">4970 (4780&#x2013;5150)</td>
            <td align="Center" scope="col">980 (840&#x2013;1130)</td>
            <td colspan="2" align="Center" scope="col">64&#x2013;194</td>
            </tr>
            </tbody>
            </table><section id="_666"><h4 id="_666_toc">Sobrediagn&#xF3;stico</h4><p id="_684" tabindex="-1">El sobrediagn&#xF3;stico se presenta cuando los procedimientos de detecci&#xF3;n permiten detectar c&#xE1;nceres que nunca hubieran tenido importancia cl&#xED;nica. Se discute la magnitud del sobrediagn&#xF3;stico, en particular, en cuanto a CDIS, un precursor del c&#xE1;ncer con una evoluci&#xF3;n natural desconocida. Debido a esta incapacidad de predecir con confianza el comportamiento del tumor en el momento del diagn&#xF3;stico, el tratamiento est&#xE1;ndar de los c&#xE1;nceres invasivos y el CDIS puede conducir a sobretratamiento. Los perjuicios relacionados incluyen los efectos secundarios vinculados con el tratamiento y el n&#xFA;mero de perjuicios relacionados con el diagn&#xF3;stico del c&#xE1;ncer, que son inmediatos. Por el contrario, un beneficio de mortalidad se presenta en un momento incierto en el futuro.</p><p id="_685" tabindex="-1">Un abordaje para entender el sobrediagn&#xF3;stico es examinar la prevalencia de c&#xE1;ncer oculto en las mujeres que mueren por otras causas no vinculadas al c&#xE1;ncer. En un resumen de 7 estudios de autopsia, la mediana de la prevalencia de c&#xE1;ncer de mama invasivo fue de 1,3&#xA0;% (intervalo, 0&#x2013;1,8&#xA0;%) y de CDIS fue de 8,9&#xA0;% (intervalo, 0&#x2013;14,7&#xA0;%).[<a href="#cit/section_3.87">87</a>,<a href="#cit/section_3.88">88</a>]</p><p id="_686" tabindex="-1">Es posible medir el sobrediagn&#xF3;stico de forma indirecta al comparar la incidencia del c&#xE1;ncer de mama en poblaciones sometidas a ex&#xE1;menes de detecci&#xF3;n versus la incidencia del c&#xE1;ncer de mama en poblaciones no sometidas a detecci&#xF3;n. Estas comparaciones crean confusi&#xF3;n debido a las diferencias de tipo temporal y geogr&#xE1;fico en las poblaciones, o a diferencias de comportamientos de salud y uso de hormonas. Los c&#xE1;lculos de sobrediagn&#xF3;stico var&#xED;an seg&#xFA;n el ajuste por el sesgo de anticipaci&#xF3;n diagn&#xF3;stica.[<a href="#cit/section_3.89">89</a>,<a href="#cit/section_3.90">90</a>] En un resumen de 29 estudios se describieron tasas calculadas de sobrediagn&#xF3;stico de 0&#x2013;54&#xA0;%; las tasas de los estudios aleatorizados oscilaron entre 11&#xA0;y 22&#xA0;%.[<a href="#cit/section_3.91">91</a>] En Dinamarca, pa&#xED;s donde hubo al mismo tiempo poblaciones sometidas o no a ex&#xE1;menes de detecci&#xF3;n, se calcul&#xF3; con dos metodolog&#xED;as diferentes que la tasa de sobrediagn&#xF3;stico de c&#xE1;ncer invasivo fue de 14 y 39&#xA0;%. Cuando se incluyeron los casos de CDIS, las tasas de sobrediagn&#xF3;stico fueron de 24 y 48&#xA0;%. La segunda metodolog&#xED;a tiene en cuenta las diferencias regionales en mujeres que eran m&#xE1;s j&#xF3;venes que las mujeres en la edad de detecci&#xF3;n y es probable que sea m&#xE1;s precisa.[<a href="#cit/section_3.92">92</a>]</p><p id="_687" tabindex="-1">En teor&#xED;a, la detecci&#xF3;n de m&#xE1;s c&#xE1;nceres de mama en estadio temprano en una poblaci&#xF3;n dada producir&#xED;a una reducci&#xF3;n posterior de la incidencia de c&#xE1;nceres en estadio avanzado. Esto no ocurri&#xF3; en ninguna de las poblaciones estudiadas hasta la fecha. En consecuencia, es probable que la detecci&#xF3;n de c&#xE1;nceres en estadio temprano represente un sobrediagn&#xF3;stico. En un estudio poblacional realizado en los Pa&#xED;ses Bajos, se observ&#xF3; que cerca de la mitad de todos los c&#xE1;nceres de mama detectados mediante ex&#xE1;menes de detecci&#xF3;n, incluso el CDIS, representar&#xED;an un sobrediagn&#xF3;stico; esto es congruente con otros estudios en los que se observaron tasas importantes de sobrediagn&#xF3;stico relacionadas con los ex&#xE1;menes de detecci&#xF3;n.[<a href="#cit/section_3.93">93</a>]</p><p id="_688" tabindex="-1">En un estudio de cohortes realizado en Noruega, se compar&#xF3; el aumento de la incidencia del c&#xE1;ncer en las mujeres aptas para someterse a ex&#xE1;menes de detecci&#xF3;n, con la incidencia del c&#xE1;ncer en mujeres m&#xE1;s j&#xF3;venes que no eran aptas para la detecci&#xF3;n; los criterios de admisibilidad fueron la edad y el lugar de residencia. Se observ&#xF3; que las mujeres aptas para la detecci&#xF3;n exhibieron un aumento de 60&#xA0;% en la incidencia de c&#xE1;nceres localizados (RR, 1,60; IC 95&#xA0;%, 1,42&#x2013;1,79), mientras que la incidencia de c&#xE1;nceres en estadio avanzado permaneci&#xF3; similar en ambos grupos (RR, 1,08; IC 95&#xA0;%, 0,86&#x2013;1,35).[<a href="#cit/section_3.94">94</a>]</p><p id="_689" tabindex="-1">En un estudio de poblaci&#xF3;n en el que se compararon diferentes condados de los Estados Unidos, se observ&#xF3; que las tasas m&#xE1;s altas de uso de ex&#xE1;menes de detecci&#xF3;n con mamograf&#xED;a se relacionaban con tasas m&#xE1;s altas de diagn&#xF3;sticos de c&#xE1;ncer de mama; sin embargo, no se observ&#xF3; una disminuci&#xF3;n correspondiente en la mortalidad a 10 a&#xF1;os por c&#xE1;ncer de mama.[<a href="#cit/section_3.95">95</a>] Los puntos fuertes de este estudio son el gran tama&#xF1;o de la muestra (16 millones de mujeres), adem&#xE1;s de la potencia y la congruencia de la correlaci&#xF3;n observada entre los condados. Las limitaciones de este estudio incluyen la autonotificaci&#xF3;n de las mamograf&#xED;as realizadas, el uso de un per&#xED;odo de 2 a&#xF1;os para calcular la prevalencia de los ex&#xE1;menes de detecci&#xF3;n y el per&#xED;odo analizado (con uso de hormonas para la menopausia).[<a href="#cit/section_3.95">95</a>]</p><p id="_690" tabindex="-1">En el CNBSS, un ensayo cl&#xED;nico aleatorizado, se calcul&#xF3; la magnitud del sobrediagn&#xF3;stico. Al final de los cinco ciclos de ex&#xE1;menes de detecci&#xF3;n, se diagnostic&#xF3; un exceso de 142 casos de c&#xE1;ncer de mama invasivo en el grupo de mamograf&#xED;a en comparaci&#xF3;n con el grupo de control.[<a href="#cit/section_3.96">96</a>] A los 15 a&#xF1;os, el exceso del n&#xFA;mero de casos de c&#xE1;ncer en el grupo de mamograf&#xED;a versus el grupo de control fue de 106; esto representa una tasa de sobrediagn&#xF3;stico de 22&#xA0;% de los 484 c&#xE1;nceres invasivos identificados mediante ex&#xE1;menes de detecci&#xF3;n.[<a href="#cit/section_3.96">96</a>]</p><p id="_713" tabindex="-1">Como consecuencia del uso de las mamograf&#xED;as de detecci&#xF3;n, ahora se identifican un mayor n&#xFA;mero de c&#xE1;nceres de mama de crecimiento lento que resulta en una posibilidad de sobretratamiento. En un an&#xE1;lisis secundario de un ensayo aleatorizado de tamoxifeno versus ninguna terapia sist&#xE9;mica en pacientes con c&#xE1;ncer de mama, los autores utilizaron la prueba MammaPrint que analiza 70 genes e identificaron a 15&#xA0;% los pacientes con un riesgo sumamente bajo, con tasas de supervivencia a 20 a&#xF1;os por enfermedad espec&#xED;fica de 97&#xA0;% en el grupo de tamoxifeno y de 94&#xA0;% en el grupo de control. Por lo tanto, es probable que estos pacientes tengan desenlaces excelentes con cirug&#xED;a sola. La frecuencia de estos c&#xE1;nceres de riesgo sumamente bajo en la poblaci&#xF3;n que se somete a ex&#xE1;menes de detecci&#xF3;n es de alrededor de 25&#xA0;%. Es posible que se utilicen pruebas como MammaPrint de 70 genes en el futuro para identificar estos canceres y as&#xED; disminuir el riesgo de sobretratamiento. Sin embargo, se necesitan nuevos estudios prospectivos para validar estos resultados.[<a href="#cit/section_3.97">97</a>]</p><p id="_691" tabindex="-1">En el <a href="/espanol/tipos/seno/pro/deteccion-seno-pdq#link/_483">Cuadro 1</a> de arriba, se muestran los resultados de un per&#xED;odo de 10 a&#xF1;os de ex&#xE1;menes de detecci&#xF3;n en 10&#xA0;000 mujeres, con un c&#xE1;lculo del n&#xFA;mero de mujeres identificadas con c&#xE1;ncer de mama o CDIS que nunca hubieran tenido importancia cl&#xED;nica (sobrediagn&#xF3;stico). No hubo sobrediagn&#xF3;sticos en el estudio Health Insurance Plan, en el que se realizaron mamograf&#xED;as de tecnolog&#xED;a anticuada y ECM. El sobrediagn&#xF3;stico ha adquirido mayor importancia en la era de la mamograf&#xED;a de tecnolog&#xED;a mejorada. No obstante, no se ha demostrado que la tecnolog&#xED;a mejorada disminuya la mortalidad.[<a href="#cit/section_3.79">79</a>]</p></section><section id="_406"><h4 id="_406_toc">Resultados positivos falsos que conducen a intervenciones adicionales</h4><p id="_407" tabindex="-1">Debido a que menos de 5 de cada 1000 mujeres que se someten a ex&#xE1;menes de detecci&#xF3;n tienen c&#xE1;ncer de mama, la mayor&#xED;a de las mamograf&#xED;as anormales son positivos falsos, incluso con 90&#xA0;% de especificidad de la mamograf&#xED;a (es decir, 90&#xA0;% de todas las mujeres que no tienen c&#xE1;ncer de mama obtendr&#xE1;n un resultado negativo en la mamograf&#xED;a).[<a href="#cit/section_3.55">55</a>]</p><p id="_698" tabindex="-1">Este c&#xE1;lculo de tasas altas de positivos falsos de la mamograf&#xED;a es muy bajo y tal vez parezca il&#xF3;gico debido a un sesgo cognitivo estad&#xED;stico que se llama falacia de las tasas de base. Debido a que la tasa de base del c&#xE1;ncer de mama es baja (5/1000), la tasa de positivos falsos supera de forma amplia la tasa positiva verdadera, aunque se utilice una prueba muy precisa.</p><p id="_699" tabindex="-1">La verdadera tasa positiva de la mamograf&#xED;a de alrededor de 90&#xA0;% significa que, de las mujeres con c&#xE1;ncer de mama, alrededor de 90&#xA0;% tendr&#xE1; un resultado positivo. La verdadera tasa negativa de la mamograf&#xED;a de alrededor de 90&#xA0;% significa que, de las mujeres sin c&#xE1;ncer de mama, alrededor de 90&#xA0;% tendr&#xE1; un resultado negativo. Una tasa positiva falsa de 10&#xA0;% por 1000 personas significa que habr&#xE1; 100 positivos falsos en 1000 personas. Si 5 de cada 1000 mujeres tienen c&#xE1;ncer de mama, entonces 4,5 mujeres con c&#xE1;ncer de mama tendr&#xE1;n un examen con resultado positivo. Es decir, se producen alrededor de 100 positivos falsos por cada 4,5 positivos verdaderos.</p><p id="_700" tabindex="-1">Asimismo, los resultados anormales de las mamograf&#xED;as de detecci&#xF3;n generan pruebas y procedimientos adicionales, como m&#xE1;s proyecciones mamogr&#xE1;ficas de la regi&#xF3;n que motiva preocupaci&#xF3;n, ecograf&#xED;as, im&#xE1;genes por resonancia magn&#xE9;tica y extracci&#xF3;n de muestras de tejido (por aspiraci&#xF3;n con aguja fina, biopsia central o biopsia por escisi&#xF3;n). En general, se deben sopesar los perjuicios provocados por la realizaci&#xF3;n de pruebas y tratamientos innecesarios con el beneficio de la detecci&#xF3;n precoz.</p><p id="_408" tabindex="-1">En un estudio de ex&#xE1;menes de detecci&#xF3;n del c&#xE1;ncer de mama con 2400 mujeres inscritas en una organizaci&#xF3;n de mantenimiento de la salud, se encontr&#xF3; que, en un per&#xED;odo de 10 a&#xF1;os, se diagnosticaron 88 c&#xE1;nceres, 58 de los cuales se identificaron con mamograf&#xED;a. Un tercio de las mujeres tuvieron un resultado anormal para la mamograf&#xED;a que necesit&#xF3; pruebas adicionales: 539 mamograf&#xED;as adicionales, 186 ecograf&#xED;as y 188 biopsias. La tasa acumulada de biopsias (la tasa de resultados positivos verdaderos) fundamentada en hallazgos mamogr&#xE1;ficos fue de alrededor de 1 en 4 (23,6&#xA0;%). El VPP de un examen de detecci&#xF3;n anormal con mamograf&#xED;a en esta poblaci&#xF3;n fue de 6,3&#xA0;% para las mujeres de 40 a 49 a&#xF1;os, 6,6&#xA0;% para las mujeres de 50 a 59 a&#xF1;os y 7,8&#xA0;% para las mujeres de 60 a 69 a&#xF1;os.[<a href="#cit/section_3.98">98</a>] En un an&#xE1;lisis posterior en el que se modelaron los datos de la misma cohorte de mujeres, se calcul&#xF3; que el riesgo de tener al menos un resultado positivo falso de la mamograf&#xED;a era de 7,4&#xA0;% (IC 95&#xA0;%, 6,4&#x2013;8,5&#xA0;%) en la primera mamograf&#xED;a, 26,0&#xA0;% (IC 95&#xA0;%, 24,0&#x2013;28,2&#xA0;%) en la quinta mamograf&#xED;a y 43,1&#xA0;% (IC 95&#xA0;%, 36,6&#x2013;53,6&#xA0;%) en la novena mamograf&#xED;a.[<a href="#cit/section_3.99">99</a>] El riesgo acumulado de por lo menos un resultado positivo falso, dependi&#xF3; de cuatro variables relacionadas con las pacientes (edad m&#xE1;s joven, mayor n&#xFA;mero de biopsias de mama anteriores, antecedentes familiares de c&#xE1;ncer de mama y uso vigente de estr&#xF3;geno) y tres variables radiol&#xF3;gicas (tiempo m&#xE1;s prolongado entre los ex&#xE1;menes de detecci&#xF3;n, falta de comparaci&#xF3;n entre de las mamograf&#xED;as actuales con las anteriores y la tendencia individual del radi&#xF3;logo a interpretar las mamograf&#xED;as como anormales). En t&#xE9;rminos generales, el mayor factor de riesgo para un resultado positivo falso de la mamograf&#xED;a fue la tendencia individual del radi&#xF3;logo a interpretarlas como anormales.</p><p id="_453" tabindex="-1">En un estudio prospectivo de cohortes sobre ex&#xE1;menes comunitarios de detecci&#xF3;n, se encontr&#xF3; que una mayor proporci&#xF3;n de mujeres sometidas a ex&#xE1;menes selectivos anuales recibieron por lo menos un resultado positivo falso despu&#xE9;s de 10 a&#xF1;os que las mujeres sometidas cada 2 a&#xF1;os a estos ex&#xE1;menes, independientemente de la densidad de la mama. Para las mujeres de 40 a&#xF1;os con densidades fibroglandulares dispersas, la diferencia fue de 68,9&#xA0;% (ex&#xE1;menes anuales) versus 46,3&#xA0;% (ex&#xE1;menes bienales). Para las mujeres de 50 a 74 a&#xF1;os, la diferencia para este grupo de densidad fue de 49,8&#xA0;% (ex&#xE1;menes anuales) versus 30,7&#xA0;% (ex&#xE1;menes bienales).[<a href="#cit/section_3.76">76</a>]</p><p id="_631" tabindex="-1">Como se muestra en el <a href="/espanol/tipos/seno/pro/deteccion-seno-pdq#link/_483">Cuadro 1</a>, el n&#xFA;mero calculado de cada 10&#xA0;000 mujeres sometidas cada a&#xF1;o a una mamograf&#xED;a de detecci&#xF3;n durante un per&#xED;odo de 10 a&#xF1;os que tendr&#xE1; por lo menos un resultado positivo falso de una prueba es de 6130 mujeres de 40 a 50 a&#xF1;os y 4970 de mujeres de 60 a&#xF1;os. Se calcula que el n&#xFA;mero de mujeres con un resultado positivo falso de una prueba que conduce a una biopsia es de 700 a 980, seg&#xFA;n la edad.[<a href="#cit/section_3.79">79</a>]</p></section><section id="_412"><h4 id="_412_toc">Resultados negativos falsos que conducen a una posible sensaci&#xF3;n falsa de seguridad</h4><p id="_413" tabindex="-1">La sensibilidad de la mamograf&#xED;a oscila entre 70 y 90&#xA0;%, seg&#xFA;n las caracter&#xED;sticas del radi&#xF3;logo a cargo de su interpretaci&#xF3;n (nivel de experiencia) y las caracter&#xED;sticas de la mujer (edad y densidad mamaria, estado hormonal y alimentaci&#xF3;n). Al suponer una sensibilidad media de 80&#xA0;%, las mamograf&#xED;as no identificar&#xE1;n alrededor de 20&#xA0;% de los c&#xE1;nceres de mama que est&#xE1;n presentes en el momento de los ex&#xE1;menes de detecci&#xF3;n (resultados negativos falsos). Muchos de estos c&#xE1;nceres que se pasan por alto son de riesgo alto y tienen caracter&#xED;sticas biol&#xF3;gicas adversas. Si un resultado <em>normal</em> de una mamograf&#xED;a hace que la mujer o su m&#xE9;dico demoren la evaluaci&#xF3;n de s&#xED;ntomas mamarios o piensen que no la necesitan, la mujer podr&#xED;a sufrir consecuencias indeseables. Por lo tanto, una mamograf&#xED;a con resultado negativo nunca debe disuadir a una mujer o su m&#xE9;dico de realizar una evaluaci&#xF3;n adicional de los s&#xED;ntomas mamarios.</p></section><section id="_429"><h4 id="_429_toc">Incomodidad</h4><p id="_430" tabindex="-1">La compresi&#xF3;n de la mama reduce distorsiones por el movimiento y mejora la calidad de la imagen. Se notific&#xF3; dolor e incomodidad en 90&#xA0;% de las mujeres sometidas la mamograf&#xED;a; 12&#xA0;% calificaron la sensaci&#xF3;n como intensa e intolerable.[<a href="#cit/section_3.100">100</a>] En una revisi&#xF3;n sistem&#xE1;tica de 22 estudios de investigaci&#xF3;n sobre el dolor y la incomodidad relacionados con la mamograf&#xED;a se encontraron variaciones amplias, algunas vinculadas con la etapa del ciclo menstrual, la ansiedad y la anticipaci&#xF3;n del dolor antes de someterse a la mamograf&#xED;a.[<a href="#cit/section_3.101">101</a>]</p></section><section id="_414"><h4 id="_414_toc">Exposici&#xF3;n a la radiaci&#xF3;n</h4><p id="_415" tabindex="-1">Los factores de riesgo principales para el c&#xE1;ncer de mama relacionado con la radiaci&#xF3;n son la edad temprana en el momento de la exposici&#xF3;n y la dosis; sin embargo, en muy pocas ocasiones, algunas mujeres presentan una predisposici&#xF3;n heredada a sufrir da&#xF1;os provocados por la radiaci&#xF3;n que deben evitar la exposici&#xF3;n a la radiaci&#xF3;n a cualquier edad.[<a href="#cit/section_3.102">102</a>,<a href="#cit/section_3.103">103</a>] Para las mujeres mayores de 40 a&#xF1;os, los beneficios de las mamograf&#xED;as anuales probablemente compensan los posibles riesgos.[<a href="#cit/section_3.104">104</a>,<a href="#cit/section_3.102">102</a>,<a href="#cit/section_3.105">105</a>] La mamograf&#xED;a de detecci&#xF3;n est&#xE1;ndar con dos proyecciones expone a las mamas a una dosis media de 4 mSv, y a todo el cuerpo a una dosis de 0,29 mSv.[<a href="#cit/section_3.103">103</a>,<a href="#cit/section_3.106">106</a>] Por lo tanto, es posible que se induzca hasta 1 c&#xE1;ncer de mama cada 1000 mujeres de 40 a 80 a&#xF1;os sometidas a mamograf&#xED;as anuales. Este riesgo se duplica en las mujeres con senos grandes que necesitan dosis radiactivas m&#xE1;s elevadas y en mujeres que necesitan proyecciones adicionales debido a implantes que se hicieron para agrandar las mamas. El riesgo de c&#xE1;ncer de mama inducido por radiaci&#xF3;n se podr&#xED;a reducir a un quinto si las mujeres comenzaran los ex&#xE1;menes de detecci&#xF3;n bianuales a partir de los 50 a&#xF1;os, en vez de comenzarlos anualmente a partir de los 40 a&#xF1;os.[<a href="#cit/section_3.107">107</a>]</p></section><section id="_431"><h4 id="_431_toc">Prejuicios psicol&#xF3;gicos de los resultados positivos falsos</h4><p id="_432" tabindex="-1">En una encuesta telef&#xF3;nica de 308 mujeres 3 meses despu&#xE9;s de las mamograf&#xED;as de detecci&#xF3;n, se revel&#xF3; que cerca de un cuarto de las 68 mujeres a quienes se volvi&#xF3; a llamar para someterse a m&#xE1;s ex&#xE1;menes a&#xFA;n sent&#xED;an preocupaci&#xF3;n que se manifestaba en su estado de &#xE1;nimo o funcionamiento, a pesar de que los ex&#xE1;menes hab&#xED;an descartado un diagn&#xF3;stico de c&#xE1;ncer.[<a href="#cit/section_3.108">108</a>] Durante la investigaci&#xF3;n sobre el efecto psicol&#xF3;gico prolongado de una prueba con resultado positivo falso se encontraron resultados contradictorios. En un estudio de cohortes realizado en Espa&#xF1;a en 2002, se encontr&#xF3; un efecto psicol&#xF3;gico inmediato en la mujer que recibe un resultado positivo falso de una mamograf&#xED;a; sin embargo, estos efectos se disiparon en pocos meses.[<a href="#cit/section_3.109">109</a>] En un estudio de cohortes realizado en Dinamarca en 2013 para medir los efectos psicol&#xF3;gicos de un resultado positivo falso varios a&#xF1;os despu&#xE9;s de recibirlo, se hall&#xF3; que hubo consecuencias psicol&#xF3;gicas negativas a largo plazo.[<a href="#cit/section_3.110">110</a>] Sin embargo, en varios estudios se indica que la ansiedad despu&#xE9;s de la evaluaci&#xF3;n de un examen con resultado positivo falso conduce a la participaci&#xF3;n en ex&#xE1;menes de detecci&#xF3;n futuros.[<a href="#cit/section_3.111">111</a>-<a href="#cit/section_3.114">114</a>]</p></section><section id="_695"><h4 id="_695_toc">Tensi&#xF3;n financiera y costo de oportunidad</h4><p id="_696" tabindex="-1">No se han investigado a fondo los perjuicios posibles de los ex&#xE1;menes de detecci&#xF3;n, pero es evidente que existen.</p></section></section><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_3.1">Siu AL; U.S. Preventive Services Task Force: Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 164 (4): 279-96, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26757170&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26757170&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.2">Sickles EA: Findings at mammographic screening on only one standard projection: outcomes analysis. Radiology 208 (2): 471-5, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9680578&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9680578&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.3">Dibden A, Offman J, Parmar D, et al.: Reduction in interval cancer rates following the introduction of two-view mammography in the UK breast screening programme. Br J Cancer 110 (3): 560-4, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24366303&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24366303&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.4">Lillie-Blanton M: Mammography Quality Standards Act : X-ray Quality Improved, Access Unaffected, but Impact on Health Outcomes Unknown: Testimony Before the Subcommittee on Health and the Environment, Committee on Commerce, House of Representatives. Washington, D.C.: Committee on Commerce, 1998. <a href="https://www.ncbi.nlm.nih.gov/nlmcatalog/?term=Mammography+Quality+Standards+Act+%3A+X-ray+Quality+Improved%2C+Access+Unaffected%2C+but+Impact+on+Health+Outcomes+Unknown%3A+Testimony+Before+the+Subcommittee+on+Health+and+the+Environment%2C+Committee+on+Commerce%2C+House+of+Representatives" title="https://www.ncbi.nlm.nih.gov/nlmcatalog/?term=Mammography+Quality+Standards+Act+%3A+X-ray+Quality+Improved%2C+Access+Unaffected%2C+but+Impact+on+Health+Outcomes+Unknown%3A+Testimony+Before+the+Subcommittee+on+Health+and+the+Environment%2C+Committee+on+Commerce%2C+House+of+Representatives">Available online</a>. Last accessed October 8, 2018.</li><li id="section_3.5">D'Orsi CJ, Sickles EA, Mendelson EB, et al.: ACR BI-RADS Atlas, Breast Imaging Reporting and Data System. 5th ed. Reston, Va: American College of Radiology, 2013. <a href="https://www.acr.org/Quality-Safety/Resources/BIRADS" title="https://www.acr.org/Quality-Safety/Resources/BIRADS">Also available online</a>. Last accessed October 8, 2018.</li><li id="section_3.6">Rosenberg RD, Yankaskas BC, Abraham LA, et al.: Performance benchmarks for screening mammography. Radiology 241 (1): 55-66, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16990671&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16990671&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.7">Sickles EA, D'Orsi CJ, Bassett LW, et al.: ACR BI-RADS Mammography. In: D'Orsi CJ, Sickles EA, Mendelson EB, et al.: ACR BI-RADS Atlas, Breast Imaging Reporting and Data System. 5th ed. Reston, Va: American College of Radiology, 2013, pp 3-171. <a href="https://www.acr.org/Quality-Safety/Resources/BIRADS/Mammography" title="https://www.acr.org/Quality-Safety/Resources/BIRADS/Mammography">Also available online</a>. Last accessed October 8, 2018.</li><li id="section_3.8">Pisano ED, Gatsonis C, Hendrick E, et al.: Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 353 (17): 1773-83, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16169887&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16169887&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.9">Pisano ED, Hendrick RE, Yaffe MJ, et al.: Diagnostic accuracy of digital versus film mammography: exploratory analysis of selected population subgroups in DMIST. Radiology 246 (2): 376-83, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18227537&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18227537&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.10">Kerlikowske K, Hubbard RA, Miglioretti DL, et al.: Comparative effectiveness of digital versus film-screen mammography in community practice in the United States: a cohort study. Ann Intern Med 155 (8): 493-502, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22007043&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22007043&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.11">van Luijt PA, Fracheboud J, Heijnsdijk EA, et al.: Nation-wide data on screening performance during the transition to digital mammography: observations in 6 million screens. Eur J Cancer 49 (16): 3517-25, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23871248&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23871248&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.12">Souza FH, Wendland EM, Rosa MI, et al.: Is full-field digital mammography more accurate than screen-film mammography in overall population screening? A systematic review and meta-analysis. Breast 22 (3): 217-24, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23489759&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23489759&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.13">Gur D, Sumkin JH, Rockette HE, et al.: Changes in breast cancer detection and mammography recall rates after the introduction of a computer-aided detection system. J Natl Cancer Inst 96 (3): 185-90, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14759985&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14759985&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.14">Ciatto S, Del Turco MR, Risso G, et al.: Comparison of standard reading and computer aided detection (CAD) on a national proficiency test of screening mammography. Eur J Radiol 45 (2): 135-8, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12536093&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12536093&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.15">Fenton JJ, Taplin SH, Carney PA, et al.: Influence of computer-aided detection on performance of screening mammography. N Engl J Med 356 (14): 1399-409, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17409321&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17409321&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.16">Elmore JG, Carney PA: Computer-aided detection of breast cancer: has promise outstripped performance? J Natl Cancer Inst 96 (3): 162-3, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14759974&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14759974&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.17">Fenton JJ, Xing G, Elmore JG, et al.: Short-term outcomes of screening mammography using computer-aided detection: a population-based study of medicare enrollees. Ann Intern Med 158 (8): 580-7, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23588746&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23588746&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.18">Lehman CD, Wellman RD, Buist DS, et al.: Diagnostic Accuracy of Digital Screening Mammography With and Without Computer-Aided Detection. JAMA Intern Med 175 (11): 1828-37, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26414882&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26414882&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.19">Killelea BK, Long JB, Chagpar AB, et al.: Evolution of breast cancer screening in the Medicare population: clinical and economic implications. J Natl Cancer Inst 106 (8): , 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25031307&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25031307&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.20">Joensuu H, Lehtim&#xE4;ki T, Holli K, et al.: Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 292 (9): 1064-73, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15339900&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15339900&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.21">Shen Y, Yang Y, Inoue LY, et al.: Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 97 (16): 1195-203, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16106024&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16106024&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.22">Wishart GC, Greenberg DC, Britton PD, et al.: Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone? Br J Cancer 98 (11): 1741-4, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18506175&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18506175&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.23">Moody-Ayers SY, Wells CK, Feinstein AR: "Benign" tumors and "early detection" in mammography-screened patients of a natural cohort with breast cancer. Arch Intern Med 160 (8): 1109-15, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10789603&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10789603&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.24">Carney PA, Miglioretti DL, Yankaskas BC, et al.: Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 138 (3): 168-75, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12558355&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12558355&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.25">Rosenberg RD, Hunt WC, Williamson MR, et al.: Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico. Radiology 209 (2): 511-8, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9807581&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9807581&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.26">Kerlikowske K, Grady D, Barclay J, et al.: Likelihood ratios for modern screening mammography. Risk of breast cancer based on age and mammographic interpretation. JAMA 276 (1): 39-43, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8667537&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8667537&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.27">New PIAA Study Analyzes Diagnosis and Treatment of Breast Cancer [News Release]. Rockville, MD: Physician's Insurance Association of America, 2013. <a href="https://www.piaa.us/docs/News_Releases/2013_PressRelease_BreastCancerStudy.pdf" title="https://www.piaa.us/docs/News_Releases/2013_PressRelease_BreastCancerStudy.pdf">Available online</a>. Last accessed October 8, 2018.</li><li id="section_3.28">Porter PL, El-Bastawissi AY, Mandelson MT, et al.: Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 91 (23): 2020-8, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10580027&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10580027&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.29">Hakama M, Holli K, Isola J, et al.: Aggressiveness of screen-detected breast cancers. Lancet 345 (8944): 221-4, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7741862&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7741862&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.30">Tab&#xE1;r L, Faberberg G, Day NE, et al.: What is the optimum interval between mammographic screening examinations? An analysis based on the latest results of the Swedish two-county breast cancer screening trial. Br J Cancer 55 (5): 547-51, 1987.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3606947&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3606947&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.31">Payne JI, Caines JS, Gallant J, et al.: A review of interval breast cancers diagnosed among participants of the Nova Scotia Breast Screening Program. Radiology 266 (1): 96-103, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23169791&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23169791&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.32">Buist DS, Porter PL, Lehman C, et al.: Factors contributing to mammography failure in women aged 40-49 years. J Natl Cancer Inst 96 (19): 1432-40, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15467032&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15467032&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.33">Pankow JS, Vachon CM, Kuni CC, et al.: Genetic analysis of mammographic breast density in adult women: evidence of a gene effect. J Natl Cancer Inst 89 (8): 549-56, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9106643&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9106643&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.34">Boyd NF, Dite GS, Stone J, et al.: Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med 347 (12): 886-94, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12239257&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12239257&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.35">White E, Velentgas P, Mandelson MT, et al.: Variation in mammographic breast density by time in menstrual cycle among women aged 40-49 years. J Natl Cancer Inst 90 (12): 906-10, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9637139&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9637139&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.36">Harvey JA, Pinkerton JV, Herman CR: Short-term cessation of hormone replacement therapy and improvement of mammographic specificity. J Natl Cancer Inst 89 (21): 1623-5, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9362162&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9362162&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.37">Laya MB, Larson EB, Taplin SH, et al.: Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J Natl Cancer Inst 88 (10): 643-9, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8627640&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8627640&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.38">Baines CJ, Dayan R: A tangled web: factors likely to affect the efficacy of screening mammography. J Natl Cancer Inst 91 (10): 833-8, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10340902&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10340902&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.39">Brisson J, Brisson B, Cot&#xE9; G, et al.: Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 9 (9): 911-5, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11008908&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11008908&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.40">Boyd NF, Greenberg C, Lockwood G, et al.: Effects at two years of a low-fat, high-carbohydrate diet on radiologic features of the breast: results from a randomized trial. Canadian Diet and Breast Cancer Prevention Study Group. J Natl Cancer Inst 89 (7): 488-96, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9086005&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9086005&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.41">Crouchley K, Wylie E, Khong E: Hormone replacement therapy and mammographic screening outcomes in Western Australia. J Med Screen 13 (2): 93-7, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16792833&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16792833&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.42">Banks E, Reeves G, Beral V, et al.: Influence of personal characteristics of individual women on sensitivity and specificity of mammography in the Million Women Study: cohort study. BMJ 329 (7464): 477, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15331472&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15331472&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.43">Yankaskas BC, Taplin SH, Ichikawa L, et al.: Association between mammography timing and measures of screening performance in the United States. Radiology 234 (2): 363-73, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15670994&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15670994&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.44">Elmore JG, Carney PA, Abraham LA, et al.: The association between obesity and screening mammography accuracy. Arch Intern Med 164 (10): 1140-7, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15159273&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15159273&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.45">Wallis MG, Walsh MT, Lee JR: A review of false negative mammography in a symptomatic population. Clin Radiol 44 (1): 13-5, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1873944&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1873944&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.46">Tilanus-Linthorst M, Verhoog L, Obdeijn IM, et al.: A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer 102 (1): 91-5, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12353239&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12353239&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.47">Ganott MA, Harris KM, Klaman HM, et al.: Analysis of False-Negative Cancer Cases Identified with a Mammography Audit. Breast J 5 (3): 166-175, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11348280&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11348280&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.48">Elmore JG, Jackson SL, Abraham L, et al.: Variability in interpretive performance at screening mammography and radiologists' characteristics associated with accuracy. Radiology 253 (3): 641-51, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19864507&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19864507&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.49">Meyer JE, Eberlein TJ, Stomper PC, et al.: Biopsy of occult breast lesions. Analysis of 1261 abnormalities. JAMA 263 (17): 2341-3, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2157903&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2157903&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.50">Taplin S, Abraham L, Barlow WE, et al.: Mammography facility characteristics associated with interpretive accuracy of screening mammography. J Natl Cancer Inst 100 (12): 876-87, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18544742&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18544742&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.51">Jackson SL, Taplin SH, Sickles EA, et al.: Variability of interpretive accuracy among diagnostic mammography facilities. J Natl Cancer Inst 101 (11): 814-27, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19470953&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19470953&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.52">Goldman LE, Walker R, Miglioretti DL, et al.: Accuracy of diagnostic mammography at facilities serving vulnerable women. Med Care 49 (1): 67-75, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20966780&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20966780&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.53">Smith-Bindman R, Chu PW, Miglioretti DL, et al.: Comparison of screening mammography in the United States and the United kingdom. JAMA 290 (16): 2129-37, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14570948&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14570948&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.54">Elmore JG, Nakano CY, Koepsell TD, et al.: International variation in screening mammography interpretations in community-based programs. J Natl Cancer Inst 95 (18): 1384-93, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=13130114&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=13130114&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.55">Kerlikowske K, Grady D, Barclay J, et al.: Positive predictive value of screening mammography by age and family history of breast cancer. JAMA 270 (20): 2444-50, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8230621&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8230621&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.56">The Breast Screening Frequency Trial Group: The frequency of breast cancer screening: results from the UKCCCR Randomised Trial. United Kingdom Co-ordinating Committee on Cancer Research. Eur J Cancer 38 (11): 1458-64, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12110490&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12110490&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.57">White E, Miglioretti DL, Yankaskas BC, et al.: Biennial versus annual mammography and the risk of late-stage breast cancer. J Natl Cancer Inst 96 (24): 1832-9, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15601639&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15601639&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.58">Mandelblatt JS, Cronin KA, Bailey S, et al.: Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med 151 (10): 738-47, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19920274&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19920274&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.59">Parvinen I, Chiu S, Pylkk&#xE4;nen L, et al.: Effects of annual vs triennial mammography interval on breast cancer incidence and mortality in ages 40-49 in Finland. Br J Cancer 105 (9): 1388-91, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21934688&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21934688&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.60">G&#xF8;tzsche PC, Olsen O: Is screening for breast cancer with mammography justifiable? Lancet 355 (9198): 129-34, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10675181&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10675181&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.61">G&#xF8;tzsche PC, Nielsen M: Screening for breast cancer with mammography. Cochrane Database Syst Rev  (4): CD001877, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17054145&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17054145&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.62">Nystr&#xF6;m L, Andersson I, Bjurstam N, et al.: Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 359 (9310): 909-19, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11918907&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11918907&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.63">Kerlikowske K: Efficacy of screening mammography among women aged 40 to 49 years and 50 to 69 years: comparison of relative and absolute benefit. J Natl Cancer Inst Monogr  (22): 79-86, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9709281&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9709281&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.64">Glasziou PP, Woodward AJ, Mahon CM: Mammographic screening trials for women aged under 50. A quality assessment and meta-analysis. Med J Aust 162 (12): 625-9, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7603372&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7603372&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.65">Nelson HD, Tyne K, Naik A, et al.: Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med 151 (10): 727-37, W237-42, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19920273&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19920273&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.66">Duffy SW, Tab&#xE1;r L, Chen HH, et al.: The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties. Cancer 95 (3): 458-69, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12209737&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12209737&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.67">Jonsson H, Nystr&#xF6;m L, T&#xF6;rnberg S, et al.: Service screening with mammography of women aged 50-69 years in Sweden: effects on mortality from breast cancer. J Med Screen 8 (3): 152-60, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11678556&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11678556&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.68">Autier P, Koechlin A, Smans M, et al.: Mammography screening and breast cancer mortality in Sweden. J Natl Cancer Inst 104 (14): 1080-93, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22811439&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22811439&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.69">Broeders MJ, Peer PG, Straatman H, et al.: Diverging breast cancer mortality rates in relation to screening? A comparison of Nijmegen to Arnhem and the Netherlands, 1969-1997. Int J Cancer 92 (2): 303-8, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11291061&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11291061&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.70">Verbeek AL, Hendriks JH, Holland R, et al.: Reduction of breast cancer mortality through mass screening with modern mammography. First results of the Nijmegen project, 1975-1981. Lancet 1 (8388): 1222-4, 1984.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6144933&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6144933&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.71">Elmore JG, Reisch LM, Barton MB, et al.: Efficacy of breast cancer screening in the community according to risk level. J Natl Cancer Inst 97 (14): 1035-43, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16030301&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16030301&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.72">Autier P, Boniol M, Gavin A, et al.: Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ 343: d4411, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21798968&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21798968&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.73">Harris R, Yeatts J, Kinsinger L: Breast cancer screening for women ages 50 to 69 years a systematic review of observational evidence. Prev Med 53 (3): 108-14, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21820465&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21820465&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.74">Bleyer A, Welch HG: Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 367 (21): 1998-2005, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23171096&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23171096&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.75">Welch HG, Prorok PC, O'Malley AJ, et al.: Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. N Engl J Med 375 (15): 1438-1447, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27732805&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27732805&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.76">Kerlikowske K, Zhu W, Hubbard RA, et al.: Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy. JAMA Intern Med 173 (9): 807-16, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23552817&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23552817&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.77">Berry DA, Cronin KA, Plevritis SK, et al.: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353 (17): 1784-92, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16251534&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16251534&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.78">Plevritis SK, Munoz D, Kurian AW, et al.: Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012. JAMA 319 (2): 154-164, 2018.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=29318276&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=29318276&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.79">Pace LE, Keating NL: A systematic assessment of benefits and risks to guide breast cancer screening decisions. JAMA 311 (13): 1327-35, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24691608&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24691608&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.80">Welch HG, Passow HJ: Quantifying the benefits and harms of screening mammography. JAMA Intern Med 174 (3): 448-54, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24380095&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24380095&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.81">Miller AB, To T, Baines CJ, et al.: The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years. Ann Intern Med 137 (5 Part 1): 305-12, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12204013&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12204013&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.82">Miller AB, To T, Baines CJ, et al.: Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years. J Natl Cancer Inst 92 (18): 1490-9, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10995804&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10995804&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.83">Tab&#xE1;r L, Vitak B, Chen TH, et al.: Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology 260 (3): 658-63, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21712474&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21712474&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.84">Hubbard RA, Kerlikowske K, Flowers CI, et al.: Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann Intern Med 155 (8): 481-92, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22007042&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22007042&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.85">Braithwaite D, Zhu W, Hubbard RA, et al.: Screening outcomes in older US women undergoing multiple mammograms in community practice: does interval, age, or comorbidity score affect tumor characteristics or false positive rates? J Natl Cancer Inst 105 (5): 334-41, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23385442&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23385442&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.86">Zackrisson S, Andersson I, Janzon L, et al.: Rate of over-diagnosis of breast cancer 15 years after end of Malm&#xF6; mammographic screening trial: follow-up study. BMJ 332 (7543): 689-92, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16517548&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16517548&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.87">Welch HG, Black WC: Using autopsy series to estimate the disease "reservoir" for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med 127 (11): 1023-8, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9412284&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9412284&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.88">Black WC, Welch HG: Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med 328 (17): 1237-43, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8464435&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8464435&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.89">Duffy SW, Lynge E, Jonsson H, et al.: Complexities in the estimation of overdiagnosis in breast cancer screening. Br J Cancer 99 (7): 1176-8, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18766185&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18766185&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.90">G&#xF8;tzsche PC, J&#xF8;rgensen KJ, Maehlen J, et al.: Estimation of lead time and overdiagnosis in breast cancer screening. Br J Cancer 100 (1): 219; author reply 220, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19127274&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19127274&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.91">Nelson HD, Pappas M, Cantor A, et al.: Harms of Breast Cancer Screening: Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation. Ann Intern Med 164 (4): 256-67, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26756737&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26756737&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.92">J&#xF8;rgensen KJ, G&#xF8;tzsche PC, Kalager M, et al.: Breast Cancer Screening in Denmark: A Cohort Study of Tumor Size and Overdiagnosis. Ann Intern Med 166 (5): 313-323, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28114661&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28114661&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.93">Autier P, Boniol M, Koechlin A, et al.: Effectiveness of and overdiagnosis from mammography screening in the Netherlands: population based study. BMJ 359: j5224, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=29208760&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=29208760&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.94">Lousdal ML, Kristiansen IS, M&#xF8;ller B, et al.: Effect of organised mammography screening on stage-specific incidence in Norway: population study. Br J Cancer 114 (5): 590-6, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26835975&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26835975&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.95">Harding C, Pompei F, Burmistrov D, et al.: Breast Cancer Screening, Incidence, and Mortality Across US Counties. JAMA Intern Med 175 (9): 1483-9, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26147578&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26147578&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.96">Miller AB, Wall C, Baines CJ, et al.: Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ 348: g366, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24519768&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24519768&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.97">Esserman LJ, Yau C, Thompson CK, et al.: Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades. JAMA Oncol 3 (11): 1503-1510, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28662222&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28662222&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.98">Elmore JG, Barton MB, Moceri VM, et al.: Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 338 (16): 1089-96, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9545356&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9545356&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.99">Christiansen CL, Wang F, Barton MB, et al.: Predicting the cumulative risk of false-positive mammograms. J Natl Cancer Inst 92 (20): 1657-66, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11036111&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11036111&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.100">Freitas R 2nd, Fiori WF, Ramos FJ, et al.: [Discomfort and pain during mammography]. Rev Assoc Med Bras 52 (5): 333-6, 2006 Sep-Oct.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17160308&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17160308&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.101">Armstrong K, Moye E, Williams S, et al.: Screening mammography in women 40 to 49 years of age: a systematic review for the American College of Physicians. Ann Intern Med 146 (7): 516-26, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17404354&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17404354&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.102">Swift M, Morrell D, Massey RB, et al.: Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 325 (26): 1831-6, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1961222&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1961222&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.103">Kopans DB: Mammography and radiation risk. In: Janower ML, Linton OW, eds.: Radiation Risk: a Primer. Reston, Va: American College of Radiology, 1996, pp 21-22.</li><li id="section_3.104">Feig SA, Ehrlich SM: Estimation of radiation risk from screening mammography: recent trends and comparison with expected benefits. Radiology 174 (3 Pt 1): 638-47, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2305043&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2305043&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.105">Helzlsouer KJ, Harris EL, Parshad R, et al.: Familial clustering of breast cancer: possible interaction between DNA repair proficiency and radiation exposure in the development of breast cancer. Int J Cancer 64 (1): 14-7, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7665242&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7665242&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.106">Suleiman OH, Spelic DC, McCrohan JL, et al.: Mammography in the 1990s: the United States and Canada. Radiology 210 (2): 345-51, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10207413&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10207413&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.107">Miglioretti DL, Lange J, van den Broek JJ, et al.: Radiation-Induced Breast Cancer Incidence and Mortality From Digital Mammography Screening: A Modeling Study. Ann Intern Med 164 (4): 205-14, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26756460&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26756460&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.108">Lerman C, Trock B, Rimer BK, et al.: Psychological side effects of breast cancer screening. Health Psychol 10 (4): 259-67, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1915212&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1915212&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.109">Sandin B, Chorot P, Valiente RM, et al.: Adverse psychological effects in women attending a second-stage breast cancer screening. J Psychosom Res 52 (5): 303-9, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12023127&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12023127&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.110">Brodersen J, Siersma VD: Long-term psychosocial consequences of false-positive screening mammography. Ann Fam Med 11 (2): 106-15, 2013 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23508596&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23508596&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.111">Gram IT, Lund E, Slenker SE: Quality of life following a false positive mammogram. Br J Cancer 62 (6): 1018-22, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2257206&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2257206&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.112">Burman ML, Taplin SH, Herta DF, et al.: Effect of false-positive mammograms on interval breast cancer screening in a health maintenance organization. Ann Intern Med 131 (1): 1-6, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10391809&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10391809&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.113">Pisano ED, Earp J, Schell M, et al.: Screening behavior of women after a false-positive mammogram. Radiology 208 (1): 245-9, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9646820&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9646820&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.114">Brewer NT, Salz T, Lillie SE: Systematic review: the long-term effects of false-positive mammograms. Ann Intern Med 146 (7): 502-10, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17404352&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17404352&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _543
      field_pdq_section_title:
        - format: plain_text
          value: 'Otras modalidades de obtención de imágenes: ecografía, imágenes por resonancia magnética y termografía'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_543" class="pdq-sections"><p id="_709" tabindex="-1">
            <strong>Ecograf&#xED;a</strong>
            </p><p id="_544" tabindex="-1">La ecograf&#xED;a se usa para la evaluaci&#xF3;n diagn&#xF3;stica de masas palpables o identificadas con mamograf&#xED;a, no como modalidad primaria de detecci&#xF3;n. En una revisi&#xF3;n de la bibliograf&#xED;a m&#xE9;dica y las opiniones de expertos del European Group for Breast Cancer Screening, se concluy&#xF3; que "son escasos los datos probatorios para respaldar el uso de la ecograf&#xED;a como examen de detecci&#xF3;n del c&#xE1;ncer de mama en la poblaci&#xF3;n de cualquier edad".[<a href="#cit/section_4.1">1</a>]</p><p id="_710" tabindex="-1">
            <strong>Im&#xE1;genes por resonancia magn&#xE9;tica de la mama</strong>
            </p><p id="_692" tabindex="-1">Las im&#xE1;genes por resonancia magn&#xE9;tica (IRM) de la mama se usan en las mujeres para una evaluaci&#xF3;n diagn&#xF3;stica, incluso la evaluaci&#xF3;n de la integridad de los implantes mamarios de silicona, la evaluaci&#xF3;n de masas palpables posterior a la cirug&#xED;a o la radioterapia, la detecci&#xF3;n de c&#xE1;ncer de mama inadvertido por mamograf&#xED;a y ecograf&#xED;a en pacientes con met&#xE1;stasis ganglionar axilar, as&#xED; como la planificaci&#xF3;n preoperatoria de algunas pacientes con c&#xE1;ncer de mama identificado. No hay exposici&#xF3;n a la radiaci&#xF3;n ionizante durante este procedimiento. Las IRM de la mama se promovieron como examen de detecci&#xF3;n para el c&#xE1;ncer de mama de mujeres con riesgo elevado de presentar este c&#xE1;ncer por mutaciones en <em>BRCA1/2</em>, antecedentes familiares importantes de c&#xE1;ncer de mama o varios s&#xED;ndromes gen&#xE9;ticos como el de Li-Fraumeni o la enfermedad de Cowden.[<a href="#cit/section_4.2">2</a>-<a href="#cit/section_4.4">4</a>] Las IRM de la mama es m&#xE1;s sensible, pero menos espec&#xED;fica que los ex&#xE1;menes de detecci&#xF3;n con mamograf&#xED;a [<a href="#cit/section_4.5">5</a>,<a href="#cit/section_4.6">6</a>] y es hasta 35 veces m&#xE1;s costosa.[<a href="#cit/section_4.7">7</a>-<a href="#cit/section_4.11">11</a>]</p><p id="_711" tabindex="-1">
            <strong>Termograf&#xED;a</strong>
            </p><p id="_548" tabindex="-1">Con el uso de t&#xE9;cnicas de obtenci&#xF3;n de im&#xE1;genes infrarrojas, la termograf&#xED;a de la mama identifica cambios de temperatura en la piel que tal vez indiquen un tumor subyacente porque muestran estos cambios en patrones de colores. La Administraci&#xF3;n de Alimentos y Medicamentos de los Estados Unidos aprob&#xF3; el uso de los dispositivos termogr&#xE1;ficos mediante el proceso 510(k); sin embargo, no se realizaron ensayos aleatorizados que comparen la termograf&#xED;a con otras modalidades de detecci&#xF3;n. En estudios de cohortes peque&#xF1;os, no se indica ning&#xFA;n beneficio adicional por el uso de la termograf&#xED;a como una modalidad auxiliar.[<a href="#cit/section_4.12">12</a>,<a href="#cit/section_4.13">13</a>]</p><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_4.1">Teh W, Wilson AR: The role of ultrasound in breast cancer screening. A consensus statement by the European Group for Breast Cancer Screening. Eur J Cancer 34 (4): 449-50, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9713292&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9713292&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.2">Warner E, Plewes DB, Hill KA, et al.: Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292 (11): 1317-25, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15367553&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15367553&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.3">Kriege M, Brekelmans CT, Boetes C, et al.: Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351 (5): 427-37, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15282350&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15282350&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.4">Warner E, Hill K, Causer P, et al.: Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 29 (13): 1664-9, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21444874&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21444874&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.5">Lord SJ, Lei W, Craft P, et al.: A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer 43 (13): 1905-17, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17681781&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17681781&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.6">Lehman CD, Gatsonis C, Kuhl CK, et al.: MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 356 (13): 1295-303, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17392300&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17392300&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.7">Pataky R, Armstrong L, Chia S, et al.: Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers. BMC Cancer 13: 339, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23837641&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23837641&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.8">Saadatmand S, Tilanus-Linthorst MM, Rutgers EJ, et al.: Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging. J Natl Cancer Inst 105 (17): 1314-21, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23940285&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23940285&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.9">Ahern CH, Shih YC, Dong W, et al.: Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk. Br J Cancer 111 (8): 1542-51, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25137022&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25137022&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.10">Pistolese CA, Ciarrapico AM, della Gatta F, et al.: Inappropriateness of breast imaging: cost analysis. Radiol Med 118 (6): 984-94, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23801396&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23801396&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.11">Cott Chubiz JE, Lee JM, Gilmore ME, et al.: Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers. Cancer 119 (6): 1266-76, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23184400&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23184400&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.12">Wishart GC, Campisi M, Boswell M, et al.: The accuracy of digital infrared imaging for breast cancer detection in women undergoing breast biopsy. Eur J Surg Oncol 36 (6): 535-40, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20452740&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20452740&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.13">Arora N, Martins D, Ruggerio D, et al.: Effectiveness of a noninvasive digital infrared thermal imaging system in the detection of breast cancer. Am J Surg 196 (4): 523-6, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18809055&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18809055&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _121
      field_pdq_section_title:
        - format: plain_text
          value: 'Modalidades de detección sin imágenes'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_121" class="pdq-sections"><section id="_187"><h3 id="_187_toc">Examen cl&#xED;nico de la mama</h3><p id="_188" tabindex="-1">A&#xFA;n no se ha establecido por completo la repercusi&#xF3;n del examen cl&#xED;nico de la mama (ECM) en la mortalidad por c&#xE1;ncer de mama. En el Canadian National Breast Screening Study (CNBSS), se compar&#xF3; el uso del ECM de calidad alta junto con la mamograf&#xED;a, con el uso del ECM solo en mujeres de 50 a 59 a&#xF1;os. Profesionales de la salud capacitados llevaron a cabo ECM que duraron de 5 a 10 minutos por mama y se incluyeron evaluaciones peri&#xF3;dicas de la calidad del procedimiento. La frecuencia del diagn&#xF3;stico de c&#xE1;ncer, el estadio de c&#xE1;ncer, los casos de c&#xE1;ncer de intervalo y la mortalidad por c&#xE1;ncer de mama fueron similares en los dos grupos y los desenlaces similares al uso de la mamograf&#xED;a sola.[<a href="#cit/section_5.1">1</a>] Tras un seguimiento promedio de 13 a&#xF1;os, la mortalidad por c&#xE1;ncer de mama fue semejante en los dos grupos (cociente de tasa de mortalidad, 1,02; (intervalo de confianza [IC] 95&#xA0;%, 0,78&#x2013;1,33]).[<a href="#cit/section_5.2">2</a>] Los investigadores calcularon las caracter&#xED;sticas operatorias del ECM solo; en 19&#xA0;965 mujeres de 50 a 59 a&#xF1;os, la sensibilidad fue de 83, 71, 57, 83 y 77&#xA0;% en los a&#xF1;os 1, 2, 3, 4 y 5 del ensayo, respectivamente, y la especificidad oscil&#xF3; entre 88 y 96&#xA0;%. El valor pron&#xF3;stico positivo (VPP), que es la proporci&#xF3;n de c&#xE1;nceres que se detectan por examen anormal, se calcul&#xF3; entre 3 y 4&#xA0;%. Para 25&#xA0;620 mujeres de 40 a 49 a&#xF1;os que solo se sometieron a un examen al ingresar en el ensayo, se calcul&#xF3; una sensibilidad de 71&#xA0;%, una especificidad de 84&#xA0;%, y un VPP de 1,5&#xA0;%.[<a href="#cit/section_5.3">3</a>]</p><p id="_189" tabindex="-1">En los ensayos cl&#xED;nicos en los que participaron m&#xE9;dicos comunitarios, el ECM tuvo una especificidad m&#xE1;s alta (97&#x2013;99&#xA0;%) [<a href="#cit/section_5.4">4</a>] y una sensibilidad m&#xE1;s baja (22&#x2013;36&#xA0;%) que la obtenida por los examinadores.[<a href="#cit/section_5.5">5</a>-<a href="#cit/section_5.8">8</a>] En un estudio de ex&#xE1;menes de detecci&#xF3;n practicados a mujeres con antecedentes familiares de c&#xE1;ncer de mama, se observ&#xF3; que, tras una evaluaci&#xF3;n inicial normal, la paciente misma o el m&#xE9;dico que realiz&#xF3; el ECM identific&#xF3; m&#xE1;s c&#xE1;nceres que la mamograf&#xED;a.[<a href="#cit/section_5.9">9</a>]</p><p id="_708" tabindex="-1">En otro estudio, se examin&#xF3; la utilidad de agregar el ECM a los ex&#xE1;menes de detecci&#xF3;n con mamograf&#xED;a; en 61&#xA0;688 mujeres mayores de 40 a&#xF1;os y sometidas a mamograf&#xED;a y ECM, la sensibilidad de la mamograf&#xED;a fue de 78&#xA0;%, y de la mamograf&#xED;a y el ECM combinados fue de 82&#xA0;%. La especificidad fue m&#xE1;s baja en las mujeres que se sometieron a ambas modalidades de ex&#xE1;menes de detecci&#xF3;n, que en las que solo se sometieron a mamograf&#xED;a (97 vs. 99&#xA0;%).[<a href="#cit/section_5.10">10</a>] Otros ensayos internacionales de ECM se encuentran en curso; dos en India y uno en Egipto.</p></section><section id="_190"><h3 id="_190_toc">Autoexamen de la mama</h3><p id="_191" tabindex="-1">Se ha promovido el autoexamen de la mama (AEM) mensual, pero no hay datos probatorios s&#xF3;lidos de su eficacia en la reducci&#xF3;n de la mortalidad por c&#xE1;ncer de mama.[<a href="#cit/section_5.11">11</a>,<a href="#cit/section_5.12">12</a>] En el &#xFA;nico ensayo cl&#xED;nico aleatorizado grande bien realizado de AEM, se asign&#xF3; al azar a 266&#xA0;064 mujeres trabajadoras de una f&#xE1;brica en Shangh&#xE1;i a recibir educaci&#xF3;n sobre el AEM con refuerzo y motivaci&#xF3;n para hac&#xE9;rselo, o educaci&#xF3;n para la prevenci&#xF3;n del lumbago. Ning&#xFA;n grupo se someti&#xF3; a otro examen de detecci&#xF3;n del c&#xE1;ncer de mama. Al cabo de 10 a 11 a&#xF1;os de seguimiento, hubo 135 muertes por c&#xE1;ncer de mama en el grupo que recibi&#xF3; la capacitaci&#xF3;n y 131, en el grupo de control (riesgo relativo [RR] = 1,04; IC 95&#xA0;%, 0,82&#x2013;1,33). Si bien el n&#xFA;mero de c&#xE1;nceres de mama invasivos que se diagnostic&#xF3; en los dos grupos fue pr&#xE1;cticamente el mismo, las mujeres del grupo de capacitaci&#xF3;n tuvieron m&#xE1;s biopsias de mama y m&#xE1;s lesiones benignas que las mujeres del grupo de control.[<a href="#cit/section_5.13">13</a>]</p><p id="_192" tabindex="-1">Otros resultados de investigaci&#xF3;n sobre AEM provienen de tres ensayos. En primer lugar, m&#xE1;s de 100&#xA0;000 mujeres de Leningrado se asignaron a la capacitaci&#xF3;n para el AEM o a grupos de control aleatorizados; el grupo con capacitaci&#xF3;n en AEM se someti&#xF3; a m&#xE1;s biopsias de mama sin que mejorara la mortalidad por c&#xE1;ncer de mama.[<a href="#cit/section_5.14">14</a>] En segundo lugar, en el Trial of Early Detection of Breast Cancer en dos distritos del Reino Unido, se invit&#xF3; a m&#xE1;s de 63&#xA0;500 mujeres de 45 a 64 a&#xF1;os a sesiones educativas sobre el AEM. Al cabo de 10 a&#xF1;os de seguimiento, las tasas de mortalidad por c&#xE1;ncer de mama fueron similares a las tasas observadas en los centros sin capacitaci&#xF3;n organizada para el AEM (RR = 1,07; IC 95&#xA0;%, 0,93&#x2013;1,22).[<a href="#cit/section_5.15">15</a>] En tercer lugar, y por el contrario, en un estudio anidado de casos y controles del NBSS canadiense, se compararon la frecuencia de la realizaci&#xF3;n del AEM, informada por las mismas pacientes antes de su inscripci&#xF3;n, con la mortalidad por c&#xE1;ncer de mama. Las mujeres que se examinaron las mamas visualmente y utilizaron la yema de los tres dedos del medio para palparlas tuvieron una tasa de mortalidad por c&#xE1;ncer de mama m&#xE1;s baja.[<a href="#cit/section_5.16">16</a>]</p></section><section id="_201"><h3 id="_201_toc">Muestreo de tejido (aspiraci&#xF3;n con aguja fina, aspiraci&#xF3;n por pez&#xF3;n, lavado ductal)</h3><p id="_202" tabindex="-1">Se han propuesto distintos m&#xE9;todos para analizar el tejido mamario para encontrar neoplasias malignas mediante la detecci&#xF3;n del c&#xE1;ncer de mama, pero ninguno de estos se relaciona con una disminuci&#xF3;n de la mortalidad.</p></section><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_5.1">Baines CJ: The Canadian National Breast Screening Study: a perspective on criticisms. Ann Intern Med 120 (4): 326-34, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8291826&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8291826&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.2">Miller AB, To T, Baines CJ, et al.: Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years. J Natl Cancer Inst 92 (18): 1490-9, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10995804&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10995804&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.3">Baines CJ, Miller AB, Bassett AA: Physical examination. Its role as a single screening modality in the Canadian National Breast Screening Study. Cancer 63 (9): 1816-22, 1989.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2702588&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2702588&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.4">Fenton JJ, Rolnick SJ, Harris EL, et al.: Specificity of clinical breast examination in community practice. J Gen Intern Med 22 (3): 332-7, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17356964&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17356964&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.5">Fenton JJ, Barton MB, Geiger AM, et al.: Screening clinical breast examination: how often does it miss lethal breast cancer? J Natl Cancer Inst Monogr  (35): 67-71, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16287888&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16287888&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.6">Bobo JK, Lee NC, Thames SF: Findings from 752,081 clinical breast examinations reported to a national screening program from 1995 through 1998. J Natl Cancer Inst 92 (12): 971-6, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10861308&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10861308&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.7">Oestreicher N, White E, Lehman CD, et al.: Predictors of sensitivity of clinical breast examination (CBE). Breast Cancer Res Treat 76 (1): 73-81, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12408378&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12408378&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.8">Kolb TM, Lichy J, Newhouse JH: Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology 225 (1): 165-75, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12355001&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12355001&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.9">Gui GP, Hogben RK, Walsh G, et al.: The incidence of breast cancer from screening women according to predicted family history risk: Does annual clinical examination add to mammography? Eur J Cancer 37 (13): 1668-73, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11527694&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11527694&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.10">Oestreicher N, Lehman CD, Seger DJ, et al.: The incremental contribution of clinical breast examination to invasive cancer detection in a mammography screening program. AJR Am J Roentgenol 184 (2): 428-32, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15671358&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15671358&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.11">Baxter N; Canadian Task Force on Preventive Health Care: Preventive health care, 2001 update: should women be routinely taught breast self-examination to screen for breast cancer? CMAJ 164 (13): 1837-46, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11450279&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11450279&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.12">Humphrey LL, Helfand M, Chan BK, et al.: Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137 (5 Part 1): 347-60, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12204020&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12204020&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.13">Thomas DB, Gao DL, Ray RM, et al.: Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst 94 (19): 1445-57, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12359854&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12359854&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.14">Semiglazov VF, Moiseyenko VM, Bavli JL, et al.: The role of breast self-examination in early breast cancer detection (results of the 5-years USSR/WHO randomized study in Leningrad). Eur J Epidemiol 8 (4): 498-502, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1397215&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1397215&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.15">Ellman R, Moss SM, Coleman D, et al.: Breast cancer mortality after 10 years in the UK trial of early detection of breast cancer. UK Trial of Early Detection of Breast Cancer Group. The Breast  2 (1): 13-20, 1993.</li><li id="section_5.16">Harvey BJ, Miller AB, Baines CJ, et al.: Effect of breast self-examination techniques on the risk of death from breast cancer. CMAJ 157 (9): 1205-12, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9361639&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9361639&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _377
      field_pdq_section_title:
        - format: plain_text
          value: 'Apéndice de ensayos controlados aleatorizados'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_377" class="pdq-sections"><p id="_73" tabindex="-1">
            <strong>Health Insurance Plan, Estados Unidos, 1963</strong>
            [<a href="#cit/section_6.1">1</a>,<a href="#cit/section_6.2">2</a>]
            </p><div class="pdq-content-list"><ul id="_378" class="pdq-address-block"><li><strong>Edad en el  momento del ingreso:</strong> 40 a 64 a&#xF1;os.</li><li><strong>Aleatorizaci&#xF3;n:</strong> individual, pero con desequilibrios marcados en la distribuci&#xF3;n de las mujeres entre los grupos asignados, seg&#xFA;n se confirm&#xF3; por el estado menop&#xE1;usico (<em>P</em> &lt; 0,0001) y el grado de escolaridad (<em>P</em> = 0,05).</li><li><strong>Tama&#xF1;o de la muestra:</strong> de 30&#xA0;000 a 31&#xA0;092 en el grupo de estudio y de 30&#xA0;565 a 30&#xA0;765 en el grupo de control.</li><li><strong>Congruencia de los informes:</strong> variaci&#xF3;n en los informes sobre el tama&#xF1;o de las muestras.</li><li><strong>Intervenci&#xF3;n:</strong> mamograf&#xED;a con dos proyecciones (MMG) y examen cl&#xED;nico de la mama (ECM) anual durante 3 a&#xF1;os.</li><li><strong>Control:</strong> atenci&#xF3;n normal.</li><li><strong>Cumplimiento:</strong> las mujeres que faltaron al primer examen de detecci&#xF3;n (35&#xA0;% de la poblaci&#xF3;n examinada) no recibieron una segunda invitaci&#xF3;n.</li><li><strong>Contaminaci&#xF3;n:</strong> el examen de detecci&#xF3;n con MMG no se ofreci&#xF3; fuera del ensayo; se desconoce la frecuencia del ECM en las mujeres del grupo de control.</li><li><strong>Atribuci&#xF3;n de la causa de muerte: </strong> las mujeres que se diagnosticaron antes de ingresar al estudio y que murieron por c&#xE1;ncer de mama se excluyeron de la comparaci&#xF3;n entre los grupos de examen de detecci&#xF3;n y de control. Sin embargo, estas exclusiones se determinaron de manera diferente en los dos grupos. Las mujeres del grupo de ex&#xE1;menes de detecci&#xF3;n se excluyeron seg&#xFA;n decisiones tomadas durante el per&#xED;odo del estudio en que se sometieron a ex&#xE1;menes de detecci&#xF3;n tras las consultas iniciales. Estas mujeres no se volvieron a tener en cuenta en el estudio. Desde el punto de vista del dise&#xF1;o, los controles no recibieron consultas cl&#xED;nicas sistem&#xE1;ticas, por lo que no se determin&#xF3; el estado del c&#xE1;ncer de estas pacientes antes del estudio. Ante la muerte de una paciente del grupo de control por c&#xE1;ncer de mama, se realiz&#xF3; un an&#xE1;lisis retrospectivo a fin de determinar la fecha de diagn&#xF3;stico de la enfermedad. Si la fecha era anterior al per&#xED;odo de estudio, el paciente del grupo de control se excluy&#xF3; del an&#xE1;lisis. Es posible que esta diferencia en la metodolog&#xED;a cree un sesgo marcado en la comparaci&#xF3;n de la mortalidad por c&#xE1;ncer de mama entre los dos grupos, y es probable que dicho sesgo favorezca los ex&#xE1;menes de detecci&#xF3;n.</li><li><strong>An&#xE1;lisis:</strong> seguimiento.</li><li><strong>Auditor&#xED;a externa:</strong> ninguna.</li><li><strong>Duraci&#xF3;n del seguimiento:</strong> 18 a&#xF1;os.</li><li><strong>Riesgo relativo de muerte por c&#xE1;ncer de mama en el grupo de ex&#xE1;menes de detecci&#xF3;n en comparaci&#xF3;n con el grupo de control (intervalo de confianza [IC] 95&#xA0;%):</strong> 0,71 (0,55&#x2013;0,93) a 10 a&#xF1;os y 0,77 (0,61&#x2013;0,97) a 15 a&#xF1;os.</li><li><strong>Comentarios:</strong> la calidad de las MMG fue precaria en comparaci&#xF3;n con las que se realizaron en ensayos posteriores debido a equipos y t&#xE9;cnicas obsoletos. La intervenci&#xF3;n incluy&#xF3; tanto MMG como ECM. Las preocupaciones principales sobre la eficacia del ensayo son la validez de la aleatorizaci&#xF3;n inicial y la exclusi&#xF3;n diferencial de las mujeres con antecedentes de c&#xE1;ncer de mama.</li></ul></div><p id="_379" tabindex="-1">
            <strong>Malmo, Suecia 1976</strong>
            [<a href="#cit/section_6.3">3</a>,<a href="#cit/section_6.4">4</a>]
            </p><div class="pdq-content-list"><ul id="_113" class="pdq-address-block"><li><strong>Edad en el momento del ingreso:</strong> 45 a 69 a&#xF1;os.</li><li><strong>Aleatorizaci&#xF3;n:</strong> individual, para cada cohorte de a&#xF1;o de nacimiento para el ensayo de detecci&#xF3;n con MMG en la primera fase (MMST I). Individual para toda la cohorte constituida por fecha de nacimiento entre 1933 y 1945 para MMST II, pero con variaciones impuestas por la escasez de recursos. La validaci&#xF3;n por an&#xE1;lisis de edad en ambos grupos no revela ninguna diferencia marcada.</li><li><strong>Exclusiones:</strong> en un metan&#xE1;lisis sueco, se excluy&#xF3; a 393 mujeres con c&#xE1;ncer de mama preexistente del grupo de intervenci&#xF3;n y a 412 del grupo de control. Sin embargo, en general, se excluy&#xF3; a 86 mujeres m&#xE1;s del grupo de intervenci&#xF3;n que del grupo de control.</li><li><strong>Tama&#xF1;o de la muestra:</strong> 21&#xA0;088 en el grupo de estudio y 21&#xA0;195 en el grupo de control.</li><li><strong>Congruencia de los informes:</strong> los n&#xFA;meros de pacientes no se modificaron.</li><li><strong>Intervenci&#xF3;n:</strong> MMG de dos proyecciones  cada 18 a 24 meses &#xD7; 5.</li><li><strong>Control:</strong> atenci&#xF3;n normal, con MMG al final del estudio.</li><li><strong>Cumplimiento:</strong> no se les dio seguimiento a las participantes que migraron de Malmo (2&#xA0;% por a&#xF1;o). La tasa de participaci&#xF3;n de las mujeres en el estudio fue de 74&#xA0;% para el primer ciclo y de 70&#xA0;% para los ciclos posteriores.</li><li><strong>Contaminaci&#xF3;n:</strong> 24% de todas las mujeres del grupo de control se sometieron al menos a una MMG, al igual que 35&#xA0;% de las mujeres del grupo de control de 45 a 49 a&#xF1;os.</li><li><strong>Atribuci&#xF3;n de la causa de muerte:</strong> tasa de autopsia de 76&#xA0;% en el informe preliminar, tasa m&#xE1;s baja despu&#xE9;s. Evaluaci&#xF3;n de la causa de muerte con anonimato para las mujeres con diagn&#xF3;stico de c&#xE1;ncer de mama. Vinculado al Swedish Cause of Death Registry.</li><li><strong>An&#xE1;lisis:</strong> evaluaci&#xF3;n inicial. An&#xE1;lisis de seguimiento, como parte del metan&#xE1;lisis sueco.[<a href="#cit/section_6.5">5</a>]</li><li><strong>Auditor&#xED;a externa:</strong> ninguna.</li><li><strong>Duraci&#xF3;n del seguimiento:</strong> 12 a&#xF1;os.</li><li><strong>Riesgo relativo de muerte por c&#xE1;ncer de mama, en el grupo de ex&#xE1;menes de detecci&#xF3;n en comparaci&#xF3;n con el grupo de control (IC 95&#xA0;%):</strong> 0,81 (0,62&#x2013;1,07).</li><li><strong>Comentarios:</strong> el an&#xE1;lisis evaluativo exigi&#xF3; un factor de ajuste para el retraso en la realizaci&#xF3;n de la MMG en el grupo de control. En la mayor&#xED;a de los an&#xE1;lisis, se combinaron los dos ensayos de Malmo: MMST I y MMST II.</li></ul></div><p id="_380" tabindex="-1">
            <strong>&#xD6;sterg&#xF6;tland (County E of Two-County Trial), Suecia, 1977</strong>
            [<a href="#cit/section_6.6">6</a>-<a href="#cit/section_6.8">8</a>]
            </p><div class="pdq-content-list"><ul id="_381" class="pdq-address-block"><li><strong>Edad en el  momento del ingreso:</strong> 40 a 74 a&#xF1;os.</li><li><strong>Aleatorizaci&#xF3;n:</strong> agrupaci&#xF3;n geogr&#xE1;fica con estratificaci&#xF3;n conforme a la residencia (urbana o rural), factores socioecon&#xF3;micos y tama&#xF1;o. La incidencia del c&#xE1;ncer de mama y mortalidad de referencia fueron comparables entre los grupos geogr&#xE1;ficos asignados al azar. Las mujeres del estudio eran mayores que las mujeres del grupo de control, <em>P</em> &lt; 0,0001, lo que no afectar&#xED;a mucho el resultado del ensayo.</li><li><strong>Exclusiones:</strong> las mujeres con c&#xE1;ncer de mama preexistente se excluyeron de ambos grupos, pero los n&#xFA;meros se notifican de manera diferente en las distintas publicaciones. El metan&#xE1;lisis sueco excluy&#xF3; a todas las mujeres con diagn&#xF3;stico previo de c&#xE1;ncer de mama, independientemente del grupo al que se asignaron.</li><li><strong>Tama&#xF1;o de la muestra:</strong> notificaci&#xF3;n variable, que oscil&#xF3; entre 38&#xA0;405 y 39&#xA0;034 en el grupo de estudio y entre 37&#xA0;145 y 37&#xA0;936 en el grupo de control.</li><li><strong>Congruencia de los informes:</strong> variable.</li><li><strong>Intervenci&#xF3;n:</strong> 3 MMG de proyecci&#xF3;n &#xFA;nica cada 2 a&#xF1;os para las mujeres menores de 50 a&#xF1;os, y cada 33 meses para las mujeres de 50 a&#xF1;os y m&#xE1;s.</li><li><strong>Referencia:</strong> atenci&#xF3;n normal, con MMG al final del estudio.</li><li><strong>Cumplimiento:</strong> 89&#xA0;% de quienes se sometieron a detecci&#xF3;n.</li><li><strong>Contaminaci&#xF3;n:</strong> 13&#xA0;% de las mujeres en el ensayo Two-County se sometieron a MMG como parte de la atenci&#xF3;n sistem&#xE1;tica; la mayor&#xED;a en 1983 y 1984.</li><li><strong>Atribuci&#xF3;n de la causa de muerte:</strong> determinada por un equipo de m&#xE9;dicos locales. Cuando se recalcularon los resultados en el metan&#xE1;lisis sueco, con datos del Swedish Cause of Death Registry, el beneficio de los ex&#xE1;menes de detecci&#xF3;n fue inferior al que se notific&#xF3; antes.</li><li><strong>An&#xE1;lisis:</strong> evaluaci&#xF3;n en un inicio, con ajuste por retraso en la MMG del grupo de control. An&#xE1;lisis de seguimiento, como parte del metan&#xE1;lisis sueco.[<a href="#cit/section_6.5">5</a>]</li><li><strong>Auditor&#xED;a externa:</strong> no. Sin embargo, un grupo sueco conformado por los investigadores del ensayo adjudic&#xF3; los casos de c&#xE1;ncer de mama y las muertes.[<a href="#cit/section_6.9">9</a>]</li><li><strong>Duraci&#xF3;n del seguimiento:</strong> 12 a&#xF1;os.</li><li><strong>Riesgo relativo de muerte por c&#xE1;ncer de mama, en el grupo de ex&#xE1;menes de detecci&#xF3;n en comparaci&#xF3;n con el grupo de control (IC 95&#xA0;%):</strong> 0,82 (0,64&#x2013;1,05), Ostrogotia.</li><li><strong>Comentarios:</strong> se expresaron inquietudes sobre la metodolog&#xED;a de aleatorizaci&#xF3;n y el an&#xE1;lisis de evaluaci&#xF3;n, que exigieron un ajuste por la realizaci&#xF3;n tard&#xED;a de la MMG en el grupo de control. El metan&#xE1;lisis sueco resolvi&#xF3; estas cuestiones correctamente.</li></ul></div><p id="_382" tabindex="-1">
            <strong>Kopparberg (County W of Two-County Trial), Suecia, 1977</strong>
            [<a href="#cit/section_6.6">6</a>-<a href="#cit/section_6.8">8</a>]</p><div class="pdq-content-list"><ul id="_383" class="pdq-address-block"><li><strong>Edad en el  momento del ingreso:</strong> 40 a 74 a&#xF1;os.</li><li><strong>Aleatorizaci&#xF3;n:</strong> agrupaci&#xF3;n geogr&#xE1;fica con estratificaci&#xF3;n conforme a la residencia (urbana o rural), factores socioecon&#xF3;micos y tama&#xF1;o. No se describi&#xF3; el proceso de aleatorizaci&#xF3;n. Las mujeres del estudio eran mayores que las mujeres del grupo de control, <em>P</em> &lt; 0,0001, pero esto no deber&#xED;a haber tenido un efecto importante en el resultado del ensayo.</li><li><strong>Exclusiones:</strong> las mujeres con c&#xE1;ncer de mama preexistente se excluyeron de ambos grupos, pero los n&#xFA;meros se notificaron de manera diferente en las publicaciones.</li><li><strong>Tama&#xF1;o de la muestra:</strong> notificaci&#xF3;n variable, que oscil&#xF3; entre 38&#xA0;562 y 39&#xA0;051 en el grupo de intervenci&#xF3;n, y entre 18&#xA0;478 y 18&#xA0;846 en el grupo de control.</li><li><strong>Congruencia de los informes:</strong> variable.</li><li><strong>Intervenci&#xF3;n:</strong> 3 MMG de proyecci&#xF3;n &#xFA;nica cada 2 a&#xF1;os para mujeres menores de 50 a&#xF1;os, y cada 33 meses para mujeres de 50 a&#xF1;os y m&#xE1;s.</li><li><strong>Control:</strong> atenci&#xF3;n normal, con MMG al final del estudio.</li><li><strong>Cumplimiento:</strong> 89&#xA0;% de las participantes.</li><li><strong>Contaminaci&#xF3;n:</strong> 13&#xA0;% de las mujeres en el Two-County Trial se sometieron a MMG como parte de la atenci&#xF3;n sistem&#xE1;tica, en la mayor&#xED;a de los casos entre 1983 y 1984.</li><li><strong>Atribuci&#xF3;n de la causa de muerte:</strong> se determin&#xF3; por parte de un equipo de m&#xE9;dicos locales (ver Ostrogotia).</li><li><strong>An&#xE1;lisis:</strong> evaluaci&#xF3;n.</li><li><strong>Auditor&#xED;a externa:</strong> no. Sin embargo, un grupo sueco conformado por los investigadores del ensayo adjudic&#xF3; los casos de c&#xE1;ncer de mama y las muertes.[<a href="#cit/section_6.9">9</a>]</li><li><strong>Duraci&#xF3;n del seguimiento:</strong> 12 a&#xF1;os.</li><li><strong>Riesgo relativo de muerte por c&#xE1;ncer de mama, en el grupo de detecci&#xF3;n en comparaci&#xF3;n con el grupo de control (IC 95&#xA0;%):</strong> 0,68 (0,52&#x2013;0,89).</li></ul></div><p id="_384" tabindex="-1">
            <strong>Edimburgo, Reino Unido, 1976</strong>
            [<a href="#cit/section_6.10">10</a>]
            </p><div class="pdq-content-list"><ul id="_385" class="pdq-address-block"><li><strong>Edad en el  momento del ingreso:</strong> 45 a 64 a&#xF1;os.</li><li><strong>Aleatorizaci&#xF3;n:</strong> agrupaci&#xF3;n por consultorios m&#xE9;dicos, si bien se modificaron muchas asignaciones a aleatorizaci&#xF3;n despu&#xE9;s del inicio  del estudio. En cada consultorio, la inscripci&#xF3;n de mujeres fue incongruente y dependi&#xF3; de la opini&#xF3;n del m&#xE9;dico sobre la aptitud de cada mujer para el ensayo. No se reconocieron grandes diferencias en el nivel socioecon&#xF3;mico entre los consultorios hasta despu&#xE9;s del final del estudio.</li><li><strong>Exclusiones:</strong> se excluy&#xF3; a m&#xE1;s mujeres con c&#xE1;ncer de mama previo del grupo de intervenci&#xF3;n (338) que del grupo de control (177).</li><li><strong>Tama&#xF1;o de la muestra:</strong> 23&#xA0;226 en el grupo de estudio y 21&#xA0;904 en el grupo de control.</li><li><strong>Congruencia de los informes:</strong> buena.</li><li><strong>Intervenci&#xF3;n:</strong> al inicio, MMG de 2 proyecciones y ECM; luego, ECM anual con MMG de proyecci&#xF3;n &#xFA;nica en el tercer, quinto y s&#xE9;ptimo a&#xF1;o.</li><li><strong>Control:</strong> atenci&#xF3;n normal.</li><li><strong>Cumplimiento:</strong> 61&#xA0;% de quienes se sometieron a detecci&#xF3;n.</li><li><strong>Contaminaci&#xF3;n:</strong> ninguna.</li><li><strong>Atribuci&#xF3;n de la causa de muerte:</strong> datos del registro de c&#xE1;ncer.</li><li><strong>An&#xE1;lisis:</strong> seguimiento.</li><li><strong>Auditor&#xED;a externa:</strong> ninguna.</li><li><strong>Duraci&#xF3;n del seguimiento:</strong> 10 a&#xF1;os.</li><li><strong>Riesgo relativo de muerte por c&#xE1;ncer de mama: grupo de detecci&#xF3;n en comparaci&#xF3;n con el grupo de control (IC 95&#xA0;%):</strong> 0,84 (0,63-1,12).</li><li><strong>Comentarios:</strong> el proceso de aleatorizaci&#xF3;n present&#xF3; fallas. Es probable que las diferencias socioecon&#xF3;micas entre los grupos de estudio y de control expliquen la mortalidad m&#xE1;s alta por todas las causas en las mujeres del grupo de control, en comparaci&#xF3;n con las mujeres que se sometieron a los ex&#xE1;menes de detecci&#xF3;n. Esta diferencia en la mortalidad por todas las causas fue cuatro veces superior a la mortalidad por c&#xE1;ncer de mama en el grupo de control y, por lo tanto, es posible explicar la mortalidad m&#xE1;s alta por c&#xE1;ncer de mama en el grupo de control, en comparaci&#xF3;n con las mujeres que se sometieron a ex&#xE1;menes de detecci&#xF3;n. Si bien se utiliz&#xF3; un factor de correcci&#xF3;n en el an&#xE1;lisis final, es posible que este no ajuste el an&#xE1;lisis lo suficiente.</li></ul></div><p id="_386" tabindex="-1">El dise&#xF1;o y la realizaci&#xF3;n del estudio dificultan la evaluaci&#xF3;n de estos resultados o su combinaci&#xF3;n con los resultados de otros ensayos.</p><p id="_387" tabindex="-1">
            <strong>National Breast Screening Study (NBSS)-1, Canad&#xE1;, 1980</strong>
            [<a href="#cit/section_6.11">11</a>]
            </p><div class="pdq-content-list"><ul id="_388" class="pdq-address-block"><li><strong>Edad en el momento del ingreso:</strong> 40 a 49 a&#xF1;os.</li><li><strong>Aleatorizaci&#xF3;n:</strong> voluntarias individuales, con nombres ingresados sucesivamente en las listas de asignaci&#xF3;n. Si bien se presentaron cr&#xED;ticas con respecto al procedimiento de aleatorizaci&#xF3;n, en una revisi&#xF3;n independiente y minuciosa no se hallaron pruebas de subversi&#xF3;n; adem&#xE1;s, esa subversi&#xF3;n fue improbable a una escala lo suficientemente grande como para influir en los resultados.[<a href="#cit/section_6.12">12</a>]</li><li><strong>Exclusiones:</strong> pocas, equilibradas entre los grupos.</li><li><strong>Tama&#xF1;o de la muestra:</strong> 25&#xA0;214 en el grupo de estudio (100&#xA0;% sometido a ex&#xE1;menes de detecci&#xF3;n despu&#xE9;s del ECM de ingreso) y 25&#xA0;216 en el grupo de control.</li><li><strong>Congruencia de los informes:</strong> buena.</li><li><strong>Intervenci&#xF3;n:</strong> MMG anual de 2 proyecciones y ECM durante 4 a 5 a&#xF1;os.</li><li><strong>Control:</strong> atenci&#xF3;n normal.</li><li><strong>Cumplimiento:</strong> 100&#xA0;% al inicio, disminuy&#xF3; a 85,5&#xA0;% en el quinto examen de detecci&#xF3;n.</li><li><strong>Contaminaci&#xF3;n:</strong> 26,4&#xA0;% en el grupo de atenci&#xF3;n usual.</li><li><strong>Atribuci&#xF3;n de la causa de muerte:</strong> partidas de defunci&#xF3;n, con revisi&#xF3;n de casos cuestionables por parte de un grupo de revisi&#xF3;n con anonimato. Vinculada tambi&#xE9;n con las estad&#xED;sticas de la Canadian Mortality Data Base, Statistics Canada.</li><li><strong>An&#xE1;lisis:</strong> seguimiento.</li><li><strong>Auditor&#xED;a externa:</strong> s&#xED;. Independiente, con el an&#xE1;lisis de datos realizado por varios revisores.</li><li><strong>Duraci&#xF3;n del seguimiento:</strong> 25 a&#xF1;os.</li><li><strong>Riesgo relativo de muerte por c&#xE1;ncer de mama: grupo de detecci&#xF3;n en comparaci&#xF3;n con el grupo de control (IC 95&#xA0;%):</strong> 1,09 (0,80-1,49).</li><li><strong>Comentarios:</strong> este es el &#xFA;nico ensayo dise&#xF1;ado espec&#xED;ficamente para estudiar a mujeres de 40 a 49 a&#xF1;os. Se incluyeron los c&#xE1;nceres que se diagnosticaron en el momento del ingreso en los grupos de estudio y control. Antes de finalizar el ensayo, se expresaron inquietudes sobre la suficiencia t&#xE9;cnica de las MMG, la capacitaci&#xF3;n de los radi&#xF3;logos y la homologaci&#xF3;n de los equipos, lo cual llev&#xF3; a una revisi&#xF3;n externa independiente. La deficiencia principal que identific&#xF3; esta revisi&#xF3;n fue el uso de la proyecci&#xF3;n mediolateral entre 1980 y 1985, en lugar de la proyecci&#xF3;n oblicua mediolateral que se utiliz&#xF3; despu&#xE9;s de 1985.[<a href="#cit/section_6.13">13</a>] En an&#xE1;lisis posteriores, se determin&#xF3; que el tama&#xF1;o y el estadio de los c&#xE1;nceres que se detectaron con mamograf&#xED;a en este ensayo eran equivalentes a los de otros ensayos.[<a href="#cit/section_6.14">14</a>] Este ensayo y el NBSS-2 difieren de los otros ECA en el uso congruente de la hormonoterapia y quimioterapia adyuvantes tras el tratamiento local del c&#xE1;ncer de mama en mujeres con enfermedad en los ganglios axilares.</li></ul></div><p id="_389" tabindex="-1">
            <strong>NBSS-2, Canad&#xE1;, 1980</strong>
            [<a href="#cit/section_6.15">15</a>]
            </p><div class="pdq-content-list"><ul id="_390" class="pdq-address-block"><li><strong>Edad en el momento del ingreso:</strong> 50 a 59 a&#xF1;os.</li><li><strong>Aleatorizaci&#xF3;n:</strong> voluntaria individual (ver <a href="/espanol/tipos/seno/pro/deteccion-seno-pdq#link/_387">NBSS-1</a>).</li><li><strong>Exclusiones:</strong> pocas, equilibradas entre los grupos.</li><li><strong>Tama&#xF1;o de la muestra:</strong> 19&#xA0;711 en el grupo de estudio (100&#xA0;% sometido a ex&#xE1;menes de detecci&#xF3;n despu&#xE9;s del ECM de ingreso) y 19&#xA0;694 en el grupo de control.</li><li><strong>Intervenci&#xF3;n:</strong> MMG de 2 proyecciones y ECM anuales.</li><li><strong>Control:</strong> ECM anual.</li><li><strong>Cumplimiento:</strong> 100&#xA0;% inicialmente; disminuy&#xF3; a 86,7&#xA0;% en el quinto examen de detecci&#xF3;n en el grupo que se someti&#xF3; a MMG y ECM. 100&#xA0;% inicialmente; disminuy&#xF3; a 85,4&#xA0;% en el quinto examen de detecci&#xF3;n en el grupo que se someti&#xF3; solo a ECM.</li><li><strong>Contaminaci&#xF3;n:</strong> 16,9&#xA0;% del grupo que solo se someti&#xF3; a ECM.</li><li><strong>Atribuci&#xF3;n de la causa de muerte:</strong> partidas de defunci&#xF3;n, con revisi&#xF3;n de casos cuestionables por parte de un grupo de revisi&#xF3;n con anonimato. Vinculada tambi&#xE9;n con las estad&#xED;sticas de la Canadian Mortality Data Base, Statistics Canada.</li><li><strong>An&#xE1;lisis:</strong> seguimiento.</li><li><strong>auditor&#xED;a externa:</strong> s&#xED;. Independiente, con el an&#xE1;lisis de los datos por varios revisores.</li><li><strong>Duraci&#xF3;n del seguimiento:</strong> 25 a&#xF1;os.</li><li><strong>Riesgo relativo de muerte por c&#xE1;ncer de mama, detecci&#xF3;n vs. control:</strong> 1,02 (IC 95&#xA0;%, 0,77&#x2013;1,36).</li><li><strong>Comentarios:</strong> este ensayo es &#xFA;nico debido a que se compara una modalidad de ex&#xE1;menes de detecci&#xF3;n con otra y no incluye a un grupo de control que no se somete a los ex&#xE1;menes. En relaci&#xF3;n con las cr&#xED;ticas y los comentarios sobre este ensayo, ver el <a href="/espanol/tipos/seno/pro/deteccion-seno-pdq#link/_387">NBSS-1</a>.</li></ul></div><p id="_391" tabindex="-1">
            <strong>Estocolmo, Suecia, 1981</strong> [<a href="#cit/section_6.16">16</a>]
            </p><div class="pdq-content-list"><ul id="_120" class="pdq-address-block"><li><strong>Edad en el  momento del ingreso:</strong> 40 a 64 a&#xF1;os.</li><li><strong>Aleatorizaci&#xF3;n:</strong> agrupaci&#xF3;n por fecha de nacimiento. Se realizaron dos ensayos secundarios, con aleatorizaci&#xF3;n equilibrada en el primero y un desequilibrio marcado en el segundo, con 508 mujeres m&#xE1;s en el grupo de ex&#xE1;menes de detecci&#xF3;n que en el grupo de control.</li><li><strong>Exclusiones:</strong> notificaci&#xF3;n incongruente.</li><li><strong>Tama&#xF1;o de la muestra:</strong> en los informes publicados, el tama&#xF1;o disminuy&#xF3; de 40&#xA0;318 a 38&#xA0;525 en el grupo de intervenci&#xF3;n y aument&#xF3; de 19&#xA0;943 a 20&#xA0;978 en el grupo de control.</li><li><strong>Congruencia de los informes:</strong> variable.</li><li><strong>Intervenci&#xF3;n:</strong> MMG de proyecci&#xF3;n &#xFA;nica cada 28 meses &#xD7; 2.</li><li><strong>Control:</strong> MMG en el quinto a&#xF1;o.</li><li><strong>Cumplimiento:</strong> 82&#xA0;% sometidas a ex&#xE1;menes de detecci&#xF3;n.</li><li><strong>Contaminaci&#xF3;n:</strong> a 25&#xA0;% de las mujeres que ingresaron en el estudio se les realiz&#xF3; una MMG en los tres a&#xF1;os previos al ingreso.</li><li><strong>Atribuci&#xF3;n de la causa de muerte:</strong> vinculada con el Swedish Cause of Death Registry.</li><li><strong>An&#xE1;lisis:</strong> evaluaci&#xF3;n, con retraso de 1 a&#xF1;o en la MMG posterior al ensayo en el grupo de control. An&#xE1;lisis de seguimiento, como parte del metan&#xE1;lisis sueco.[<a href="#cit/section_6.5">5</a>]</li><li><strong>auditor&#xED;a externa:</strong> ninguna.</li><li><strong>Duraci&#xF3;n del seguimiento:</strong> 8 a&#xF1;os.</li><li><strong>Riesgo relativo de muerte por c&#xE1;ncer de mama, grupo de ex&#xE1;menes de detecci&#xF3;n en comparaci&#xF3;n con el grupo de control (IC 95&#xA0;%):</strong> 0,80 (0,53&#x2013;1,22).</li><li><strong>Comentarios:</strong> hubo inquietudes sobre la aleatorizaci&#xF3;n, en particular en el segundo ensayo secundario, as&#xED; como sobre las exclusiones y el retraso en la MMG en el grupo de control. La inclusi&#xF3;n de estos datos en el metan&#xE1;lisis sueco resuelve muchos de estos interrogantes.</li></ul></div><p id="_392" tabindex="-1">
            <strong>Gotemburgo, Suecia, 1982</strong>
            </p><div class="pdq-content-list"><ul id="_393" class="pdq-address-block"><li><strong>Edad en el momento del ingreso:</strong> 39 a 59 a&#xF1;os.</li><li><strong>Aleatorizaci&#xF3;n:</strong> compleja; agrupaci&#xF3;n al azar seg&#xFA;n el a&#xF1;o de nacimiento por d&#xED;a de nacimiento en el grupo de mayor edad (de 50 a 59 a&#xF1;os) y por individuo en el grupo m&#xE1;s joven (de 39 a 49 a&#xF1;os); el cociente entre el grupo de estudio y el de control se modific&#xF3; seg&#xFA;n el a&#xF1;o, de acuerdo con la disponibilidad de la MMG (la aleatorizaci&#xF3;n se realiz&#xF3; entre 1982 y 1984).</li><li><strong>Exclusiones:</strong> se excluy&#xF3; una proporci&#xF3;n similar de mujeres de ambos grupos debido a diagn&#xF3;stico de c&#xE1;ncer de mama previo (1,2&#xA0;% cada uno).</li><li><strong>Tama&#xF1;o de la muestra en la publicaci&#xF3;n m&#xE1;s reciente:</strong> 21&#xA0;650 en el grupo de estudio; 29&#xA0;961 en el grupo de control.</li><li><strong>Congruencia de los informes:</strong> variable.</li><li><strong>Intervenci&#xF3;n:</strong> MMG inicial con 2 proyecciones, luego MMG de proyecci&#xF3;n &#xFA;nica cada 18 meses &#xD7; 4. Lectura simple en las tres primeras rondas, luego lectura doble.</li><li><strong>Control:</strong> el grupo de control se someti&#xF3; a un examen de detecci&#xF3;n entre 3 y 8 meses despu&#xE9;s del examen de detecci&#xF3;n final en el grupo de estudio.</li><li><strong>Atribuci&#xF3;n de la causa de muerte:</strong> vinculada al Swedish Cause of Death Registry; tambi&#xE9;n particip&#xF3; un comit&#xE9; independiente de criterios de valoraci&#xF3;n.</li><li><strong>An&#xE1;lisis:</strong> m&#xE9;todos de evaluaci&#xF3;n y de seguimiento.[<a href="#cit/section_6.5">5</a>]</li><li><strong>Auditor&#xED;a externa:</strong> ninguna.</li><li><strong>Duraci&#xF3;n del seguimiento:</strong> 12 a 14 a&#xF1;os.</li><li><strong>Riesgo relativo de muerte por c&#xE1;ncer de mama, grupo de ex&#xE1;menes de detecci&#xF3;n en comparaci&#xF3;n con el grupo de control (IC 95&#xA0;%):</strong> mujeres entre 39 y 59 a&#xF1;os: 0,79 (0,58&#x2013;1,08) [evaluaci&#xF3;n]; 0,77 (0,60&#x2013;1,00) [seguimiento].</li><li><strong>Comentarios:</strong> no hubo reducci&#xF3;n para las mujeres de 50 a 54 a&#xF1;os,  pero hubo reducciones similares para otros grupos que abarcaban 5 a&#xF1;os de edad.</li><li><strong>Conclusiones:</strong> el retraso en realizar la MMG en el grupo de control y los n&#xFA;meros desiguales de mujeres en el grupo invitado y el de control (proceso de aleatorizaci&#xF3;n complejo) complica la interpretaci&#xF3;n.</li></ul></div><p id="_375" tabindex="-1">
            <strong>Ensayo AGE</strong>
            [<a href="#cit/section_6.17">17</a>,<a href="#cit/section_6.18">18</a>]
            </p><div class="pdq-content-list"><ul id="_376" class="pdq-address-block"><li><strong>Edad en el momento del ingreso:</strong> 39 a 41 a&#xF1;os.</li><li><strong>Aleatorizaci&#xF3;n:</strong> mujeres de listas de m&#xE9;dicos generales en zonas geogr&#xE1;ficamente definidas de Inglaterra, Gales y Escocia; se ocult&#xF3; la asignaci&#xF3;n.</li><li><strong>Exclusiones:</strong> n&#xFA;mero peque&#xF1;o (n = 30 en el grupo invitado y n = 51 en el grupo no invitado) en cada grupo porque no se pudo ubicar a las personas o fallecieron.</li><li><strong>Tama&#xF1;o de la muestra:</strong> 160&#xA0;921 (53&#xA0;884 invitadas; 106&#xA0;956 no invitadas).</li><li><strong>Congruencia de los informes:</strong> no corresponde.</li><li><strong>Intervenci&#xF3;n:</strong> se ofreci&#xF3; un examen de detecci&#xF3;n anual con MMG (primer examen de detecci&#xF3;n de dos proyecciones, seguida de proyecci&#xF3;n oblicua mediolateral &#xFA;nica en adelante) al grupo invitado de 48 a&#xF1;os y menos; 68&#xA0;% acept&#xF3; el examen de detecci&#xF3;n en la primera ocasi&#xF3;n. Luego, se volvi&#xF3; a invitar a alrededor de 69&#x2013;70&#xA0;% de las mujeres (81&#xA0;% asisti&#xF3; a por lo menos 1 examen de detecci&#xF3;n).</li><li><strong>Control:</strong> las mujeres no invitadas recibieron atenci&#xF3;n m&#xE9;dica habitual, sin saber si participaban o no; pocas se hab&#xED;an sometido a un examen de detecci&#xF3;n antes de la aleatorizaci&#xF3;n.</li><li><strong>Atribuci&#xF3;n de la causa de muerte:</strong> seg&#xFA;n el c&#xF3;digo de la partida de defunci&#xF3;n aceptado en el registro central del National Health Service (NHS).</li><li><strong>An&#xE1;lisis:</strong> m&#xE9;todo de seguimiento con intenci&#xF3;n de tratar (si bien el NHS ofrecer&#xED;a ex&#xE1;menes de detecci&#xF3;n a todas las mujeres de 50 a&#xF1;os).</li><li><strong>Auditor&#xED;a externa:</strong> ninguna.</li><li><strong>Duraci&#xF3;n del seguimiento:</strong> 10,7 a&#xF1;os.</li><li><strong>Riesgo relativo de muerte por c&#xE1;ncer de mama, grupo de ex&#xE1;menes de detecci&#xF3;n en comparaci&#xF3;n con el grupo de control (IC 95&#xA0;%):</strong> 0,83 (0,66&#x2013;1,04).</li><li><strong>Conclusiones:</strong> no es un resultado con significaci&#xF3;n estad&#xED;stica, pero se corresponde con otros estudios.</li><li><strong>Duraci&#xF3;n del seguimiento:</strong> restringido a 10 a&#xF1;os despu&#xE9;s de la aleatorizaci&#xF3;n.</li><li><strong>Riesgo relativo de muerte por c&#xE1;ncer de mama: grupo de detecci&#xF3;n en comparaci&#xF3;n con el grupo de control (IC 95&#xA0;%):</strong> 0,75 (0,58&#x2013;0,97).</li><li><strong>Conclusiones:</strong> resultado con significaci&#xF3;n estad&#xED;stica.</li><li><strong>Duraci&#xF3;n del seguimiento:</strong> mediana de 17,7 a&#xF1;os.</li><li><strong>Riesgo relativo de muerte por c&#xE1;ncer de mama: grupo de detecci&#xF3;n en comparaci&#xF3;n con el grupo de control (IC 95&#xA0;%):</strong> 0,88 (0,74&#x2013;1,04).</li><li><strong>Conclusiones:</strong> resultado sin significaci&#xF3;n estad&#xED;stica.</li><li><strong>Duraci&#xF3;n del seguimiento:</strong> mediana de 17,7 a&#xF1;os.</li><li><strong>Riesgo relativo de mortalidad por todas las causas, detecci&#xF3;n vs. control (IC 95&#xA0;%):</strong> 0,98 (0,93&#x2013;1,03).</li><li><strong>Conclusiones:</strong> resultado sin significaci&#xF3;n estad&#xED;stica.</li></ul></div><p id="_588" tabindex="-1">La reducci&#xF3;n de la mortalidad por c&#xE1;ncer de mama en el momento de una mediana de seguimiento de 17,7 a&#xF1;os corresponde a una reducci&#xF3;n absoluta del riesgo de 0,1 de 1000 (o 1 de 10&#xA0;000) de menos defunciones.</p><p id="_589" tabindex="-1">Los datos probatorios son insuficientes para corroborar la conclusi&#xF3;n de una disminuci&#xF3;n de la mortalidad por c&#xE1;ncer de mama de importancia cl&#xED;nica atribuible a la iniciaci&#xF3;n de ex&#xE1;menes de detecci&#xF3;n con mamograf&#xED;a en mujeres de 39 a 49 a&#xF1;os. La disminuci&#xF3;n de la mortalidad por c&#xE1;ncer de mama notificada es muy peque&#xF1;a y transitoria seg&#xFA;n un cronograma sin estandarizar de pruebas de im&#xE1;genes, un protocolo sin estandarizar de estas pruebas y un umbral sin estandarizar para la biopsia; por lo tanto, esa reducci&#xF3;n tiene una importancia incierta para la poblaci&#xF3;n general. En t&#xE9;rminos absolutos, representa una reducci&#xF3;n del riesgo absoluto de 0,1 de 1000 (1 en 10&#xA0;000) defunciones. Adem&#xE1;s, la reducci&#xF3;n de la mortalidad se fundament&#xF3; en un nuevo an&#xE1;lisis del conjunto original de datos que no tuvieron significaci&#xF3;n estad&#xED;stica y el nuevo c&#xE1;lculo de la mortalidad por c&#xE1;ncer de mama en un subgrupo se restringi&#xF3; a 10 a&#xF1;os de seguimiento. A los 20 a&#xF1;os de seguimiento, no hubo una disminuci&#xF3;n estad&#xED;sticamente significativa en el riesgo de c&#xE1;ncer de mama ni de la mortalidad por todas las causas.[<a href="#cit/section_6.18">18</a>]</p><p id="_590" tabindex="-1">Las pruebas son insuficientes para determinar con claridad la magnitud del sobrediagn&#xF3;stico. Debido a que los datos probatorios se basan en an&#xE1;lisis de subgrupos y un esquema no estandarizado de las pruebas de im&#xE1;genes, el protocolo para estas pruebas y un umbral no estandarizado para la biopsia cuya importancia es incierta para la poblaci&#xF3;n en general, los datos no apoyan la conclusi&#xF3;n de los investigadores de que "en el peor de los casos, solo se trata de muy pocos sobrediagn&#xF3;sticos".[<a href="#cit/section_6.18">18</a>]</p><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_6.1">Shapiro S, Venet W, Strax P, et al.: Ten- to fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst 69 (2): 349-55, 1982.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6955542&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6955542&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.2">Shapiro S: Periodic screening for breast cancer: the Health Insurance Plan project and its sequelae, 1963-1986. Baltimore, Md: Johns Hopkins University Press, 1988.</li><li id="section_6.3">Andersson I, Aspegren K, Janzon L, et al.: Mammographic screening and mortality from breast cancer: the Malm&#xF6; mammographic screening trial. BMJ 297 (6654): 943-8, 1988.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3142562&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3142562&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.4">Nystr&#xF6;m L, Rutqvist LE, Wall S, et al.: Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet 341 (8851): 973-8, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8096941&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8096941&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.5">Nystr&#xF6;m L, Andersson I, Bjurstam N, et al.: Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 359 (9310): 909-19, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11918907&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11918907&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.6">Tab&#xE1;r L, Fagerberg CJ, Gad A, et al.: Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet 1 (8433): 829-32, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2858707&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2858707&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.7">Tab&#xE0;r L, Fagerberg G, Duffy SW, et al.: Update of the Swedish two-county program of mammographic screening for breast cancer. Radiol Clin North Am 30 (1): 187-210, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1732926&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1732926&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.8">Tabar L, Fagerberg G, Duffy SW, et al.: The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit. J Epidemiol Community Health 43 (2): 107-14, 1989.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2512366&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2512366&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.9">Holmberg L, Duffy SW, Yen AM, et al.: Differences in endpoints between the Swedish W-E (two county) trial of mammographic screening and the Swedish overview: methodological consequences. J Med Screen 16 (2): 73-80, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19564519&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19564519&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.10">Roberts MM, Alexander FE, Anderson TJ, et al.: Edinburgh trial of screening for breast cancer: mortality at seven years. Lancet 335 (8684): 241-6, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1967717&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1967717&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.11">Miller AB, To T, Baines CJ, et al.: The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years. Ann Intern Med 137 (5 Part 1): 305-12, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12204013&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12204013&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.12">Bailar JC 3rd, MacMahon B: Randomization in the Canadian National Breast Screening Study: a review for evidence of subversion. CMAJ 156 (2): 193-9, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9012720&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9012720&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.13">Baines CJ, Miller AB, Kopans DB, et al.: Canadian National Breast Screening Study: assessment of technical quality by external review. AJR Am J Roentgenol 155 (4): 743-7; discussion 748-9, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2119103&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2119103&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.14">Fletcher SW, Black W, Harris R, et al.: Report of the International Workshop on Screening for Breast Cancer. J Natl Cancer Inst 85 (20): 1644-56, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8105098&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8105098&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.15">Miller AB, Baines CJ, To T, et al.: Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years. CMAJ 147 (10): 1477-88, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1423088&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1423088&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.16">Frisell J, Eklund G, Hellstr&#xF6;m L, et al.: Randomized study of mammography screening--preliminary report on mortality in the Stockholm trial. Breast Cancer Res Treat 18 (1): 49-56, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1854979&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1854979&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.17">Moss SM, Cuckle H, Evans A, et al.: Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet 368 (9552): 2053-60, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17161727&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17161727&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.18">Moss SM, Wale C, Smith R, et al.: Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial. Lancet Oncol 16 (9): 1123-32, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26206144&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26206144&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _715
      field_pdq_section_title:
        - format: plain_text
          value: 'Modificaciones a este sumario (06/19/2018)'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_715" class="pdq-sections"><p id="_716" tabindex="-1">Los sumarios del PDQ con informaci&#xF3;n sobre el c&#xE1;ncer se revisan con regularidad y se actualizan a medida que se obtiene nueva informaci&#xF3;n.  Esta secci&#xF3;n describe los cambios m&#xE1;s recientes introducidos en este sumario a partir de la fecha arriba indicada.</p><p id="_720" tabindex="-1"><strong><a href="/espanol/tipos/seno/pro/deteccion-seno-pdq#link/_1">Aspectos generales</a></strong></p><p id="_721" tabindex="-1">El nombre de esta secci&#xF3;n se cambi&#xF3; de Resumen de los datos probatorios a Aspectos generales.</p><p id="_722" tabindex="-1"><strong><a href="/espanol/tipos/seno/pro/deteccion-seno-pdq#link/_51">Mamograf&#xED;a</a></strong></p><p id="_723" tabindex="-1">Se a&#xF1;adi&#xF3; <a href="/espanol/tipos/seno/pro/deteccion-seno-pdq#link/_719">texto</a> para indicar que hay poco datos sobre la reducci&#xF3;n de la mortalidad, vista a lo largo del tiempo a partir de 1990, que se puede atribuir a los avances en las t&#xE9;cnicas de im&#xE1;genes que se usan como ex&#xE1;menes de detecci&#xF3;n y qu&#xE9; tanta reducci&#xF3;n es el resultado de la mejora en la eficacia del tratamiento. Tambi&#xE9;n se a&#xF1;adi&#xF3; texto sobre un estudio de la Cancer Intervention and Surveillance Modeling Network (CISNET) de modelos de simulaci&#xF3;n en los que se encontr&#xF3; que cerca de un tercio de la disminuci&#xF3;n en la mortalidad por c&#xE1;ncer de mama en 2012 se atribuy&#xF3; a la detecci&#xF3;n y el resto se atribuy&#xF3; al tratamiento; en este estudio de la CISNET, el c&#xE1;lculo de la media de reducci&#xF3;n en la tasa de mortalidad general por c&#xE1;ncer de mama fue de 49&#xA0;%, en relaci&#xF3;n con la tasa de referencia calculada en 2012 sin ex&#xE1;menes de detecci&#xF3;n ni tratamiento; 37&#xA0;% de esta reducci&#xF3;n se relacion&#xF3; con la detecci&#xF3;n y 63&#xA0;% de esta reducci&#xF3;n se relacion&#xF3; con el tratamiento (se cit&#xF3; a Plevritis et al. como referencia 78).</p><p id="_724" tabindex="-1">Se a&#xF1;adi&#xF3; <a href="/espanol/tipos/seno/pro/deteccion-seno-pdq#link/_687">texto</a> sobre un estudio poblacional realizado en los Pa&#xED;ses Bajos en el que se observ&#xF3; que cerca de la mitad de todos los c&#xE1;nceres de mama detectados mediante ex&#xE1;menes de detecci&#xF3;n, incluso el carcinoma ductal <em>in situ</em>, representar&#xED;an un sobrediagn&#xF3;stico; esto es congruente con otros estudios en los que se observaron tasas importantes de sobrediagn&#xF3;stico relacionadas con los ex&#xE1;menes de detecci&#xF3;n (se cit&#xF3; a Autier et al. como referencia 93).</p><p id="_disclaimerHP_3" tabindex="-1">Este sumario est&#xE1; redactado y mantenido por el <a href="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/deteccion-prevencion" title="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/deteccion-prevencion">Consejo editorial del PDQ sobre los ex&#xE1;menes de detecci&#xF3;n y la prevenci&#xF3;n</a>, que es editorialmente independiente del NCI. El sumario refleja una revisi&#xF3;n independiente de la bibliograf&#xED;a y no representa una declaraci&#xF3;n de pol&#xED;ticas del NCI o de los NIH. Para mayor informaci&#xF3;n sobre las pol&#xED;ticas de los sumarios y la funci&#xF3;n de los  consejos editoriales  del PDQ que mantienen los sumarios del PDQ, consultar en <a href="/espanol/tipos/seno/pro/deteccion-seno-pdq#link/_AboutThis_1">Informaci&#xF3;n sobre este sumario del PDQ</a> y  la p&#xE1;gina sobre <a href="https://www.cancer.gov/espanol/publicaciones/pdq" title="https://www.cancer.gov/espanol/publicaciones/pdq">Banco de datos de informaci&#xF3;n de c&#xE1;ncer - PDQ&#xAE;</a>.
            </p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _AboutThis_1
      field_pdq_section_title:
        - format: plain_text
          value: 'Información sobre este sumario del PDQ'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_AboutThis_1" class="pdq-sections"><section id="_AboutThis_2"><h3 id="_AboutThis_2_toc">Prop&#xF3;sito de este sumario</h3><p id="_AboutThis_3" tabindex="-1">Este sumario del PDQ con informaci&#xF3;n sobre el c&#xE1;ncer para profesionales de la salud proporciona informaci&#xF3;n integral revisada por expertos y con fundamento en datos probatorios sobre los ex&#xE1;menes de detecci&#xF3;n del c&#xE1;ncer de mama. El prop&#xF3;sito es servir como fuente de informaci&#xF3;n y ayuda para los m&#xE9;dicos que atienden a pacientes de c&#xE1;ncer. No  ofrece pautas ni recomendaciones formales para tomar decisiones relacionadas con la atenci&#xF3;n sanitaria.</p></section><section id="_AboutThis_21"><h3 id="_AboutThis_21_toc">Revisores y actualizaciones</h3><p id="_AboutThis_22" tabindex="-1">El  <a href="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/deteccion-prevencion" title="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/deteccion-prevencion">Consejo editorial del PDQ sobre los ex&#xE1;menes de detecci&#xF3;n y la prevenci&#xF3;n</a>, cuya funci&#xF3;n editorial es independiente del Instituto Nacional del C&#xE1;ncer (NCI), revisa con regularidad este sumario y, en caso necesario,   lo actualiza. Este sumario refleja una revisi&#xF3;n bibliogr&#xE1;fica independiente y no constituye una declaraci&#xF3;n de la pol&#xED;tica del Instituto Nacional del C&#xE1;ncer ni de los Institutos Nacionales de la Salud (NIH).</p><p id="_AboutThis_26" tabindex="-1">Cada mes, los miembros de este Consejo  examinan art&#xED;culos  publicados recientemente para determinar si se deben:</p><div class="pdq-content-list"><ul id="_AboutThis_23"><li>tratar en una reuni&#xF3;n,</li><li>citar textualmente, o</li><li>sustituir o actualizar, si ya se citaron con anterioridad.</li></ul></div><p id="_AboutThis_24" tabindex="-1">Los cambios en los sumarios se deciden mediante consenso, una vez que  los integrantes del Consejo eval&#xFA;an la solidez de los datos probatorios en los art&#xED;culos publicados y determinan la forma en que se incorporar&#xE1;n al sumario.</p><p id="_AboutThis_25" tabindex="-1">Cualquier comentario o pregunta sobre el contenido de este sumario se debe enviar mediante el   <a href="https://www.cancer.gov/espanol/contactenos/correo-electronico" title="https://www.cancer.gov/espanol/contactenos/correo-electronico">formulario de comunicaci&#xF3;n</a> en Cancer.gov/espanol del NCI.  No comunicarse con los miembros del Consejo para enviar preguntas o comentarios sobre los sumarios.  Los miembros del Consejo no responder&#xE1;n a preguntas del p&#xFA;blico. </p></section><section id="_AboutThis_9"><h3 id="_AboutThis_9_toc">Grados de comprobaci&#xF3;n cient&#xED;fica</h3><p id="_AboutThis_10" tabindex="-1">En algunas referencias bibliogr&#xE1;ficas de este sumario se indica el grado de comprobaci&#xF3;n cient&#xED;fica. El prop&#xF3;sito de estas designaciones es ayudar al lector a evaluar la solidez de los datos probatorios que sustentan el uso de  ciertas intervenciones  o enfoques. El Consejo editorial del PDQ sobre los ex&#xE1;menes de detecci&#xF3;n y la prevenci&#xF3;n emplea un <a href="/espanol/publicaciones/pdq/grados-comprobacion/deteccion-prevencion">sistema de jerarquizaci&#xF3;n formal</a> para establecer  las designaciones del grado de comprobaci&#xF3;n cient&#xED;fica.</p></section><section id="_AboutThis_11"><h3 id="_AboutThis_11_toc">Permisos para el uso de este sumario</h3><p id="_AboutThis_12" tabindex="-1">PDQ (Physician Data Query) es una marca registrada. Se autoriza el libre uso del texto  de los documentos del PDQ. Sin embargo, no se podr&#xE1; identificar como un sumario de informaci&#xF3;n sobre c&#xE1;ncer del PDQ del  NCI,  salvo que se reproduzca en su totalidad y se actualice con regularidad. Por otra parte, se permitir&#xE1; que un autor  escriba una oraci&#xF3;n como &#x201C;En el sumario del PDQ  del NCI de informaci&#xF3;n sobre la prevenci&#xF3;n del c&#xE1;ncer de mama se describen, en breve, los siguientes riesgos: [incluir fragmento del sumario]&#x201D;.</p><p id="_AboutThis_13" tabindex="-1">Se sugiere citar la referencia bibliogr&#xE1;fica de este sumario del PDQ de la siguiente forma:</p><p id="_AboutThis_14" tabindex="-1">PDQ&#xAE; sobre los ex&#xE1;menes de detecci&#xF3;n y la prevenci&#xF3;n. PDQ Ex&#xE1;menes de detecci&#xF3;n del c&#xE1;ncer de seno (mama). Bethesda, MD: National Cancer Institute. Actualizaci&#xF3;n:  &lt;MM/DD/YYYY&gt;. Disponible en: <a href="https://www.cancer.gov/espanol/tipos/seno/pro/deteccion-seno-pdq" title="https://www.cancer.gov/espanol/tipos/seno/pro/deteccion-seno-pdq">https://www.cancer.gov/espanol/tipos/seno/pro/deteccion-seno-pdq</a>.  Fecha de acceso: &lt;MM/DD/YYYY&gt;. </p><p id="_AboutThis_15" tabindex="-1">Las im&#xE1;genes  en este sumario se reproducen  con el permiso del autor, el artista o la  editorial para uso exclusivo en los sumarios del PDQ. La utilizaci&#xF3;n de las im&#xE1;genes fuera del  PDQ requiere la autorizaci&#xF3;n del propietario, que el Instituto Nacional del C&#xE1;ncer no  puede otorgar. Para obtener m&#xE1;s informaci&#xF3;n sobre el uso de las ilustraciones de este sumario o de  otras im&#xE1;genes relacionadas con el c&#xE1;ncer, consultar <a href="https://visualsonline.cancer.gov/" title="https://visualsonline.cancer.gov/">Visuals Online</a>, una colecci&#xF3;n de m&#xE1;s de 2000 im&#xE1;genes cient&#xED;ficas.</p></section><section id="_AboutThis_16"><h3 id="_AboutThis_16_toc">Cl&#xE1;usula sobre el descargo de responsabilidad</h3><p id="_AboutThis_18" tabindex="-1">La informaci&#xF3;n en estos sumarios  no se debe utilizar como base para determinar reembolsos por parte de las aseguradoras. Para obtener m&#xE1;s informaci&#xF3;n  sobre la cobertura de seguros, consultar la p&#xE1;gina <a href="https://www.cancer.gov/espanol/cancer/manejo-del-cancer" title="https://www.cancer.gov/espanol/cancer/manejo-del-cancer">Manejo de la atenci&#xF3;n del c&#xE1;ncer</a> disponible en Cancer.gov/espanol.</p></section><section id="_AboutThis_19"><h3 id="_AboutThis_19_toc">Para obtener m&#xE1;s informaci&#xF3;n</h3><p id="_AboutThis_20" tabindex="-1">En Cancer.gov/espanol,  se ofrece m&#xE1;s informaci&#xF3;n sobre c&#xF3;mo comunicarse o recibir ayuda en  <a href="https://www.cancer.gov/espanol/contactenos" title="https://www.cancer.gov/espanol/contactenos">&#xBF;En qu&#xE9; podemos ayudarle?</a>.
            Tambi&#xE9;n se puede enviar un mensaje de  correo electr&#xF3;nico  mediante este  <a href="https://www.cancer.gov/espanol/contactenos/correo-electronico" title="https://www.cancer.gov/espanol/contactenos/correo-electronico">formulario</a>.</p></section></div>

- entity: node
  type: pdq_cancer_information_summary
  title: 'Lung Cancer Screening (PDQ®)–Health Professional Version'
  status: 1
  langcode: en
  field_hhs_syndication:
    - syndicate: 1
      keywords: lung cancer, disease screening
  moderation_state:
    value: published
  field_pdq_url:
    value: /types/lung/hp/lung-screening-pdq
  field_pdq_cdr_id:
    value: 62832
  field_pdq_audience:
    value: Health Professionals
  field_pdq_summary_type:
    value: Screening
  field_date_posted:
    value: '2019-03-11'
  field_date_updated:
    value: '2018-02-02'
  field_browser_title:
    value: 'Lung Cancer Screening'
  field_page_description:
    value: 'Lung cancer screening with low-dose spiral CT scans has been shown to decrease the risk of dying from lung cancer in heavy smokers. Screening with chest x-ray or sputum cytology does not reduce lung cancer mortality. Get detailed information about lung cancer screening in this clinician summary.'
  field_public_use:
    value: 1
  field_summary_sections:
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _1
      field_pdq_section_title:
        - format: plain_text
          value: 'Overview'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_1" class="pdq-sections"><div class="pdq-hp-patient-toggle"><a href="/types/lung/patient/lung-screening-pdq">Go to Patient Version</a></div><p id="_2" tabindex="-1">Separate PDQ summaries on <a href="/types/lung/hp/lung-prevention-pdq">Lung Cancer Prevention</a>, <a href="/types/lung/hp/small-cell-lung-treatment-pdq">Small Cell Lung
            Cancer Treatment</a>,  <a href="/types/lung/hp/non-small-cell-lung-treatment-pdq">Non-Small Cell Lung Cancer Treatment</a>, and <a href="/publications/pdq/levels-evidence/screening-prevention">Levels of Evidence for Cancer Screening and Prevention Studies</a>  are also available.</p><section id="_69"><h3 id="_69_toc">Evidence of Benefit Associated With Screening</h3><section id="_70"><h4 id="_70_toc">Screening by low-dose helical computed tomography</h4><section id="_198"><h5 id="_198_toc">Benefits</h5><p id="_199" tabindex="-1">One large randomized trial reported that screening persons aged 55 to 74 years who have cigarette smoking histories of 30 or more pack-years and who, if they are former smokers, have quit within the last 15 years reduces lung cancer mortality by 20% (95% confidence interval [CI], 6.8&#x2013;26.7; <em>P</em> = .004)  and all-cause mortality by 6.7% (95% CI, 1.2&#x2013;13.6; <em>P</em> = .02).[<a href="#cit/section_1.1">1</a>] An updated analysis showed that the estimated reduction in lung  cancer mortality was 16% (95% CI, 5&#x2013;25).[<a href="#cit/section_1.2">2</a>]</p><p id="_200" tabindex="-1"><strong>Magnitude of Effect: 16% relative reduction in lung cancer&#x2013;specific mortality. </strong></p><div class="pdq-content-list"><ul id="_201" class="pdq-address-block"><li><strong>Study Design</strong>: Evidence obtained from a randomized controlled trial.</li><li><strong>Internal Validity</strong>: Good.</li><li><strong>Consistency</strong>: Not applicable (N/A)&#x2014;one randomized trial to date.</li><li><strong>External Validity</strong>: Fair.</li></ul></div></section><section id="_202"><h5 id="_202_toc">Harms</h5><p id="_203" tabindex="-1">Based on solid evidence, approximately 96% of all positive, low-dose helical computed tomography screening exams  do not result in a lung cancer diagnosis.[<a href="#cit/section_1.1">1</a>] False-positive exams may result in unnecessary invasive diagnostic procedures.</p><p id="_204" tabindex="-1"><strong>Magnitude of Effect: Based on the findings from a large randomized trial, the average false-positive rate per screening round was 23.3%. A total of 0.06% of all false-positive  screening results led to a major complication after an invasive procedure performed as diagnostic follow-up to the positive screening result. Over three screening rounds, 1.8% of  participants who did not have lung cancer had an invasive procedure following a positive screening result.</strong></p><div class="pdq-content-list"><ul id="_205" class="pdq-address-block"><li><strong>Study Design</strong>: Evidence obtained from a randomized controlled trial.</li><li><strong>Internal Validity</strong>: Good.</li><li><strong>Consistency</strong>: Good.</li><li><strong>External Validity</strong>: Fair.</li></ul></div></section></section></section><section id="_206"><h3 id="_206_toc">Evidence of No Benefit Associated With Screening</h3><section id="_207"><h4 id="_207_toc">Screening by chest x-ray and/or sputum cytology</h4><section id="_208"><h5 id="_208_toc">Benefits</h5><p id="_209" tabindex="-1">Based on solid evidence, screening with chest x-ray and/or sputum cytology does not reduce mortality from lung cancer in the general population or in ever-smokers.</p><p id="_210" tabindex="-1"><strong>Magnitude of Effect: N/A. </strong></p><div class="pdq-content-list"><ul id="_211" class="pdq-address-block"><li><strong>Study Design</strong>: Randomized controlled trials.</li><li><strong>Internal Validity</strong>: Good.</li><li><strong>Consistency</strong>: Good.</li><li><strong>External Validity</strong>: Good.</li></ul></div></section><section id="_212"><h5 id="_212_toc">Harms</h5><section id="_213"><h6 id="_213_toc">False-positive exams</h6><p id="_214" tabindex="-1">Based on solid evidence, at least 95% of all positive chest x-ray screening exams  do not result in a lung cancer diagnosis. False-positive exams result in unnecessary invasive diagnostic procedures.</p><div class="pdq-content-list"><ul id="_215" class="pdq-address-block"><li><strong>Study Design</strong>: Randomized controlled trials.</li><li><strong>Internal Validity</strong>: Good.</li><li><strong>Consistency</strong>: Good.</li><li><strong>External Validity</strong>: Good.</li></ul></div></section><section id="_216"><h6 id="_216_toc">Overdiagnosis</h6><p id="_217" tabindex="-1">Based on solid evidence, a modest but non-negligible percentage of lung cancers detected by screening chest x-ray and/or sputum cytology appear to represent overdiagnosed cancer; the magnitude of overdiagnosis appears to be between 5% and 25%. These cancers result in unnecessary diagnostic procedures and also lead to unnecessary treatment.  Harms of diagnostic procedures and treatment occur most frequently among long-term and/or heavy smokers because of smoking-associated comorbidities that increase risk propagation.</p><p id="_218" tabindex="-1"><strong>Magnitude of Effect: Between 5% and 25%, depending on characteristics of screened population and screening regimen.</strong></p><div class="pdq-content-list"><ul id="_219" class="pdq-address-block"><li><strong>Study Design</strong>: Randomized controlled trials.</li><li><strong>Internal Validity</strong>: Good.</li><li><strong>Consistency</strong>: Good.</li><li><strong>External Validity</strong>: Good.</li></ul></div></section></section></section></section><h6 do-not-show="toc">References</h6><ol><li id="section_1.1">Aberle DR, Adams AM, Berg CD, et al.: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365 (5): 395-409, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21714641&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21714641&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.2">Pinsky PF, Church TR, Izmirlian G, et al.: The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer 119 (22): 3976-83, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24037918&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24037918&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _8
      field_pdq_section_title:
        - format: plain_text
          value: 'Description of the Evidence'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_8" class="pdq-sections"><section id="_327"><h3 id="_327_toc">Incidence and Mortality</h3><p id="_328" tabindex="-1">Lung cancer is the  third most common form of noncutaneous cancer in the United States and is the leading cause of cancer death in men and in women.  In 2018 alone, it is estimated  that 121,680 men and 112,350 women will be  diagnosed with lung cancer, and 83,550 men and  70,500 women will die from this disease.   The lung cancer
            death rate rose rapidly over several decades in both sexes, with a persistent decline for
            men commencing in 1991. From 2011 to 2015, death rates  decreased by 3.8% per year in men and by 2.3% per year in women.[<a href="#cit/section_2.1">1</a>]</p></section><section id="_222"><h3 id="_222_toc">Risk Factors</h3><p id="_284" tabindex="-1">The most important risk factor for lung cancer (as for many other
            cancers) is tobacco use.[<a href="#cit/section_2.2">2</a>,<a href="#cit/section_2.3">3</a>]  Cigarette smoking has been definitively
            established by epidemiologic and preclinical animal experimental data as the
            primary cause of lung cancer.  This causative link has been widely recognized
            since the 1960s, when national reports in Great Britain and the United States
            brought the cancer risk of smoking prominently to the public&#x2019;s attention.[<a href="#cit/section_2.3">3</a>]
            The percentages of lung cancers estimated to be caused by tobacco smoking in
            males and females are 90% and 78%, respectively.</p><p id="_285" tabindex="-1">For a complete description of factors associated with an increased or decreased risk of lung cancer, refer to the PDQ summary on <a href="/types/lung/hp/lung-prevention-pdq">Lung Cancer Prevention</a> for more information.</p></section><section id="_227"><h3 id="_227_toc">Evidence of Benefit Associated With Screening</h3><section id="_229"><h4 id="_229_toc">Screening by low-dose helical computed tomography</h4><p id="_230" tabindex="-1">There have been intensive efforts to improve lung cancer screening with newer
            technologies, including low-dose helical computed tomography (LDCT).[<a href="#cit/section_2.4">4</a>,<a href="#cit/section_2.5">5</a>]  LDCT was shown to be   more sensitive than chest
            radiography.  In the Early Lung Cancer Action Project (ELCAP),[<a href="#cit/section_2.5">5</a>]   LDCT detected almost six times as
            many stage I lung cancers as chest radiography, and most of these tumors were no larger than 1
            cm in diameter.   </p><p id="_267" tabindex="-1">A systematic analysis [<a href="#cit/section_2.6">6</a>] summarized 13 observational studies of LDCT undertaken between 1993 and 2004 and  that included 60 to 5,201 participants.  Some Japanese studies included nonsmokers, but the others were limited to current and former smokers.  Variability in detection of nodules&#x2014;between 3% and 51%&#x2014;may be attributed to several factors:</p><div class="pdq-content-list"><ul id="_283"><li>The definition of nodules (some studies required a size threshold).</li><li>The CT technology (thin slice detects more and smaller nodules).</li><li>Geographic variation in endemic granulomatous disease.</li></ul></div><p id="_286" tabindex="-1">    Overall, lung cancer was diagnosed in 1.1% to 4.7% of screened participants; most of these diagnoses were early-stage disease.[<a href="#cit/section_2.6">6</a>]</p><p id="_268" tabindex="-1">With completion of the National Lung Screening Trial (NLST), there is now evidence that screening with LDCT can reduce lung cancer mortality risk in ever-smokers who have smoked 30 pack-years or more and in former smokers who have quit within the past 15 years. The NLST included 33 centers across the United States. Eligible participants were between the ages of 55 years and 74 years at randomization, had a history of at least 30 pack-years of cigarette smoking, and, if former smokers, had quit within the past 15 years.   A total of 53,454 persons were enrolled; 26,722 persons were randomly assigned to receive screening with LDCT, and 26,732 persons were randomly assigned to receive screening with chest x-ray. Any noncalcified nodule found on LDCT that measured at least 4 mm in any diameter and any noncalcified nodule or mass identified on x-ray images were classified as positive. Radiologists, however, had the option of calling a final screen negative if a noncalcified nodule had been stable on the three screening exams. The LDCT group had a substantially higher rate of positive screening tests than did the radiography group (round 1, 27.3% vs. 9.2%; round 2, 27.9% vs. 6.2%; and round 3, 16.8% vs. 5.0%). Overall, 39.1% of participants in the LDCT group and 16.0% in the radiography group had at least one positive screening result. Of those who screened positive, the false-positive rate was 96.4% in the LDCT group and 94.5% in the chest radiography group. This was consistent across all three rounds.[<a href="#cit/section_2.7">7</a>]</p><p id="_269" tabindex="-1">In the LDCT group, 649 cancers were diagnosed after a positive screening test, 44 after a negative screening test, and 367 among participants who either missed the screening or received the diagnosis after the completion of the screening phase. In the radiography group, 279 cancers were diagnosed after a positive screening test, 137 after a negative screening test, and 525 among participants who either missed the screening or received the diagnosis after the completion of the screening phase. Three hundred fifty-six deaths from lung cancer occurred in the LDCT group, and 443 deaths from lung cancer occurred in the chest x-ray  group, with a relative reduction in the rate of death from lung cancer of 20% (95% confidence interval [CI], 6.8&#x2013;26.7) with LDCT screening.[<a href="#cit/section_2.7">7</a>] An updated analysis showed that the estimated reduction in lung  cancer mortality was 16% (95% CI, 5&#x2013;25).[<a href="#cit/section_2.8">8</a>]  Overall, mortality was reduced by 6.7% (95% CI, 1.2&#x2013;13.6).  The number needed to screen with LDCT to prevent one death from lung cancer was 320.[<a href="#cit/section_2.7">7</a>]</p><p id="_271" tabindex="-1">Since the publication of the results of the NLST, more has been learned about who may benefit the most from screening for lung cancer using LDCT.[<a href="#cit/section_2.9">9</a>-<a href="#cit/section_2.11">11</a>]  One group of investigators developed an individual risk model to assess who might benefit from screening. The model used additional factors not used as inclusion criteria in the NLST, such as a history of chronic obstructive pulmonary disease, personal or family history of lung cancer and a more detailed smoking history. More persons would have been eligible to be screened using the trial's criteria as opposed to the inclusion criteria of the NLST without missing patients with cancer.[<a href="#cit/section_2.10">10</a>]  A second group performed a reanalysis of the NLST data and calculated each patient&#x2019;s risk of developing lung cancer and estimated each patient's lung cancer mortality.[<a href="#cit/section_2.11">11</a>] The investigators then divided the NLST participants into five groups on the basis of risk.  The number needed to screen to avoid a lung cancer death in the low-risk group was 5,276; 161 screens were needed in the high-risk group to avoid a lung cancer death.  Further, the number of false-positive screens decreased from 1,648 in the lowest quintile of risk to 65 in the highest risk group.  The three highest quintiles of risk accounted for 88% of the mortality reduction from screening, whereas the lowest quintile accounted for only a 1% reduction in mortality.  These studies illustrate possible improvements for determining the population of patients who may benefit the most from screening, potentially reducing the number of false positives, and reducing the potential harm related to the adverse events associated with their evaluation.  One other benefit of calculating individual risk is the ability to incorporate the findings into a shared decision-making process so that patients can decide whether to undergo screening.[<a href="#cit/section_2.11">11</a>]</p><p id="_273" tabindex="-1">Other randomized clinical trials (RCTs) of LDCT are under way or are already completed in a number of countries.[<a href="#cit/section_2.12">12</a>] The largest is the Dutch-Belgian Randomized Lung Cancer Screening Trial (or NELSON trial).[<a href="#cit/section_2.13">13</a>] This study differs from the NLST in that the control group does not have chest radiographic screening.  Other smaller trials in Europe also compare a nonscreening arm with LDCT.[<a href="#cit/section_2.14">14</a>-<a href="#cit/section_2.17">17</a>]  These smaller trials are largely not powered to assess mortality as an endpoint, but there is an effort under way to combine the findings from these studies with the NELSON
            data, once the data are fully mature.  These studies may also be able to assess consistency with the NLST findings.  In addition to the data gleaned from ongoing trials, the NLST data are being analyzed to examine other important issues in lung cancer screening, including cost effectiveness, quality of life, and whether screening would benefit individuals younger than those enrolled in the NLST and those with fewer than 30 pack-years of smoking exposure. Data from the U.S. Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial suggest that, in the absence of screening, the risk of lung cancer death for current smokers who have a smoking history of 20 to 29 pack-years is no different than that of former smokers who have quit within 15 years and have a smoking history of more than 30 pack-years (hazard ratio, 1.07; CI, 0.75&#x2013;1.5). Although the risk for the former-smokers group is no different than that of the current-smokers group (for whom LDCT screening is recommended by the U.S. Preventive Services Task Force), the efficacy of screening is unknown in the former-smokers group.[<a href="#cit/section_2.18">18</a>]</p><p id="_263" tabindex="-1">[<em>Note: A <a href="https://www.cancer.gov/types/lung/research/NLSTstudyGuidePatientsPhysicians.pdf" title="https://www.cancer.gov/types/lung/research/NLSTstudyGuidePatientsPhysicians.pdf">Guide</a>  has been developed to help patients and physicians assess the benefits and harms of LDCT screening for lung cancer.<a href="#cit/citation.19">19</a></em>]</p></section><section id="_288"><h4 id="_288_toc">Screening and smoking cessation</h4><p id="_289" tabindex="-1">The target population for lung cancer screening has a high prevalence of current smokers compared with the general population.  A lung cancer screening program could potentially impact the likelihood of smoking cessation, theoretically promoting cessation among those screened who have lung abnormalities detected on their screen. Conversely, screening could also be a deterrent to cessation among those with no evidence of lung abnormalities on their screen.  The Danish Lung Cancer Screening Trial is a randomized trial that compared LDCT with no intervention among participants aged 50 to 70 years who had at least a 20 pack-year smoking history.[<a href="#cit/section_2.20">20</a>]  The proportion of participants who had quit smoking was monitored every year for 5 years of follow-up and remained virtually identical in the two groups from baseline (CT group and control group each had 23% ex-smokers) until the 5-year follow-up (43% ex-smokers in both groups).  The comparison of these two randomized groups indicates that the CT screening program had zero net effect on the likelihood of smoking cessation.</p><p id="_290" tabindex="-1">Another report used data from the NLST to address the question of whether the screening result influenced the likelihood of smoking cessation.[<a href="#cit/section_2.21">21</a>]  The NLST compared CT with chest x-ray, and data from both arms were pooled to examine the impact of abnormal findings on the likelihood of smoking cessation.  Compared with those who did not have abnormal findings, current smokers who had a screening examination that was suspicious for lung cancer (but was not lung cancer) were significantly more likely to have stopped smoking 1 year later.  The associations with quitting smoking among those who had a major lung abnormality, which was not suspicious for lung cancer, or a minor abnormality were weaker and not uniformly statistically significant.</p><p id="_321" tabindex="-1">A third study from the U.K. Lung Cancer Screening pilot trial of a low-dose CT scan found that screening was associated with a statistically significant increase in short- and long-term cessation, and this effect was greatest among those whose initial screening test was positive, warranting additional clinical investigation.[<a href="#cit/section_2.22">22</a>]</p><p id="_291" tabindex="-1">The results of these studies suggest that the net impact of a CT program on smoking cessation  varied,[<a href="#cit/section_2.20">20</a>] but there appears to be a higher likelihood of smoking cessation among current smokers who have findings suspicious for lung cancer.[<a href="#cit/section_2.21">21</a>]  This is an important research area that needs to be clarified.</p></section></section><section id="_241"><h3 id="_241_toc">Evidence of No Benefit Associated With Screening</h3><section id="_242"><h4 id="_242_toc">Screening by chest x-ray and/or sputum cytology</h4><p id="_243" tabindex="-1">The question of lung cancer screening dates back to the 1950s, when rising lung cancer incidence and mortality rates indicated a need for intervention. In  response to the emerging lung cancer problem, five studies of chest imaging, two of which were controlled, were undertaken during the 1950s and 1960s.[<a href="#cit/section_2.23">23</a>-<a href="#cit/section_2.30">30</a>]  Two studies also included sputum cytology.[<a href="#cit/section_2.23">23</a>-<a href="#cit/section_2.27">27</a>] The results of these studies suggested no overall benefit of screening, although design limitations prevented the studies from providing definitive evidence. </p><p id="_244" tabindex="-1">In the early 1970s, the National Cancer Institute funded the Cooperative Early Lung Cancer Detection Program,[<a href="#cit/section_2.31">31</a>] which was designed to assess the ability of screening with radiologic chest imaging and sputum cytology to reduce lung cancer mortality in male smokers. The program comprised three separate RCTs, each enrolling about 10,000 male participants aged 45 years and older who smoked at least one pack of cigarettes a day in the previous year. One study was conducted at the Mayo Clinic,[<a href="#cit/section_2.32">32</a>-<a href="#cit/section_2.34">34</a>] one at Johns Hopkins University,[<a href="#cit/section_2.35">35</a>-<a href="#cit/section_2.37">37</a>] and one at Memorial Sloan-Kettering.[<a href="#cit/section_2.37">37</a>-<a href="#cit/section_2.40">40</a>] The Hopkins and Sloan-Kettering studies employed the same design: persons randomly assigned to the intervention arm received sputum cytology every 4 months and annual chest imaging, while persons randomly assigned to the control arm received annual chest imaging. Neither study observed a reduction in lung cancer mortality with screening.[<a href="#cit/section_2.37">37</a>] The two studies were interpreted as showing no benefit of frequent sputum cytology when added to an annual regimen of chest x-ray.</p><p id="_245" tabindex="-1">The design of the Mayo Clinic study (known as the Mayo Lung Project, or MLP), was different. All potential participants were screened with chest imaging and sputum cytology, and those known or suspected to have lung cancer, as well as those in poor health, were excluded. Remaining persons were randomly assigned to either an intervention arm that received chest imaging and sputum cytology every 4 months for 6 years, or to a control arm that received a one-time recommendation at trial entry to receive the same tests on an annual basis.  No reduction in lung cancer mortality was observed. The MLP was interpreted in the 1970s as showing no benefit of an intense screening regimen with chest x-ray and sputum        cytology.</p><p id="_274" tabindex="-1">One RCT of lung cancer screening with chest imaging was conducted in Europe in the 1970s. The Czechoslovakian study began with a prevalence screen (chest imaging and sputum cytology) of 6,364 males aged 40 to 64 years who were current smokers with a lifetime consumption of at least 150,000 cigarettes.[<a href="#cit/section_2.41">41</a>,<a href="#cit/section_2.42">42</a>] All participants except the 18 diagnosed with lung cancer as a result of the prevalence screen were randomly assigned to one of two arms: an intervention arm, which received semi-annual screening for 3 years, or a control arm, which received screening during the third year only. The investigators reported 19 lung cancer deaths in the intervention arm and 13 in the control arm, and concluded that frequent screening was not necessary.</p><p id="_246" tabindex="-1">By 1990, the medical community was still unsure about the relationship between screening with chest imaging (using traditional chest x-ray) and lung cancer mortality. Although previous studies showed no benefit, findings were not definitive because of a lack of statistical power. A multiphasic trial with ample statistical power,  the PLCO Cancer Screening Trial,[<a href="#cit/section_2.43">43</a>]  began in 1992.  PLCO enrolled 154,901 participants aged  55 to 74 years, including women (50%) and never smokers (45%).  Half were randomly assigned to screening, and the other half were advised to receive their usual medical care. PLCO had 90% power to detect a 20% reduction in lung cancer mortality.</p><p id="_247" tabindex="-1">The lung component of PLCO addressed the question of whether annual single-view (posterior-anterior) chest x-ray was capable of reducing lung cancer mortality as compared with usual medical care. When the study began, all participants randomly assigned to screening were invited to receive a baseline and three annual chest x-ray screens, although the protocol ultimately was changed to screen never-smokers only three times. At 13 years of follow-up, 1,213 lung cancer deaths were observed in the intervention group, compared with 1,230 lung cancer deaths in the usual-care group (mortality relative risk, 0.99; 95% CI, 0.87&#x2013;1.22). Sub-analyses suggested no differential effect by sex or smoking status.[<a href="#cit/section_2.43">43</a>]</p><p id="_248" tabindex="-1">Given the abundance and consistency of evidence, as well as the lack of benefit observed in the PLCO trial, it is appropriate to conclude that lung cancer screening with chest
            x-ray and/or sputum cytology, regardless of sex or smoking status, does not reduce lung cancer mortality.</p></section></section><h6 do-not-show="toc">References</h6><ol><li id="section_2.1">American Cancer Society: Cancer Facts and Figures 2018. Atlanta, Ga: American Cancer Society, 2018. <a href="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf" title="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf">Available online</a>. Last accessed August 3, 2018.</li><li id="section_2.2">The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, Ga: U.S. Department of Health and Human Services, CDC, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004. <a href="https://www.cdc.gov/tobacco/data_statistics/sgr/2004/index.htm" title="https://www.cdc.gov/tobacco/data_statistics/sgr/2004/index.htm">Also available online</a>.                Last accessed August 13, 2018.</li><li id="section_2.3">Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service. Washington, DC: US Department of Health, Education, and Welfare, 1965. PHS Publ No 1103.</li><li id="section_2.4">Ahrendt SA, Chow JT, Xu LH, et al.: Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 91 (4): 332-9, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10050866&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10050866&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.5">Henschke CI, McCauley DI, Yankelevitz DF, et al.: Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 354 (9173): 99-105, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10408484&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10408484&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.6">Bach PB, Mirkin JN, Oliver TK, et al.: Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 307 (22): 2418-29, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22610500&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22610500&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.7">Aberle DR, Adams AM, Berg CD, et al.: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365 (5): 395-409, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21714641&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21714641&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.8">Pinsky PF, Church TR, Izmirlian G, et al.: The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer 119 (22): 3976-83, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24037918&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24037918&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.9">Moyer VA; U.S. Preventive Services Task Force: Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 160 (5): 330-8, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24378917&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24378917&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.10">Tammem&#xE4;gi MC, Katki HA, Hocking WG, et al.: Selection criteria for lung-cancer screening. N Engl J Med 368 (8): 728-36, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23425165&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23425165&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.11">Kovalchik SA, Tammemagi M, Berg CD, et al.: Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med 369 (3): 245-54, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23863051&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23863051&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.12">Doria-Rose VP, Szabo E: Screening and prevention of lung cancer. In: Kernstine KH, Reckamp KL, eds.: Lung Cancer: A Multidisciplinary Approach to Diagnosis and Management. New York, NY: Demos Medical, 2011, pp 53-72.</li><li id="section_2.13">Horeweg N, van der Aalst CM, Vliegenthart R, et al.: Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial. Eur Respir J 42 (6): 1659-67, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23845716&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23845716&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.14">Paci E, Puliti D, Lopes Pegna A, et al.: Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial. Thorax 72 (9): 825-831, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28377492&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28377492&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.15">Wille MM, Dirksen A, Ashraf H, et al.: Results of the Randomized Danish Lung Cancer Screening Trial with Focus on High-Risk Profiling. Am J Respir Crit Care Med 193 (5): 542-51, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26485620&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26485620&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.16">Infante M, Cavuto S, Lutman FR, et al.: Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography. Am J Respir Crit Care Med 191 (10): 1166-75, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25760561&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25760561&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.17">Pastorino U, Rossi M, Rosato V, et al.: Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev 21 (3): 308-15, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22465911&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22465911&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.18">Pinsky PF, Kramer BS: Lung Cancer Risk and Demographic Characteristics of Current 20-29 Pack-year Smokers: Implications for Screening. J Natl Cancer Inst 107 (11): , 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26483244&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26483244&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.19">Woloshin S, Schwartz LM, Black WC, et al.: Cancer screening campaigns--getting past uninformative persuasion. N Engl J Med 367 (18): 1677-9, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23113476&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23113476&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.20">Ashraf H, Saghir Z, Dirksen A, et al.: Smoking habits in the randomised Danish Lung Cancer Screening Trial with low-dose CT: final results after a 5-year screening programme. Thorax 69 (6): 574-9, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24443174&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24443174&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.21">Tammem&#xE4;gi MC, Berg CD, Riley TL, et al.: Impact of lung cancer screening results on smoking cessation. J Natl Cancer Inst 106 (6): dju084, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24872540&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24872540&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.22">Brain K, Carter B, Lifford KJ, et al.: Impact of low-dose CT screening on smoking cessation among high-risk participants in the UK Lung Cancer Screening Trial. Thorax 72 (10): 912-918, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28710339&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28710339&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.23">An evaluation of radiologic and cytologic screening for the early detection of lung cancer: a cooperative pilot study of the American Cancer Society and the Veterans Administration. Cancer Res 26 (10): 2083-121, 1966.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5922259&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5922259&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.24">Boucot KR, Weiss W: Is curable lung cancer detected by semiannual screening? JAMA 224 (10): 1361-5, 1973.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4739985&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4739985&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.25">Brett GZ: The value of lung cancer detection by six-monthly chest radiographs. Thorax 23 (4): 414-20, 1968.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5664703&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5664703&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.26">Brett GZ: Earlier diagnosis and survival in lung cancer. Br Med J 4 (678): 260-2, 1969.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5345935&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5345935&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.27">Dales LG, Friedman GD, Collen MF: Evaluating periodic multiphasic health checkups: a controlled trial. J Chronic Dis 32 (5): 385-404, 1979.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=109452&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=109452&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.28">Nash FA, Morgan JM, Tomkins JG: South London Lung Cancer Study. Br Med J 2 (607): 715-21, 1968.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5690439&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5690439&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.29">Weiss W, Boucot KR, Cooper DA: The Philadelphia pulmonary neoplasm research project. Survival factors in bronchogenic carcinoma. JAMA 216 (13): 2119-23, 1971.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5108675&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5108675&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.30">Weiss W, Boucot KR: The Philadelphia Pulmonary Neoplasm Research Project. Early roentgenographic appearance of bronchogenic carcinoma. Arch Intern Med 134 (2): 306-11, 1974.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4843198&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4843198&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.31">Berlin NI: Overview of the NCI Cooperative Early Lung Cancer Detection Program. Cancer 89 (11 Suppl): 2349-51, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11147610&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11147610&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.32">Fontana RS, Sanderson DR, Taylor WF, et al.: Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic study. Am Rev Respir Dis 130 (4): 561-5, 1984.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6091507&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6091507&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.33">Fontana RS, Sanderson DR, Woolner LB, et al.: Lung cancer screening: the Mayo program. J Occup Med 28 (8): 746-50, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3528436&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3528436&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.34">Fontana RS, Sanderson DR, Woolner LB, et al.: Screening for lung cancer. A critique of the Mayo Lung Project. Cancer 67 (4 Suppl): 1155-64, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1991274&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1991274&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.35">Frost JK, Ball WC Jr, Levin ML, et al.: Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study. Am Rev Respir Dis 130 (4): 549-54, 1984.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6091505&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6091505&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.36">Levin ML, Tockman MS, Frost JK, et al.: Lung cancer mortality in males screened by chest X-ray and cytologic sputum examination: a preliminary report. Recent Results Cancer Res 82: 138-46, 1982.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7111836&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7111836&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.37">Doria-Rose VP, Marcus PM, Szabo E, et al.: Randomized controlled trials of the efficacy of lung cancer screening by sputum cytology revisited: a combined mortality analysis from the Johns Hopkins Lung Project and the Memorial Sloan-Kettering Lung Study. Cancer 115 (21): 5007-17, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19637354&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19637354&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.38">Flehinger BJ, Kimmel M, Polyak T, et al.: Screening for lung cancer. The Mayo Lung Project revisited. Cancer 72 (5): 1573-80, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8394199&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8394199&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.39">Melamed M, Flehinger B, Miller D, et al.: Preliminary report of the lung cancer detection program in New York. Cancer 39 (2): 369-82, 1977.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=837325&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=837325&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.40">Melamed MR, Flehinger BJ, Zaman MB, et al.: Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. Chest 86 (1): 44-53, 1984.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6734291&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6734291&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.41">Kub&#xED;k A, Pol&#xE1;k J: Lung cancer detection. Results of a randomized prospective study in Czechoslovakia. Cancer 57 (12): 2427-37, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3697941&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3697941&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.42">Kubik A, Parkin DM, Khlat M, et al.: Lack of benefit from semi-annual screening for cancer of the lung: follow-up report of a randomized controlled trial on a population of high-risk males in Czechoslovakia. Int J Cancer 45 (1): 26-33, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2404878&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2404878&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.43">Oken MM, Hocking WG, Kvale PA, et al.: Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA 306 (17): 1865-73, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22031728&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22031728&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _249
      field_pdq_section_title:
        - format: plain_text
          value: 'Harms of Screening'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_249" class="pdq-sections"><section id="_279"><h3 id="_279_toc">Screening by Low-Dose Helical Computed Tomography </h3><section id="_252"><h4 id="_252_toc">False-positive exams</h4><p id="_253" tabindex="-1">False-positive exams are particularly problematic in the context of lung cancer screening. Persons most likely to be screened for lung cancer, i.e., heavy smokers, have comorbidities (such as chronic obstructive pulmonary disease and heart disease) that make them poor candidates for certain diagnostic procedures.</p><p id="_275" tabindex="-1">False-positive test results must be considered when lung cancer screening with low-dose helical computed tomography (LDCT) is being evaluated. A false-positive test may lead to anxiety and invasive diagnostic procedures, such as percutaneous needle biopsy or thoracotomy. The percentage of false-positive findings varies substantially among studies and is primarily attributable to differences in how a positive scan is defined (the size criteria), the thickness of the slice used between cuts (smaller slice thicknesses lead to detection of more nodules) and whether the subject resides in a geographic location where granulomatous disease is highly prevalent. A systematic review of the benefits and harms of computed tomography (CT) screening for lung cancer reported that the follow-up of a screen-detected nodule most often included further imaging, which varied among 21 screening trials between 1% and nearly 45%.   Positron emission tomography scanning was performed in 2.5% to 5% of patients.[<a href="#cit/section_3.1">1</a>]  The frequency of nonsurgical biopsies or procedures in screening trials ranges from 0.7% to 4.4%. Of those biopsied, there was marked variation in the finding of a benign result (6%&#x2013;79%). The rate of surgical resection for screen detected nodules in screening trials is between 0.9% and 5.6%. Of patients who underwent surgery, between 6% and 45% had a benign nodule discovered during surgery,[<a href="#cit/section_3.2">2</a>]  a potential harm of lung cancer screening. In the National Lung Screening Trial (NLST), most major complications related to invasive procedures and surgeries occurred in patients diagnosed with lung cancer, with a major complication rate of 14%. Additionally, a complication rate of 4.1 deaths and 4.5 complications per 10,000 diagnostic events can be expected in patients determined to have a benign nodule. The rates of complications from the NLST may not be generalizable to a community setting;  participants in the NLST were younger, better educated, and less likely to be current smokers (therefore healthier) than the population of smokers and former smokers in the general U.S. population who would be eligible for screening. Of note, 82% of the participants were enrolled at large academic medical centers, and 76% of the enrollees were seen at National Cancer Institute&#x2013;designated cancer centers.  This may account for the extremely low complication rate and surgical mortality (1%) found in the NLST that led the multisociety position paper to strongly recommend that screening be carried out at centers with the same patient-management resources as those in the NLST.[<a href="#cit/section_3.1">1</a>]</p><p id="_318" tabindex="-1">The rates of potential screening harms can vary as lung cancer screening is implemented in a real-world setting. In one study, the authors examined the effects of introducing a LDCT lung cancer screening program into selected Veterans Health Administration (VA) hospitals across the United States.[<a href="#cit/section_3.3">3</a>] In another study, 93,000 patients were assessed for eligibility to receive one round of LDCT screening: 4,246 patients met the criteria (as per the 2013 U.S. Preventive Service Task Force recommendations);[<a href="#cit/section_3.4">4</a>] of those eligible, 58% of patients agreed to be screened, and 50% of patients (n = 2,106) actually underwent screening. Sixty percent of patients had a false-positive test, 56% of patients had a suspicious nodule that required ongoing monitoring, and 3.5% of patients underwent diagnostic evaluation for a positive screen. The high rate of false-positive tests (compared with 27.3% of patients in the NLST for a first screen) may be attributed to the VA program&#x2019;s definition of a positive screen, which used Fleischer Society guidelines for management of CT-detected nodules,[<a href="#cit/section_3.5">5</a>] whereas the NLST had an absolute cut-off value of 4 mm to define a positive nodule.[<a href="#cit/section_3.2">2</a>] Most nodules detected in the VA pilot program were 4 mm or less (55%). However, there is currently no uniformly accepted protocol for nodule management in LDCT lung cancer screening, so wide rates of variability in false-positive results could be likely with broad implementation. Additionally, 41% of participants in the VA program had incidental findings of unclear significance that were reported by the reading radiologist to likely require follow-up or further evaluation.[<a href="#cit/section_3.3">3</a>]</p></section><section id="_257"><h4 id="_257_toc">Overdiagnosis</h4><p id="_258" tabindex="-1">A less familiar harm is overdiagnosis,  which means the diagnosis of a condition that would not have become clinically significant had it not been detected by screening.[<a href="#cit/section_3.6">6</a>] Had the patient not been diagnosed with cancer, the patient would have died of other competing comorbidities. In the case of screening with LDCT, overdiagnosis could lead to unnecessary diagnosis of lung cancer requiring some combination of surgery (e.g., lobectomy, chemotherapy, and radiation therapy). Autopsy studies suggest that a significant number of individuals die with lung cancer rather than from it. In one study, about one-sixth of all lung cancers found at autopsy had not been clinically recognized before death.[<a href="#cit/section_3.7">7</a>] This may be an underestimate; depending on the extent of the autopsy,  many small lung cancers that are detectable by CT may go unrecorded in an autopsy record.[<a href="#cit/section_3.8">8</a>] Studies in Japan provide additional evidence that screening with LDCT could lead to a substantial amount of overdiagnosis.[<a href="#cit/section_3.9">9</a>]  Studies are needed to establish the level of overdiagnosis that might be associated with CT screening for lung cancer. However, in one study, the volume-doubling times of 61 lung cancers were estimated using an exponential model and successive CT images. Lesions were classified into three of the following types:</p><div class="pdq-content-list"><ul id="_281"><li>Type G (ground glass opacity).</li><li>Type GS (focal glass opacity with a solid central component).</li><li>Type S (solid nodule).</li></ul></div><p id="_282" tabindex="-1">The mean-doubling times were 813 days, 457 days, and 149 days for types G, GS, and S, respectively. In this study, annual CT screening identified a large number of slowly growing adenocarcinomas that were not visible on chest x-ray, suggesting overdiagnosis.[<a href="#cit/section_3.10">10</a>]</p><p id="_276" tabindex="-1">In a  screening trial with more than 5,000 participants, the proportion of cancers that would be considered overdiagnoses was evaluated.  Volume-doubling time was used as a surrogate for overdiagnosis. Patients with a calculated volume-doubling time of more than 400 days before surgical resection were considered to have an overdiagnosed cancer.[<a href="#cit/section_3.11">11</a>]  	The investigators discovered that 25% of those ultimately diagnosed with lung cancer met the criteria of an indolent screen-detected nodule, suggesting that one in four cancers in that trial were overdiagnosed.[<a href="#cit/section_3.11">11</a>]  Similar rates of overdiagnosis have been documented in breast cancer.  This rate is consistent with previous chest radiograph screening studies and for other solid tumors. The rate of overdiagnosis in the NLST has yet to be calculated, but the study data show a persistent gap of about 120 excess lung cancer cases in the LDCT group compared with the chest radiograph group, although long-term follow-up is needed.[<a href="#cit/section_3.12">12</a>] Additional evidence of overdiagnosis with LDCT screening was observed in the randomized Danish Lung Cancer Screening Trial. At 10 years of follow-up (5 years after the last screening exam), almost twice as many lung cancers had been diagnosed in the screening group than in the control group (5.1 vs. 2.7 cases per 1,000 person-years or 100 vs. 53 lung cancer cases in 4,104 total participants, respectively); most of  the lung cancers were early stage adenocarcinomas, with no statistically significant difference in the number of stage III and IV cancers between the two groups.[<a href="#cit/section_3.13">13</a>]</p><p id="_287" tabindex="-1">About 20 years of follow-up of the Mayo Lung Project (MLP) cohort indicates that 17% of lung cancers diagnosed as the result of an intense regimen of chest x-ray and sputum cytology are overdiagnosed;[<a href="#cit/section_3.14">14</a>] 585 lung cancers had been diagnosed in the intervention arm as compared with 500 in the usual-care arm. After 13 years of follow-up of the Prostate, Lung, Colorectal and Ovarian (PLCO) cohort, 1,696 lung cancers had been diagnosed in the intervention arm as compared with 1,620 lung cancers in the usual-care arm.[<a href="#cit/section_3.15">15</a>] This suggests that about 6% of cancers diagnosed as the result of annual chest x-ray are overdiagnosed, although that percentage was not significantly different from 0%.</p></section><section id="_255"><h4 id="_255_toc">Complications of diagnostic evaluation</h4><p id="_256" tabindex="-1">In the PLCO,[<a href="#cit/section_3.15">15</a>] 0.4% of participants with at least one positive screen who had a diagnostic evaluation had a complication associated with a diagnostic procedure. The most common of the 69 complications were pneumothorax (29%), atelectasis (15%), and infection (10%).</p></section><section id="_259"><h4 id="_259_toc">Increase in lung cancer mortality </h4><p id="_260" tabindex="-1">Findings from the MLP hinted at the possibility of an increase in lung cancer mortality for persons screened with an intense regimen of chest x-ray and sputum cytology.[<a href="#cit/section_3.16">16</a>] At the end of 20 years of follow-up, the lung cancer mortality rate was 4.4 cases per 1,000 deaths in the intervention arm and 3.9 cases per 1,000 deaths in the usual-care arm. The two rates were not statistically different from one another (<em>P</em> = .09). No increase in risk was seen in the intervention arms of the John Hopkins University and Memorial Sloan-Kettering studies (relative risk [RR],  0.88; 95% confidence interval [CI], 0.74&#x2013;1.05), and the PLCO (RR, 0.99; 95% CI, 0.87&#x2013;1.22).</p></section><section id="_277"><h4 id="_277_toc">Radiation exposure</h4><p id="_278" tabindex="-1">Another potential risk from screening with LDCT is radiation exposure.  The average exposure is very low for an LDCT at 1.5 mSv.  It is estimated that over a 3-year period of screening, NLST participants have been exposed to an average of 8 mSv of radiation (which accounts for radiation from screens and additional imaging for screen-detected nodules).  Modeling from previous work on radiation exposure and the development of cancer suggests that there could be one death per 2,500 screens in those participating in a screening program such as the NLST, although the benefit of screening (1 death avoided per 320 screens) far outweighs the risk.  Younger persons and those without a significant risk of lung cancer may be more likely to suffer a radiation-induced lung cancer from screening than to be spared a lung cancer death.[<a href="#cit/section_3.1">1</a>]</p></section></section><section id="_250"><h3 id="_250_toc">Screening by Chest X-ray and/or Sputum Cytology</h3><p id="_251" tabindex="-1">Unless reported above, data on harms associated with sputum cytology or a combined regimen of sputum cytology and chest x-ray have not been published.</p><p id="_254" tabindex="-1">In the PLCO Cancer Screening Trial, the percentage of false positive screens (among all positive lung cancer screens) was 98%.[<a href="#cit/section_3.17">17</a>] When smoking status was considered, the percentage of false-positive screens (among all positive screens) was highest in never-smokers (&gt;99%) and lowest in current smokers (95%). After adjustment for smoking, the percentage of false-positive screens did not differ by sex.</p></section><h6 do-not-show="toc">References</h6><ol><li id="section_3.1">Bach PB, Mirkin JN, Oliver TK, et al.: Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 307 (22): 2418-29, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22610500&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22610500&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.2">Aberle DR, Adams AM, Berg CD, et al.: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365 (5): 395-409, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21714641&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21714641&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.3">Kinsinger LS, Anderson C, Kim J, et al.: Implementation of Lung Cancer Screening in the Veterans Health Administration. JAMA Intern Med 177 (3): 399-406, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28135352&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28135352&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.4">Moyer VA; U.S. Preventive Services Task Force: Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 160 (5): 330-8, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24378917&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24378917&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.5">MacMahon H, Austin JH, Gamsu G, et al.: Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology 237 (2): 395-400, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16244247&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16244247&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.6">Black WC: Overdiagnosis: An underrecognized cause of confusion and harm in cancer screening. J Natl Cancer Inst 92 (16): 1280-2, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10944539&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10944539&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.7">Chan CK, Wells CK, McFarlane MJ, et al.: More lung cancer but better survival. Implications of secular trends in "necropsy surprise" rates. Chest 96 (2): 291-6, 1989.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2787730&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2787730&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.8">Dammas S, Patz EF Jr, Goodman PC: Identification of small lung nodules at autopsy: implications for lung cancer screening and overdiagnosis bias. Lung Cancer 33 (1): 11-6, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11429191&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11429191&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.9">Marcus PM, Fagerstrom RM, Prorok PC, et al.: Screening for lung cancer with helical CT scanning. Clinical Pulmonary Medicine  9 (6): 323-9, 2002.</li><li id="section_3.10">Hasegawa M, Sone S, Takashima S, et al.: Growth rate of small lung cancers detected on mass CT screening. Br J Radiol 73 (876): 1252-9, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11205667&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11205667&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.11">Veronesi G, Maisonneuve P, Bellomi M, et al.: Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: a cohort study. Ann Intern Med 157 (11): 776-84, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23208167&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23208167&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.12">Patz EF Jr, Pinsky P, Gatsonis C, et al.: Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med 174 (2): 269-74, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24322569&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24322569&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.13">Wille MM, Dirksen A, Ashraf H, et al.: Results of the Randomized Danish Lung Cancer Screening Trial with Focus on High-Risk Profiling. Am J Respir Crit Care Med 193 (5): 542-51, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26485620&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26485620&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.14">Marcus PM, Bergstralh EJ, Zweig MH, et al.: Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis. J Natl Cancer Inst 98 (11): 748-56, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16757699&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16757699&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.15">Oken MM, Hocking WG, Kvale PA, et al.: Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA 306 (17): 1865-73, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22031728&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22031728&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.16">Marcus PM, Bergstralh EJ, Fagerstrom RM, et al.: Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst 92 (16): 1308-16, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10944552&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10944552&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.17">Hocking WG, Hu P, Oken MM, et al.: Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. J Natl Cancer Inst 102 (10): 722-31, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20442215&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20442215&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _299
      field_pdq_section_title:
        - format: plain_text
          value: 'Informed Medical Decision Making'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_299" class="pdq-sections"><p id="_300" tabindex="-1">Informed medical decision making is increasingly recommended for individuals who are considering cancer screening. Many different types and formats of decision aids have been studied. (Refer to the PDQ summary on <a href="/about-cancer/screening/hp-screening-overview-pdq">Cancer Screening Overview</a> for more information.)</p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _32
      field_pdq_section_title:
        - format: plain_text
          value: 'Changes to This Summary (02/02/2018)'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_32" class="pdq-sections"><p id="_34" tabindex="-1">The PDQ cancer information summaries are reviewed regularly and updated as
            new information becomes available.  This section describes the latest
            changes made to this summary as of the date above.</p><p id="_322" tabindex="-1"><strong><a href="/types/lung/hp/lung-screening-pdq#link/_8">Description of the Evidence</a></strong></p><p id="_325" tabindex="-1">Updated <a href="/types/lung/hp/lung-screening-pdq#link/_328">statistics</a> with estimated new cases and deaths for 2018 (cited American Cancer Society as reference 1).</p><p id="_326" tabindex="-1">Revised <a href="/types/lung/hp/lung-screening-pdq#link/_273">text</a> to state that other randomized clinical trials of low-dose helical computed tomography are under way or are already completed in a number of countries; other small trials are largely not powered to assess mortality as an endpoint, but there is an effort under way to combine the findings from these studies with the Dutch-Belgian Randomized Lung Cancer Screening Trial data, once the data are fully mature (cited Horeweg et al., Paci et al., Wille et al., Infante et al., and Pastorino et al. as references 13, 14, 15, 16, and 17, respectively).</p><p id="_disclaimerHP_3" tabindex="-1">This summary is written and maintained by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/screening-prevention" title="https://www.cancer.gov/publications/pdq/editorial-boards/screening-prevention">PDQ Screening and Prevention Editorial Board</a>, which is
            editorially independent of NCI.  The summary reflects an independent review of
            the literature and does not represent a policy statement of NCI or NIH.  More
            information about summary policies and the role of the PDQ Editorial Boards  in
            maintaining the PDQ summaries can be found on the <a href="/types/lung/hp/lung-screening-pdq#link/_AboutThis_1">About This PDQ Summary</a> and <a href="https://www.cancer.gov/publications/pdq" title="https://www.cancer.gov/publications/pdq">PDQ&#xAE; - NCI's Comprehensive Cancer Database</a> pages.
            </p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _AboutThis_1
      field_pdq_section_title:
        - format: plain_text
          value: 'About This PDQ Summary'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_AboutThis_1" class="pdq-sections"><section id="_AboutThis_2"><h3 id="_AboutThis_2_toc">Purpose of This Summary</h3><p id="_AboutThis_3" tabindex="-1">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about lung cancer screening. It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</p></section><section id="_AboutThis_4"><h3 id="_AboutThis_4_toc">Reviewers and Updates</h3><p id="_AboutThis_5" tabindex="-1">This summary is reviewed regularly and updated as necessary by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/screening-prevention" title="https://www.cancer.gov/publications/pdq/editorial-boards/screening-prevention">PDQ Screening and Prevention Editorial Board</a>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</p><p id="_AboutThis_22" tabindex="-1"> Board members review recently published articles each month to determine whether an article should:</p><div class="pdq-content-list"><ul id="_AboutThis_6"><li>be discussed at a meeting,</li><li>be cited with text, or</li><li>replace or update an existing article that is already cited.</li></ul></div><p id="_AboutThis_7" tabindex="-1">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</p><p id="_AboutThis_9" tabindex="-1">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us">Email Us</a>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</p></section><section id="_AboutThis_10"><h3 id="_AboutThis_10_toc">Levels of Evidence</h3><p id="_AboutThis_11" tabindex="-1">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Screening and Prevention Editorial Board uses a <a href="/publications/pdq/levels-evidence/screening-prevention">formal evidence ranking system</a> in developing its level-of-evidence designations.</p></section><section id="_AboutThis_12"><h3 id="_AboutThis_12_toc">Permission to Use This Summary</h3><p id="_AboutThis_13" tabindex="-1">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as &#x201C;NCI&#x2019;s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].&#x201D;</p><p id="_AboutThis_14" tabindex="-1">The preferred citation for this PDQ summary is:</p><p id="_AboutThis_15" tabindex="-1">PDQ&#xAE; Screening and Prevention Editorial Board. PDQ Lung Cancer Screening. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <a href="https://www.cancer.gov/types/lung/hp/lung-screening-pdq" title="https://www.cancer.gov/types/lung/hp/lung-screening-pdq">https://www.cancer.gov/types/lung/hp/lung-screening-pdq</a>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389268]</p><p id="_AboutThis_16" tabindex="-1">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <a href="https://visualsonline.cancer.gov/" title="https://visualsonline.cancer.gov/">Visuals Online</a>, a collection of over 2,000 scientific images.
            </p></section><section id="_AboutThis_17"><h3 id="_AboutThis_17_toc">Disclaimer</h3><p id="_AboutThis_19" tabindex="-1">The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <a href="https://www.cancer.gov/about-cancer/managing-care" title="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</a> page.</p></section><section id="_AboutThis_20"><h3 id="_AboutThis_20_toc">Contact Us</h3><p id="_AboutThis_21" tabindex="-1">More information about contacting us or receiving help with the Cancer.gov website can be found on our <a href="https://www.cancer.gov/contact" title="https://www.cancer.gov/contact">Contact Us for Help</a> page. Questions can also be submitted to Cancer.gov through the website&#x2019;s <a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us">Email Us</a>.</p></section></div>
  title__ES:
    value: 'Exámenes de detección del cáncer de pulmón (PDQ®)–Versión para profesionales de salud'
  status__ES:
    value: 1
  langcode__ES:
    value: es
  moderation_state__ES:
    value: published
  field_pdq_url__ES:
    value: /tipos/pulmon/pro/deteccion-pulmon-pdq
  field_pdq_cdr_id__ES:
    value: 700433
  field_pdq_audience__ES:
    value: Health Professionals
  field_pdq_summary_type__ES:
    value: Screening
  field_date_posted__ES:
    value: '2012-08-22'
  field_date_updated__ES:
    value: '2018-02-16'
  field_browser_title__ES:
    value: 'Exámenes de detección del cáncer de pulmón'
  field_page_description__ES:
    value: 'Resumen de información revisada por expertos acerca de las pruebas utilizadas para detectar o vigilar el cáncer de pulmón.'
  field_public_use__ES:
    value: 1
  field_summary_sections__ES:
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _1
      field_pdq_section_title:
        - format: plain_text
          value: 'Aspectos generales'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_1" class="pdq-sections"><div class="pdq-hp-patient-toggle"><a href="/espanol/tipos/pulmon/paciente/deteccion-pulmon-pdq">Vaya a la versi&#xF3;n para pacientes</a></div><p id="_2" tabindex="-1">Se dispone tambi&#xE9;n de sumarios por separado sobre <a href="/espanol/tipos/pulmon/pro/prevencion-pulmon-pdq">Prevenci&#xF3;n del c&#xE1;ncer de pulm&#xF3;n</a>, <a href="/espanol/tipos/pulmon/pro/tratamiento-pulmon-celulas-pequenas-pdq">Tratamiento del c&#xE1;ncer de pulm&#xF3;n de c&#xE9;lulas peque&#xF1;as</a>,  <a href="/espanol/tipos/pulmon/pro/tratamiento-pulmon-celulas-no-pequenas-pdq">Tratamiento del c&#xE1;ncer de pulm&#xF3;n de c&#xE9;lulas no peque&#xF1;as</a> y <a href="/espanol/publicaciones/pdq/grados-comprobacion/deteccion-prevencion">Grados de comprobaci&#xF3;n cient&#xED;fica de los estudios de investigaci&#xF3;n sobre detecci&#xF3;n y prevenci&#xF3;n del c&#xE1;ncer</a>.</p><section id="_57"><h3 id="_57_toc">Datos probatorios sobre los beneficios relacionados con los ex&#xE1;menes de detecci&#xF3;n</h3><section id="_58"><h4 id="_58_toc">Ex&#xE1;menes de detecci&#xF3;n con tomograf&#xED;a computarizada helicoidal de dosis bajas</h4><section id="_59"><h5 id="_59_toc">Beneficios</h5><p id="_60" tabindex="-1">En un ensayo aleatorizado numeroso se indic&#xF3; que someter a ex&#xE1;menes de detecci&#xF3;n a personas de 55 a 74 a&#xF1;os que tienen antecedentes de tabaquismo con un &#xED;ndice cajetillas-a&#xF1;o de 30 o m&#xE1;s y que si fumaron en el pasado, dejaron de hacerlo en los &#xFA;ltimos 15 a&#xF1;os, disminuye la mortalidad por c&#xE1;ncer de pulm&#xF3;n en 20&#xA0;% (intervalo de confianza [IC] 95&#xA0;%, 6,8&#x2013;26,7; <em>P</em> = 0,004) y la mortalidad por todas las causas en 6,7&#xA0;% (IC 95&#xA0;%, 1,2&#x2013;13,6; <em>P</em> = 0,02).[<a href="#cit/section_1.1">1</a>] En un an&#xE1;lisis actualizado se calcul&#xF3; que la reducci&#xF3;n en la mortalidad por c&#xE1;ncer de pulm&#xF3;n fue de  16&#xA0;% (IC 95&#xA0;%, 5&#x2013;25).[<a href="#cit/section_1.2">2</a>]</p><p id="_61" tabindex="-1"><strong>Magnitud del efecto: reducci&#xF3;n relativa de  16&#xA0;% en la mortalidad espec&#xED;fica por c&#xE1;ncer de pulm&#xF3;n.</strong></p><div class="pdq-content-list"><ul id="_62" class="pdq-address-block"><li><strong>Dise&#xF1;o del estudio</strong>: datos probatorios obtenidos a partir de un ensayo cl&#xED;nico controlado aleatorizado.</li><li><strong>Validez interna</strong>: buena.</li><li><strong>Congruencia</strong>: no corresponde (N/C). Un ensayo aleatorizado hasta la fecha.</li><li><strong>Validez externa</strong>: razonable.</li></ul></div></section><section id="_63"><h5 id="_63_toc">Perjuicios</h5><p id="_64" tabindex="-1">Con base en datos probatorios s&#xF3;lidos, cerca de 96&#xA0;% de todos los ex&#xE1;menes de detecci&#xF3;n con tomograf&#xED;a computarizada helicoidal de dosis bajas con resultados positivos no dan lugar a un diagn&#xF3;stico de c&#xE1;ncer de pulm&#xF3;n.[<a href="#cit/section_1.1">1</a>] Los ex&#xE1;menes con resultados positivos falsos pueden conducir a procedimientos diagn&#xF3;sticos invasivos innecesarios.</p><p id="_65" tabindex="-1"><strong>Magnitud del efecto:  con base en resultados de un ensayo aleatorizado numeroso, la tasa de resultados positivos falsos por serie de ex&#xE1;menes de detecci&#xF3;n es de 23,3&#xA0;%. De todos los resultados positivos falsos de los ex&#xE1;menes de detecci&#xF3;n, 0,06&#xA0;% producen complicaciones graves despu&#xE9;s de un procedimiento invasivo realizado durante el seguimiento diagn&#xF3;stico del resultado positivo del examen de detecci&#xF3;n. En 3 series de detecci&#xF3;n, 1,8&#xA0;% de los participantes que no ten&#xED;an c&#xE1;ncer de pulm&#xF3;n se sometieron a un procedimiento invasivo despu&#xE9;s de un resultado positivo en un examen de detecci&#xF3;n.</strong></p><div class="pdq-content-list"><ul id="_66" class="pdq-address-block"><li><strong>Dise&#xF1;o del estudio</strong>: datos probatorios obtenidos a partir de un ensayo controlado aleatorizado.</li><li><strong>Validez interna</strong>: buena.</li><li><strong>Congruencia</strong>: buena.</li><li><strong>Validez externa</strong>: razonable.</li></ul></div></section></section></section><section id="_67"><h3 id="_67_toc">Datos probatorios sobre la ausencia de beneficios relacionados con los ex&#xE1;menes de detecci&#xF3;n</h3><section id="_3"><h4 id="_3_toc">Ex&#xE1;menes de detecci&#xF3;n con radiograf&#xED;a de t&#xF3;rax o citolog&#xED;a de esputo</h4><section id="_4"><h5 id="_4_toc">Beneficios</h5><p id="_5" tabindex="-1">Con base en datos probatorios s&#xF3;lidos, los ex&#xE1;menes de detecci&#xF3;n con radiograf&#xED;a de t&#xF3;rax o estudio citol&#xF3;gico del esputo no reducen la mortalidad por c&#xE1;ncer de pulm&#xF3;n en la poblaci&#xF3;n general o en quienes alguna vez fumaron.</p><p id="_68" tabindex="-1"><strong>Magnitud del efecto: N/C.</strong></p><div class="pdq-content-list"><ul id="_6" class="pdq-address-block"><li><strong>Dise&#xF1;o del estudio</strong>: ensayos controlados aleatorizados.</li><li><strong>Validez interna</strong>: buena.</li><li><strong>Congruencia</strong>: buena.</li><li><strong>Validez externa</strong>: buena.</li></ul></div></section><section id="_7"><h5 id="_7_toc">Perjuicios</h5><section id="_107"><h6 id="_107_toc">Ex&#xE1;menes con resultados positivos falsos</h6><p id="_8" tabindex="-1">Con base en datos probatorios s&#xF3;lidos, al menos 95&#xA0;% de todos los ex&#xE1;menes de detecci&#xF3;n con radiograf&#xED;a de t&#xF3;rax con resultados positivos no dan lugar a un diagn&#xF3;stico de c&#xE1;ncer de pulm&#xF3;n.   Los ex&#xE1;menes con resultados positivos falsos conducen a procedimientos de diagn&#xF3;stico invasivos innecesarios.</p><div class="pdq-content-list"><ul id="_9" class="pdq-address-block"><li><strong>Dise&#xF1;o del estudio</strong>: ensayos  controlados aleatorizados.</li><li><strong>Validez interna</strong>: buena.</li><li><strong>Congruencia</strong>: buena.</li><li><strong>Validez externa</strong>: buena.</li></ul></div></section><section id="_69"><h6 id="_69_toc">Sobrediagn&#xF3;stico</h6><p id="_70" tabindex="-1">Con base en datos probatorios s&#xF3;lidos, una proporci&#xF3;n baja, pero no despreciable, de los c&#xE1;nceres de pulm&#xF3;n identificados mediante ex&#xE1;menes de detecci&#xF3;n con radiograf&#xED;a de t&#xF3;rax o estudio citol&#xF3;gico del esputo parece que representan sobrediagn&#xF3;sticos de c&#xE1;ncer; la magnitud notificada del sobrediagn&#xF3;stico oscila entre 5 y 25&#xA0;%. Estos c&#xE1;nceres conducen a procedimientos diagn&#xF3;sticos innecesarios y tambi&#xE9;n pueden motivar tratamientos innecesarios. Los perjuicios de los procedimientos de diagn&#xF3;stico y del tratamiento se presentan con mayor frecuencia en fumadores empedernidos o que han fumado durante largos periodos debido a las comorbilidades relacionadas con el tabaquismo que aumentan el riesgo de diseminaci&#xF3;n.</p><p id="_71" tabindex="-1"><strong>Magnitud del efecto: entre 5 y 25&#xA0;%, seg&#xFA;n las caracter&#xED;sticas de la poblaci&#xF3;n sometida a ex&#xE1;menes de detecci&#xF3;n y el r&#xE9;gimen de los mismos.</strong></p><div class="pdq-content-list"><ul id="_72" class="pdq-address-block"><li><strong>Dise&#xF1;o del estudio</strong>: ensayos  controlados aleatorizados.</li><li><strong>Validez interna</strong>: buena.</li><li><strong>Congruencia</strong>: buena.</li><li><strong>Validez externa</strong>: buena.</li></ul></div></section></section></section></section><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_1.1">Aberle DR, Adams AM, Berg CD, et al.: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365 (5): 395-409, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21714641&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21714641&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.2">Pinsky PF, Church TR, Izmirlian G, et al.: The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer 119 (22): 3976-83, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24037918&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24037918&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _73
      field_pdq_section_title:
        - format: plain_text
          value: 'Descripción de los datos probatorios'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_73" class="pdq-sections"><section id="_221"><h3 id="_221_toc">Incidencia y mortalidad</h3><p id="_222" tabindex="-1">El c&#xE1;ncer de pulm&#xF3;n es la tercera forma de c&#xE1;ncer extracut&#xE1;neo m&#xE1;s frecuente en los Estados Unidos y es la principal causa de muerte por c&#xE1;ncer en hombres y mujeres.   Solo en 2018, se calcula que se diagnosticar&#xE1;n  casos nuevos de c&#xE1;ncer de pulm&#xF3;n en 121&#xA0;680 hombres y 112&#xA0;350 mujeres, y que 83&#xA0;550 hombres y 70&#xA0;500 mujeres morir&#xE1;n por esta enfermedad.   La tasa de mortalidad por c&#xE1;ncer de pulm&#xF3;n aument&#xF3; r&#xE1;pidamente en el transcurso de varias d&#xE9;cadas para ambos sexos, con un descenso sostenido para los hombres que comenz&#xF3; en 1991.   Desde 2011 a 2015, las tasas de mortalidad disminuyeron 3,8&#xA0;% por a&#xF1;o en los hombres y 2,3&#xA0;% por a&#xF1;o en las mujeres.[<a href="#cit/section_2.1">1</a>]</p></section><section id="_77"><h3 id="_77_toc">Factores de riesgo</h3><p id="_171" tabindex="-1">El factor de riesgo m&#xE1;s importante para el c&#xE1;ncer de pulm&#xF3;n (como para muchos otros tipos de c&#xE1;ncer) es el consumo de tabaco.[<a href="#cit/section_2.2">2</a>,<a href="#cit/section_2.3">3</a>] El tabaquismo se estableci&#xF3; de forma determinante como la causa principal del c&#xE1;ncer de pulm&#xF3;n a partir de datos epidemiol&#xF3;gicos y de experimentos precl&#xED;nicos con animales. Este nexo causal se ha reconocido ampliamente desde la d&#xE9;cada de 1960, cuando en informes nacionales en Gran Breta&#xF1;a y  los Estados Unidos se advirti&#xF3; al p&#xFA;blico de forma enf&#xE1;tica sobre el riesgo de c&#xE1;ncer por tabaquismo.[<a href="#cit/section_2.3">3</a>] Los porcentajes de casos de c&#xE1;ncer de pulm&#xF3;n a causa del tabaquismo que se calculan en hombres y mujeres son de 90 y 78&#xA0;%, respectivamente.</p><p id="_172" tabindex="-1">Para obtener m&#xE1;s informaci&#xF3;n y una descripci&#xF3;n completa de los factores relacionados con aumento o disminuci&#xF3;n del riesgo de c&#xE1;ncer de pulm&#xF3;n, consultar el sumario de PDQ <a href="/espanol/tipos/pulmon/pro/prevencion-pulmon-pdq">Prevenci&#xF3;n del c&#xE1;ncer de pulm&#xF3;n</a>.</p></section><section id="_173"><h3 id="_173_toc">Datos probatorios sobre los beneficios relacionados con los ex&#xE1;menes de detecci&#xF3;n</h3><section id="_174"><h4 id="_174_toc">Ex&#xE1;menes de detecci&#xF3;n con tomograf&#xED;a computarizada helicoidal de dosis bajas</h4><p id="_175" tabindex="-1">Se han realizado esfuerzos intensos para mejorar los ex&#xE1;menes de detecci&#xF3;n con tecnolog&#xED;as m&#xE1;s nuevas, como la tomograf&#xED;a computarizada helicoidal de dosis bajas (TCDB).[<a href="#cit/section_2.4">4</a>,<a href="#cit/section_2.5">5</a>] Se observ&#xF3; que la TCDB es m&#xE1;s sensible que la radiograf&#xED;a de t&#xF3;rax. En el Early Lung Cancer Action Project (ELCAP),[<a href="#cit/section_2.5">5</a>] la TCDB detect&#xF3; casi seis veces m&#xE1;s c&#xE1;nceres de pulm&#xF3;n en estadio I que la radiograf&#xED;a de t&#xF3;rax y la mayor&#xED;a de estos tumores no med&#xED;an m&#xE1;s de 1 cm de di&#xE1;metro.</p><p id="_176" tabindex="-1">En un an&#xE1;lisis sistem&#xE1;tico,[<a href="#cit/section_2.6">6</a>] se resumieron 13 estudios de observaci&#xF3;n de TCDB realizados entre 1993 y 2004,  que incluyeron entre 60 y 5201 participantes. En algunos estudios japoneses, participaron personas que no fumaban, pero otros se limitaron a fumadores activos y exfumadores. La variabilidad en la detecci&#xF3;n de n&#xF3;dulos (entre 3 y 51&#xA0;%) se pudo atribuir a varios factores:</p><div class="pdq-content-list"><ul id="_177"><li>La definici&#xF3;n de n&#xF3;dulo (en algunos estudios se necesita un umbral de tama&#xF1;o).</li><li>La tecnolog&#xED;a de TC (los cortes delgados permiten detectar m&#xE1;s n&#xF3;dulos y n&#xF3;dulos m&#xE1;s peque&#xF1;os).</li><li>La variaci&#xF3;n geogr&#xE1;fica de las enfermedades granulomatosas end&#xE9;micas.</li></ul></div><p id="_178" tabindex="-1">En general, se diagnostic&#xF3; c&#xE1;ncer de pulm&#xF3;n en 1,1 a 4,7&#xA0;% de los participantes sometidos a ex&#xE1;menes de detecci&#xF3;n; la mayor&#xED;a de estos diagn&#xF3;sticos eran de enfermedad en estadio temprano.[<a href="#cit/section_2.6">6</a>]</p><p id="_179" tabindex="-1">Desde que se complet&#xF3;  el National Lung Screening Trial (NLST), hay datos probatorios que permiten indicar que los ex&#xE1;menes de detecci&#xF3;n con TCDB reducen el riesgo de mortalidad por c&#xE1;ncer de pulm&#xF3;n en fumadores con un &#xED;ndice cajetillas-a&#xF1;o de 30 o mayor, y en exfumadores que dejaron de fumar en los &#xFA;ltimos 15 a&#xF1;os. En el NLST participaron 33 centros a lo largo y ancho  de los Estados Unidos. Los participantes aptos ten&#xED;an entre 55 y 74 a&#xF1;os de edad en la aleatorizaci&#xF3;n,  antecedentes de tabaquismo con un &#xED;ndice de por lo menos 30 cajetillas-a&#xF1;o y, si eran exfumadores, hab&#xED;an dejado de fumar dentro de los &#xFA;ltimos 15 a&#xF1;os. Se inscribi&#xF3; a 53&#xA0;454 personas, se asign&#xF3; al azar a 26&#xA0;722 personas para someterse a ex&#xE1;menes de detecci&#xF3;n con TCDB y a 26&#xA0;732 para someterse a ex&#xE1;menes de detecci&#xF3;n con radiograf&#xED;a de t&#xF3;rax. Cualquier n&#xF3;dulo no calcificado que se encontr&#xF3; en los ex&#xE1;menes de detecci&#xF3;n con TCDB que midiera por lo menos 4 mm en cualquier di&#xE1;metro y cualquier n&#xF3;dulo o masa no calcificados identificados en las im&#xE1;genes de rayos X  se clasific&#xF3; como positivo. Sin embargo, los radi&#xF3;logos tuvieron la opci&#xF3;n de considerar como negativo un examen de detecci&#xF3;n final si un n&#xF3;dulo no calcificado hab&#xED;a permanecido estable en tres ex&#xE1;menes de detecci&#xF3;n. El grupo de TCDB tuvo una tasa sustancialmente m&#xE1;s alta de pruebas de detecci&#xF3;n con resultados positivos que el grupo de radiograf&#xED;a (serie 1, 27,3 vs. 9,2&#xA0;%; serie 2, 27,9 vs. 6,2&#xA0;%, y serie 3, 16,8 vs. 5,0&#xA0;%). En general, 39,1&#xA0;% de los participantes en el grupo TCDB y 16,0&#xA0;% en el de radiograf&#xED;a tuvieron al menos un resultado de detecci&#xF3;n positivo. De quienes tuvieron un resultado de detecci&#xF3;n positivo, la tasa de positivos falsos fue de 96,4&#xA0;% en el grupo TCDB y de 94,5&#xA0;% en el grupo de radiograf&#xED;a de t&#xF3;rax. Esto fue congruente en las tres series.[<a href="#cit/section_2.7">7</a>]</p><p id="_180" tabindex="-1">En el grupo de TCDB, se diagnosticaron 649 c&#xE1;nceres despu&#xE9;s de un resultado positivo de una prueba de detecci&#xF3;n, 44 c&#xE1;nceres despu&#xE9;s de un resultado negativo y 367 c&#xE1;nceres en los participantes que no se sometieron a la detecci&#xF3;n o bien que recibieron el diagn&#xF3;stico despu&#xE9;s de completar la fase de detecci&#xF3;n. En el grupo de radiograf&#xED;a, se diagnosticaron 279 c&#xE1;nceres despu&#xE9;s de un resultado positivo en una prueba de detecci&#xF3;n, 137 c&#xE1;nceres despu&#xE9;s de un resultado negativo y 525 c&#xE1;nceres en los participantes que no se sometieron a la detecci&#xF3;n o bien que recibieron el diagn&#xF3;stico despu&#xE9;s de completar la fase de detecci&#xF3;n. Se produjeron 356 muertes por c&#xE1;ncer de pulm&#xF3;n en el grupo de TCDB y 443 muertes por c&#xE1;ncer de pulm&#xF3;n en el grupo de radiograf&#xED;a de t&#xF3;rax, con una reducci&#xF3;n relativa de la tasa de mortalidad por c&#xE1;ncer de pulm&#xF3;n de 20&#xA0;% (intervalo de confianza [IC] 95&#xA0;%, 6,8&#x2013;26,7) para la detecci&#xF3;n con TCDB.[<a href="#cit/section_2.7">7</a>] En un an&#xE1;lisis actualizado se calcul&#xF3; que la reducci&#xF3;n en la mortalidad por c&#xE1;ncer de pulm&#xF3;n fue de  16&#xA0;% (IC 95&#xA0;%, 5&#x2013;25).[<a href="#cit/section_2.8">8</a>] En general, la mortalidad se redujo en 6,7&#xA0;% (IC 95&#xA0;%, 1,2&#x2013;13,6). El n&#xFA;mero que se necesitaba someter a detecci&#xF3;n con TCDB para prevenir una muerte por c&#xE1;ncer de pulm&#xF3;n fue de 320.[<a href="#cit/section_2.7">7</a>]</p><p id="_181" tabindex="-1">Desde la publicaci&#xF3;n de los resultados del NLST, se ha aprendido m&#xE1;s sobre qui&#xE9;nes se pueden beneficiar m&#xE1;s de la detecci&#xF3;n del c&#xE1;ncer de pulm&#xF3;n mediante TCDB.[<a href="#cit/section_2.9">9</a>-<a href="#cit/section_2.11">11</a>] Un grupo de investigadores cre&#xF3; un modelo de riesgo individual para evaluar qui&#xE9;n se podr&#xED;a beneficiar de los ex&#xE1;menes de detecci&#xF3;n. El modelo incluy&#xF3; factores adicionales no utilizados como criterios de inclusi&#xF3;n en el NLST, como los  antecedentes de enfermedad pulmonar obstructiva cr&#xF3;nica, los antecedentes familiares o personales de c&#xE1;ncer de pulm&#xF3;n y una historia  m&#xE1;s detallada del tabaquismo. De usarse los criterios del ensayo en oposici&#xF3;n a los criterios de inclusi&#xF3;n del NLST, m&#xE1;s personas hubiesen sido aptas para la detecci&#xF3;n, sin omisi&#xF3;n de pacientes con c&#xE1;ncer.[<a href="#cit/section_2.10">10</a>] Un segundo grupo llev&#xF3; a cabo un an&#xE1;lisis nuevo de los datos de NLST y calcul&#xF3; el riesgo de cada paciente de presentar c&#xE1;ncer de pulm&#xF3;n y de morir por el mismo tipo de c&#xE1;ncer.[<a href="#cit/section_2.11">11</a>] Luego, los investigadores dividieron a los participantes del NLST en cinco grupos en funci&#xF3;n del riesgo. El n&#xFA;mero que se necesitaba someter a  ex&#xE1;menes de detecci&#xF3;n para evitar una muerte por c&#xE1;ncer de pulm&#xF3;n en el grupo de riesgo bajo fue 5276; se necesitaban 161 ex&#xE1;menes de detecci&#xF3;n en el grupo de riesgo alto para evitar una muerte por c&#xE1;ncer de pulm&#xF3;n. Adem&#xE1;s, el n&#xFA;mero de resultados positivos falsos de los ex&#xE1;menes de detecci&#xF3;n disminuy&#xF3; de 1648 en el quintil de riesgo m&#xE1;s bajo a 65 en el grupo de riesgo m&#xE1;s alto. Los tres quintiles m&#xE1;s altos de riesgo dieron cuenta de 88&#xA0;% de la reducci&#xF3;n en la mortalidad debida a los ex&#xE1;menes detecci&#xF3;n, mientras que el quintil m&#xE1;s bajo solo representaba 1&#xA0;% de la reducci&#xF3;n de mortalidad. Estos estudios ilustran las posibles mejoras en la determinaci&#xF3;n de la poblaci&#xF3;n de pacientes que tal vez se beneficien m&#xE1;s de los ex&#xE1;menes de detecci&#xF3;n, lo que podr&#xED;a reducir el n&#xFA;mero de resultados positivos falsos y el perjuicio potencial derivado de las consecuencias adversas relacionadas con la evaluaci&#xF3;n. Otro beneficio de calcular el riesgo individual es la capacidad de incorporar los hallazgos en un proceso conjunto de toma de decisiones para que los pacientes puedan decidir si se someten a estos ex&#xE1;menes de detecci&#xF3;n.[<a href="#cit/section_2.11">11</a>]</p><p id="_182" tabindex="-1">Hay otros ensayos cl&#xED;nicos aleatorizados (ECA) con TCDB en varios pa&#xED;ses que se completaron o se encuentran en curso.[<a href="#cit/section_2.12">12</a>] El m&#xE1;s grande es el Dutch-Belgian Randomized Lung Cancer Screening Trial (o ensayo NELSON).[<a href="#cit/section_2.13">13</a>] Este estudio difiere del NLST en que el grupo de control no se somete a detecci&#xF3;n con radiograf&#xED;a de t&#xF3;rax. En otros ensayos europeos m&#xE1;s peque&#xF1;os tambi&#xE9;n se compara  un grupo sin ex&#xE1;menes de detecci&#xF3;n con uno de TCDB.[<a href="#cit/section_2.14">14</a>-<a href="#cit/section_2.17">17</a>] La mayor&#xED;a de estos ensayos m&#xE1;s peque&#xF1;os no parecen tener potencia para evaluar la mortalidad como criterio de valoraci&#xF3;n, pero est&#xE1; en curso una iniciativa para combinar los resultados de estos estudios con los datos de NELSON,
            una vez que los datos sean definitivos. En estos estudios tambi&#xE9;n se podr&#xE1; evaluar la congruencia con los hallazgos del NLST. Adem&#xE1;s de los datos recopilados en los ensayos en curso, se est&#xE1;n analizando los datos del NLST para examinar otros aspectos importantes de los ex&#xE1;menes de detecci&#xF3;n del c&#xE1;ncer de pulm&#xF3;n, como la rentabilidad, la calidad de vida y si los ex&#xE1;menes de detecci&#xF3;n beneficiar&#xED;an a personas m&#xE1;s j&#xF3;venes que las inscritas en el NLST y aquellas con un &#xED;ndice menor de exposici&#xF3;n al cigarrillo de 30 cajetillas-a&#xF1;o. Los datos del U.S. Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial indican que, en ausencia de ex&#xE1;menes de detecci&#xF3;n, el riesgo de c&#xE1;ncer de pulm&#xF3;n para los fumadores actuales que tienen antecedentes de 20 a 29 cajetillas-a&#xF1;o, no es diferente a la de los ex fumadores que dejaron de fumar en un t&#xE9;rmino de 15 a&#xF1;os y tienen antecedentes de haber fumado m&#xE1;s de 30 cajetillas-a&#xF1;o (cociente de riesgos instant&#xE1;neos, 1,07; IC, 0,75&#x2013;1,5). Si bien el riesgo de los ex fumadores no es diferente al del grupo de los fumadores actuales  (para quienes el U.S. Preventive Services Task Force recomienda una TCDB), se desconoce la eficacia de los ex&#xE1;menes de detecci&#xF3;n en el grupo de ex fumadores.[<a href="#cit/section_2.18">18</a>]</p><p id="_183" tabindex="-1">[<em>Nota: Se cre&#xF3; una <a href="https://www.cancer.gov/types/lung/research/NLSTstudyGuidePatientsPhysicians.pdf" title="https://www.cancer.gov/types/lung/research/NLSTstudyGuidePatientsPhysicians.pdf">gu&#xED;a</a> en ingl&#xE9;s para ayudar a los pacientes y los m&#xE9;dicos a evaluar los beneficios y perjuicios de los ex&#xE1;menes de detecci&#xF3;n del c&#xE1;ncer de pulm&#xF3;n con TCDB.<a href="#cit/citation.19">19</a></em>]</p></section><section id="_163"><h4 id="_163_toc">Ex&#xE1;menes de detecci&#xF3;n y desabituaci&#xF3;n tab&#xE1;quica</h4><p id="_164" tabindex="-1">La poblaci&#xF3;n de inter&#xE9;s para ser sometida a ex&#xE1;menes de detecci&#xF3;n de c&#xE1;ncer de pulm&#xF3;n tiene una prevalencia alta de fumadores activos en comparaci&#xF3;n con la poblaci&#xF3;n general. Es posible que un programa de ex&#xE1;menes de detecci&#xF3;n afecte la probabilidad de lograr la desabituaci&#xF3;n tab&#xE1;quica al promover, en teor&#xED;a, el cese en aquellos sometidos a detecci&#xF3;n en quienes se detectan anormalidades pulmonares en dichos ex&#xE1;menes. Por otra parte, los ex&#xE1;menes de detecci&#xF3;n tambi&#xE9;n podr&#xED;an desalentar el cese en aquellos sin indicios de anormalidades pulmonares en los ex&#xE1;menes de detecci&#xF3;n. El         Danish Lung Cancer Screening Trial es un ensayo aleatorizado en el que se compar&#xF3; la TCDB con la ausencia de intervenci&#xF3;n en participantes de 50 a 70 a&#xF1;os de edad con antecedentes de tabaquismo de al menos 20 seg&#xFA;n el &#xED;ndice de cajetillas-a&#xF1;o.[<a href="#cit/section_2.20">20</a>] Se control&#xF3; la proporci&#xF3;n de participantes que hab&#xED;a dejado de fumar anualmente, durante 5 a&#xF1;os de seguimiento y se mantuvieron virtualmente id&#xE9;nticas en los dos grupos desde el inicio (cada uno de los grupos de TC y de control ten&#xED;a 23&#xA0;% de exfumadores) hasta los 5 a&#xF1;os de seguimiento (43&#xA0;% de exfumadores en ambos grupos). La comparaci&#xF3;n de estos dos grupos aleatorizados indic&#xF3; que el programa de ex&#xE1;menes de detecci&#xF3;n con TC tiene un efecto neto igual a cero sobre la probabilidad de abandonar el tabaquismo.</p><p id="_165" tabindex="-1">En otro informe se usaron datos de NLST para abordar el tema de si los resultados de los ex&#xE1;menes de detecci&#xF3;n podr&#xED;an afectar la probabilidad de abandonar el tabaquismo.[<a href="#cit/section_2.21">21</a>] En el NLST se compar&#xF3; la TC con la radiograf&#xED;a de t&#xF3;rax, y se analiz&#xF3; en conjunto los datos de ambos grupos para examinar el efecto de los hallazgos anormales sobre la probabilidad de abandonar el tabaquismo. Al cabo de un a&#xF1;o, fue significativamente m&#xE1;s probable que hubiesen dejado de fumar aquellos fumadores activos que presentaron una evaluaci&#xF3;n de detecci&#xF3;n en la que se sospechaba c&#xE1;ncer de pulm&#xF3;n (pero no era c&#xE1;ncer de pulm&#xF3;n) en comparaci&#xF3;n con aquellos sin hallazgos an&#xF3;malos. La relaci&#xF3;n con la desabituaci&#xF3;n tab&#xE1;quica en quienes ten&#xED;an una alteraci&#xF3;n pulmonar importante que no originaba sospecha de c&#xE1;ncer de pulm&#xF3;n o una anomal&#xED;a menor fue m&#xE1;s d&#xE9;bil y sin uniformidad en la significaci&#xF3;n estad&#xED;stica.</p><p id="_217" tabindex="-1">En un tercer estudio del ensayo piloto de U.K. Lung Cancer Screening sobre la TC de dosis baja, se encontr&#xF3; que el examen de detecci&#xF3;n se relacion&#xF3; con un aumento estad&#xED;sticamente significativo de la deshabituaci&#xF3;n tab&#xE1;quica a corto y largo plazos; adem&#xE1;s, este efecto fue mayor entre quienes su examen de detecci&#xF3;n inicial fue positivo por lo que se justificaba una investigaci&#xF3;n cl&#xED;nica adicional.[<a href="#cit/section_2.22">22</a>]</p><p id="_166" tabindex="-1">Los resultados de estos estudios indican que el efecto neto de un programa de TC sobre la desabituaci&#xF3;n tab&#xE1;quica es variado,[<a href="#cit/section_2.20">20</a>] pero parece brindar una probabilidad m&#xE1;s alta de deshabituaci&#xF3;n tab&#xE1;quica en los fumadores activos que presentan hallazgos que hacen sospechar un c&#xE1;ncer de pulm&#xF3;n.[<a href="#cit/section_2.21">21</a>] Este es un campo de investigaci&#xF3;n importante que se debe esclarecer.</p></section></section><section id="_184"><h3 id="_184_toc">Datos probatorios sobre la ausencia de beneficios relacionados con los ex&#xE1;menes de detecci&#xF3;n</h3><section id="_185"><h4 id="_185_toc">Ex&#xE1;menes de detecci&#xF3;n con radiograf&#xED;a de t&#xF3;rax o estudio citol&#xF3;gico del esputo</h4><p id="_186" tabindex="-1">El tema de los ex&#xE1;menes de detecci&#xF3;n del c&#xE1;ncer de pulm&#xF3;n se remonta a la d&#xE9;cada de 1950, cuando el aumento de la incidencia de c&#xE1;ncer de pulm&#xF3;n y las tasas de mortalidad indic&#xF3; la necesidad de intervenci&#xF3;n. En respuesta al problema emergente del c&#xE1;ncer de pulm&#xF3;n, se realizaron cinco estudios de im&#xE1;genes del t&#xF3;rax durante las d&#xE9;cadas de 1950 y 1960, de los cuales dos fueron controlados.[<a href="#cit/section_2.23">23</a>-<a href="#cit/section_2.30">30</a>] En dos estudios tambi&#xE9;n se incluy&#xF3; estudio citol&#xF3;gico del esputo.[<a href="#cit/section_2.23">23</a>-<a href="#cit/section_2.27">27</a>]. En los resultados de estos estudios se indic&#xF3; que no hay beneficio general de los ex&#xE1;menes de detecci&#xF3;n, aunque las limitaciones de dise&#xF1;o impidieron que estos estudios aportaran datos probatorios definitivos.</p><p id="_187" tabindex="-1">A principios de la d&#xE9;cada de 1970, el Instituto Nacional del C&#xE1;ncer cre&#xF3; el Cooperative Early Lung Cancer Detection Program,[<a href="#cit/section_2.31">31</a>] que se dise&#xF1;&#xF3; para evaluar la capacidad de los ex&#xE1;menes de detecci&#xF3;n con im&#xE1;genes radiol&#xF3;gicas de t&#xF3;rax y estudios citol&#xF3;gicos del esputo para reducir la mortalidad por c&#xE1;ncer de pulm&#xF3;n en hombres fumadores. El programa const&#xF3; de tres ECA separados; en cada ensayo se inscribieron cerca de 10&#xA0;000 hombres de 45 a&#xF1;os o m&#xE1;s que fumaron al menos una cajetilla de cigarrillos por d&#xED;a durante el a&#xF1;o anterior. Uno de los estudios lo realiz&#xF3; la Mayo Clinic,[<a href="#cit/section_2.32">32</a>-<a href="#cit/section_2.34">34</a>] un estudio la Johns Hopkins University,[<a href="#cit/section_2.35">35</a>-<a href="#cit/section_2.37">37</a>] y uno el Memorial Sloan-Kettering [<a href="#cit/section_2.37">37</a>-<a href="#cit/section_2.40">40</a>]. En los estudios de Hopkins y Sloan-Kettering, se us&#xF3; el mismo dise&#xF1;o: las personas asignadas al azar al grupo de intervenci&#xF3;n fueron sometidas a estudios citol&#xF3;gicos del esputo cada 4 meses e im&#xE1;genes de t&#xF3;rax anuales, mientras que las personas asignadas al azar al grupo de control fueron sometidas a im&#xE1;genes de t&#xF3;rax anuales. En ning&#xFA;n estudio se observ&#xF3; reducci&#xF3;n de la mortalidad por c&#xE1;ncer de pulm&#xF3;n debida a los ex&#xE1;menes de detecci&#xF3;n.[<a href="#cit/section_2.37">37</a>] En los dos estudios se interpret&#xF3; que no hay beneficio de los estudios citol&#xF3;gicos del esputo frecuentes cuando estas se a&#xF1;aden a un r&#xE9;gimen anual de radiograf&#xED;a de t&#xF3;rax.</p><p id="_188" tabindex="-1">El dise&#xF1;o del estudio de la Mayo Clinic (conocido como Mayo Lung Project o MLP) fue diferente. Se someti&#xF3; a todos los posibles participantes a ex&#xE1;menes de detecci&#xF3;n con im&#xE1;genes de t&#xF3;rax y estudios citol&#xF3;gicos del esputo, y se excluy&#xF3; a aquellos de los que se sab&#xED;a o sospechaba que ten&#xED;an c&#xE1;ncer de pulm&#xF3;n, as&#xED; como a aquellos con salud precaria. Las personas que quedaron se asignaron al azar a un grupo de intervenci&#xF3;n que se someti&#xF3; a im&#xE1;genes de t&#xF3;rax y estudios citol&#xF3;gicos del esputo cada 4 meses durante 6 a&#xF1;os, o a un grupo de control que recibi&#xF3; una &#xFA;nica recomendaci&#xF3;n en el momento de entrar al ensayo de someterse a los mismos ex&#xE1;menes una vez por a&#xF1;o. No se observ&#xF3; ninguna reducci&#xF3;n en la mortalidad por c&#xE1;ncer de pulm&#xF3;n. En la d&#xE9;cada de 1970, se interpret&#xF3; que en el MLP el r&#xE9;gimen intenso de ex&#xE1;menes de detecci&#xF3;n con radiograf&#xED;a de t&#xF3;rax y estudios citol&#xF3;gicos del esputo no mostr&#xF3; ning&#xFA;n beneficio.</p><p id="_189" tabindex="-1">En la d&#xE9;cada de 1970, se realiz&#xF3; en Europa un ECA de ex&#xE1;menes de detecci&#xF3;n del c&#xE1;ncer de pulm&#xF3;n con im&#xE1;genes de t&#xF3;rax. El estudio checoslovaco comenz&#xF3; con ex&#xE1;menes de detecci&#xF3;n de prevalencia (im&#xE1;genes de t&#xF3;rax y estudios citol&#xF3;gicos del esputo) de 6364 hombres de 40 a 64 a&#xF1;os que eran fumadores activos con un consumo m&#xED;nimo de 150&#xA0;000 cigarrillos durante toda su vida.[<a href="#cit/section_2.41">41</a>,<a href="#cit/section_2.42">42</a>] Todos los participantes, excepto los 18 con diagn&#xF3;stico de c&#xE1;ncer de pulm&#xF3;n como resultado de los ex&#xE1;menes de detecci&#xF3;n de prevalencia, fueron asignados al azar a uno de dos grupos: un grupo de intervenci&#xF3;n, que se someti&#xF3; a ex&#xE1;menes de detecci&#xF3;n semestrales durante 3 a&#xF1;os o un grupo de control, que se someti&#xF3; a ex&#xE1;menes de detecci&#xF3;n solo durante el tercer a&#xF1;o. Los investigadores notificaron 19 muertes por c&#xE1;ncer de pulm&#xF3;n en el grupo de intervenci&#xF3;n y 13 en el grupo de control; estos concluyeron que no era necesario someterse con frecuencia a ex&#xE1;menes de detecci&#xF3;n.</p><p id="_190" tabindex="-1">En la d&#xE9;cada de 1990, la comunidad m&#xE9;dica todav&#xED;a dudaba sobre la relaci&#xF3;n entre los ex&#xE1;menes de detecci&#xF3;n mediante im&#xE1;genes de t&#xF3;rax (con radiograf&#xED;a de t&#xF3;rax tradicional) y la mortalidad por c&#xE1;ncer de pulm&#xF3;n. Aunque en  estudios previos no se observ&#xF3; beneficio, los hallazgos no fueron definitivos por la falta de potencia estad&#xED;stica. En 1992 comenz&#xF3; el PLCO Cancer Screening Trial,[<a href="#cit/section_2.43">43</a>] un ensayo multif&#xE1;sico de gran potencia estad&#xED;stica. En el PLCO se inscribieron 154 901 participantes de 55 a 74 a&#xF1;os; 50&#xA0;% eran mujeres y 45&#xA0;% eran personas que nunca hab&#xED;an fumado. La mitad se asign&#xF3; al azar a ex&#xE1;menes de detecci&#xF3;n, y a la otra mitad se le recomend&#xF3; recibir su atenci&#xF3;n m&#xE9;dica habitual. El PLCO tuvo una potencia de 90&#xA0;% para detectar 20&#xA0;% de reducci&#xF3;n en la mortalidad por c&#xE1;ncer de pulm&#xF3;n.</p><p id="_191" tabindex="-1">En el componente pulmonar de PLCO se abord&#xF3; el interrogante de si la radiograf&#xED;a de t&#xF3;rax de vista simple (posteroanterior) anual pod&#xED;a reducir la mortalidad por c&#xE1;ncer de pulm&#xF3;n en comparaci&#xF3;n con la atenci&#xF3;n m&#xE9;dica habitual. Cuando comenz&#xF3; el estudio, se invit&#xF3; a todos los participantes asignados al azar a los ex&#xE1;menes de detecci&#xF3;n a someterse a un examen de detecci&#xF3;n de referencia y tres radiograf&#xED;as de t&#xF3;rax anuales, aunque finalmente se cambi&#xF3; el protocolo para someter a ex&#xE1;menes de detecci&#xF3;n solo tres veces a las personas que nunca hab&#xED;an fumado. Despu&#xE9;s de 13 a&#xF1;os de seguimiento, se observaron 1213 muertes por c&#xE1;ncer de pulm&#xF3;n en el grupo de intervenci&#xF3;n, en comparaci&#xF3;n con 1230 muertes por c&#xE1;ncer de pulm&#xF3;n en el grupo de atenci&#xF3;n m&#xE9;dica habitual (riesgo relativo de mortalidad, 0,99; IC 95&#xA0;%, 0,87&#x2013;1,22). En los suban&#xE1;lisis se indic&#xF3; ausencia de  efectos diferenciales en cuanto al sexo o la condici&#xF3;n de fumador.[<a href="#cit/section_2.43">43</a>]</p><p id="_192" tabindex="-1">Debido a la abundancia y la congruencia de los datos probatorios, as&#xED; como la ausencia de beneficio observada en el ensayo PLCO, es pertinente concluir que los ex&#xE1;menes de detecci&#xF3;n del c&#xE1;ncer de pulm&#xF3;n con radiograf&#xED;a de t&#xF3;rax o estudio citol&#xF3;gico del esputo, independientemente del sexo o la condici&#xF3;n de fumador, no reducen la mortalidad por c&#xE1;ncer de pulm&#xF3;n.</p></section></section><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_2.1">American Cancer Society: Cancer Facts and Figures 2018. Atlanta, Ga: American Cancer Society, 2018. <a href="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf" title="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf">Available online</a>. Last accessed August 3, 2018.</li><li id="section_2.2">The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, Ga: U.S. Department of Health and Human Services, CDC, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004. <a href="https://www.cdc.gov/tobacco/data_statistics/sgr/2004/index.htm" title="https://www.cdc.gov/tobacco/data_statistics/sgr/2004/index.htm">Also available online</a>.                Last accessed August 13, 2018.</li><li id="section_2.3">Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service. Washington, DC: US Department of Health, Education, and Welfare, 1965. PHS Publ No 1103.</li><li id="section_2.4">Ahrendt SA, Chow JT, Xu LH, et al.: Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 91 (4): 332-9, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10050866&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10050866&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.5">Henschke CI, McCauley DI, Yankelevitz DF, et al.: Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 354 (9173): 99-105, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10408484&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10408484&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.6">Bach PB, Mirkin JN, Oliver TK, et al.: Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 307 (22): 2418-29, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22610500&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22610500&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.7">Aberle DR, Adams AM, Berg CD, et al.: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365 (5): 395-409, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21714641&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21714641&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.8">Pinsky PF, Church TR, Izmirlian G, et al.: The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer 119 (22): 3976-83, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24037918&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24037918&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.9">Moyer VA; U.S. Preventive Services Task Force: Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 160 (5): 330-8, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24378917&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24378917&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.10">Tammem&#xE4;gi MC, Katki HA, Hocking WG, et al.: Selection criteria for lung-cancer screening. N Engl J Med 368 (8): 728-36, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23425165&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23425165&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.11">Kovalchik SA, Tammemagi M, Berg CD, et al.: Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med 369 (3): 245-54, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23863051&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23863051&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.12">Doria-Rose VP, Szabo E: Screening and prevention of lung cancer. In: Kernstine KH, Reckamp KL, eds.: Lung Cancer: A Multidisciplinary Approach to Diagnosis and Management. New York, NY: Demos Medical, 2011, pp 53-72.</li><li id="section_2.13">Horeweg N, van der Aalst CM, Vliegenthart R, et al.: Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial. Eur Respir J 42 (6): 1659-67, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23845716&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23845716&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.14">Paci E, Puliti D, Lopes Pegna A, et al.: Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial. Thorax 72 (9): 825-831, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28377492&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28377492&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.15">Wille MM, Dirksen A, Ashraf H, et al.: Results of the Randomized Danish Lung Cancer Screening Trial with Focus on High-Risk Profiling. Am J Respir Crit Care Med 193 (5): 542-51, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26485620&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26485620&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.16">Infante M, Cavuto S, Lutman FR, et al.: Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography. Am J Respir Crit Care Med 191 (10): 1166-75, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25760561&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25760561&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.17">Pastorino U, Rossi M, Rosato V, et al.: Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev 21 (3): 308-15, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22465911&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22465911&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.18">Pinsky PF, Kramer BS: Lung Cancer Risk and Demographic Characteristics of Current 20-29 Pack-year Smokers: Implications for Screening. J Natl Cancer Inst 107 (11): , 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26483244&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26483244&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.19">Woloshin S, Schwartz LM, Black WC, et al.: Cancer screening campaigns--getting past uninformative persuasion. N Engl J Med 367 (18): 1677-9, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23113476&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23113476&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.20">Ashraf H, Saghir Z, Dirksen A, et al.: Smoking habits in the randomised Danish Lung Cancer Screening Trial with low-dose CT: final results after a 5-year screening programme. Thorax 69 (6): 574-9, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24443174&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24443174&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.21">Tammem&#xE4;gi MC, Berg CD, Riley TL, et al.: Impact of lung cancer screening results on smoking cessation. J Natl Cancer Inst 106 (6): dju084, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24872540&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24872540&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.22">Brain K, Carter B, Lifford KJ, et al.: Impact of low-dose CT screening on smoking cessation among high-risk participants in the UK Lung Cancer Screening Trial. Thorax 72 (10): 912-918, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28710339&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28710339&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.23">An evaluation of radiologic and cytologic screening for the early detection of lung cancer: a cooperative pilot study of the American Cancer Society and the Veterans Administration. Cancer Res 26 (10): 2083-121, 1966.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5922259&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5922259&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.24">Boucot KR, Weiss W: Is curable lung cancer detected by semiannual screening? JAMA 224 (10): 1361-5, 1973.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4739985&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4739985&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.25">Brett GZ: The value of lung cancer detection by six-monthly chest radiographs. Thorax 23 (4): 414-20, 1968.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5664703&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5664703&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.26">Brett GZ: Earlier diagnosis and survival in lung cancer. Br Med J 4 (678): 260-2, 1969.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5345935&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5345935&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.27">Dales LG, Friedman GD, Collen MF: Evaluating periodic multiphasic health checkups: a controlled trial. J Chronic Dis 32 (5): 385-404, 1979.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=109452&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=109452&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.28">Nash FA, Morgan JM, Tomkins JG: South London Lung Cancer Study. Br Med J 2 (607): 715-21, 1968.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5690439&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5690439&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.29">Weiss W, Boucot KR, Cooper DA: The Philadelphia pulmonary neoplasm research project. Survival factors in bronchogenic carcinoma. JAMA 216 (13): 2119-23, 1971.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5108675&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5108675&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.30">Weiss W, Boucot KR: The Philadelphia Pulmonary Neoplasm Research Project. Early roentgenographic appearance of bronchogenic carcinoma. Arch Intern Med 134 (2): 306-11, 1974.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4843198&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4843198&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.31">Berlin NI: Overview of the NCI Cooperative Early Lung Cancer Detection Program. Cancer 89 (11 Suppl): 2349-51, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11147610&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11147610&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.32">Fontana RS, Sanderson DR, Taylor WF, et al.: Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic study. Am Rev Respir Dis 130 (4): 561-5, 1984.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6091507&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6091507&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.33">Fontana RS, Sanderson DR, Woolner LB, et al.: Lung cancer screening: the Mayo program. J Occup Med 28 (8): 746-50, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3528436&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3528436&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.34">Fontana RS, Sanderson DR, Woolner LB, et al.: Screening for lung cancer. A critique of the Mayo Lung Project. Cancer 67 (4 Suppl): 1155-64, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1991274&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1991274&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.35">Frost JK, Ball WC Jr, Levin ML, et al.: Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study. Am Rev Respir Dis 130 (4): 549-54, 1984.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6091505&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6091505&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.36">Levin ML, Tockman MS, Frost JK, et al.: Lung cancer mortality in males screened by chest X-ray and cytologic sputum examination: a preliminary report. Recent Results Cancer Res 82: 138-46, 1982.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7111836&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7111836&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.37">Doria-Rose VP, Marcus PM, Szabo E, et al.: Randomized controlled trials of the efficacy of lung cancer screening by sputum cytology revisited: a combined mortality analysis from the Johns Hopkins Lung Project and the Memorial Sloan-Kettering Lung Study. Cancer 115 (21): 5007-17, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19637354&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19637354&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.38">Flehinger BJ, Kimmel M, Polyak T, et al.: Screening for lung cancer. The Mayo Lung Project revisited. Cancer 72 (5): 1573-80, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8394199&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8394199&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.39">Melamed M, Flehinger B, Miller D, et al.: Preliminary report of the lung cancer detection program in New York. Cancer 39 (2): 369-82, 1977.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=837325&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=837325&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.40">Melamed MR, Flehinger BJ, Zaman MB, et al.: Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. Chest 86 (1): 44-53, 1984.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6734291&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6734291&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.41">Kub&#xED;k A, Pol&#xE1;k J: Lung cancer detection. Results of a randomized prospective study in Czechoslovakia. Cancer 57 (12): 2427-37, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3697941&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3697941&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.42">Kubik A, Parkin DM, Khlat M, et al.: Lack of benefit from semi-annual screening for cancer of the lung: follow-up report of a randomized controlled trial on a population of high-risk males in Czechoslovakia. Int J Cancer 45 (1): 26-33, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2404878&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2404878&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.43">Oken MM, Hocking WG, Kvale PA, et al.: Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA 306 (17): 1865-73, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22031728&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22031728&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _120
      field_pdq_section_title:
        - format: plain_text
          value: 'Perjuicios de los exámenes de detección'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_120" class="pdq-sections"><section id="_121"><h3 id="_121_toc">Ex&#xE1;menes de detecci&#xF3;n con tomograf&#xED;a computarizada helicoidal de dosis bajas</h3><section id="_122"><h4 id="_122_toc">Resultados positivos falsos de los ex&#xE1;menes</h4><p id="_123" tabindex="-1">Los resultados positivos falsos de los ex&#xE1;menes son particularmente problem&#xE1;ticos en el contexto de la detecci&#xF3;n del c&#xE1;ncer de pulm&#xF3;n. Las personas que tienen mayor probabilidad de ser sometidas a ex&#xE1;menes de detecci&#xF3;n de c&#xE1;ncer de pulm&#xF3;n, es decir, los fumadores empedernidos, presentan comorbilidades (como enfermedad pulmonar obstructiva cr&#xF3;nica y cardiopat&#xED;as) que los hacen poco aptos para ciertos procedimientos diagn&#xF3;sticos.</p><p id="_124" tabindex="-1">Se deben tener en cuenta los resultados positivos falsos de los ex&#xE1;menes cuando se eval&#xFA;a la detecci&#xF3;n del c&#xE1;ncer de pulm&#xF3;n con tomograf&#xED;a computarizada helicoidal de dosis bajas (TCDB). Un resultado positivo falso de una prueba genera ansiedad y procedimientos diagn&#xF3;sticos invasivos, como biopsia por punci&#xF3;n percut&#xE1;nea o toracotom&#xED;a. El porcentaje de resultados positivos falsos var&#xED;a en forma substancial entre los estudios, lo que se debe principalmente a las diferentes definiciones de los resultados positivos de una exploraci&#xF3;n (criterio de tama&#xF1;o), el grosor de la secci&#xF3;n utilizada entre los cortes (las secciones o cortes m&#xE1;s delgados permiten detectar m&#xE1;s n&#xF3;dulos) y la residencia de los participantes en una zona geogr&#xE1;fica en donde la prevalencia de enfermedades granulomatosas es alta. En una revisi&#xF3;n sistem&#xE1;tica de los beneficios y perjuicios de los ex&#xE1;menes de detecci&#xF3;n de c&#xE1;ncer de pulm&#xF3;n con tomograf&#xED;a computarizada (TC), se notific&#xF3; que el seguimiento de un n&#xF3;dulo detectado mediante dichos ex&#xE1;menes con frecuencia implica nuevas im&#xE1;genes, que oscilaron entre 1 y casi 45&#xA0;% en los 21 estudios de detecci&#xF3;n. Se llevaron a cabo ex&#xE1;menes de detecci&#xF3;n con tomograf&#xED;a con emisi&#xF3;n de positrones en 2,5 a 5&#xA0;% de los pacientes.[<a href="#cit/section_3.1">1</a>] La frecuencia de las biopsias no quir&#xFA;rgicas o los procedimientos  en los estudios sobre ex&#xE1;menes de detecci&#xF3;n oscila entre 0,7 y 4,4&#xA0;%. En aquellos sometidos a biopsias, se encontr&#xF3; una marcada variaci&#xF3;n en el hallazgo de un resultado benigno  (6&#x2013;79&#xA0;%). En los ensayos sobre ex&#xE1;menes de detecci&#xF3;n, las tasas de resecci&#xF3;n quir&#xFA;rgica de los n&#xF3;dulos identificados mediante dichos ex&#xE1;menes  oscilan entre 0,9 y 5,6&#xA0;%. De los pacientes sometidos a cirug&#xED;a, entre 6 y 45&#xA0;% ten&#xED;an un n&#xF3;dulo benigno descubierto durante tal  intervenci&#xF3;n,[<a href="#cit/section_3.2">2</a>] lo que representa un posible perjuicio de los ex&#xE1;menes de detecci&#xF3;n del c&#xE1;ncer de pulm&#xF3;n. En el National Lung Screening Trial (NLST) la mayor&#xED;a de las complicaciones relacionadas con las cirug&#xED;as y los procedimientos invasivos se presentaron en pacientes con diagn&#xF3;stico de c&#xE1;ncer de pulm&#xF3;n; la tasa de complicaciones graves fue de 14&#xA0;%. Adem&#xE1;s, cabe esperar tasas de complicaciones de 4,1 muertes y 4,5 complicaciones por 10&#xA0;000 episodios diagn&#xF3;sticos en los pacientes en quienes se determin&#xF3; la presencia de un n&#xF3;dulo benigno. Las tasas de complicaciones del NLST no se pueden generalizar a un entorno comunitario; los participantes del NLST eran m&#xE1;s j&#xF3;venes, estaban mejor educados y era menos probable que fueran fumadores activos (por lo tanto eran m&#xE1;s sanos) que la poblaci&#xF3;n de fumadores y exfumadores que hace parte de la poblaci&#xF3;n estadounidense que ser&#xED;a apta para someterse a ex&#xE1;menes de detecci&#xF3;n. Cabe resaltar que 82&#xA0;% de los participantes se inscribieron en grandes centros m&#xE9;dicos universitarios y 76&#xA0;% de los inscritos se valoraron en centros oncol&#xF3;gicos designados por el Instituto Nacional del C&#xE1;ncer. Esta pudo ser la raz&#xF3;n de la tasa extremadamente baja de complicaciones y mortalidad quir&#xFA;rgica (1&#xA0;%) observadas en el NLST y que condujeron al art&#xED;culo de posici&#xF3;n de m&#xFA;ltiples sociedades en el que se recomend&#xF3; con firmeza que los ex&#xE1;menes de detecci&#xF3;n se realicen en centros que cuenten con los mismos recursos del NLST para el tratamiento de pacientes.[<a href="#cit/section_3.1">1</a>]</p><p id="_213" tabindex="-1">En la pr&#xE1;ctica cl&#xED;nica de los ex&#xE1;menes de detecci&#xF3;n de c&#xE1;ncer de pulm&#xF3;n, las tasas de perjuicio de estos ex&#xE1;menes pueden variar. En un estudio, los autores analizaron los efectos de iniciar un programa de TCDB en determinados hospitales de la Veterans Health Administration (VA) en diferentes sitios de los Estados Unidos.[<a href="#cit/section_3.3">3</a>] En otro estudio, se evalu&#xF3; a 93&#xA0;000 pacientes para determinar si eran aptos para someterse a un ciclo de ex&#xE1;menes de detecci&#xF3;n con TCDB: 4246 pacientes cumpl&#xED;an con los criterios de selecci&#xF3;n (seg&#xFA;n las recomendaciones de la U.S. Preventive Service Task Force de 2013);[<a href="#cit/section_3.4">4</a>] de los pacientes aptos, 58&#xA0;% aceptaron someterse a los ex&#xE1;menes de detecci&#xF3;n; 50&#xA0;% de los pacientes (n = 2106) se sometieron en definitiva a los ex&#xE1;menes de detecci&#xF3;n. Sesenta por ciento de los pacientes obtuvieron resultados positivos falsos, 56&#xA0;% presentaron un n&#xF3;dulo que se sospechaba maligno y exig&#xED;a vigilancia continua, y 3,5&#xA0;% de los pacientes se sometieron a una evaluaci&#xF3;n diagn&#xF3;stica tras un examen de detecci&#xF3;n con resultado positivo. Es posible que la tasa alta de pruebas positivas falsas (en comparaci&#xF3;n con 27,3&#xA0;% de los pacientes en el primer examen de detecci&#xF3;n del NLST) se vincule con la definici&#xF3;n de resultado positivo de detecci&#xF3;n en el programa de la VA, que sigui&#xF3; las pautas de la Fleischer Society para la evaluaci&#xF3;n de n&#xF3;dulos detectados por TC,[<a href="#cit/section_3.5">5</a>] mientras que en el NLST se aplic&#xF3; un valor de corte absoluto de 4 mm para definir la afectaci&#xF3;n de un n&#xF3;dulo.[<a href="#cit/section_3.2">2</a>] La mayor&#xED;a de los n&#xF3;dulos detectados en el programa piloto de la VA med&#xED;an 4 mm o menos (55&#xA0;%). Sin embargo, en la actualidad no hay un protocolo de aceptaci&#xF3;n uniforme para la evaluaci&#xF3;n de n&#xF3;dulos en la detecci&#xF3;n de c&#xE1;ncer de pulm&#xF3;n por TCDB; por lo tanto, es probable que el uso generalizado de los ex&#xE1;menes produzca variaciones amplias en los resultados positivos falsos. Adem&#xE1;s, en 41&#xA0;% de los participantes del programa de la VA, el radi&#xF3;logo notific&#xF3; hallazgos casuales de significaci&#xF3;n dudosa que es probable que exijan seguimiento o m&#xE1;s evaluaci&#xF3;n.[<a href="#cit/section_3.3">3</a>]</p></section><section id="_126"><h4 id="_126_toc">Sobrediagn&#xF3;stico</h4><p id="_127" tabindex="-1">Un perjuicio menos com&#xFA;n es el sobrediagn&#xF3;stico, que significa el diagn&#xF3;stico de una afecci&#xF3;n que no hubiera adquirido importancia cl&#xED;nica si no se hubiera detectado por medio de ex&#xE1;menes de detecci&#xF3;n.[<a href="#cit/section_3.6">6</a>] Si no se hubiera diagnosticado c&#xE1;ncer en el paciente, hubiera muerto por otras comorbilidades rivales. En el caso de los ex&#xE1;menes de detecci&#xF3;n con TCDB, el sobrediagn&#xF3;stico puede conducir a un diagn&#xF3;stico de c&#xE1;ncer de pulm&#xF3;n innecesario que demanda una combinaci&#xF3;n de intervenciones (por ejemplo, lobectom&#xED;a, quimioterapia y radioterapia). En los estudios de necropsias, se indica que un n&#xFA;mero importante de personas mueren con c&#xE1;ncer de pulm&#xF3;n, pero no por esta causa. En un estudio, casi la sexta parte de todos los casos de c&#xE1;ncer de pulm&#xF3;n encontrados en las necropsias no hab&#xED;an sido identificados por hallazgos cl&#xED;nicos antes de la muerte.[<a href="#cit/section_3.7">7</a>] Esto puede ser una subestimaci&#xF3;n. Seg&#xFA;n la magnitud de la necropsia, muchos c&#xE1;nceres de pulm&#xF3;n peque&#xF1;os que se pueden detectar con TC podr&#xED;an pasar inadvertidos en el informe de necropsia.[<a href="#cit/section_3.8">8</a>] En estudios japoneses, se aportan datos probatorios adicionales que permiten indicar que los ex&#xE1;menes de detecci&#xF3;n con TCDB podr&#xED;an conducir a una cantidad importante de sobrediagn&#xF3;sticos.[<a href="#cit/section_3.9">9</a>] Se necesitan estudios para establecer el grado de sobrediagn&#xF3;stico que podr&#xED;a estar relacionado con los ex&#xE1;menes de detecci&#xF3;n del c&#xE1;ncer de pulm&#xF3;n con TC. No obstante, en un estudio se calcul&#xF3; el tiempo de duplicaci&#xF3;n del volumen de 61 c&#xE1;nceres de pulm&#xF3;n por medio de un modelo exponencial e im&#xE1;genes sucesivas por TC. Las lesiones se clasificaron en los tres tipos descritos a continuaci&#xF3;n:</p><div class="pdq-content-list"><ul id="_128"><li>Tipo G (opacidad en vidrio esmerilado).</li><li>Tipo GS (opacidad focal vidriosa con un componente central s&#xF3;lido).</li><li>Tipo S (n&#xF3;dulo s&#xF3;lido).</li></ul></div><p id="_129" tabindex="-1">Las medias de los tiempos de duplicaci&#xF3;n fueron 813, 457 y 149 d&#xED;as para los tipos G, GS y S, respectivamente. En este estudio, los ex&#xE1;menes de detecci&#xF3;n anuales con TC permitieron identificar un gran n&#xFA;mero de adenocarcinomas de crecimiento lento que no eran visibles en las radiograf&#xED;as de t&#xF3;rax, lo que indica sobrediagn&#xF3;stico.[<a href="#cit/section_3.10">10</a>]</p><p id="_130" tabindex="-1">En un ensayo sobre ex&#xE1;menes de detecci&#xF3;n con m&#xE1;s de 5000 participantes, se evalu&#xF3; la proporci&#xF3;n de c&#xE1;nceres que hubiesen sido considerados sobrediagn&#xF3;sticos. Se utiliz&#xF3; el tiempo de duplicaci&#xF3;n del volumen como una valoraci&#xF3;n indirecta de sobrediagn&#xF3;stico. Se consider&#xF3; que los pacientes con un tiempo de duplicaci&#xF3;n del volumen calculado en m&#xE1;s de 400 d&#xED;as antes de la resecci&#xF3;n quir&#xFA;rgica ten&#xED;an un sobrediagn&#xF3;stico de c&#xE1;ncer.[<a href="#cit/section_3.11">11</a>] Los investigadores descubrieron que 25&#xA0;% de aquellos que finalmente contaban con un diagn&#xF3;stico de  c&#xE1;ncer de pulm&#xF3;n cumpl&#xED;an con los criterios de n&#xF3;dulo de crecimiento lento detectado por ex&#xE1;menes de detecci&#xF3;n, lo que indica que en ese ensayo  se sobrediagnosticaron 1 de cada 4 c&#xE1;nceres.[<a href="#cit/section_3.11">11</a>] Se han documentado tasas semejantes de sobrediagn&#xF3;stico para el c&#xE1;ncer de mama. Esta tasa es congruente con las de estudios anteriores de ex&#xE1;menes de detecci&#xF3;n con radiograf&#xED;a de t&#xF3;rax y las de otros tumores s&#xF3;lidos. Todav&#xED;a no se ha calculado la tasa de sobrediagn&#xF3;stico en el NLST, pero los datos del estudio muestran una brecha persistente de exceso de unos 120 casos de c&#xE1;ncer de pulm&#xF3;n en el grupo de TCDB en comparaci&#xF3;n con el de radiograf&#xED;a de t&#xF3;rax, aunque se necesita de seguimiento a largo plazo.[<a href="#cit/section_3.12">12</a>] Se observaron pruebas adicionales de sobrediagn&#xF3;stico de los ex&#xE1;menes de detecci&#xF3;n con TCDB en el  ensayo aleatorizado Danish Lung Cancer Screening Trial. A los 10 a&#xF1;os de seguimiento (5 a&#xF1;os despu&#xE9;s del &#xFA;ltimo examen de detecci&#xF3;n) se hab&#xED;a diagnosticado casi el doble de c&#xE1;nceres de pulm&#xF3;n en el grupo de ex&#xE1;menes de detecci&#xF3;n que en el grupo de control (5,1 vs. 2,7 casos por 1000 a&#xF1;os-persona o 100 vs. 53 casos de c&#xE1;ncer de pulm&#xF3;n en 4104 participantes en total, respectivamente); la mayor&#xED;a de los c&#xE1;nceres de pulm&#xF3;n eran adenocarcinomas en estadio temprano, sin diferencia estad&#xED;sticamente significativa en el n&#xFA;mero de c&#xE1;nceres en estadios III y IV entre los dos grupos.[<a href="#cit/section_3.13">13</a>]</p><p id="_131" tabindex="-1">Casi 20 a&#xF1;os de seguimiento de la cohorte del Mayo Lung Project (MLP) permiten indicar que 17&#xA0;% de los diagn&#xF3;sticos de c&#xE1;nceres  de pulm&#xF3;n que derivan de un r&#xE9;gimen intenso con radiograf&#xED;a de t&#xF3;rax y estudio citol&#xF3;gico del esputo son sobrediagn&#xF3;sticos;[<a href="#cit/section_3.14">14</a>] se diagnosticaron 585 c&#xE1;nceres de pulm&#xF3;n en el grupo de intervenci&#xF3;n en comparaci&#xF3;n con 500 en el grupo de atenci&#xF3;n habitual. Despu&#xE9;s de 13 a&#xF1;os de seguimiento de la cohorte del Prostate, Lung, Colorectal and Ovarian (PLCO), se diagnosticaron 1696 casos de c&#xE1;ncer de pulm&#xF3;n en el grupo de intervenci&#xF3;n en comparaci&#xF3;n con 1620 casos, en el grupo de atenci&#xF3;n habitual.[<a href="#cit/section_3.15">15</a>] Esto indica que cerca de 6&#xA0;% de los diagn&#xF3;sticos de c&#xE1;ncer que derivan de una radiograf&#xED;a de t&#xF3;rax anual constituyen sobrediagn&#xF3;stico, aunque el porcentaje no difiri&#xF3; en forma significativa de 0&#xA0;%.</p></section><section id="_193"><h4 id="_193_toc">Complicaciones de la evaluaci&#xF3;n diagn&#xF3;stica</h4><p id="_194" tabindex="-1">En el PLCO,[<a href="#cit/section_3.15">15</a>] 0,4&#xA0;% de los participantes que ten&#xED;an al menos un resultado positivo de  un examen de detecci&#xF3;n y que hab&#xED;an sido sometidos a una evaluaci&#xF3;n diagn&#xF3;stica presentaron una complicaci&#xF3;n relacionada con un procedimiento diagn&#xF3;stico. Entre 69 complicaciones, las m&#xE1;s frecuentes fueron neumot&#xF3;rax (29&#xA0;%), atelectasias (15&#xA0;%) e infecciones (10&#xA0;%).</p></section><section id="_134"><h4 id="_134_toc">Aumento de la mortalidad por c&#xE1;ncer de pulm&#xF3;n</h4><p id="_135" tabindex="-1">En los resultados de MLP se insin&#xFA;a la posibilidad de un aumento de la mortalidad por c&#xE1;ncer de pulm&#xF3;n en las personas sometidas a ex&#xE1;menes de detecci&#xF3;n con un r&#xE9;gimen intenso con radiograf&#xED;a de t&#xF3;rax y estudio citol&#xF3;gico del esputo.[<a href="#cit/section_3.16">16</a>] Al t&#xE9;rmino de 20 a&#xF1;os de seguimiento, la tasa de mortalidad por c&#xE1;ncer de pulm&#xF3;n fue de 4,4 casos por 1000 muertes en el grupo de intervenci&#xF3;n y de 3,9 casos por 1000 muertes en el grupo de tratamiento habitual. Las tasas no difirieron estad&#xED;sticamente (<em>P</em> = 0,09) entre s&#xED;. No se observ&#xF3; aumento del riesgo en los grupos de intervenci&#xF3;n de los estudios de John Hopkins University y Memorial Sloan-Kettering (riesgo relativo [RR], 0,88; intervalo de confianza [IC] 95&#xA0;%, 0,74&#x2013;1,05) ni en el PLCO (RR, 0,99; IC 95&#xA0;%, 0,87&#x2013;1,22).</p></section><section id="_136"><h4 id="_136_toc">Exposici&#xF3;n a la radiaci&#xF3;n</h4><p id="_137" tabindex="-1">Otro riesgo  de los ex&#xE1;menes de detecci&#xF3;n con TCDB es la exposici&#xF3;n a la radiaci&#xF3;n. El promedio de exposici&#xF3;n de una TCDB es muy bajo: 1,5 mSv. Se calcul&#xF3; que los participantes del NLST fueron expuestos a un promedio de 8 mSv de radiaci&#xF3;n (que representa la radiaci&#xF3;n de exploraciones e im&#xE1;genes adicionales para los n&#xF3;dulos identificados mediante ex&#xE1;menes de detecci&#xF3;n) en el transcurso de 3 a&#xF1;os de ex&#xE1;menes de detecci&#xF3;n. En los modelos de trabajos anteriores sobre la exposici&#xF3;n a la radiaci&#xF3;n y la presentaci&#xF3;n de c&#xE1;ncer, se indica que se podr&#xED;a presentar una defunci&#xF3;n por cada 2500 ex&#xE1;menes de detecci&#xF3;n entre aquellos participantes de un programa de detecci&#xF3;n como el NLST, aunque el beneficio de los ex&#xE1;menes de detecci&#xF3;n (que se evite una defunci&#xF3;n por cada 320 ex&#xE1;menes de detecci&#xF3;n) supera con creces el riesgo. Es m&#xE1;s probable que las personas m&#xE1;s j&#xF3;venes y aquellos sin riesgo importante de presentar c&#xE1;ncer de pulm&#xF3;n padezcan de c&#xE1;ncer de pulm&#xF3;n inducido por la radiaci&#xF3;n de los ex&#xE1;menes de detecci&#xF3;n en contraposici&#xF3;n a que se salven de morir por c&#xE1;ncer de pulm&#xF3;n.[<a href="#cit/section_3.1">1</a>]</p></section></section><section id="_138"><h3 id="_138_toc">Ex&#xE1;menes de detecci&#xF3;n con radiograf&#xED;a de t&#xF3;rax y estudio citol&#xF3;gico del esputo</h3><p id="_139" tabindex="-1">A menos que se haya informado m&#xE1;s arriba, no se han publicado datos sobre los perjuicios relacionados con el estudio citol&#xF3;gico del esputo o con un r&#xE9;gimen combinado de estudio citol&#xF3;gico del esputo y radiograf&#xED;a de t&#xF3;rax.</p><p id="_214" tabindex="-1">En el Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, el porcentaje de todos los ex&#xE1;menes de detecci&#xF3;n de c&#xE1;ncer de pulm&#xF3;n con  resultados positivos falsos fue de 98&#xA0;%.[<a href="#cit/section_3.17">17</a>] Cuando se consider&#xF3; el antecedente de tabaquismo, el porcentaje de resultados positivos falsos de los ex&#xE1;menes de detecci&#xF3;n (entre todos los resultados positivos) fue mayor en quienes nunca hab&#xED;an fumado (&gt;99&#xA0;%) y menor en los fumadores activos (95&#xA0;%). Despu&#xE9;s del ajuste por tabaquismo, el porcentaje de resultados positivos falsos de los ex&#xE1;menes de detecci&#xF3;n fue igual para ambos sexos.</p></section><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_3.1">Bach PB, Mirkin JN, Oliver TK, et al.: Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 307 (22): 2418-29, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22610500&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22610500&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.2">Aberle DR, Adams AM, Berg CD, et al.: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365 (5): 395-409, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21714641&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21714641&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.3">Kinsinger LS, Anderson C, Kim J, et al.: Implementation of Lung Cancer Screening in the Veterans Health Administration. JAMA Intern Med 177 (3): 399-406, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28135352&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28135352&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.4">Moyer VA; U.S. Preventive Services Task Force: Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 160 (5): 330-8, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24378917&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24378917&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.5">MacMahon H, Austin JH, Gamsu G, et al.: Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology 237 (2): 395-400, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16244247&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16244247&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.6">Black WC: Overdiagnosis: An underrecognized cause of confusion and harm in cancer screening. J Natl Cancer Inst 92 (16): 1280-2, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10944539&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10944539&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.7">Chan CK, Wells CK, McFarlane MJ, et al.: More lung cancer but better survival. Implications of secular trends in "necropsy surprise" rates. Chest 96 (2): 291-6, 1989.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2787730&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2787730&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.8">Dammas S, Patz EF Jr, Goodman PC: Identification of small lung nodules at autopsy: implications for lung cancer screening and overdiagnosis bias. Lung Cancer 33 (1): 11-6, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11429191&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11429191&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.9">Marcus PM, Fagerstrom RM, Prorok PC, et al.: Screening for lung cancer with helical CT scanning. Clinical Pulmonary Medicine  9 (6): 323-9, 2002.</li><li id="section_3.10">Hasegawa M, Sone S, Takashima S, et al.: Growth rate of small lung cancers detected on mass CT screening. Br J Radiol 73 (876): 1252-9, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11205667&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11205667&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.11">Veronesi G, Maisonneuve P, Bellomi M, et al.: Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: a cohort study. Ann Intern Med 157 (11): 776-84, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23208167&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23208167&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.12">Patz EF Jr, Pinsky P, Gatsonis C, et al.: Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med 174 (2): 269-74, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24322569&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24322569&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.13">Wille MM, Dirksen A, Ashraf H, et al.: Results of the Randomized Danish Lung Cancer Screening Trial with Focus on High-Risk Profiling. Am J Respir Crit Care Med 193 (5): 542-51, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26485620&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26485620&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.14">Marcus PM, Bergstralh EJ, Zweig MH, et al.: Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis. J Natl Cancer Inst 98 (11): 748-56, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16757699&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16757699&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.15">Oken MM, Hocking WG, Kvale PA, et al.: Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA 306 (17): 1865-73, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22031728&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22031728&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.16">Marcus PM, Bergstralh EJ, Fagerstrom RM, et al.: Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst 92 (16): 1308-16, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10944552&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10944552&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.17">Hocking WG, Hu P, Oken MM, et al.: Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. J Natl Cancer Inst 102 (10): 722-31, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20442215&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20442215&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _195
      field_pdq_section_title:
        - format: plain_text
          value: 'Toma de decisiones médicas con conocimiento de causa'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_195" class="pdq-sections"><p id="_196" tabindex="-1">  Cada vez se recomienda m&#xE1;s realizar un proceso de toma de decisiones m&#xE9;dicas con conocimiento de causa orientado a las personas que est&#xE1;n pensando en someterse a un examen de detecci&#xF3;n del c&#xE1;ncer. Se han estudiado distintos formas y materiales de  apoyo para ayudar en el proceso de decisi&#xF3;n. (Para obtener m&#xE1;s informaci&#xF3;n, consultar el sumario <a href="/espanol/cancer/deteccion/aspectos-generales-deteccion-pro-pdq">Aspectos generales de los ex&#xE1;menes de detecci&#xF3;n del c&#xE1;ncer</a>).</p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _48
      field_pdq_section_title:
        - format: plain_text
          value: 'Modificaciones a este sumario (02/16/2018)'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_48" class="pdq-sections"><p id="_49" tabindex="-1">Los sumarios del PDQ con informaci&#xF3;n sobre el c&#xE1;ncer se revisan con regularidad y se actualizan a medida  que se obtiene nueva informaci&#xF3;n.  Esta secci&#xF3;n describe los cambios m&#xE1;s recientes introducidos en este sumario a partir de la fecha arriba indicada.</p><p id="_218" tabindex="-1"><strong><a href="/espanol/tipos/pulmon/pro/deteccion-pulmon-pdq#link/_73">Descripci&#xF3;n de los datos probatorios</a></strong></p><p id="_223" tabindex="-1">Se actualizaron las <a href="/espanol/tipos/pulmon/pro/deteccion-pulmon-pdq#link/_222">estad&#xED;sticas</a> con el c&#xE1;lculo del n&#xFA;mero de casos nuevos y defunciones en 2018 (se cit&#xF3; la American Cancer Society como referencia 1).</p><p id="_224" tabindex="-1">Se revis&#xF3; el <a href="/espanol/tipos/pulmon/pro/deteccion-pulmon-pdq#link/_182">texto</a> para indicar que en varios pa&#xED;ses hay ensayos cl&#xED;nicos aleatorizados con tomograf&#xED;a computarizada helicoidal de dosis bajas que se completaron o est&#xE1;n en curso; la mayor&#xED;a de los ensayos peque&#xF1;os no parecen tener potencia para evaluar la mortalidad como criterio de valoraci&#xF3;n, pero est&#xE1; en curso una iniciativa para combinar los resultados de estos estudios con los datos del Dutch-Belgian Randomized Lung Cancer Screening Trial, una vez que estos datos sean definitivos (se citaron a Horeweg et al., Paci et al., Wille et al., Infante et al. y Pastorino et al. como referencias 13, 14, 15, 16 y 17, respectivamente).</p><p id="_disclaimerHP_3" tabindex="-1">Este sumario est&#xE1; redactado y mantenido por el <a href="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/deteccion-prevencion" title="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/deteccion-prevencion">Consejo editorial del PDQ sobre los ex&#xE1;menes de detecci&#xF3;n y la prevenci&#xF3;n</a>, que es editorialmente independiente del NCI. El sumario refleja una revisi&#xF3;n independiente de la bibliograf&#xED;a y no representa una declaraci&#xF3;n de pol&#xED;ticas del NCI o de los NIH. Para mayor informaci&#xF3;n sobre las pol&#xED;ticas de los sumarios y la funci&#xF3;n de los  consejos editoriales  del PDQ que mantienen los sumarios del PDQ, consultar en <a href="/espanol/tipos/pulmon/pro/deteccion-pulmon-pdq#link/_AboutThis_1">Informaci&#xF3;n sobre este sumario del PDQ</a> y  la p&#xE1;gina sobre <a href="https://www.cancer.gov/espanol/publicaciones/pdq" title="https://www.cancer.gov/espanol/publicaciones/pdq">Banco de datos de informaci&#xF3;n de c&#xE1;ncer - PDQ&#xAE;</a>.
            </p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _AboutThis_1
      field_pdq_section_title:
        - format: plain_text
          value: 'Información sobre este sumario del PDQ'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_AboutThis_1" class="pdq-sections"><section id="_AboutThis_2"><h3 id="_AboutThis_2_toc">Prop&#xF3;sito de este sumario</h3><p id="_AboutThis_3" tabindex="-1">Este sumario del PDQ con informaci&#xF3;n sobre el c&#xE1;ncer para profesionales de la salud proporciona informaci&#xF3;n integral revisada por expertos y con fundamento en datos probatorios sobre los ex&#xE1;menes de detecci&#xF3;n del c&#xE1;ncer de pulm&#xF3;n. El prop&#xF3;sito es servir como fuente de informaci&#xF3;n y ayuda para los m&#xE9;dicos que atienden a pacientes de c&#xE1;ncer. No  ofrece pautas ni recomendaciones formales para tomar decisiones relacionadas con la atenci&#xF3;n sanitaria.</p></section><section id="_AboutThis_21"><h3 id="_AboutThis_21_toc">Revisores y actualizaciones</h3><p id="_AboutThis_22" tabindex="-1">El  <a href="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/deteccion-prevencion" title="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/deteccion-prevencion">Consejo editorial del PDQ sobre los ex&#xE1;menes de detecci&#xF3;n y la prevenci&#xF3;n</a>, cuya funci&#xF3;n editorial es independiente del Instituto Nacional del C&#xE1;ncer (NCI), revisa con regularidad este sumario y, en caso necesario,   lo actualiza. Este sumario refleja una revisi&#xF3;n bibliogr&#xE1;fica independiente y no constituye una declaraci&#xF3;n de la pol&#xED;tica del Instituto Nacional del C&#xE1;ncer ni de los Institutos Nacionales de la Salud (NIH).</p><p id="_AboutThis_26" tabindex="-1">Cada mes, los miembros de este Consejo  examinan art&#xED;culos  publicados recientemente para determinar si se deben:</p><div class="pdq-content-list"><ul id="_AboutThis_23"><li>tratar en una reuni&#xF3;n,</li><li>citar textualmente, o</li><li>sustituir o actualizar, si ya se citaron con anterioridad.</li></ul></div><p id="_AboutThis_24" tabindex="-1">Los cambios en los sumarios se deciden mediante consenso, una vez que  los integrantes del Consejo eval&#xFA;an la solidez de los datos probatorios en los art&#xED;culos publicados y determinan la forma en que se incorporar&#xE1;n al sumario.</p><p id="_AboutThis_25" tabindex="-1">Cualquier comentario o pregunta sobre el contenido de este sumario se debe enviar mediante el   <a href="https://www.cancer.gov/espanol/contactenos/correo-electronico" title="https://www.cancer.gov/espanol/contactenos/correo-electronico">formulario de comunicaci&#xF3;n</a> en Cancer.gov/espanol del NCI.  No comunicarse con los miembros del Consejo para enviar preguntas o comentarios sobre los sumarios.  Los miembros del Consejo no responder&#xE1;n a preguntas del p&#xFA;blico. </p></section><section id="_AboutThis_9"><h3 id="_AboutThis_9_toc">Grados de comprobaci&#xF3;n cient&#xED;fica</h3><p id="_AboutThis_10" tabindex="-1">En algunas referencias bibliogr&#xE1;ficas de este sumario se indica el grado de comprobaci&#xF3;n cient&#xED;fica. El prop&#xF3;sito de estas designaciones es ayudar al lector a evaluar la solidez de los datos probatorios que sustentan el uso de  ciertas intervenciones  o enfoques. El Consejo editorial del PDQ sobre los ex&#xE1;menes de detecci&#xF3;n y la prevenci&#xF3;n emplea un <a href="/espanol/publicaciones/pdq/grados-comprobacion/deteccion-prevencion">sistema de jerarquizaci&#xF3;n formal</a> para establecer  las designaciones del grado de comprobaci&#xF3;n cient&#xED;fica.</p></section><section id="_AboutThis_11"><h3 id="_AboutThis_11_toc">Permisos para el uso de este sumario</h3><p id="_AboutThis_12" tabindex="-1">PDQ (Physician Data Query) es una marca registrada. Se autoriza el libre uso del texto  de los documentos del PDQ. Sin embargo, no se podr&#xE1; identificar como un sumario de informaci&#xF3;n sobre c&#xE1;ncer del PDQ del  NCI,  salvo que se reproduzca en su totalidad y se actualice con regularidad. Por otra parte, se permitir&#xE1; que un autor  escriba una oraci&#xF3;n como &#x201C;En el sumario del PDQ  del NCI de informaci&#xF3;n sobre la prevenci&#xF3;n del c&#xE1;ncer de mama se describen, en breve, los siguientes riesgos: [incluir fragmento del sumario]&#x201D;.</p><p id="_AboutThis_13" tabindex="-1">Se sugiere citar la referencia bibliogr&#xE1;fica de este sumario del PDQ de la siguiente forma:</p><p id="_AboutThis_14" tabindex="-1">PDQ&#xAE; sobre los ex&#xE1;menes de detecci&#xF3;n y la prevenci&#xF3;n. PDQ Ex&#xE1;menes de detecci&#xF3;n del c&#xE1;ncer de pulm&#xF3;n. Bethesda, MD: National Cancer Institute. Actualizaci&#xF3;n:  &lt;MM/DD/YYYY&gt;. Disponible en: <a href="https://www.cancer.gov/espanol/tipos/pulmon/pro/deteccion-pulmon-pdq" title="https://www.cancer.gov/espanol/tipos/pulmon/pro/deteccion-pulmon-pdq">https://www.cancer.gov/espanol/tipos/pulmon/pro/deteccion-pulmon-pdq</a>.  Fecha de acceso: &lt;MM/DD/YYYY&gt;. </p><p id="_AboutThis_15" tabindex="-1">Las im&#xE1;genes  en este sumario se reproducen  con el permiso del autor, el artista o la  editorial para uso exclusivo en los sumarios del PDQ. La utilizaci&#xF3;n de las im&#xE1;genes fuera del  PDQ requiere la autorizaci&#xF3;n del propietario, que el Instituto Nacional del C&#xE1;ncer no  puede otorgar. Para obtener m&#xE1;s informaci&#xF3;n sobre el uso de las ilustraciones de este sumario o de  otras im&#xE1;genes relacionadas con el c&#xE1;ncer, consultar <a href="https://visualsonline.cancer.gov/" title="https://visualsonline.cancer.gov/">Visuals Online</a>, una colecci&#xF3;n de m&#xE1;s de 2000 im&#xE1;genes cient&#xED;ficas.</p></section><section id="_AboutThis_16"><h3 id="_AboutThis_16_toc">Cl&#xE1;usula sobre el descargo de responsabilidad</h3><p id="_AboutThis_18" tabindex="-1">La informaci&#xF3;n en estos sumarios  no se debe utilizar como base para determinar reembolsos por parte de las aseguradoras. Para obtener m&#xE1;s informaci&#xF3;n  sobre la cobertura de seguros, consultar la p&#xE1;gina <a href="https://www.cancer.gov/espanol/cancer/manejo-del-cancer" title="https://www.cancer.gov/espanol/cancer/manejo-del-cancer">Manejo de la atenci&#xF3;n del c&#xE1;ncer</a> disponible en Cancer.gov/espanol.</p></section><section id="_AboutThis_19"><h3 id="_AboutThis_19_toc">Para obtener m&#xE1;s informaci&#xF3;n</h3><p id="_AboutThis_20" tabindex="-1">En Cancer.gov/espanol,  se ofrece m&#xE1;s informaci&#xF3;n sobre c&#xF3;mo comunicarse o recibir ayuda en  <a href="https://www.cancer.gov/espanol/contactenos" title="https://www.cancer.gov/espanol/contactenos">&#xBF;En qu&#xE9; podemos ayudarle?</a>.
            Tambi&#xE9;n se puede enviar un mensaje de  correo electr&#xF3;nico  mediante este  <a href="https://www.cancer.gov/espanol/contactenos/correo-electronico" title="https://www.cancer.gov/espanol/contactenos/correo-electronico">formulario</a>.</p></section></div>
